Allergan 10-K 16 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2017	Feb. 13, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	AGN
Entity Registrant Name	Allergan plc
Entity Central Index Key	1,578,845
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		330,320,420
Entity Public Float			$ 81
Warner Chilcott Limited [Member]
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	WARNER CHILCOTT LIMITED
Entity Central Index Key	1,620,602
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 1,817.2	$ 1,724
Marketable securities	4,632.1	11,501.5
Accounts receivable, net	2,899	2,531
Inventories	904.5	718
Prepaid expenses and other current assets	1,123.9	1,383.4
Total current assets	11,376.7	17,857.9
Property, plant and equipment, net	1,785.4	1,611.3
Investments and other assets	267.9	282.1
Non current assets held for sale	81.6	27
Deferred tax assets	319.1	233.3
Product rights and other intangibles	54,648.3	62,618.6
Goodwill	49,862.9	46,356.1
Total assets	118,341.9	128,986.3
Current liabilities:
Accounts payable and accrued expenses	5,541.4	5,019
Income taxes payable	74.9	57.8
Current portion of long-term debt and capital leases	4,231.8	2,797.9
Total current liabilities	9,848.1	7,874.7
Long-term debt and capital leases	25,843.5	29,970.8
Other long-term liabilities	886.9	1,085
Other taxes payable	1,573.9	886.2
Deferred tax liabilities	6,352.4	12,969.1
Total liabilities	44,504.8	52,785.8
Commitments and contingencies (Refer to Note 24)
Equity:
Preferred shares, $0.0001 par value per share, 5.1 million shares authorized, 5.1 million and 5.1 million shares issued and outstanding, respectively	4,929.7	4,929.7
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 330.2 million and 334.9 million shares issued and outstanding, respectively	0	0
Additional paid-in capital	54,013.5	53,958.9
Retained earnings	12,957.2	18,342.5
Accumulated other comprehensive income / (loss)	1,920.7	(1,038.4)
Total shareholders’ equity	73,821.1	76,192.7
Noncontrolling interest	16	7.8
Total equity	73,837.1	76,200.5
Total liabilities and equity	118,341.9	128,986.3
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	1,816.3	1,713.2
Marketable securities	4,632.1	11,501.5
Accounts receivable, net	2,899	2,531
Receivables from Parents	5,797.4	9,289.2
Inventories	904.5	718
Prepaid expenses and other current assets	1,123	1,382.1
Total current assets	17,172.3	27,135
Property, plant and equipment, net	1,785.4	1,611.3
Investments and other assets	267.9	282.1
Non current receivables from Parents	3,964	3,964
Non current assets held for sale	81.6	27
Deferred tax assets	316	233.3
Product rights and other intangibles	54,648.3	62,618.6
Goodwill	49,862.9	46,356.1
Total assets	128,098.4	142,227.4
Current liabilities:
Accounts payable and accrued expenses	5,515.6	4,993.3
Payables to Parents	2,340.6	1,372.8
Income taxes payable	74.9	57.8
Current portion of long-term debt and capital leases	4,231.8	2,797.9
Total current liabilities	12,162.9	9,221.8
Long-term debt and capital leases	25,843.5	29,970.8
Other long-term liabilities	886.9	1,086
Other taxes payable	1,573.5	886.2
Deferred tax liabilities	6,349.4	12,969.1
Total liabilities	46,816.2	54,133.9
Commitments and contingencies (Refer to Note 24)
Equity:
Member's capital	72,935.1	72,935.1
Retained earnings	6,410.4	16,189
Accumulated other comprehensive income / (loss)	1,920.7	(1,038.4)
Noncontrolling interest	16	7.8
Total equity	81,282.2	88,093.5
Total members’ equity	81,266.2	88,085.7
Total liabilities and equity	$ 128,098.4	$ 142,227.4

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred shares, par value	$ 0.0001	$ 0.0001
Preferred shares, shares authorized	5,100,000	5,100,000
Preferred shares, shares issued	5,100,000	5,100,000
Preferred shares, shares outstanding	5,100,000	5,100,000
Ordinary shares, par value	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	1,000,000,000	1,000,000,000
Ordinary shares, shares issued	330,200,000	334,900,000
Ordinary shares, shares outstanding	330,200,000	334,900,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net revenues	$ 15,940.7	$ 14,570.6	$ 12,688.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	2,168	1,860.8	2,751.8
Research and development	2,100.1	2,575.7	2,358.5
Selling and marketing	3,514.8	3,266.4	2,765.1
General and administrative	1,501.9	1,473.9	1,716.4
Amortization	7,197.1	6,470.4	5,443.7
In-process research and development impairments	1,452.3	743.9	511.6
Asset sales and impairments, net	3,927.7	5	272
Total operating expenses	21,861.9	16,396.1	15,819.1
Operating (loss)	(5,921.2)	(1,825.5)	(3,131)
Interest income	67.7	69.9	10.6
Interest (expense)	(1,095.6)	(1,295.6)	(1,193.3)
Other (expense) / income , net	(3,437.3)	219.2	(233.8)
Total other income (expense), net	(4,465.2)	(1,006.5)	(1,416.5)
Income / (loss) before income taxes and noncontrolling interest	(10,386.4)	(2,832)	(4,547.5)
(Benefit) for income taxes	(6,670.4)	(1,897)	(1,605.9)
Net income / (loss) from continuing operations, net of tax	(3,716)	(935)	(2,941.6)
(Loss) / income from discontinued operations, net of tax	(402.9)	15,914.5	6,861
Net (loss) / income	(4,118.9)	14,979.5	3,919.4
(Income) attributable to noncontrolling interest	(6.6)	(6.1)	(4.2)
Net (loss) / income attributable to shareholders	(4,125.5)	14,973.4	3,915.2
Dividends on preferred shares	278.4	278.4	232
Net (loss) / income attributable to ordinary shareholders	$ (4,403.9)	$ 14,695	$ 3,683.2
(Loss) / income per share attributable to ordinary shareholders - basic:
Continuing operations	$ (11.99)	$ (3.17)	$ (8.64)
Discontinued operations	(1.20)	41.35	18.65
Net (loss) / income per share - basic	(13.19)	38.18	10.01
(Loss) / income per share attributable to ordinary shareholders - diluted:
Continuing operations	(11.99)	(3.17)	(8.64)
Discontinued operations	(1.20)	41.35	18.65
Net (loss) / income per share - diluted	(13.19)	$ 38.18	$ 10.01
Dividends per ordinary share	$ 2.80
Weighted average ordinary shares outstanding:
Basic	333.8	384.9	367.8
Diluted	333.8	384.9	367.8
Warner Chilcott Limited [Member]
Net revenues	$ 15,940.7	$ 14,570.6	$ 12,688.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	2,168	1,860.8	2,751.8
Research and development	2,100.1	2,575.7	2,358.5
Selling and marketing	3,514.8	3,266.4	2,765.1
General and administrative	1,402.3	1,350.4	1,581
Amortization	7,197.1	6,470.4	5,443.7
In-process research and development impairments	1,452.3	743.9	511.6
Asset sales and impairments, net	3,927.7	5	272
Total operating expenses	21,762.3	16,272.6	15,683.7
Operating (loss)	(5,821.6)	(1,702)	(2,995.6)
Interest income	166.3	111.1	10.6
Interest (expense)	(1,095.6)	(1,295.6)	(1,193.3)
Other (expense) / income , net	(3,437.3)	172.2	(233.8)
Total other income (expense), net	(4,366.6)	(1,012.3)	(1,416.5)
Income / (loss) before income taxes and noncontrolling interest	(10,188.2)	(2,714.3)	(4,412.1)
(Benefit) for income taxes	(6,670.4)	(1,897)	(1,605.9)
Net income / (loss) from continuing operations, net of tax	(3,517.8)	(817.3)	(2,806.2)
(Loss) / income from discontinued operations, net of tax	(402.9)	15,914.5	6,861
Net (loss) / income	(3,920.7)	15,097.2	4,054.8
(Income) attributable to noncontrolling interest	(6.6)	(6.1)	(4.2)
Net (loss) / income attributable to shareholders	(3,927.3)	15,091.1	4,050.6
Net (loss) / income attributable to members	$ (3,927.3)	$ 15,091.1	$ 4,050.6

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) / Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net (loss) / income	$ (4,118.9)	$ 14,979.5	$ 3,919.4
Other comprehensive income / (loss)
Foreign currency translation gains / (losses)	1,248	(441.6)	(129.9)
Net impact of other-than-temporary loss on investment in Teva securities	1,599.4
Impact of Teva Transaction		1,544.8
Unrealized gains / (losses), net of tax	111.7	(1,647.5)	101.2
Total other comprehensive income / (loss), net of tax	2,959.1	(544.3)	(28.7)
Comprehensive (loss) / income	(1,159.8)	14,435.2	3,890.7
Comprehensive (income) attributable to noncontrolling interest	(6.6)	(6.1)	(4.2)
Comprehensive (loss) / income attributable to ordinary shareholders	(1,166.4)	14,429.1	3,886.5
Warner Chilcott Limited [Member]
Net (loss) / income	(3,920.7)	15,097.2	4,054.8
Other comprehensive income / (loss)
Foreign currency translation gains / (losses)	1,248	(441.6)	(129.9)
Net impact of other-than-temporary loss on investment in Teva securities	1,599.4
Impact of Teva Transaction		1,544.8
Unrealized gains / (losses), net of tax	111.7	(1,647.5)	101.2
Total other comprehensive income / (loss), net of tax	2,959.1	(544.3)	(28.7)
Comprehensive (loss) / income	(961.6)	14,552.9	4,026.1
Comprehensive (income) attributable to noncontrolling interest	(6.6)	(6.1)	(4.2)
Comprehensive (loss) / income attributable to ordinary shareholders	$ (968.2)	$ 14,546.8	$ 4,021.9

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Cash Flows From Operating Activities:
Net (loss) / income	$ (4,118.9)	$ 14,979.5	$ 3,919.4
Reconciliation to net cash provided by operating activities:
Depreciation	171.5	155.8	218.3
Amortization	7,197.1	6,475.2	5,777
Provision for inventory reserve	102.2	181.4	140.9
Share-based compensation	293.3	334.5	690.4
Deferred income tax benefit	(7,783.1)	(1,443.9)	(7,380.1)
Pre-tax gain on sale of businesses to Teva		(24,511.1)
Non-cash tax effect of gain on sale of businesses to Teva		5,285.2
In-process research and development impairments	1,452.3	743.9	511.6
Loss on asset sales and impairments, net	3,927.7	5	334.4
Charge to settle Teva related matters	387.4
Loss on forward sale of Teva shares	62.9
Amortization of inventory step-up	131.7	42.4	1,192.9
Non-cash extinguishment of debt	(15.7)
Amortization of deferred financing costs	27.8	51	298.3
Contingent consideration adjustments, including accretion	(133.2)	(66.8)	108.8
Other, net	(37)	(59.9)	66.4
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(188.3)	(191)	(1,034.3)
Decrease / (increase) in inventories	(144.8)	(268.4)	(226.2)
Decrease / (increase) in prepaid expenses and other current assets	27.9	29.9	70.9
Increase / (decrease) in accounts payable and accrued expenses	95.9	313.5	142.5
Increase / (decrease) in income and other taxes payable	1,114.1	(326.6)	(87.8)
Increase / (decrease) in other assets and liabilities	29.1	(283.9)	(137.3)
Net cash provided by operating activities	5,873.4	1,445.7	4,606.1
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(349.9)	(331.4)	(454.9)
Additions to product rights and other intangibles	(614.3)	(2)	(154.7)
Sale of businesses to Teva		33,804.2
Additions to investments	(9,783.8)	(15,743.5)	(24.3)
Proceeds from sale of investments and other assets	15,153.3	7,771.6	883
Proceeds from sales of property, plant and equipment	7.1	33.3	140.1
Acquisitions of businesses, net of cash acquired	(5,290.4)	(1,198.9)	(37,510.1)
Net cash (used in) / provided by investing activities	(878)	24,333.3	(37,120.9)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility	3,550	1,050	30,137.7
Debt issuance and other financing costs	(20.6)		(310.8)
Payments on debt, including capital lease obligations and credit facility	(6,413.6)	(10,848.7)	(5,134.2)
Proceeds from issuance of preferred shares			4,929.7
Proceeds from issuance of ordinary shares			4,071.1
Proceeds from stock plans	183.4	172.1	230
Other financing, including contingent consideration	(511.6)	(161.1)	(230.1)
Repurchase of ordinary shares	(493)	(15,076.4)	(118)
Dividends paid	(1,218.2)	(278.4)	(208.1)
Net cash (used in) / provided by financing activities	(4,923.6)	(25,142.5)	33,367.3
Effect of currency exchange rate changes on cash and cash equivalents	21.4	(8.5)	(6.5)
Net (decrease) / increase in cash and cash equivalents	93.2	628	846
Cash and cash equivalents at beginning of period	1,724	1,096	250
Cash and cash equivalents at end of period	1,817.2	1,724	1,096
Cash paid during the year for:
Income taxes other, net of refunds	(5.1)	3,692.7	377.6
Interest	1,144.4	1,277.9	689.9
Schedule of Non-Cash Investing and Financing Activities:
Dividends accrued	24.6	23.2	24
Teva [Member]
Reconciliation to net cash provided by operating activities:
Deferred income tax benefit		5,276.6
Pre-tax gain on sale of businesses to Teva	(466)
Net income impact of other-than-temporary loss on investment in Teva securities	3,273.5
Schedule of Non-Cash Investing and Financing Activities:
Receipt of ordinary shares in connection with the sale of the generics business		5,038.6
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(3,920.7)	15,097.2	4,054.8
Reconciliation to net cash provided by operating activities:
Depreciation	171.5	155.8	218.3
Amortization	7,197.1	6,475.2	5,777
Provision for inventory reserve	102.2	181.4	140.9
Share-based compensation	293.3	334.5	690.4
Deferred income tax benefit	(7,783.1)	(1,443.9)	(7,380.1)
Pre-tax gain on sale of businesses to Teva		(24,511.1)
Non-cash tax effect of gain on sale of businesses to Teva		5,285.2
In-process research and development impairments	1,452.3	743.9	511.6
Loss on asset sales and impairments, net	3,927.7	5	334.4
Net income impact of other-than-temporary loss on investment in Teva securities	3,273.5
Charge to settle Teva related matters	387.4
Loss on forward sale of Teva shares	62.9
Amortization of inventory step-up	131.7	42.4	1,192.9
Non-cash extinguishment of debt	(15.7)
Amortization of deferred financing costs	27.8	51	298.3
Contingent consideration adjustments, including accretion	(133.2)	(66.8)	108.8
Other, net	(37)	(59.9)	66.4
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(188.3)	(191)	(1,033.6)
Decrease / (increase) in inventories	(144.8)	(268.4)	(226.2)
Decrease / (increase) in prepaid expenses and other current assets	28.8	28.6	71.3
Increase / (decrease) in accounts payable and accrued expenses	121.7	339.2	193.5
Increase / (decrease) in income and other taxes payable	1,114.1	(326.6)	(87.8)
Increase / (decrease) in other assets and liabilities	(45.5)	(292.7)	(266.9)
Net cash provided by operating activities	6,023.7	1,579	4,664
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(349.9)	(331.4)	(454.9)
Additions to product rights and other intangibles	(614.3)	(2)	(154.7)
Sale of businesses to Teva		33,804.2
Additions to investments	(9,783.8)	(15,743.5)	(24.3)
Proceeds from sale of investments and other assets	15,153.3	7,771.6	883
Loans to Parents		(13,232.2)
Proceeds from sales of property, plant and equipment	7.1	33.3	140.1
Acquisitions of businesses, net of cash acquired	(5,290.4)	(1,198.9)	(37,510.1)
Net cash (used in) / provided by investing activities	(878)	11,101.1	(37,120.9)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility	3,550	1,050	30,137.7
Debt issuance and other financing costs	(20.6)		(310.8)
Payments on debt, including capital lease obligations and credit facility	(6,413.6)	(10,848.7)	(5,134.2)
Other financing, including contingent consideration	(511.6)	(161.1)	(230.1)
Dividend to Parent	(1,668.2)	(2,034.8)	(208.1)
Contribution from Parent			9,000.8
Net cash (used in) / provided by financing activities	(5,064)	(11,994.6)	33,255.3
Effect of currency exchange rate changes on cash and cash equivalents	21.4	(8.5)	(6.5)
Net (decrease) / increase in cash and cash equivalents	103.1	677	791.9
Cash and cash equivalents at beginning of period	1,713.2	1,036.2	244.3
Cash and cash equivalents at end of period	1,816.3	1,713.2	1,036.2
Cash paid during the year for:
Income taxes other, net of refunds	(5.1)	3,692.7	377.6
Interest	1,144.4	1,277.9	689.9
Schedule of Non-Cash Investing and Financing Activities:
Non-cash dividends to Parents	4,203.9
Teva [Member]
Reconciliation to net cash provided by operating activities:
Net income impact of other-than-temporary loss on investment in Teva securities	3,273.5
Teva [Member] | Warner Chilcott Limited [Member]
Reconciliation to net cash provided by operating activities:
Net income impact of other-than-temporary loss on investment in Teva securities	3,273.5
Schedule of Non-Cash Investing and Financing Activities:
Receipt of ordinary shares in connection with the sale of the generics business		$ 5,038.6
Allergan, Inc. [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets			34,687.2
Kythera [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets			$ 40
Zeltiq [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets	$ 8.5

Consolidated Statements of Shar

Consolidated Statements of Shareholders' and Members' Equity - USD ($) $ in Millions	Total	Warner Chilcott Limited [Member]	Teva [Member]	Teva [Member]Warner Chilcott Limited [Member]	Allergan, Inc. [Member]	Kythera [Member]	Zeltiq [Member]	Mandatory Convertible Preferred Shares [Member]	Ordinary Shares [Member]	Ordinary Shares [Member]Allergan, Inc. [Member]	Preferred Shares [Member]	Preferred Shares [Member]Mandatory Convertible Preferred Shares [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Allergan, Inc. [Member]	Additional Paid-in Capital [Member]Kythera [Member]	Additional Paid-in Capital [Member]Zeltiq [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]Warner Chilcott Limited [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]Teva [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]Teva [Member]Warner Chilcott Limited [Member]	Member's Capital [Member]Warner Chilcott Limited [Member]	Retained Earnings [Member]	Retained Earnings [Member]Warner Chilcott Limited [Member]
Balance at Dec. 31, 2014	$ 28,331.1												$ 28,994.7				$ (465.4)					$ (198.2)
Balance, shares at Dec. 31, 2014									265,900,000
Balance at Dec. 31, 2014		$ 28,072.6																$ (465.4)			$ 29,455.9		$ (917.9)
Balance, shares at Dec. 31, 2014																					100
Comprehensive income:
Net income attributable to shareholders	3,915.2	4,050.6																				3,915.2	4,050.6
Other comprehensive (loss), net of tax	(28.7)	(28.7)															(28.7)	(28.7)
Comprehensive (loss) / income attributable to ordinary shareholders	3,886.5	4,021.9
Contribution from Parent		43,687.3																			$ 43,687.3
Dividend to Parent		(208.1)																			(208.1)
Share-based compensation	690.4												690.4
Ordinary shares issued in connection with acquisition					$ 38,757.6	$ 40								$ 38,757.6	$ 40
Ordinary shares issued in connection with acquisition, shares										126,300,000
Issuance of Mandatory Convertible Preferred Shares								$ 4,929.7				$ 4,929.7
Issuance of Mandatory Convertible Preferred Shares, shares												5,100,000
Ordinary shares issued under employee stock plans	230												230
Ordinary shares issued under employee stock plans, shares									2,700,000
Tax benefits from exercise of options	76.1												76.1
Dividends declared	(232)												(162.5)									(69.5)
Repurchase of ordinary shares	(118)												(118)
Repurchase of ordinary shares, shares									(400,000)
Balance at Dec. 31, 2015	76,591.4										$ 4,929.7		68,508.3				(494.1)					3,647.5
Balance, shares at Dec. 31, 2015									394,500,000		5,100,000
Balance at Dec. 31, 2015		75,573.7																(494.1)			$ 72,935.1		3,132.7
Balance, shares at Dec. 31, 2015																					100
Comprehensive income:
Net income attributable to shareholders	14,973.4	15,091.1																				14,973.4	15,091.1
Other comprehensive (loss), net of tax	(2,089.1)	(2,089.1)															(2,089.1)	(2,089.1)
Other comprehensive income resulting from the Teva Transaction			$ 1,544.8	$ 1,544.8															$ 1,544.8	$ 1,544.8
Comprehensive (loss) / income attributable to ordinary shareholders	14,429.1	14,546.8
Dividend to Parent		(2,034.8)																					(2,034.8)
Share-based compensation	334.5												334.5
Ordinary shares issued under employee stock plans	172.1												172.1
Ordinary shares issued under employee stock plans, shares									2,300,000
Tax benefits from exercise of options	20.4												20.4
Dividends declared	(278.4)																					(278.4)
Repurchase of ordinary shares under the share repurchase programs	(15,000)												(15,000)
Repurchase of ordinary shares under the share repurchase programs, shares									(61,600,000)
Repurchase of ordinary shares	$ (76.4)												(76.4)
Repurchase of ordinary shares, shares	(61,600,000)								(300,000)
Balance at Dec. 31, 2016	$ 76,192.7										$ 4,929.7		53,958.9				(1,038.4)					18,342.5
Balance, shares at Dec. 31, 2016									334,900,000		5,100,000
Balance at Dec. 31, 2016		88,085.7																(1,038.4)			$ 72,935.1		16,189
Balance, shares at Dec. 31, 2016																					100
Comprehensive income:
Net income attributable to shareholders	(4,125.5)	(3,927.3)																				(4,125.5)	(3,927.3)
Other comprehensive (loss), net of tax	1,359.7	1,359.7															1,359.7	1,359.7
Net impact of other-than-temporary loss on investment in Teva securities			1,599.4																$ 1,599.4
Comprehensive (loss) / income attributable to ordinary shareholders	(1,166.4)	(968.2)
Impact of change in accounting for share-based compensation plans	20.8												62.4									(41.6)
Net impact of other-than-temporary loss on investment in Teva securities			$ 1,599.4	$ 1,599.4																$ 1,599.4
Dividend to Parent		(5,872.1)																					(5,872.1)
Share-based compensation	293.3												293.3
Ordinary shares issued in connection with acquisition							$ 8.5									$ 8.5
Ordinary shares issued under employee stock plans	183.4												183.4
Ordinary shares issued under employee stock plans, shares									2,200,000
Impact of change in accounting for share-based compensation plans	20.8												62.4									(41.6)
Dividends declared	(1,218.2)																					(1,218.2)
Repurchase of ordinary shares under the share repurchase programs	(450)												(450)
Repurchase of ordinary shares under the share repurchase programs, shares									(6,800,000)
Repurchase of ordinary shares	$ (43)												(43)
Repurchase of ordinary shares, shares	(4,200,000)								(100,000)
Balance at Dec. 31, 2017	$ 73,821.1										$ 4,929.7		$ 54,013.5				$ 1,920.7					$ 12,957.2
Balance, shares at Dec. 31, 2017									330,200,000		5,100,000
Balance at Dec. 31, 2017		81,266.2																$ 1,920.7			$ 72,935.1		6,410.4
Balance, shares at Dec. 31, 2017																					100
Comprehensive income:
Impact of change in accounting for share-based compensation plans		$ 20.8																					$ 20.8

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Description of Business	NOTE 1 — Description of Business Allergan plc is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceutical (“brand”, “branded” or “specialty brand”) Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. The Company has operations in more than 100 countries. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc and has the same principal business activities. On August 2, 2016 we completed the divestiture of our global generics business and certain other assets to Teva Pharmaceutical Industries Ltd. (“Teva”) (the “Teva Transaction”) for $33.3 billion in cash, net of cash acquired by Teva, which included estimated working capital and other contractual adjustments, and 100.3 million unregistered Teva ordinary shares (or American Depository Shares with respect thereto), which at the time of the closing approximated $5.0 billion in value using the closing date Teva opening stock price discounted at a rate of 5.9 percent due to the lack of marketability (“Teva Shares”). As part of the Teva Transaction, Teva acquired our global generics business, including the United States (“U.S.”) and international generic commercial units, our third-party supplier Medis, our global generic manufacturing operations, our global generic research and development (“R&D”) unit, our international over-the-counter (“OTC”) commercial unit (excluding OTC eye care products) and certain established international brands. On October 3, 2016, the Company completed the divestiture of the Anda Distribution business to Teva for $500.0 million. The Anda Distribution business distributed generic, branded, specialty and OTC pharmaceutical products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices across the U.S. The Company recognized a combined gain on the sale of the Anda Distribution business and the Teva Transaction of $15,932.2 million in the year ended December 31, 2016, as well as deferred liabilities relating to other elements of our arrangements with Teva of $299.2 million. In October 2016, pursuant to our agreement with Teva, Teva provided the Company with its proposed estimated adjustment to the closing date working capital balance. The Company disagreed with Teva’s proposed adjustment, and, pursuant to our agreement with Teva, each of the Company’s and Teva’s proposed adjustments were submitted to arbitration (“Working Capital Arbitration”) to determine the working capital amount in accordance with GAAP as applied by the Company consistent with past practice. Teva initially proposed an adjustment of approximately $1.4 billion and subsequently submitted a revised adjustment of approximately $1.5 billion to the arbitrator. In addition, on October 30, 2017, Teva submitted a Notice of Direct and Third Party Claims seeking indemnification for virtually all of the same items for which Teva sought a proposed adjustment in the Working Capital Arbitration as well as several new items as to which no quantity of damages had been asserted. On January 31, 2018, Allergan plc and Teva entered into a Settlement Agreement and Mutual Releases (the “Agreement”). The Agreement provides that the Company will make a one-time payment of $700.0 million to Teva; the Company and Teva will jointly dismiss their working capital dispute arbitration, and the Company and Teva will release all actual or potential claims under the Master Purchase Agreement, dated July 26, 2015, by and between the Company and Teva, for breach of any representation, warranty, or covenant (other than any breach of a post-closing covenant not known as of the date of the Agreement). The Company recorded a pre-tax charge of $466.0 million as a component of other (expense) / income, net from discontinued operations relating to the settlement in the year ended December 31, 2017. As a result of the Teva Transaction and the divestiture of the Company’s Anda Distribution business, and in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-08 “Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” the financial results of the businesses held for sale were reclassified to discontinued operations for all periods presented in our consolidated financial statements. The results of our discontinued operations include the results of our generic product development, manufacturing and distribution of off-patent pharmaceutical products, certain established international brands marketed similarly to generic products and out-licensed generic pharmaceutical products primarily in Europe through our Medis third-party business through August 2, 2016, as well as our Anda Distribution business through October 3, 2016.

Formation of the Company

Formation of the Company	12 Months Ended
	Dec. 31, 2017
Regulated Operations [Abstract]
Formation of the Company	NOTE 2 — Formation of the Company Allergan plc (formerly known as Actavis plc) was incorporated in Ireland on May 16, 2013 as a private limited company and re-registered effective September 20, 2013 as a public limited company. It was established for the purpose of facilitating the business combination between Allergan Finance, LLC (formerly known as Actavis, Inc.) and Warner Chilcott plc (“Warner Chilcott”). Following the consummation of the Warner Chilcott acquisition on October 1, 2013 (the “Warner Chilcott Acquisition”), Allergan Finance, LLC and Warner Chilcott became wholly-owned subsidiaries of Allergan plc. Each of Allergan Finance, LLC’s common shares was converted into one Company ordinary share. Effective October 1, 2013, through a series of related-party transactions, Allergan plc contributed its indirect subsidiaries, including Allergan Finance, LLC, to its subsidiary Warner Chilcott Limited. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, the consolidated financial statements and disclosures are for two separate registrants, Allergan plc and Warner Chilcott Limited. The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Allergan plc and Warner Chilcott Limited, references throughout this document relate to both Allergan plc and Warner Chilcott Limited. Refer to “Note 3 —Reconciliation of Warner Chilcott Limited results to Allergan plc results” in the accompanying “Notes to the Consolidated Financial Statements” in this document for a summary of the details on the differences between Allergan plc and Warner Chilcott Limited. On March 17, 2015, the Company acquired Allergan, Inc. (“Legacy Allergan”) for approximately $77.0 billion including outstanding indebtedness assumed of $2.2 billion, cash consideration of $40.1 billion and equity consideration of $34.7 billion, which included then outstanding equity awards (the “Allergan Acquisition”). Under the terms of the agreement, Legacy Allergan shareholders received 111.2 million of the Company’s ordinary shares, 7.0 million of the Company’s non-qualified stock options and 0.5 million of the Company’s share units. The addition of Legacy Allergan’s therapeutic franchises in ophthalmology, neurosciences and medical aesthetics/dermatology/plastic surgery complemented the Company’s existing central nervous system, gastroenterology, women’s health and urology franchises. The combined company benefits from Legacy Allergan’s global brand equity and consumer awareness of key products, including Botox ® In connection with the Allergan Acquisition, the Company changed its name from Actavis plc to Allergan plc. Actavis plc’s ordinary shares were traded on the NYSE under the symbol “ACT” until the opening of trading on June 15, 2015, at which time Actavis plc changed its corporate name to “Allergan plc” and changed its ticker symbol to “AGN.” Pursuant to Rule 12g-3(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Allergan plc is the successor issuer to Actavis plc’s ordinary shares and Actavis plc’s mandatory convertible preferred shares, both of which are deemed to be registered under Section 12(b) of the Exchange Act, and Allergan plc is subject to the informational requirements of the Exchange Act, and the rules and regulations promulgated thereunder. References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Allergan plc. References to “Warner Chilcott Limited” refer to Warner Chilcott Limited, the Company’s indirect wholly-owned subsidiary, and, unless the context otherwise requires, its subsidiaries. References throughout to “Ordinary Shares” refer to Allergan Finance, LLC’s Class A common shares, par value $0.0033 per share, prior to the consummation of the Warner Chilcott transactions and to Allergan plc’s ordinary shares, par value $0.0001 per share, since the consummation of the Warner Chilcott transactions.

Reconciliation of Warner Chilco

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	12 Months Ended
	Dec. 31, 2017
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	NOTE 3 — Reconciliation of Warner Chilcott Limited results to Allergan plc results Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc, the ultimate parent of the group, (together with other Warner Chilcott Limited parents, the “Parents”). The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Warner Chilcott Limited and the Parents (including Allergan plc), content throughout this filing relates to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited representations relate only to itself and not to any other company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, these notes relate to the consolidated financial statements for both separate registrants, Allergan plc and Warner Chilcott Limited. In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the financial position and results of operations of Warner Chilcott Limited to Allergan plc ($ in millions): December 31, 2017 December 31, 2016 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 1,817.2 $ 1,816.3 $ 0.9 $ 1,724.0 $ 1,713.2 $ 10.8 Prepaid expenses and other current assets 1,123.9 1,123.0 0.9 1,383.4 1,382.1 1.3 Deferred tax assets 319.1 316.0 3.1 233.3 233.3 - Accounts payable and accrued liabilities 5,541.4 5,515.6 25.8 5,019.0 4,993.3 25.7 Other long-term liabilities 886.9 886.9 - 1,085.0 1,086.0 (1.0 ) Other taxes payables 1,573.9 1,573.5 0.4 886.2 886.2 - Deferred tax liabilities 6,352.4 6,349.4 3.0 12,969.1 12,969.1 - Year Ended December 31, 2017 Year Ended December 31, 2016 Year Ended December 31, 2015 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 1,501.9 $ 1,402.3 $ 99.6 $ 1,473.9 $ 1,350.4 $ 123.5 $ 1,716.4 $ 1,581.0 $ 135.4 Operating (loss) (5,921.2 ) (5,821.6 ) (99.6 ) (1,825.5 ) (1,702.0 ) (123.5 ) (3,131.0 ) (2,995.6 ) (135.4 ) Interest Income 67.7 166.3 (98.6 ) 69.9 111.1 (41.2 ) 10.6 10.6 - Other income / (expense), net (3,437.3 ) (3,437.3 ) - 219.2 172.2 47.0 (233.8 ) (233.8 ) - (Loss) before income taxes and noncontrolling interest (10,386.4 ) (10,188.2 ) (198.2 ) (2,832.0 ) (2,714.3 ) (117.7 ) (4,547.5 ) (4,412.1 ) (135.4 ) Net (loss) from continuing operations, net of tax (3,716.0 ) (3,517.8 ) (198.2 ) (935.0 ) (817.3 ) (117.7 ) (2,941.6 ) (2,806.2 ) (135.4 ) Net (loss) / income (4,118.9 ) (3,920.7 ) (198.2 ) 14,979.5 15,097.2 (117.7 ) 3,919.4 4,054.8 (135.4 ) Dividends on preferred shares 278.4 - 278.4 278.4 - 278.4 232.0 - 232.0 Net (loss) / income attributable to ordinary shareholders/members (4,403.9 ) (3,927.3 ) (476.6 ) 14,695.0 15,091.1 (396.1 ) 3,683.2 4,050.6 (367.4 ) The difference between general and administrative expenses in the years ending December 31, 2017, 2016 and 2015 were due to corporate related expenses incurred at Allergan plc as well as non-recurring transaction costs incurred as part of the acquisitions of the Company, including Allergan, Forest and the terminated transaction with Pfizer Inc. Movements in equity are due to historical differences in the results of operations of the companies and differences in equity awards. As of December 31, 2017 and December 31, 2016, Warner Chilcott Limited had $5.8 billion and $9.3 billion in Receivables from Parents, respectively. As of December 31, 2017 and December 31, 2016 Warner Chilcott Limited had $4.0 billion and $4.0 billion in Non current Receivables from Parents, respectively. These receivables related to intercompany loans between Allergan plc and each of the Allergan Capital, S.a.r.l (formerly known as Actavis Capital, S.a.r.l) and Forest Finance B.V., subsidiaries of Warner Chilcott Limited. These loans are interest-bearing loans with varying term dates. Total interest income recognized during the years ended December 31, 2017 and December 31, 2016 was $98.6 million and $41.2 million, respectively.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 4 — Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented. The Company’s consolidated financial statements include the financial results of all acquired companies subsequent to the acquisition date. Reclassifications In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Effective January 1, 2017, the Company prospectively adopted the guidance and as a result of implementation, the Company reduced previously reported Retained Earnings by $62.4 million and increased previously reported Additional-Paid-In-Capital by $62.4 million. In addition, the Company decreased its net Deferred Tax Liabilities and increased Retained Earnings by $20.8 million for the tax impact of this change. The Company also revised its presentation of previously reported cash flows by eliminating the presentation of “Excess tax benefit from stock-based compensation” which raised operating cash flows and reduced financing cash flows for the year ended December 31, 2016 by $20.4 million. Use of Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to the determination of SRAs (defined below) included within either accounts receivable or accrued liabilities, the valuation of inventory balances, the determination of useful lives for intangible assets, pension and other post-retirement benefit plan assumptions, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment and recognition and measurement of assets acquired and liabilities assumed in business combinations at fair value. The estimation process required to prepare the Company’s consolidated financial statements requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. The Company’s actual results could differ materially from those estimates. Foreign Currency Translation For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive (loss) / income. The effects of revaluing non-functional currency assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. The Company realizes foreign currency gains / (losses) in the normal course of business based on movement in the applicable exchange rates. These transactional gains / (losses) are included as a component of general and administrative expenses. Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in banks, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, investments, trade accounts payable, and long-term debt, including the current portion. The carrying amounts of cash and cash equivalents, marketable securities, accounts and other receivables and trade accounts payable are representative of their respective fair values due to their relatively short maturities. The fair values of investments in companies that are publicly traded and not accounted for under the equity method are based on quoted market prices. The Company estimates the fair value of its fixed rate long-term obligations based on quoted market rates. Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventory includes brand pharmaceutical and medical aesthetic products which represent Food and Drug Administration (“FDA”) approved or likely to be approved indications. Inventory valuation reserves are established based on a number of factors/situations including, but not limited to, raw materials, work in process or finished goods not meeting product specifications, product obsolescence, or application of the lower of cost (first-in, first-out method) or market (net realizable value) concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. Assumptions utilized in our quantification of inventory reserves include, but are not limited to, estimates of future product demand, consideration of current and future market conditions, product net selling price, anticipated product launch dates, potential product obsolescence and other events relating to special circumstances surrounding certain products. No material adjustments have been required to our inventory reserve estimates for the periods presented. Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Major renewals and improvements are capitalized, while routine maintenance and repairs are expensed as incurred. The Company capitalizes interest on qualified construction projects. At the time property, plant and equipment are retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is computed principally on the straight-line method, over the estimated useful lives of the related assets. The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years The Company assesses property, plant and equipment for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Investments The Company’s equity investments are accounted for under the equity method of accounting when the Company can exert significant influence and the Company’s ownership interest does not exceed 50%. The Company records equity method investments at cost and adjusts for the appropriate share of investee net earnings or losses. Investments in which the Company owns less than a 20% interest and cannot exert significant influence are accounted for using the cost method if the fair value of such investments is not readily determinable. Marketable Securities The Company’s marketable securities consist of U.S. treasury and agency securities and debt and equity securities of publicly-held companies. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices. Unrealized temporary adjustments to fair value were included on the balance sheet in a separate component of shareholders’ equity as unrealized gains and losses and are reported as a component of accumulated other comprehensive income / (loss) as of December 31, 2017. No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Product Rights and Other Definite-Lived Intangible Assets Our product rights and other definite-lived intangible assets are stated at cost, less accumulated amortization, and are amortized using the economic benefit model or the straight-line method, if results are materially aligned, over their estimated useful lives. We determine amortization periods for product rights and other definite-lived intangible assets based on our assessment of various factors impacting estimated useful lives and cash flows. Such factors include the product’s position in its life cycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in a reduction in the intangibles useful life and an acceleration of related amortization expense, which could cause our net results to decline. Product rights and other definite-lived intangible assets are tested periodically for impairment when events or changes in circumstances indicate that an asset’s carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in net (loss) / income in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Our projections of discounted cash flows use a discount rate determined by our management to be commensurate with the risk inherent in our business model. Our estimates of future cash flows attributable to our other definite-lived intangible assets require significant judgment based on our historical and anticipated results and are subject to many factors. Different assumptions and judgments could materially affect the calculation of the fair value of the other definite-lived intangible assets which could trigger impairment. Goodwill and Intangible Assets with Indefinite-Lives The Company tests goodwill and intangible assets with indefinite-lives for impairment annually in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income and this could result in a material impact to net income / (loss) and income / (loss) per share. Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to acquired research and development projects that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that the Company has acquired with respect to products and/or processes that have not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired, if there is no future alternative use or no market for which to sell the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, R&D costs, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. Changes in these assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of the product, we will make a separate determination of the useful life of the intangible, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life. Contingent Consideration Contingent consideration is recorded at the acquisition date estimated fair value of the contingent payment for all applicable acquisitions. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statements of operations. (Refer to “NOTE 23 — Fair Value Measurement” for additional details regarding the fair value of contingent consideration.) Revenue Recognition General During the years ended December 31, 2017, 2016 and 2015, revenue from product sales was recognized when title and risk of loss to the product transfers to the customer, which is based on the transaction shipping terms. Recognition of revenue also requires reasonable assurance of collection of sales proceeds, the seller’s price to the buyer to be fixed or determinable and the completion of all performance obligations. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, sales returns and allowances, commercial and government rebates, customer loyalty programs and fee-for-service arrangements with certain distributors, which we refer to in the aggregate as “SRA”. Royalty and commission revenue is recognized as a component of net revenues in accordance with the terms of their respective contractual agreements when collectability is reasonably assured and when revenue can be reasonably measured. Provisions for SRAs As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes gross revenue from the sale of products, an estimate of SRA is recorded, which reduces the product revenues. Accounts receivable and/or accrued liabilities are also reduced and/or increased by the SRA amount depending on whether we have the right of offset with the customer. These provisions are estimated based on historical payment experience, historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material revenue adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback payments. We continually monitor current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states / authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for the cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, promotional allowances, and loyalty cards. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are not permitted. Customer returns of product are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes which may impact future expected returns. Promotional allowances are credits that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Loyalty cards allow the end user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2014 $ 28.0 $ 995.8 $ 255.2 $ 16.3 $ 1,295.3 Add: Allergan Acquisition 14.1 306.4 100.4 8.6 429.5 Provision related to sales in 2015 649.9 4,035.7 659.9 275.6 5,621.1 Credits and payments (613.8 ) (3,993.5 ) (648.0 ) (275.4 ) (5,530.7 ) Balance at December 31, 2015 $ 78.2 $ 1,344.4 $ 367.5 $ 25.1 $ 1,815.2 Provision related to sales in 2016 1,003.2 4,338.7 1,390.1 306.5 7,038.5 Credits and payments (967.2 ) (4,069.1 ) (1,341.7 ) (296.9 ) (6,674.9 ) Balance at December 31, 2016 $ 114.2 $ 1,614.0 $ 415.9 $ 34.7 $ 2,178.8 Provision related to sales in 2017 1,098.7 4,891.4 1,799.3 330.6 8,120.0 Credits and payments (1,135.7 ) (4,710.4 ) (1,734.7 ) (328.8 ) (7,909.6 ) Add: LifeCell and Zeltiq Acquisitions - 4.2 37.1 - 41.3 Balance at December 31, 2017 $ 77.2 $ 1,799.2 $ 517.6 $ 36.5 $ 2,430.5 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): As of December 31, 2017 2016 Accounts receivable $ 250.6 $ 287.4 Accounts payable and accrued expenses 2,179.9 1,891.4 $ 2,430.5 $ 2,178.8 The provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Years Ended December 31, Gross Product Sales Chargebacks Rebates Returns and Other Allowances Cash Discounts Net Product Sales Percentage of Gross Product Sales 2015 $ 18,125.1 $ 649.9 $ 4,035.7 $ 659.9 $ 275.6 $ 12,504.0 69.0 % 2016 $ 21,398.6 $ 1,003.2 $ 4,338.7 $ 1,390.1 $ 306.5 $ 14,360.1 67.1 % 2017 $ 23,688.4 $ 1,098.7 $ 4,891.4 $ 1,799.3 $ 330.6 $ 15,568.4 65.7 % The following table summarizes the activity from discontinued operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2014 $ 536.9 $ 750.8 $ 356.9 $ 44.4 $ 1,689.0 Provision related to sales in 2015 5,907.2 1,991.9 729.4 277.3 8,905.8 Credits and payments (5,825.1 ) (2,011.7 ) (757.7 ) (261.6 ) (8,856.1 ) Balance at December 31, 2015 $ 619.0 $ 731.0 $ 328.6 $ 60.1 $ 1,738.7 Provision related to sales in 2016 3,525.4 1,290.4 583.0 159.1 5,557.9 Credits and payments (3,655.0 ) (1,350.0 ) (496.3 ) (155.4 ) (5,656.7 ) Disposal of businesses (489.4 ) (671.4 ) (415.3 ) (63.8 ) (1,639.9 ) Balance at December 31, 2016 $ - $ - $ - $ - $ - The Company’s divested generics business also had the following type of SRAs: • Pricing adjustments, included shelf stock adjustments which are credits issued to reflect price decreases in selling prices charged to the Company’s direct customers. Shelf stock adjustments are based upon the amount of product our customers have in their inventory at the time of an agreed-upon price reduction. The provision for shelf stock adjustments was based upon specific terms with the Company’s customers and includes estimates of existing customer inventory levels based upon their historical purchasing patterns. • Billback adjustments are credits that are issued to certain customers who purchase directly from us as well as indirectly through a wholesaler. These credits are issued in the event there was a difference between the customer’s direct and indirect contract price. The provision for billbacks was estimated based upon historical purchasing patterns of qualified customers who purchase product directly from us and supplement their purchases indirectly through our wholesale customers. Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with FASB Accounting Standards Codification (“ASC”) Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts progress or as additional information becomes available. Acquired contingencies in business combinations are recorded at fair value to the extent determinable, otherwise in accordance with ASC 450. Refer to “NOTE 24 — Commitments and Contingencies” for more information. R&D Activities R&D activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and acquisition and license related milestone payments, if any. As of December 31, 2017, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including the following: Product Therapeutic Area Indication Expected Launch Year Phase Esmya Women's Health Uterine Fibroids 2018 Review Cariprazine CNS Bipolar Depression 2019 III Ubrogepant CNS Acute Migraine 2020 III Abicipar Eye Care Age Related Macular Degeneration 2020 III Bimatoprost SR Eye Care Glaucoma 2020 III Rapastinel CNS Depression 2021 III Cenicriviroc Gastrointestinal NASH 2021 III Relamorelin Gastrointestinal Gastroparesis 2023 III Pilo/Oxy Eye Care Presbyopia 2021 II RORyT Medical Aesthetics Psoriasis 2022 II Atogepant CNS Migraine Prevention 2022 II Abicipar Eye Care Diabetic Macular Edema 2023 II Brazikumab Gastrointestinal Crohn's Disease 2024 II Botox Medical Aesthetics Platysma/Masseter 2025/2023 II Brazikumab Gastrointestinal Ulcerative Colitis 2025 I We also have a number of products in development as part of our life-cycle management strategy for our existing product portfolio. Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed We account for acquired businesses using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values as determined using a market participant concept. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The most material line items impacted by the allocation of acquisition fair values are: • Intangible assets (including IPR&D assets upon successful completion of the project and approval of the product) which are amortized to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected future net cash flow streams, the timing of approvals and the probability of success for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the future useful lives. For these and other reasons, actual results may vary significantly from estimated results. • Inventory is recorded at fair market value factoring in selling price and costs to dispose. Inventory acquired is typically valued higher than replacement cost. Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax basis of assets and liabilities at the applicable tax rates. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets by assessing its valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in applicable tax jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company’s effective tax rate on future earnings. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first financial reporting period in which that threshold is no longer met. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within the consolidated statements of operations as income tax expense. The income tax effects of the TCJA have been initially accounted for on a provisional basis pursuant to the guidance in Staff Accouting Bulletin (“SAB”) 118. Reasonable estimates for all material tax effects of the TCJA (other than amounts related to accounting policy elections) have been provided and adjustments to provisional amounts will be made in subsequent reporting periods as information becomes available to complete provisional computations. The provisional impact of the TCJA for the Federal tax rate change and the resulting deferred tax liability for unremitted earnings will be completed in subsequent measurement periods when the required computations for the 2017 tax year and the related tax returns for the relevant entities have been completed. The final amount for the toll charge is dependent on amounts that cannot be determined until the 2018 financial results of certain non-US subsidiaries are completed. In addition, the IRS continues to issue interpretive guidance on the computation of the tax on deferred foreign earnings and therefore the computations cannot be finalized until all relevant IRS guidance has been promulgated and its impact assessed. The TCJA introduced an additional U.S. tax on certain non-U.S. subsidiaries’ earnings which are considered to be Global Intangible Low Taxed Income (referred to as “GILTI”). Under this provision, the amount of GILTI included by a U.S. shareholder will be taxed at a rate of 10.5% for tax years beginning after December 31, 2017 (increasing to 13.125% for tax years beginning after December 31, 2025) with a partial offset for foreign tax credits. Due to the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the TCJA and the application of ASC 740 and are con

Business Development

Business Development	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Development	NOTE 5 — Business Development During the year ended December 31, 2015, the Company acquired material assets and businesses. The unaudited pro forma results of the businesses acquired that materially impacted the reported results of the Company are as follows ($ in millions except per share information): Year Ended December 31, 2015 (unaudited) As reported Allergan Acquisition Pro Forma Net revenues $ 12,688.1 $ 1,523.0 $ 14,211.1 Net income attributable to ordinary shareholders $ 3,683.2 $ 377.7 $ 4,060.9 Net income per share Basic $ 10.01 $ 10.32 Diluted $ 10.01 $ 10.32 2017 Significant Business Developments The following are the material transactions that were completed in the year ended December 31, 2017. Acquisitions Keller Medical, Inc. On June 23, 2017, the Company acquired Keller Medical, Inc. (“Keller”), a privately held medical device company and developer of the Keller Funnel ® ® Zeltiq Aesthetics, Inc. On April 28, 2017, the Company acquired Zeltiq Aesthetics, Inc. (“Zeltiq”) for an acquisition accounting purchase price of $2,405.4 million (the “Zeltiq Acquisition”). Zeltiq was focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform (Coolsculpting ® Assets Acquired and Liabilities Assumed at Fair Value The Zeltiq Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. As of December 31, 2017, certain amounts relating to the valuation of tax related matters and intangible assets have not been finalized. The finalization of these matters may result in changes to goodwill. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Preliminary Valuation as of December 31, 2017 Cash and cash equivalents $ 36.7 Accounts receivable 47.0 Inventories 59.3 Property, plant and equipment 12.4 Intangible assets 1,185.0 Goodwill 1,200.6 Other assets 17.1 Accounts payable and accrued expenses (93.6 ) Deferred revenue (10.6 ) Deferred taxes, net (47.2 ) Other liabilities (1.3 ) Net assets acquired $ 2,405.4 IPR&D and Intangible Assets The estimated fair value of the intangible assets, including customer relationships, was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D costs, selling and marketing costs, other allocated costs, and working capital/contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream. This technique is referred to herein as the “IPR&D and Intangible Asset Valuation Technique.” The fair value of the intangible assets acquired in the Zeltiq Acquisition was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for these acquired intangible assets ranged from 10.0% to 11.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. The discount rate of the Zeltiq Acquisition was driven by the life-cycle stage of the products and the therapeutic indication. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite-lived assets Consumables $ 985.0 6.7 System 43.0 3.7 Total CMP 1,028.0 Customer Relationships 157.0 6.6 Total definite-lived assets $ 1,185.0 Goodwill Among the reasons the Company acquired Zeltiq and the factors that contributed to the preliminary recognition of goodwill was the expansion of the Company’s leading medical aesthetics portfolio. Goodwill from the Zeltiq Acquisition of $ 954.7 Inventories The fair value of inventories acquired included an acquisition accounting fair market value step-up of $22.9 million which was recognized as a component of cost of sales as the inventory acquired was sold to the Company’s customers in the year ended December 31, 2017. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. LifeCell Corporation On February 1, 2017, the Company acquired LifeCell Corporation (“LifeCell”), a regenerative medicine company, for an acquisition accounting price of $2,883.1 million (the “LifeCell Acquisition”). The LifeCell Acquisition combines LifeCell's novel, regenerative medicines business, including its high-quality and durable portfolio of dermal matrix products with Allergan's leading portfolio of medical aesthetic products, breast implants and tissue expanders. The LifeCell Acquisition expanded the Company’s medical aesthetics portfolio by adding Alloderm ® ® Assets Acquired and Liabilities Assumed at Fair Value The LifeCell Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Valuation as of December 31, 2017 Cash and cash equivalents $ 8.7 Accounts receivable 50.8 Inventories 175.4 Property, plant and equipment, net 53.7 Currently marketed products ("CMP") intangible assets 2,010.0 In-process research and development ("IPR&D") intangible assets 10.0 Goodwill 1,449.1 Accounts payable and accrued expenses (149.6 ) Deferred tax liabilities, net (746.2 ) Other 21.2 Net assets acquired $ 2,883.1 IPR&D and Intangible Assets The fair value of the acquired intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for these acquired intangible assets was 7.5% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections in the LifeCell Acquisition. The discount rate of the LifeCell Acquisition was driven by the life-cycle stage of the products, the advanced nature of IPR&D projects, and IPR&D assets acquired and the therapeutic indication. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite-lived assets Alloderm ® $ 1,385.0 6.9 Revolve ® 80.0 7.1 Strattice ® 320.0 5.1 Artia ® 115.0 8.8 Other 10.0 2.8 Total CMP 1,910.0 Customer Relationships 100.0 6.3 Total definite-lived assets 2,010.0 In-process research and development Other 10.0 Total IPR&D 10.0 Total intangible assets $ 2,020.0 Goodwill Among the reasons the Company acquired LifeCell and the factors that contributed to the recognition of goodwill was the expansion of the Company’s leading medical aesthetic portfolio. Goodwill from the LifeCell Acquisition of $ 1,449.1 Inventories The fair value of inventories acquired included an acquisition accounting fair market value step-up of $108.4 million which was recognized as a component of cost of sales as the inventory acquired was sold to the Company’s customers in the year ended December 31, 2017, excluding currency impact. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. Licenses and Other Transactions Accounted for as Asset Acquisitions Lyndra, Inc. On July 31, 2017, the Company entered into a collaboration, option and license agreement with Lyndra, Inc. (“Lyndra”) to develop orally administered ultra-long-acting (once-weekly) products for the treatment of Alzheimer’s disease and an additional, unspecified indication. The total upfront payment of $15.0 million was expensed as a component of R&D expense in the year ended December 31, 2017. The future option exercise payments, if any, and any future success based milestones relating to the licensed products of up to $85.0 million will be recorded if the corresponding events become probable. Editas Medicine, Inc. On March 14, 2017, the Company entered into a strategic alliance and option agreement with Editas Medicine, Inc. (“Editas”) for access to early stage, first-in-class eye care programs. Pursuant to the agreement, Allergan made an upfront payment of $90.0 million for the right to license up to five of Editas’ gene-editing programs in eye care, including its lead program for Leber Congenital Amaurosis (“LCA”). Under the terms of the agreement, if an option is exercised, Editas is eligible to receive contingent research and development and commercial milestones plus royalties based on net sales. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business. The total upfront payment of $90.0 million was expensed as a component of R&D expense in the year ended December 31, 2017. The future option exercise payments, if any, and any future success based milestones relating to the licensed products will be recorded if the corresponding events become probable. Assembly Biosciences, Inc. On January 9, 2017, the Company entered into a licensing agreement with Assembly Biosciences, Inc. (“Assembly”) for the worldwide rights to Assembly’s microbiome gastrointestinal development programs. Under the terms of the agreement, the Company made an upfront payment to Assembly of $50.0 million for the exclusive, worldwide rights to develop and commercialize certain development compounds. Additionally, Assembly will be eligible to receive success-based development and commercial milestone payments plus royalties based on net sales. The Company and Assembly will generally share development costs through proof-of-concept (“POC”) studies, and Allergan will assume all post-POC development costs. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as the lack of certain other inputs and processes that the transaction did not qualify as a business. The total upfront payment of $50.0 million was expensed as a component of R&D expense in the year ended December 31, 2017 and the future success based milestone payments of up to $2,771.0 million, including amounts for additional development programs not committed to as of December 31, 2017, will be recorded if the corresponding events become probable. Lysosomal Therapeutics, Inc. On January 9, 2017, the Company entered into a definitive agreement for the option to acquire Lysosomal Therapeutics, Inc. (“LTI”). LTI is focused on innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Pursuant to the agreement, Allergan acquired an option right directly from LTI shareholders to acquire LTI for $150.0 million plus future milestone payments following completion of a Phase Ib trial for LTI-291 as well as an upfront research and development payment. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business. The aggregate upfront payment of $145.0 million was recorded as a component of R&D expense in the year ended December 31, 2017. Other Transactions Saint Regis Mohawk Tribe On September 8, 2017, the Company entered into an agreement with the Saint Regis Mohawk Tribe, under which the Saint Regis Mohawk Tribe obtained the rights to Orange Book-listed patents covering Restasis ® 2016 Significant Business Developments The following are the material transactions that were completed in the year ended December 31, 2016. Refer to “NOTE 7 — Discontinued Operations” for material divestitures that were completed / entered into during the year ended December 31, 2016. Acquisitions Tobira On November 1, 2016, the Company acquired Tobira Therapeutics, Inc. (“Tobira”), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (“NASH”) and other liver diseases for an acquisition accounting purchase price of $570.1 million, plus contingent consideration of up to $49.84 per share in contingent value rights (“CVR”), or up to $1,101.3 million, that may be payable based on the successful completion of certain development, regulatory and commercial milestones (the “Tobira Acquisition”), of which $303.1 million was paid in the year ended December 31, 2017 for the initiation of Phase III clinical trials. The CVR had an acquisition date fair value of $479.0 million. The Tobira Acquisition added Cenicriviroc, a differentiated, complementary development program for the treatment of the multi-factorial elements of NASH, including inflammation, metabolic syndromes and fibrosis, to Allergan's global gastroenterology R&D pipeline. Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): December 31, 2016 Preliminary Valuation Measurement Period Adjustments December 31, 2017 Final Valuation Cash and cash equivalents $ 21.3 $ - $ 21.3 IPR&D intangible assets 1,357.0 - 1,357.0 Goodwill 112.7 (14.1 ) 98.6 Indebtedness (15.9 ) - (15.9 ) Contingent consideration (479.0 ) - (479.0 ) Deferred tax liabilities, net (395.9 ) 14.1 (381.8 ) Other assets and liabilities (30.1 ) - (30.1 ) Net assets acquired $ 570.1 $ - $ 570.1 IPR&D and Intangible Assets The fair value of the IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for IPR&D intangible assets was 11.5% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. The discount rate of the acquisition was driven by the stage of the product and the therapeutic indication. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. Goodwill Among the reasons the Company acquired Tobira and the factors that contributed to the preliminary recognition of goodwill was the expansion of the Company’s pipeline of NASH products. Goodwill from the Tobira Acquisition of $98.6 million was assigned to the US General Medicine segment and is non-deductible for tax purposes. Contingent Consideration As part of the acquisition, the Company is required to pay the former shareholders of Tobira up to $1,101.3 million, of which $303.1 million was paid in the year ended December 31, 2017, based on the timing of the certain development, regulatory and commercial milestones, if any. The Company estimated the fair value of the contingent consideration to be $479.0 million using a probability weighted average approach that considered the possible outcomes of scenarios related to the specified product. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. Vitae Pharmaceuticals, Inc. On October 25, 2016, the Company acquired Vitae Pharmaceuticals, Inc. (“Vitae”), a clinical-stage biotechnology company, for an acquisition accounting purchase price of $621.4 million (the “Vitae Acquisition”). The Vitae Acquisition expanded Allergan’s dermatology product pipeline with the addition of a Phase II orally active RORyt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders. In addition, the Company expanded its pipeline with the acquisition of a Phase II atopic dermatitis drug candidate. Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): December 31, 2016 Preliminary Valuation Measurement Period Adjustments December 31, 2017 Final Valuation Cash and cash equivalents $ 44.7 $ - $ 44.7 Marketable securities 20.2 - 20.2 Property, plant and equipment, net 5.0 - 5.0 IPR&D intangible assets 686.0 - 686.0 Assets held for sale 22.5 - 22.5 Goodwill 34.4 (3.8 ) 30.6 Other assets and liabilities (20.7 ) - (20.7 ) Deferred tax liabilities, net (170.7 ) 3.8 (166.9 ) Net assets acquired $ 621.4 $ - $ 621.4 IPR&D and Intangible Assets The fair value of the IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for IPR&D intangible assets was 9.5% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. The discount rate of the acquisition was driven by the stage of the product and the therapeutic indication. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. Goodwill Among the reasons the Company acquired Vitae and the factors that contributed to the preliminary recognition of goodwill was the expansion of the Company’s pipeline of dermatology products. Goodwill from the Vitae Acquisition of $30.6 million was assigned to the US Specialized Therapeutic segment and is non-deductible for tax purposes. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. Assets Held for Sale The Company held for sale certain intangible assets acquired as part of the Vitae Acquisition. These assets had an acquisition accounting value of $22.5 million. In the year ended December 31, 2017, the Company sold these assets for $22.5 million. ForSight VISION5, Inc. On September 23, 2016, the Company acquired ForSight VISION5, Inc. (“ForSight”), a privately held, clinical-stage biotechnology company focused on eye care, in an all cash transaction of approximately $95.0 million (the “ForSight Acquisition”). Under the terms of the ForSight Acquisition, the Company acquired ForSight for an acquisition accounting purchase price of $74.5 million plus the payment of outstanding indebtedness of $14.8 million and other miscellaneous charges. ForSight shareholders are eligible to receive contingent consideration of up to $125.0 million, which had an initial estimated fair value of $79.8 million, relating to commercialization milestones. The Company acquired ForSight for its lead development program, a peri-ocular ring designed for extended drug delivery and reducing elevated intraocular pressure (“IOP”) in glaucoma patients. Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): December 31, 2016 Preliminary Valuation Measurement Period Adjustments December 31, 2017 Final Valuation Cash and cash equivalents $ 1.0 $ - $ 1.0 IPR&D intangible assets 158.0 - 158.0 Goodwill 51.6 (1.1 ) 50.5 Current liabilities (14.8 ) - (14.8 ) Contingent consideration (79.8 ) - (79.8 ) Deferred tax liabilities, net (38.3 ) 1.1 (37.2 ) Other assets and liabilities (3.2 ) - (3.2 ) Net assets acquired $ 74.5 $ - $ 74.5 IPR&D and Intangible Assets The fair value of the IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for IPR&D intangible assets was 13.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. The discount rate of the acquisition was driven by the early stage of the product and the therapeutic indication. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. Goodwill Among the reasons the Company acquired ForSight and the factors that contributed to the recognition of goodwill was the expansion of the Company’s pipeline of eye care products. Goodwill from the ForSight Acquisition of $50.5 million was assigned to the US Specialized Therapeutics segment and is non-deductible for tax purposes. Contingent Consideration As part of the acquisition, the Company is required to pay the former shareholders of ForSight up to $125.0 million based on the timing of the first commercial sale, if any. The Company estimated the fair value of the contingent consideration to be $79.8 million using a probability weighted average approach that considered the possible outcomes of scenarios related to the specified product. In the year ended December 31, 2016, t he Company recognized approximately $33.0 million in impairments of the acquired ForSight IPR&D asset as the Company anticipates a delay in potential launch timing, if any. Offsetting this impairment was a corresponding reduction of acquired contingent consideration of $15.0 million, which reduced overall R&D expenses. Deferred Tax Liabilities Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions. Licenses and Asset Acquisitions Motus Therapeutics, Inc. On December 15, 2016, the Company acquired Motus Therapeutics, Inc. (“Motus”) for an upfront payment of approximately $200.0 million (the “Motus Transaction”). Motus has the worldwide rights to RM-131 (relamorelin), a peptide ghrelin agonist being developed for the treatment of diabetic gastroparesis. Under the terms of the Motus Transaction, Motus shareholders are eligible to receive contingent consideration in connection with the commercial launch of the product. The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the transaction did not qualify as a business. The total upfront net payment of $199.5 million was expensed as a component of R&D expense in the year ended December 31, 2016 and the future milestone will be recorded if the corresponding event becomes probable. Chase Pharmaceuticals Corporation On November 22, 2016, the Company acquired Chase Pharmaceuticals Corporation (“Chase”), a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders including Alzheimer's disease, for an upfront payment of approximately $125.0 million plus potential regulatory and commercial milestones of up to $875.0 million related to Chase's lead compound, CPC-201, and certain backup compounds (the “Chase Transaction”). The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the Chase transaction did not qualify as a business. The total upfront net payment of $122.9 million was expensed as a component of R&D expense in the year ended December 31, 2016 and the future milestones will be recorded if the corresponding events become probable. AstraZeneca plc License On October 2, 2016, the Company entered into a licensing agreement with MedImmune, AstraZeneca plc's (“AstraZeneca”) global biologics research and development arm, for the global rights to brazikumab (the “AstraZeneca Transaction”). Brazikumab is an anti-IL-23 monoclonal antibody for the treatment of patients with moderate-to-severe Crohn's disease and is Phase II ready for ulcerative colitis and other conditions treated with anti-IL23 monoclonal antibodies. Under the terms of the agreement, AstraZeneca received $250.0 million for the exclusive, worldwide license to develop and commercialize brazikumab and is eligible to receive contingent consideration of up to $1.27 billion, as well as tiered royalties on sales of the product. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as certain other inputs and processes that the transaction did not qualify as a business. The total upfront payment of $250.0 million was expensed as a component of R&D expense in the year ended December 31, 2016 and the future milestones will be recorded if the corresponding events become probable. RetroSense Therapeutics, LLC On September 6, 2016, the Company acquired certain assets of RetroSense Therapeutics LLC (“RetroSense”), a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness (the “RetroSense Transaction”). Under the terms of the RetroSense Transaction, RetroSense received approximately $60.0 million upfront, and is eligible to receive up to $495.0 million in contingent regulatory and commercialization milestone payments related to its lead development program, RST-001, a novel gene therapy for the treatment of retinitis pigmentosa. The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the RetroSense Transaction did not qualify as a business. The total upfront net payment of $59.7 million was expensed as a component of R&D expense in the year ended December 31, 2016 and the future milestones will be recorded if the corresponding events become probable. Akarna Therapeutics, Ltd On August 26, 2016, the Company acquired Akarna Therapeutics, Ltd (“Akarna”), a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases (the “Akarna Transaction”). Under the terms of the Akarna Transaction, Akarna shareholders received approximately $50.0 million upfront and were eligible to receive contingent development and commercialization milestones of up to $1,015.0 million. The Company concluded based on the stage of development of the assets as well as a lack of certain other inputs and processes that the Akarna Transaction did not qualify as a business. The total upfront net payment of $48.2 million was expensed as a component of R&D expense in the year ended December 31, 2016 Topokine Therapeutics, Inc. On April 21, 2016, the Company acquired Topokine Therapeutics, Inc. (“Topokine”), a privately held, clinical-stage biotechnology company focused on development stage topical medicines for fat reduction (the “Topokine Transaction”). Under the terms of the Topokine Transaction, Topokine shareholders received an upfront payment of $85.8 million and are eligible to receive contingent development and commercialization milestones of up to $260.0 million for XAF5, a first-in-class topical agent in development for the treatment of steatoblepharon, also known as undereye bags. The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the Topokine Transaction did not qualify as a business. The total upfront net payment of approximately $85.0 million was expensed as a component of R&D expense in the year ended December 31, 2016 Heptares Therapeutics Ltd On April 6, 2016, the Company entered into an agreement with Heptares Therapeutics Ltd. (“Heptares”), under which the Company licensed exclusive global rights to a portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer's disease (the “Heptares Transaction”). Under the terms of the Heptares Transaction, Heptares received an upfront payment of $125.0 million and is eligible to receive contingent milestone payments of up to approximately $665.0 million upon the successful Phase I, II and III clinical development and launch of the first three licensed compounds for multiple indications and up to approximately $2.575 billion associated with achieving certain annual sales thresholds during the several years following launch. In addition, Heptares was eligible to receive contingent tiered royalties on net sales of all products resulting from the partnership. The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the Heptares Transaction did not qualify as a business. The total upfront payment of $125.0 million was expensed as a component of R&D expense in the year ended December 31, 2016 Anterios, Inc. On January 6, 2016, the Company acquired Anterios, Inc. (“Anterios”), a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products (“the Anterios Transaction”). Under the terms of the Anterios Transaction, Anterios shareholders received an upfront net payment of approximately $90.0 million and are eligible to receive contingent development and commercialization milestone payments up to $387.5 million related to an investigational topical formulation of botulinum toxin type A in development for the potential treatment of hyperhidrosis, acne, and crow’s feet lines and the related NDS™, Anterios' proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections. The Company concluded based on the stage of development of the assets, the lack of acquired employees as well as certain other inputs and processes that the Anterios Transaction did not qualify as a business. The total upfront net payment of $89.2 million was expensed as a component of R&D expense in the year ended December 31, 2016 2015 Significant Business Developments The following are the material transactions that were completed in the year ended December 31, 2015. Acquisitions AqueSys, Inc. On October 16, 2015, the Company acquired AqueSys, Inc. (“AqueSys”), a private

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborations	NOTE 6 — Collaborations The Company has ongoing transactions with other entities through collaboration agreements. The following represent the material collaboration agreements impacting the years ended December 31, 2017, 2016 and 2015. Acquired agreements from the Allergan Acquisition Apollo EndoSurgery, Inc. On December 2, 2013, Legacy Allergan completed the sale of the obesity intervention business to Apollo Endosurgery, Inc. (“Apollo”) for cash consideration of $75.0 million, subject to certain adjustments, and certain additional consideration, including a minority equity interest in Apollo with an estimated fair value of $15.0 million as of the date of the Allergan Acquisition. In the year ended December 31, 2017, the Company recorded an other-than-temporary impairment in the investment in Apollo of $15.0 million. LiRIS On August 13, 2014, Legacy Allergan completed the acquisition of LiRIS Biomedical, Inc. (“LiRIS”), a clinical-stage specialty pharmaceutical company based in the United States focused on developing a pipeline of innovative treatments for bladder diseases, for an upfront payment of $67.5 million, plus up to an aggregate of $295.0 million in payments contingent upon achieving certain future development milestones and up to an aggregate of $225.0 million in payments contingent upon achieving certain commercial milestones. The Company accounted for the contingent consideration in the Allergan Acquisition with an initial acquisition date fair value of $169.6 million. In the year ended December 31, 2016, the Company recognized approximately $210.0 million of impairments due to clinical data not supporting continuation of the R&D study offset, in part, by a reduction of contingent liability of $186.0 million recorded in R&D. In the year ended December 31, 2017, the Company terminated its collaboration with LiRIS. Acquired agreements from the Forest Acquisition Trevena On May 9, 2013, in connection with entering into an agreement with Trevena, Inc. to acquire the option to license one of Trevena, Inc.’s products (which option has since lapsed), the Company purchased $30.0 million of Trevena preferred stock in a round of private placement financing. Trevena filed an initial public offering (“IPO”), at which time the Company’s preferred stock was converted to common stock traded on the NASDAQ stock market. In conjunction with the IPO, the Company purchased an additional $3.0 million of common stock of Trevena. In the year ended December 31, 2017, the Company recorded an other-than-temporary impairment of the Trevena investment of $11.2 million. At December 31, 2017 and 2016, the fair value of the Trevena common stock held by the Company was $5.4 million and $20.0 million, respectively and is included as a component of “investments and other assets”. Ironwood collaboration agreement In September 2007, Forest entered into a collaboration agreement with Ironwood Pharmaceuticals (“Ironwood”) to jointly develop and commercialize Linzess ® The agreement included contingent milestone payments as well as a contingent equity investment based on the achievement of specific clinical and commercial milestones. The Company may be obligated to pay up to an additional $100.0 million if certain sales milestones are achieved. Based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable guidance, the Company records receipts from and payments to Ironwood in two pools: the “Development pool” which consists of R&D expenses, and the “Commercialization pool,” which consists of revenue, cost of sales and other operating expenses. The net payment to or receipt from Ironwood for the Development pool is recorded in R&D expense and the net payment to or receipt from Ironwood for the Commercialization pool is recorded in cost of goods sold. Amgen Collaboration In December 2011, we entered into a collaboration agreement with Amgen Inc. (“Amgen”) to develop and commercialize, on a worldwide basis, biosimilar versions of Herceptin ® ® ® ®

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2017
Global Generics [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued Operations	NOTE 7 — Discontinued Operations Global Generics Business On July 27, 2015, the Company announced that it entered into the Teva Transaction, which closed on August 2, 2016. On October 3, 2016, the Company completed the divestiture of the Anda Distribution business to Teva for $500.0 million. The Company recognized a combined gain on the sale of the Anda Distribution business and the sale of the global generics business of $15,932.2 million. The Company notes the following reconciliation of the proceeds received in the combined transaction to the gain recognized in income from discontinued operations in 2016 ($ in millions): Net cash proceeds received $ 33,804.2 August 2, 2016 fair value of Teva shares 5,038.6 Total Proceeds $ 38,842.8 Net assets sold to Teva, excluding cash (12,487.7 ) Other comprehensive income disposed (1,544.8 ) Deferral of proceeds relating to additional elements of agreements with Teva (299.2 ) Pre-tax gain on sale of generics business and Anda Distribution business $ 24,511.1 Income taxes (8,578.9 ) Net gain on sale of generics business and Anda Distribution business $ 15,932.2 In October 2016, pursuant to our agreement with Teva, Teva provided the Company with its proposed estimated adjustment to the closing date working capital balance. The Company disagreed with Teva’s proposed adjustment, and, pursuant to our agreement with Teva, each of the Company’s and Teva’s proposed adjustments were submitted to arbitration to determine the working capital amount in accordance with GAAP as applied by the Company consistent with past practice. Teva initially proposed an adjustment of approximately $1.4 billion and subsequently submitted a revised adjustment of approximately $1.5 billion to the arbitrator. In addition, on October 30, 2017, Teva submitted a Notice of Direct and Third Party Claims seeking indemnification for virtually all of the same items for which Teva sought a proposed adjustment in the Working Capital Arbitration as well as several new items as to which no quantity of damages had been asserted. On January 31, 2018, Allergan plc and Teva entered into the Agreement. The Agreement provides that the Company will make a one-time payment of $700.0 million to Teva; the Company and Teva will jointly dismiss their working capital dispute arbitration, and the Company and Teva will release all actual or potential claims under the Master Purchase Agreement, dated July 26, 2015, by and between the Company and Teva, that are known as of the date of the Agreement. The Company recorded a pre-tax charge of $466.0 million as a component of other (expense) / income, net from discontinued operations relating to the settlement in the year ended December 31, 2017. The fair value of Teva Shares owned are recorded within “Marketable securities” on the Company’s Consolidated Balance Sheet. The closing August 2, 2016 Teva stock price discounted at a rate of 5.9 percent due to the lack of marketability was used to initially value the shares. During the year ended December 31, 2017, the Company recorded the following movements in its investment in Teva securities (defined herein as "Teva Share Activity") as follows ($ in millions except per share information): in million except per share amounts Shares Cost Basis Market Price Discount Movement in the Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income Gain / (Loss) Recognized in Other Income (Expense), Net Teva securities as of December 31, 2016 100.3 $ 53.39 $ 36.25 5.4 % $ 3,439.2 $ (1,599.4 ) $ - Other-than-temporary impairment recognized at March 31, 2017 100.3 $ 32.09 $ 32.09 4.9 % $ (378.6 ) $ 1,599.4 $ (1,978.0 ) Other-than-temporary impairment recognized at September 30, 2017 100.3 $ 17.60 $ 17.60 0.0 % $ (1,295.5 ) $ - $ (1,295.5 ) Sales during the twelve months ended December 31, 2017 (4.4 ) n.a. n.a. 0.0 % $ (76.7 ) $ - $ 4.2 Other fair value movements in the twelve months ended December 31, 2017 95.9 $ 17.60 $ 18.95 0.0 % $ 129.3 $ 129.3 $ - Teva securities as of and for the twelve months ended December 31, 2017 95.9 $ 17.60 $ 18.95 0.0 % $ 1,817.7 $ 129.3 $ (3,269.3 ) Financial results of the global generics business and the Anda Distribution business are presented as “(Loss) / income from discontinued operations, net of tax” on the Consolidated Statements of Operations for the years ended December 31, 2017, 2016 and 2015. The following table presents key financial results of the global generics business and the Anda Distribution business included in “(Loss) / income from discontinued operations, net of tax” for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Years Ended December 31, 2017 2016 2015 Net revenues $ - $ 4,504.3 $ 8,499.0 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - 2,798.3 4,847.5 Research and development - 269.4 422.2 Selling and marketing - 352.9 706.6 General and administrative 18.8 425.8 702.2 Amortization - 4.8 333.3 Asset sales and impairments, net 1.2 - 62.4 Total operating expenses 20.0 3,851.2 7,074.2 Operating (loss) / income (20.0 ) 653.1 1,424.8 Other (expense) / income, net (470.4 ) 15,932.2 (7.1 ) (Benefit) / provision for income taxes (87.5 ) 670.8 (5,443.3 ) (Loss) / income from discontinued operations, net of tax $ (402.9 ) $ 15,914.5 $ 6,861.0 The operating income reflects approximately seven months of operating activity of the Company’s former generics business in the year ended December 31, 2016 versus twelve months activity in the year ended December 31, 2015 and approximately nine months of operating activity of the Anda Distribution business in the year ended December 31, 2016 versus twelve months activity in the year ended December 31, 2015. “Other (expense) / income, net” included the gain on sale of the businesses to Teva. For the year ended December 31, 2015, the Company recorded a deferred tax benefit of $5,738.8 million related to investments in certain subsidiaries. The recognition of this benefit has been reflected in “Income from discontinued operations, net of tax” with the deferred tax asset reflected in non-current “Deferred tax liabilities” on the December 31, 2015 balance sheet as adjusted for activity in the fourth quarter of 2015. For the year ended December 31, 2016, the Company recorded a deferred tax expense of $462.2 million to adjust its deferred tax asset related to investments in certain subsidiaries. The recognition of this expense has been reflected in “Income from discontinued operations, net of tax”. Upon the closing of the Teva Transaction, the Company recorded the reversal of the corresponding deferred tax asset of $5,276.6 million against the current income taxes payable in continuing operations. Depreciation and amortization was ceased upon the determination that the held for sale criteria were met, which were the announcement dates of the Teva Transaction and the divestiture of the Anda Distribution business. The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows ($ in millions): Years Ended December 31, 2017 2016 2015 Depreciation from discontinued operations $ - $ 2.1 $ 93.7 Amortization from discontinued operations - 4.8 333.3 Capital expenditures - 85.3 234.5 Deferred income tax expense - 6,038.5 (5,568.8 )

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	NOTE 8 — Share-Based Compensation The Company recognizes compensation expense for all share-based compensation awards made to employees and directors based on the fair value of the awards on the date of grant. A summary of the Company’s share-based compensation plans is presented below. Equity Award Plans The Company has adopted several equity award plans which authorize the granting of options, restricted shares, restricted stock units and other forms of equity awards of the Company’s ordinary shares, subject to certain conditions. The Company grants awards with the following features: • Time-based vesting restricted stock and restricted stock units awards; • Performance-based restricted stock unit awards measured to performance-based targets defined by the Company, including, but not limited to, total shareholder return metrics, R&D milestones and EBITDA, as defined by the Company; • Non-qualified options to purchase outstanding shares; and • Cash-settled awards recorded as a liability. These cash settled awards are based on pre-established total shareholder returns metrics. Option award plans require options to be granted at the fair market value of the shares underlying the options at the date of the grant and generally become exercisable over periods ranging from three to five years. Each option granted expires ten years from the date of the grant. Restricted stock awards are grants that entitle the holder to ordinary shares, subject to certain terms. Restricted stock unit awards are grants that entitle the holder the right to receive an ordinary share, subject to certain terms. Restricted stock and restricted stock unit awards (both time-based vesting and performance-based vesting) generally have restrictions that lapse over a one to four year vesting period. Restrictions generally lapse for non-employee directors after one year. Certain restricted stock units are performance-based awards issued at a target number with the actual number of ordinary shares issued ranging based on achievement of the performance criteria. All restricted stock and restricted stock units which remain active under the Company’s equity award plans are eligible to receive cash dividend equivalent payments upon vesting. Fair Value Assumptions All restricted stock and restricted stock units (whether time-based vesting or performance-based vesting), are granted and expensed, using the fair value per share on the applicable grant date, over the applicable vesting period. Non-qualified options to purchase ordinary shares are granted to employees at exercise prices per share equal to the closing market price per share on the date of grant. The fair value of non-qualified options is determined on the applicable grant dates using the Black-Scholes method of valuation and that amount is recognized as an expense over the vesting period. Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2017 Grants 2016 Grants 2015 Grants 2015 Acquired Awards Dividend yield 1.2 % 0 % 0 % 0 % Expected volatility 27.0 % 27.0 % 26.0 - 29.0% 26.0 - 27.0% Risk-free interest rate 2.0-2.3% 1.3 - 2.4% 1.9 - 2.1% 0.1 - 2.1% Expected term (years) 7.0 7.0 - 7.5 7.0 - 7.5 up to 6.9 Share-Based Compensation Expense Share-based compensation expense recognized in the Company’s results of operations, including discontinued operations, for the years ended December 31, 2017, 2016 and 2015 was as follows ($ in millions): Year Ended December 31, 2017 2016 2015 Equity-based compensation awards $ 293.3 $ 334.5 $ 690.4 Cash-settled awards in connection with the Zeltiq Acquisition 31.5 - - Cash-settled awards in connection with the Tobira Acquisition - 27.0 - Cash-settled awards in connection with the Vitae Acquisition - 18.6 - Cash-settled awards in connection with the ForSight Acquisition - 3.1 - Cash-settled awards in connection with the Allergan Acquisition - - 127.1 Cash-settled awards in connection with the Kythera Acquisition - - 9.6 Non equity-settled awards other (16.8 ) - 98.6 Total stock-based compensation expense $ 308.0 $ 383.2 $ 925.7 In the years ended December 31, 2016, and 2015, share-based compensation expense included as discontinued operations was $12.9 million and $36.4 million, respectively. In the years ended December 31, 2017, 2016, and 2015, the related tax benefits were $105.0 million, $131.8 million and $285.9 million, respectively, relating to share-based compensation. The “non-equity settled awards other” are cash-settled awards which are fair valued based on a pre-determined total shareholder return metric. The income in “non-equity settled awards other” was due to an actuarial reversal based on the total shareholder return metrics declining in the year ended December 31, 2017 of $16.8 million. Included in the stock-based compensation awards for the years ended December 31, 2017, 2016 and 2015 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Zeltiq, Allergan, Forest and Kythera Acquisitions ($ in millions) Year Ended December 31, 2017 2016 2015 Zeltiq Acquisition $ 47.8 $ - $ - Allergan Acquisition 47.1 108.9 314.8 Forest Acquisition 10.1 45.2 109.7 Kythera Acquisition - - 64.4 Total $ 105.0 $ 154.1 $ 488.9 Unrecognized future share-based compensation expense was $404.7 million as of December 31, 2017, including $25.2 million from the Zeltiq Acquisition and $28.7 million from the Allergan acquisition. This amount will be recognized as an expense over a remaining weighted average period of 1.5 years. Share-based compensation is being amortized and charged to operations over the same period as the restrictions are eliminated for the participants, which is generally on a straight-line basis. Share Activity The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2016 through December 31, 2017: (in millions, except per share data) Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2016 1.5 $ 251.88 1.6 $ 388.0 Granted 1.2 232.18 278.6 Assumed as part of the Zeltiq Acquisition* 0.2 213.15 41.8 Vested (0.5 ) (238.39 ) (127.0 ) Forfeited (0.4 ) (265.26 ) (97.3 ) Restricted shares / units outstanding at December 31, 2017 2.0 $ 237.72 1.8 $ 484.1 The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2016 through December 31, 2017: (in millions, except per share data) Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2016 9.0 $ 113.77 5.9 $ 861.7 Granted 0.3 239.33 Exercised (1.8 ) (92.71 ) Cancelled (0.2 ) (137.80 ) Outstanding, vested and expected to vest at December 31, 2017 7.3 $ 120.94 5.2 $ 312.7

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefit Plans	NOTE 9 — Pension and Other Postretirement Benefit Plans Defined Benefit Plan Obligations The Company has numerous defined benefit plans offered to employees around the world. For these plans, retirement benefits are generally based on an employee’s years of service and compensation. Funding requirements are determined on an individual country and plan basis and are subject to local country practices and market circumstances. As of December 31, 2017, a majority of the Company’s plans were frozen for future enrollment. The net periodic benefit (income) cost of the defined benefit plans for continuing operations for the years ended December 31, 2017, 2016 and 2015 was as follows ($ in millions): Year Ended December 31, 2017 2016 2015 Service cost $ 5.5 $ 5.0 $ 5.0 Interest cost 40.7 44.5 35.0 Expected Return on plan assets (54.5 ) (53.0 ) (46.4 ) Settlement (0.1 ) (1.8 ) (4.3 ) Net periodic benefit (income) cost $ (8.4 ) $ (5.3 ) $ (10.7 ) Obligations and Funded Status Benefit obligation and asset data for the defined benefit plans for continuing operations, were as follows ($ in millions): Year Ended December 31, 2017 2016 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,093.9 $ 1,051.1 Employer contribution 15.2 37.4 Return on plan assets 117.2 116.8 Benefits paid (36.0 ) (32.5 ) Settlements (5.3 ) (47.7 ) Effects of exchange rate changes and other 50.2 (31.2 ) Fair value of plan assets at end of year $ 1,235.2 $ 1,093.9 Year Ended December 31, 2017 2016 Change in Benefit Obligation Benefit obligation at beginning of the year $ 1,234.1 $ 1,188.5 Service cost 5.5 5.0 Interest cost 40.7 44.5 Actuarial loss / (gain) 36.9 108.0 Curtailments (8.1 ) - Settlements and other (5.3 ) (46.9 ) Benefits paid (36.0 ) (32.5 ) Effects of exchange rate changes and other 62.2 (32.5 ) Benefit obligation at end of year $ 1,330.0 $ 1,234.1 Funded status at end of year $ (94.8 ) $ (140.2 ) The following table outlines the funded actuarial amounts recognized ($ in millions): As of December 31, 2017 2016 Noncurrent assets $ 21.9 $ 9.4 Current liabilities (0.8 ) (0.7 ) Noncurrent liabilities (115.9 ) (148.9 ) $ (94.8 ) $ (140.2 ) The underfunding of pension benefits is primarily a function of the different funding incentives that exist outside of the United States. In certain countries, there are no legal requirements or financial incentives provided to companies to pre-fund pension obligations. In these instances, benefit payments are typically paid directly by the Company as they become due. Plan Assets Companies are required to use a fair value hierarchy as defined in ASC Topic 820 “Fair Value Measurement,” (“ASC 820”) which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value (“Fair Value Leveling”). There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The fair values of the Company’s pension plan assets at December 31, 2017 by asset category are as follows ($ in millions): Quoted Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 33.5 $ - $ - $ 33.5 International equities 265.5 - - 265.5 Other equity securities 70.5 - - 70.5 Equity securities $ 369.5 $ - $ - $ 369.5 U.S. Treasury bonds $ - $ 96.9 $ - $ 96.9 Bonds and bond funds - 745.7 - 745.7 Other debt securities - 21.2 - 21.2 Debt securities $ - $ 863.8 $ - $ 863.8 Other investments Other - 1.9 - 1.9 Total assets $ 369.5 $ 865.7 $ - $ 1,235.2 The fair values of the Company’s pension plan assets at December 31, 2016 by asset category are as follows ($ in millions): Quoted Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 41.5 $ - $ - $ 41.5 International equities 244.4 - - 244.4 Other equity securities 87.4 - - 87.4 Equity securities $ 373.3 $ - $ - $ 373.3 U.S. Treasury bonds $ - $ 23.6 $ - $ 23.6 Bonds and bond funds - 684.8 - 684.8 Other debt securities - 8.3 - 8.3 Debt securities $ - $ 716.7 $ - $ 716.7 Other investments Other - 3.9 - 3.9 Total assets $ 373.3 $ 720.6 $ - $ 1,093.9 The assets of the pension plan are held in separately administered trusts. The investment guidelines for the Company’s pension plans is to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of the plan, given an acceptable level of risk. The target investment portfolio of the Company’s continuing operations pension plans is allocated as follows: Target Allocation as of December 31, 2017 2016 Bonds 68.8 % 68.3 % Equity securities 31.2 % 31.5 % Other investments 0.0 % 0.2 % Expected Contributions Employer contributions to the pension plan during the year ending December 31, 2018 are expected to be $11.7 million for continuing operations. Expected Benefit Payments Total expected benefit payments for the Company’s pension plans are as follows ($ in millions): Expected Benefit Payments 2018 $ 34.6 2019 36.7 2020 38.9 2021 41.3 2022 43.4 Thereafter 1,135.1 Total liability $ 1,330.0 Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service. The majority of the payments will be paid from plan assets and not Company assets. Information for defined benefit plans with an accumulated benefit obligation in excess of plan assets is presented below ($ in millions): Defined Benefit as of December 31, 2017 2016 Projected benefit obligations $ 1,330.0 $ 1,234.1 Accumulated benefit obligations $ 1,324.7 $ 1,220.1 Plan assets $ 1,235.2 $ 1,093.9 Amounts Recognized in Other Comprehensive Income / (Loss) Net (loss) / gain amounts reflect experience differentials primarily relating to differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net pension cost over the average remaining service life of employees. Balances recognized within accumulated other comprehensive income/(loss) excluding the impact of taxes that have not been recognized as components of net periodic benefit costs are as follows ($ in millions): Defined Benefit Balance as of December 31, 2015 $ 70.4 Net actuarial loss (46.0 ) Balance as of December 31, 2016 $ 24.4 Net actuarial loss 33.8 Balance as of December 31, 2017 $ 58.2 Actuarial Assumptions The weighted average assumptions used to calculate the projected benefit obligations of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2017 2016 Discount rate 2.9 % 3.3 % Salary growth rate 3.0 % 3.0 % The weighted average assumptions used to calculate the net periodic benefit cost of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2017 2016 Discount rate 3.3 % 3.8 % Expected rate of return on plan assets 5.0 % 5.1 % Salary growth rate 3.0 % 3.0 % In order to select a discount rate for purposes of valuing the plan obligations the Company uses market returns and adjusts them as needed to fit the estimated duration of the plan liabilities. The expected rate of return represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, long-term historical returns data are considered as well as actual returns on the plan assets and other capital markets experience. Using this reference information, the long-term return expectations for each asset category and a weighted average expected return was developed, according to the allocation among those investment categories. Other Post-Employment Benefit Plans The Company has post-employment benefit plans. Accumulated benefit obligationfor the defined benefit plans, were as follows ($ in millions): Accumulated Benefit Obligation Accumulated benefit obligation as of December 31, 2015 $ 50.1 Service cost 0.3 Interest cost 2.1 Actuarial charge 3.6 Benefits paid (3.4 ) Accumulated benefit obligation as of December 31, 2016 $ 52.7 Service cost - Interest cost 2.0 Actuarial charge (5.0 ) Benefits paid (2.9 ) Accumulated benefit obligation as of December 31, 2017 $ 46.8 Savings Plans The Company also maintains certain defined contribution savings plans covering substantially all U.S.-based employees. The Company contributes to the plans based upon the employee contributions. The Company’s expense for contributions to these retirement plans for amounts included in continuing operations was $89.1 million, $75.6 million and $26.6 million in the years ended December 31, 2017, 2016 and 2015, respectively. The Company’s contributions to these retirement plans for amounts included in income from discontinued operations were $23.6 million in the year ended 2015.

Other Income (Expense), Net

Other Income (Expense), Net	12 Months Ended
	Dec. 31, 2017
Other Income And Expenses [Abstract]
Other Income (Expense), Net	NOTE 10 — Other Income / (Expense), Net Other income / (expense), net consisted of the following ($ in millions): Years Ended December 31, 2017 2016 2015 Teva Share Activity (3,269.3 ) - - Debt extinguishment costs as part of the debt tender offer (161.6 ) - - Debt extinguishment other (27.6 ) - - Other-than-temporary impairments (26.1 ) - - Dividend income 85.2 68.2 - Naurex recovery 20.0 - - Forward sale of Teva shares (62.9 ) - - Pfizer termination fee (Allergan plc only) - 150.0 - Bridge loan commitment fee - - (264.9 ) Interest rate locks - - 31.0 Other (expense) / income, net 5.0 1.0 0.1 Other (expense) / income , net $ (3,437.3 ) $ 219.2 $ (233.8 ) Teva Share Activity As described in “Note 7 — Discontinued Operations”, the Company recognized an other-than-temporary impairment on its investment in Teva securities of $3,273.5 million in the year ended December 31, 2017 as well as other share activity. Debt Extinguishment Costs as Part of the Debt Tender Offer In the year ended December 31, 2017, the Company repaid $2,843.3 million of senior notes. As a result of the extinguishment, the Company recognized a loss of $161.6 million, within “Other (expense) / income” for the early tender payment and non-cash write-off of premiums and debt fees related to the repurchased notes, including $170.5 million of a make-whole premium. Debt Extinguishment Other In the year ended December 31, 2017, the Company repaid $750 million of senior notes due in the year ending December 31, 2019. As a result of the extinguishment, the Company recognized a loss of $27.6 million, within “Other (expense) / income” for the early payment and non-cash write-off of premiums and debt fees related to the repaid notes, including $35.1 million of a make-whole premium. Other-than-temporary Impairments The Company recorded other-than-temporary impairment charges on other equity investments and cost method investments of $26.1 million in the year ended December 31, 2017, respectively. Dividend Income As a result of the Teva Transaction, the Company acquired 100.3 million Teva ordinary shares. During the years ended December 31, 2017 and 2016, the Company received dividend income of $85.2 million and $68.2 million, respectively. Naurex Recovery On August 28, 2015, the Company acquired certain products in early stage development of Naurex, Inc. (“Naurex”) in an all-cash transaction, which was accounted for as an asset acquisition (the “Naurex Transaction”). The Company received a purchase price reduction of $20.0 million in the year ended December 31, 2017 based on the settlement of an open contract dispute. Forward Sale of Teva Shares In the year ended December 31, 2017, the Company recorded a $62.9 million loss on the fair value of the derivative for the forward sale of 25.0 million of Teva securities. The ASR was settled on January 12, 2018 for $413.3 million. On February 13, 2018, the Company entered into additional forward sale transactions under which we sold approximately 25.0 million Teva shares. The value of the shares will be based on the volume weighted average price of Teva shares plus a premium and is expected to settle during the second quarter of 2018. As a result of the transaction, the Company received 80% of the proceeds, or approximately $372.0 million, with the remainder of the proceeds being delivered upon settlement. Pfizer Termination Fee On November 23, 2015, the Company announced that it entered into a definitive merger agreement (the “Pfizer Agreement”) under which Pfizer Inc. (“Pfizer”), a global innovative biopharmaceutical company, and Allergan plc would merge in a stock and cash transaction. On April 6, 2016, the Company announced that its merger agreement with Pfizer was terminated by mutual agreement. In connection with the termination of the merger agreement, Pfizer paid Allergan plc $150.0 million for expenses associated with the transaction which was included as a component of other income during the year ended December 31, 2016. Bridge Loan Commitment Fee During the year ended December 31, 2015, we incurred costs associated with bridge loan commitments with the Allergan Acquisition of $264.9 million. Interest Rate Locks During the year ended December 31, 2015, the Company entered into interest rate locks on a portion of the $21.0 billion of debt issued as part of the Allergan Acquisition. As a result of the interest rate locks, the Company recorded income of $31.0 million.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories	NOTE 11 — Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work-in-process. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors, which may differ from actual results. Inventories consisted of the following ($ in millions): December 31, December 31, 2017 2016 Raw materials $ 326.9 $ 297.1 Work-in-process 158.1 145.4 Finished goods 527.8 357.7 1,012.8 800.2 Less: inventory reserves 108.3 82.2 Total Inventories $ 904.5 $ 718.0

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 12 — Accounts payable and accrued expenses Accounts payable and accrued expenses consisted of the following ($ in millions): December 31, 2017 December 31, 2016 Accrued expenses: Accrued third-party rebates $ 1,804.1 $ 1,595.5 Contractual commitments (including amount due to Teva) 705.4 264.9 Accrued payroll and related benefits 635.6 581.1 Accrued returns 375.8 295.9 Interest payable 245.9 294.2 Royalties payable 189.2 146.6 Accrued pharmaceutical fees 186.4 221.3 Accrued R&D expenditures 165.9 154.0 Accrued severance, retention and other shutdown costs 132.8 86.2 Litigation-related reserves and legal fees 78.3 101.1 Accrued non-provision taxes 76.5 55.0 Current portion of contingent consideration obligations 56.2 511.0 Accrued selling and marketing expenditures 53.0 95.9 Dividends payable 24.6 23.2 Other accrued expenses 487.2 368.2 Total accrued expenses $ 5,216.9 $ 4,794.1 Accounts payable 324.5 224.9 Total accounts payable and accrued expenses $ 5,541.4 $ 5,019.0

Property, plant and equipment,

Property, plant and equipment, net	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property, plant and equipment, net	NOTE 13 — Property, plant and equipment, net Property, plant and equipment, net consisted of the following as of December 31, 2017 and 2016 ($ in millions): Machinery and Equipment Research and Laboratory Equipment Transportation / Other Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2016 $ 437.1 $ 48.8 $ 381.4 $ 705.3 $ 446.1 $ 2,018.7 Additions 20.7 8.3 34.1 14.6 280.6 358.3 Additions due to acquisitions 14.3 0.7 18.6 31.2 1.3 66.1 Disposals/transfers/other 64.8 (1.2 ) 38.1 104.1 (224.3 ) (18.5 ) Assets held for sale - - - (49.7 ) - (49.7 ) Currency translation 8.4 2.4 3.1 9.4 3.3 26.6 At December 31, 2017 $ 545.3 $ 59.0 $ 475.3 $ 814.9 $ 507.0 $ 2,401.5 Accumulated depreciation At December 31, 2016 $ 148.4 $ 24.0 $ 164.5 $ 70.5 $ - $ 407.4 Additions 61.5 7.8 65.0 37.2 - 171.5 Disposals/transfers/impairments/other 7.2 5.3 - 18.0 - 30.5 Assets held for sale - - - (0.7 ) - (0.7 ) Currency translation 2.2 1.4 2.9 0.9 - 7.4 At December 31, 2017 $ 219.3 $ 38.5 $ 232.4 $ 125.9 $ - $ 616.1 Property, plant and equipment, net At December 31, 2017 $ 326.0 $ 20.5 $ 242.9 $ 689.0 $ 507.0 $ 1,785.4 Depreciation expense for continuing operations was $171.5 million, $153.7 million and $124.6 million in the years ended December 31, 2017, 2016 and 2015, respectively.

Prepaid Expenses, Investments a

Prepaid Expenses, Investments and Other Assets	12 Months Ended
	Dec. 31, 2017
Investments All Other Investments [Abstract]
Prepaid Expenses, Investments and Other Assets	NOTE 14 — Prepaid Expenses, Investments and Other Assets Prepaid expenses and other current assets consisted of the following ($ in millions): December 31, 2017 December 31, 2016 Prepaid taxes $ 690.9 $ 957.4 Prepaid insurance 20.9 25.7 Royalty receivables 80.1 94.3 Sales and marketing 31.9 42.5 Other 300.1 263.5 Total prepaid expenses and other current assets $ 1,123.9 $ 1,383.4 Investments in marketable securities, including those classified in cash and cash equivalents due to the maturity term of the instrument, other investments and other assets consisted of the following ($ in millions): December 31, 2017 December 31, 2016 Marketable securities: Short-term investments $ 2,814.4 $ 8,062.3 Teva shares 1,817.7 3,439.2 Total marketable securities $ 4,632.1 $ 11,501.5 Investments and other assets: Legacy Allergan Deferred executive compensation investments $ 112.4 $ 111.7 Equity method investments 11.5 12.8 Cost method investments - 15.0 Other long-term investments 60.8 67.2 Taxes receivable 32.1 36.0 Other assets 51.1 39.4 Total investments and other assets $ 267.9 $ 282.1 As of December 31, 2017, the Company owned 95.9 million Teva ordinary shares, which are subject to changes in value based on the price of Teva shares. Subsequent to December 31, 2017, the Company has sold an additional 6.3 million Teva ordinary shares for $127.9 million. As of February 13, 2018, the Company owned approximately 40.0 million Teva ordinary shares. The Company’s marketable securities and other long-term investments are classified as available-for-sale and are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non current, as appropriate, in the Company’s consolidated balance sheets. Investments in securities as of December 31, 2017 and 2016 included the following ($ in millions): Investments in Securities as of December 31, 2017: Level 1 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 1,328.1 $ - $ - $ 1,328.1 $ 1,328.1 $ - Investment in Teva ordinary shares 1,688.0 129.3 - 1,817.7 - 1,817.7 Total $ 3,016.1 $ 129.3 $ - $ 3,145.8 $ 1,328.1 $ 1,817.7 Level 2 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Commercial paper and other $ 1,248.9 $ - $ (0.7 ) $ 1,248.2 $ - $ 1,248.2 Certificates of deposit 1,566.2 - - 1,566.2 - 1,566.2 Total $ 2,815.1 $ - $ (0.7 ) $ 2,814.4 $ - $ 2,814.4 Investments in Securities as of December 31, 2016: Level 1 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 1,238.9 $ - $ - $ 1,238.9 $ 1,238.9 $ - Total $ 1,238.9 $ - $ - $ 1,238.9 $ 1,238.9 $ - Level 2 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Commercial paper and other $ 3,909.7 $ 0.2 $ - $ 3,909.9 $ - $ 3,909.9 Investment in Teva ordinary shares 5,038.6 - (1,599.4 ) 3,439.2 - 3,439.2 Certificates of deposit 4,152.4 - - 4,152.4 - 4,152.4 Total $ 13,100.7 $ 0.2 $ (1,599.4 ) $ 11,501.5 $ - $ 11,501.5 Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values are determined based on Fair Value Leveling. During the year ended December 31, 2017, the Company transferred the Investment in Teva ordinary shares from Level 2 to Level 1 as the lock-up period on these shares expired. Marketable securities and investments consist of available-for-sale investments in money market securities, U.S. treasury and agency securities, and equity and debt securities of publicly traded companies for which market prices are readily available. Unrealized gains or losses on marketable securities and investments are recorded in accumulated other comprehensive (loss) / income as of December 31, 2017. Realized gains or losses on marketable securities and investments are recorded in interest income. The Company’s marketable securities and other long-term investments are classified as available-for-sale and are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non-current, as appropriate, in the Company’s consolidated balance sheets. The Company may sell certain of its marketable securities prior to their stated maturities for strategic reasons including, but not limited to, anticipation of credit deterioration and maturity management. Excluding the Company’s investment in Teva securities, the Company generally considers the declines in market value of its marketable securities investment portfolio to be temporary in nature. The Company typically invests in highly-rated securities, and its investment policy generally limits the amount of credit exposure to any one issuer. The Company’s policy requires investments to be investment grade with the primary objective of minimizing the potential risk of principal loss. Fair values were determined for each individual security in the investment portfolio. The movements in long-term investments were as follows ($ in millions): Equity Method Investments Cost Method and Other Long-term Investments Balance at December 31, 2016 $ 12.8 $ 82.2 Additions - - Other-than-temporary impairments - (26.1 ) Other (1.3 ) 4.7 Balance at December 31, 2017 $ 11.5 $ 60.8 Other Assets Other assets include security and equipment deposits and long-term receivables.

Goodwill, Product Rights and Ot

Goodwill, Product Rights and Other Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Product Rights and Other Intangible Assets	NOTE 15 — Goodwill, Product Rights and Other Intangible Assets Goodwill Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Specialized Therapeutics US General Medicine International Total Balance as of December 31, 2016 $ 18,433.2 $ 21,426.6 $ 6,496.3 $ 46,356.1 Additions through acquisitions 2,456.0 - 245.9 2,701.9 Measurement period adjustments (29.6 ) (14.1 ) - (43.7 ) Held for sale - (12.8 ) - (12.8 ) Foreign exchange and other adjustments - - 861.4 861.4 Balance as of December 31, 2017 $ 20,859.6 $ 21,399.7 $ 7,603.6 $ 49,862.9 As of December 31, 2017 and 2016, the gross balance of goodwill, pre-impairments, was $49,880.2 million and $46,373.4 million, respectively. The following items had a significant impact on goodwill in the year ended December 31, 2017: • An increase in goodwill of $1,449.1 million, including measurement period adjustments, resulting from the LifeCell Acquisition; and • An increase in goodwill of $1,200.6 million, including measurement period adjustments, resulting from the Zeltiq Acquisition. Product Rights and Other Intangible Assets Product rights and other intangible assets consisted of the following for the years ended December 31, 2017 and 2016 ($ in millions): Cost Basis Balance as of December 31, 2016 Acquisitions Impairments IPR&D to CMP Transfers Disposals/ Held Sale/ Other Foreign Currency Translation Balance as of December 31, 2017 Intangibles with definite lives: Product rights and other intangibles $ 67,801.4 $ 3,876.9 $ - $ 1,444.0 $ (34.0 ) $ 804.2 $ 73,892.5 Trade name 690.0 - - - - - 690.0 Total definite-lived intangible assets $ 68,491.4 $ 3,876.9 $ - $ 1,444.0 $ (34.0 ) $ 804.2 $ 74,582.5 Intangibles with indefinite lives: IPR&D $ 8,758.3 $ 10.0 $ (1,452.3 ) $ (1,444.0 ) $ (6.6 ) $ 8.7 $ 5,874.1 Total indefinite- lived intangible assets $ 8,758.3 $ 10.0 $ (1,452.3 ) $ (1,444.0 ) $ (6.6 ) $ 8.7 $ 5,874.1 Total product rights and other intangibles $ 77,249.7 $ 3,886.9 $ (1,452.3 ) $ - $ (40.6 ) $ 812.9 $ 80,456.6 Accumulated Amortization Balance as of December 31, 2016 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2017 Intangibles with definite lives: Product rights and other intangibles $ (14,493.9 ) $ (7,119.6 ) $ (3,879.1 ) $ 24.8 $ (125.8 ) $ (25,593.6 ) Trade name (137.2 ) (77.5 ) - - - (214.7 ) Total definite-lived intangible assets $ (14,631.1 ) $ (7,197.1 ) $ (3,879.1 ) $ 24.8 $ (125.8 ) $ (25,808.3 ) Total product rights and other intangibles $ (14,631.1 ) $ (7,197.1 ) $ (3,879.1 ) $ 24.8 $ (125.8 ) $ (25,808.3 ) Net Product Rights and Other Intangibles $ 62,618.6 $ 54,648.3 The following items had a significant impact on net product rights and other intangibles in the year ended December 31, 2017: • The Company acquired $2,020.0 million of intangible assets in connection with the LifeCell Acquisition; • The Company acquired $1,185.0 million of intangible assets in connection with the Zeltiq Acquisition; • The Company reacquired rights on select licensed products promoted in the Company’s US General Medicine segment in an aggregate value of $574.0 million. As part of the rights reacquired, the Company is no longer obligated to pay royalties on the specific products, which increases the Company’s segment gross margin percentage; • The U.S. District Court for the Eastern District of Texas issued an adverse trial decision finding that the four asserted patents covering Restasis ® ® • The Company impaired the intangible asset, including amounts that were acquired IPR&D as part of the Allergan Acquisition, related to Aczone ® • The Company impaired a CNS IPR&D project obtained as part of the Allergan acquisition by $486.0 million related to an anticipated approval delay due to certain product specifications; • The Company impaired an IPR&D asset acquired as part of the Warner Chilcott acquisition by $278.0 million, due to a termination of a launch of a women’s healthcare project due to a decrease in product demand; • The Company impaired an IPR&D eye care project obtained as part of the Allergan acquisition by $209.0 million due to an anticipated delay in launch; • The Company terminated its License, Transfer and Development Agreement for SER-120 (nocturia) with Serenity Pharmaceuticals, LLC. As a result of this termination, the Company recorded an impairment of $140.0 million on the IPR&D intangible asset obtained as part of the Allergan acquisition; • The Company impaired a women’s healthcare IPR&D project by $91.3 million based on the Company’s intention to divest the non-strategic asset; • The Company impaired an IPR&D medical aesthetics project obtained as part of the Allergan acquisition by $29.0 million; and • The Company reclassified certain intangible assets from IPR&D to CMP primarily related to Juvederm ® ® ® Product rights and other intangible assets consisted of the following for the years ended December 31, 2016 and 2015 ($ in millions): Cost Basis Balance as of December 31, 2015 Acquisitions Impairments IPR&D Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2016 Intangibles with definite lives: Product rights and other intangibles $ 64,366.0 $ 43.6 $ - $ 3,809.9 $ (194.6 ) $ (223.5 ) $ 67,801.4 Trade name 690 - - - - - 690.0 Total definite-lived intangible assets $ 65,056.0 $ 43.6 $ - $ 3,809.9 $ (194.6 ) $ (223.5 ) $ 68,491.4 Intangibles with indefinite lives: IPR&D $ 11,128.2 $ 2,223.5 $ (743.9 ) $ (3,809.9 ) $ (22.5 ) $ (17.1 ) $ 8,758.3 Total indefinite- lived intangible assets $ 11,128.2 $ 2,223.5 $ (743.9 ) $ (3,809.9 ) $ (22.5 ) $ (17.1 ) $ 8,758.3 Total product rights and other intangibles $ 76,184.2 $ 2,267.1 $ (743.9 ) $ - $ (217.1 ) $ (240.6 ) $ 77,249.7 Accumulated Amortization Balance as of December 31, 2015 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2016 Intangibles with definite lives: Product rights and other intangibles $ (8,288.5 ) $ (6,392.7 ) $ (28.9 ) $ 176.8 $ 39.4 $ (14,493.9 ) Trade name (59.5 ) (77.7 ) - - - (137.2 ) Total definite-lived intangible assets $ (8,348.0 ) $ (6,470.4 ) $ (28.9 ) $ 176.8 $ 39.4 $ (14,631.1 ) Total product rights and other intangibles $ (8,348.0 ) $ (6,470.4 ) $ (28.9 ) $ 176.8 $ 39.4 $ (14,631.1 ) Net Product Rights and Other Intangibles $ 67,836.2 $ 62,618.6 The following items had a significant impact on net product rights and other intangibles in the year ended December 31, 2016: • The Company acquired $1,357.0 million in IPR&D assets in connection with the Tobira Acquisition; • The Company acquired $686.0 million in IPR&D assets in connection with the Vitae Acquisition; • The Company acquired $158.0 million in IPR&D assets in connection with the ForSight Acquisition; • The Company recognized approximately $210.0 million in impairments relating to a urology product acquired in the Allergan Acquisition due to clinical data not supporting continuation of the R&D study. This impairment was offset, in part, by a reduction of the contingent liability of $186.0 million which reduced overall R&D expenses; • The Company recognized approximately $106 million in impairments relating to a migraine treatment acquired in the Allergan Acquisition based on a decrease in projected cash flows due to a delay in potential launch; • The Company recognized approximately $46.0 million in impairments relating to the atopic dermatitis pipeline candidate acquired in the Vitae Acquisition; • The Company recognized approximately $33.0 million in impairments of the acquired ForSight IPR&D asset as the Company anticipates a delay in potential launch timing. Offsetting this impairment was a corresponding reduction of acquired contingent consideration of $15.0 million, which reduced overall R&D expenses; • The Company recognized approximately $42.0 million in IPR&D impairments on a gastroenterology project based on the lack of future availability of active pharmaceutical ingredients; • The Company recognized approximately $190.0 million in IPR&D impairments due to the termination of an osteoarthritis R&D project due to clinical results; • The Company impaired IPR&D assets relating to an international eye care pipeline project of $35.0 million based on a decrease in projected cash flows due to market conditions; • The Company impaired IPR&D assets of $40.0 million for a Botox ® • The Company recognized $24.0 million in IPR&D impairments relating to the termination of a women’s healthcare R&D project due to clinical results; and • The Company reclassified certain intangible assets from IPR&D to CMP primarily related to Restasis ® ® ® ® ™ ® ® ® ® Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, continuing operations related to annual amortization expense on product rights and other related intangibles as of December 31, 2017 over each of the next five years is estimated to be as follows ($ in millions): Amortization 2018 $ 6,438.3 2019 $ 6,039.4 2020 $ 5,717.4 2021 $ 4,778.2 2022 $ 4,414.8 The above amortization expense is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, finalization of preliminary fair value estimates, potential impairments, accelerated amortization or other events. In addition, the Company has certain currently marketed products for which operating contribution performance has been below that which was originally assumed in the products’ initial valuations and IPR&D projects which are subject to delays in timing or other events which may negatively impact the asset’s value. The Company, on a quarterly basis, monitors the related intangible assets for these products for potential impairments. It is reasonably possible that impairments may occur in future periods, which may have a material adverse effect on the Company’s results of operations and financial position.

Long-Term Debt and Capital Leas

Long-Term Debt and Capital Leases	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt and Capital Leases	NOTE 16 — Long-Term Debt and Capital Leases Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of Issuance Date / Acquisition Date Interest Payments December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due March 12, 2018 * March 4, 2015 Quarterly $ 500.0 $ 500.0 $ 500.6 $ 502.5 $500.0 million floating rate notes due March 12, 2020 ** March 4, 2015 Quarterly 500.0 500.0 508.1 509.4 1,000.0 1,000.0 1,008.7 1,011.9 Fixed Rate Notes $1,000.0 million 1.850% notes due March 1, 2017 March 4, 2015 Semi-annually - 1,000.0 - 1,001.1 $500.0 million 1.300% notes due June 15, 2017 June 10, 2014 Semi-annually - 500.0 - 499.7 $1,200.0 million 1.875% notes due October 1, 2017 October 2, 2012 Semi-annually - 1,200.0 - 1,202.5 $3,000.0 million 2.350% notes due March 12, 2018 March 4, 2015 Semi-annually 3,000.0 3,000.0 3,001.9 3,018.0 $250.0 million 1.350% notes due March 15, 2018 March 17, 2015 Semi-annually 250.0 250.0 249.7 248.4 $1,050.0 million 4.375% notes due February 1, 2019 July 1, 2014 Semi-annually - 1,050.0 - 1,090.0 $500.0 million 2.450% notes due June 15, 2019 June 10, 2014 Semi-annually 500.0 500.0 499.7 501.2 $400.0 million 6.125% notes due August 15, 2019 August 24, 2009 Semi-annually - 400.0 - 437.7 $3,500.0 million 3.000% notes due March 12, 2020 March 4, 2015 Semi-annually 3,500.0 3,500.0 3,528.4 3,541.8 $650.0 million 3.375% notes due September 15, 2020 March 17, 2015 Semi-annually 650.0 650.0 661.3 663.6 $750.0 million 4.875% notes due February 15, 2021 July 1, 2014 Semi-annually 450.0 750.0 474.3 803.3 $1,200.0 million 5.000% notes due December 15, 2021 July 1, 2014 Semi-annually 1,200.0 1,200.0 1,282.6 1,297.7 $3,000.0 million 3.450% notes due March 15, 2022 March 4, 2015 Semi-annually 3,000.0 3,000.0 3,044.5 3,030.7 $1,700.0 million 3.250% notes due October 1, 2022 October 2, 2012 Semi-annually 1,700.0 1,700.0 1,703.0 1,693.1 $350.0 million 2.800% notes due March 15, 2023 March 17, 2015 Semi-annually 350.0 350.0 341.6 335.6 $1,200.0 million 3.850% notes due June 15, 2024 June 10, 2014 Semi-annually 1,200.0 1,200.0 1,232.3 1,211.7 $4,000.0 million 3.800% notes due March 15, 2025 March 4, 2015 Semi-annually 4,000.0 4,000.0 4,067.1 3,995.6 $2,500.0 million 4.550% notes due March 15, 2035 March 4, 2015 Semi-annually 2,500.0 2,500.0 2,631.9 2,458.5 $1,000.0 million 4.625% notes due October 1, 2042 October 2, 2012 Semi-annually 456.7 1,000.0 471.2 967.6 $1,500.0 million 4.850% notes due June 15, 2044 June 10, 2014 Semi-annually 1,500.0 1,500.0 1,606.2 1,496.4 $2,500.0 million 4.750% notes due March 15, 2045 March 4, 2015 Semi-annually 1,200.0 2,500.0 1,277.3 2,466.9 25,456.7 31,750.0 26,073.0 31,961.1 Euro Denominated Notes €750.0 million 0.500% notes due June 1, 2021 May 26, 2017 Annually 900.4 - 895.8 - €700.0 million 1.250% notes due June 1, 2024 May 26, 2017 Annually 840.4 - 831.1 - €550.0 million 2.125% notes due June 1, 2029 May 26, 2017 Annually 660.3 - 657.8 - €700.0 million floating rate notes due June 1, 2019*** May 26, 2017 Quarterly 840.4 - 837.2 - 3,241.5 - 3,221.9 - Total Senior Notes Gross 29,698.2 32,750.0 30,303.6 32,973.0 Unamortized premium 88.9 171.2 - - Unamortized discount (81.7 ) (95.8 ) - - Total Senior Notes Net 29,705.4 32,825.4 30,303.6 32,973.0 Other Indebtedness Debt Issuance Costs (121.5 ) (144.6 ) Margin Loan 459.0 - Other 29.7 85.5 Total Other Borrowings 367.2 (59.1 ) Capital Leases 2.7 2.4 Total Indebtedness $ 30,075.3 $ 32,768.7 * Interest on the 2018 floating rate note is three month USD ** Interest on the 2020 floating rate note is three month USD *** Interest on the €700.0 million floating rate notes is the three month EURIBOR plus 0.350% per annum Fair market value in the table above is determined in accordance with Accounting Standards Codification (“ASC”) Topic 820 “Fair Value Measurement” (“ASC 820”) under Level 2 based upon quoted prices for similar items in active markets. Senior Notes Borrowings Euro Denominated Notes On May 26, 2017, Allergan Funding SCS, a limited partnership (société en commandite simple) organized under the laws of the Grand Duchy of Luxembourg and an indirect wholly-owned subsidiary of Allergan plc, issued the euro denominated notes. The notes are fully and unconditionally guaranteed by Allergan Funding SCS’s indirect parents, Warner Chilcott Limited and Allergan Capital S.a.r.l. (“Allergan Capital”), and by Allergan Finance, LLC, a subsidiary of Allergan Capital, on an unsecured and unsubordinated basis. These notes were issued to fund, in part, the payment of the tender offers described below. Floating Rate Notes On March 4, 2015, Allergan Funding SCS, issued floating rate notes which are fully and unconditionally guaranteed by Allergan Funding SCS’s indirect parents, Warner Chilcott Limited and Allergan Capital, and by Allergan Finance LLC on an unsecured and unsubordinated basis. Allergan plc has not guaranteed the notes. The previously outstanding 2016 floating rate notes were paid in full at maturity on September 1, 2016 and bore interest at the three-month LIBOR plus 0.875%. Fixed Rate Notes Acquired Allergan Notes On March 17, 2015 in connection with the Allergan Acquisition, the Company acquired, and subsequently guaranteed, along with Warner Chilcott Limited, the indebtedness of Allergan, Inc., including $800.0 million 5.750% senior notes due and redeemed in 2016 not shown in the table above. The fair value of the acquired senior notes was determined to be $2,087.5 million as of March 17, 2015. As such, as part of acquisition accounting, the Company recorded a premium of $37.5 million to be amortized as contra interest over the life of the notes. The notes acquired in the Allergan Acquisition are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. 2015 Notes Issuance On March 4, 2015, Allergan Funding SCS, issued indebetedness, in part, to fund the Allergan Acquisition. The notes are fully and unconditionally guaranteed by Allergan Funding SCS’s indirect parents, Warner Chilcott Limited and Allergan Capital, and by Allergan Finance LLC on an unsecured and unsubordinated basis. Allergan plc has not guaranteed the notes. Acquired Forest Notes On July 1, 2014 in connection with the Forest acquisition, the Company acquired the indebtedness of Forest. As a result of acquisition accounting, the notes were fair valued with a premium of $260.3 million as of July 1, 2014, which will be amortized as contra-interest over the life of the notes. The guarantor of the debt is Allergan plc. 2014 Notes Issuance On June 10, 2014, Allergan Funding SCS issued indebtedness, in part, to fund the Forest Acquisition. The guarantors of the debt are Warner Chilcott Limited, Allergan Capital, and Allergan Finance, LLC. 2012 Notes Issuance On October 2, 2012, Allergan Finance, LLC issued indebtedness which were were used for the acquisition of the Actavis Group. The guarantors of the debt are Warner Chilcott Limited and Allergan plc. 2009 Notes Issuance On August 24, 2009, Allergan Finance, LLC issued senior notes which were used to repay certain debt with the remaining net proceeds being used to fund a portion of the cash consideration for the Arrow Group acquisition. The guarantors of the debt are Warner Chilcott Limited and Allergan plc. Credit Facility Indebtedness On August 2, 2016, the Company repaid the remaining balances of all outstanding term-loan indebtedness and terminated its then existing revolving credit facility with proceeds from the Teva Transaction. The interest expense on the then-outstanding indebtedness in the years ended December 31, 2016 and 2015 was $116.2 million and $147.3 million, respectively. Margin Loan On November 10, 2017, Allergan W.C. Holding Inc., Allergan Finance, LLC and Allergan Holding B1 Inc. and JP Morgan Chase Bank executed a margin loan agreement for an aggregate principal amount not exceeding $550.0 million which was available as a single draw from the signing date to December 22, 2017 (the “Loan” or “Margin Loan Agreement”). In Q4 2017, the Company drew down $525.0 million and repaid $66.0 million. The remaining portion of this outstanding indebtedness is due in the year ending December 31, 2018. The outstanding indebtedness under this facility at any time is collateralized by the Company’s investment in Teva securities. Revolving Credit Facility On June 14, 2017, Allergan plc and certain of its subsidiaries entered into a revolving credit and guaranty agreement (the “Revolver Agreement”) among Allergan Capital, as borrower, Allergan plc, as Ultimate Parent; Warner Chilcott Limited, Allergan Finance LLC, and Allergan Funding SCS, as guarantors; the lenders from time to time party thereto (the “Revolving Lenders”); J.P. Morgan Chase Bank as Administrative Agent; J.P. Morgan Europe Limited, as London Agent; and the other financial institutions party thereto. Under the Revolver Agreement, the Revolving Lenders have committed to provide an unsecured five-year revolving credit facility in an aggregate principal amount of up to $1.5 billion, with the ability to increase the revolving credit facility by $500.0 million to an aggregate principal amount of up to $2.0 billion. The Revolver Agreement provides that loans thereunder would bear interest, at our choice, of a per annum rate equal to either (a) a base rate, plus an applicable margin per annum varying from 0.00% per annum to 1.00% per annum depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from 0.875% per annum to 2.00% per annum depending on the Debt Rating. Additionally, to maintain availability of funds, the Company pays an unused commitment fee varying from 0.070% to 0.250% per annum, depending on the Debt Rating, of the unused portion of the revolver. The obligations under the Revolver Agreement are guaranteed by Warner Chilcott Limited, Allergan Finance, LLC and Allergan Funding SCS. The Revolver Agreement contains customary affirmative covenants for facilities of this type, including, among others, covenants pertaining to the delivery of financial statements, notices of default, maintenance of corporate existence and compliance with laws, as well as customary negative covenants for facilities of this type, including, among others, limitations on secured indebtedness, non-guarantor subsidiary indebtedness, mergers and certain other fundamental changes and passive holding company status. The Revolver Agreement also contains a financial covenant requiring maintenance of a maximum consolidated leverage ratio. In addition, the Revolver Agreement also contains customary events of default (with customary grace periods and materiality thresholds). The Company was subject to, and as of December 31, 2017 was in compliance with all, financial and operational covenants under the terms of the Revolver Agreement. At December 31, 2017, there were $28.6 million of outstanding borrowings or letters of credit outstanding under the Revolver Agreement. Cash Bridge Loan Facility On April 9, 2015, the Company repaid the outstanding balance under a 60-day senior unsecured bridge credit facility, of which $2.8 billion was drawn to finance the Allergan Acquisition. 2017 Repayments The Company redeemed all senior notes during the year ended December 31, 2017 that matured within that period. Tender Offer On May 30, 2017, the Company’s wholly owned subsidiaries Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, LLC and Allergan, Inc., each as co-offeror with Warner Chilcott Limited, completed the repurchase of certain debt securities issued by the entities for cash under a previously announced tender offer. As a result of the offering, the Company repurchased $300.0 million of the $750.0 million 4.875% notes due February 15, 2021, $543.3 million of the $1,000.0 million 4.625% notes due October 1, 2042, $700.0 million of the $1,050.0 million 4.375% notes due February 1, 2019, and $1,300.0 million of the $2,500.0 million 4.750% notes due March 15, 2045. The Company paid a total of $3,013.8 million, which included an early tender penalty to repurchase the notes of $170.5 million in cash. The Company recognized a net expense of $161.6 million within “Other (expense) / income” for the early tender payment and non-cash write-off of premiums and debt fees related to the repurchased notes. Other Prepayments On November 30, 2017, the Company repaid its $400.0 million 6.125% notes due August 15, 2019 in full. The Company paid a total of $426.8 million, which included an early tender payment, to repurchase the notes of $26.8 million in cash, which was recognized as a component of “Other (expense) / income”. On December 13, 2017, the Company repaid its remaining $350.0 million obligation under its 4.375% notes due February 1, 2019. The Company recognized a deminimis net P&L charge as a result of the debt termination. Annual Debt Maturities As of December 31, 2017, annual debt maturities were as follows ($ in millions): Total Payments 2018 $ 3,750.0 2019 1,340.4 2020 4,650.0 2021 2,550.4 2022 4,700.0 2023 and after 12,707.4 Total senior notes gross $ 29,698.2 Capital leases 2.7 Debt issuance costs (121.5 ) Other short-term borrowings 488.7 Unamortized premium 88.9 Unamortized discount (81.7 ) Total Indebtedness $ 30,075.3 Amounts represent total anticipated cash payments assuming scheduled repayments. Lease Commitments The Company has operating leases for certain facilities and equipment. The terms of the operating leases for the Company’s facility leases may require the Company to pay property taxes, normal maintenance expense and maintain minimum insurance coverage. Total rental expense for operating leases for the years ended December 31, 2017, 2016, and 2015 was $72.0 million, $47.7 million and $49.9 million, respectively. The Company also has deminimis capital leases for certain facilities and equipment. The future minimum lease payments under both capital and operating leases that have remaining terms in excess of one year are ($ in millions): Total Payments 2018 $ 53.5 2019 59.1 2020 46.5 2021 44.9 2022 42.9 Thereafter 206.1 Total minimum lease payments $ 453.0 The Company has entered into certain sub-lease agreements which will offset future lease commitments.

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2017
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	NOTE 17 — Other Long-Term Liabilities Other long-term liabilities consisted of the following ($ in millions): December 31, December 31, 2017 2016 Acquisition related contingent consideration liabilities $ 420.7 $ 661.1 Long-term pension and post retirement liability 162.7 201.6 Legacy Allergan deferred executive compensation 113.8 111.7 Long-term severance and restructuring liabilities 53.1 22.0 Deferred revenue 37.9 15.7 Product warranties 28.7 28.1 Long-term contractual obligations 45.2 25.3 Other long-term liabilities 24.8 19.5 Total other long-term liabilities $ 886.9 $ 1,085.0

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 18 — Income Taxes The TCJA makes significant changes to the U.S. taxation of our domestic and international operations. Our 2017 consolidated financial statements reflect a provisional estimate of the impacts of the TCJA, as changes in tax law should be accounted for in the period of enactment. The TCJA enacted many significant changes including, but not limited to: • A mandatory deemed repatriation tax on the accumulated, untaxed post-1986 earnings and profits of certain non-U.S. subsidiaries (“toll charge”), payable over eight years; • A decrease in the U.S. Federal Corporate income tax rate from 35% to 21% beginning in years after December 31, 2017; • An additional U.S. tax on the earnings of certain non-U.S. subsidiaries which are considered Global Intangible Low Taxed Income (“GILTI”) at a tax rate of 10.5% for tax years beginning after December 31, 2017 (increasing to 13.125% for tax years beginning after December 31, 2025) with a partial offset for foreign tax credits; • A limitation on the deduction of interest expense to 30% of adjusted taxable income (EBITDA equivalent) for our U.S. subsidiaries for years beginning after December 31, 2017; and • The introduction of a 5% (10% post 2018) minimum tax referred to as the “Base Erosion Anti-Abuse Tax” which requires our U.S. subsidiaries to determine taxable income without regard to tax deductions for payments to affiliates beginning in years after December 31, 2017. As part of the enactment of the TCJA, the Company recorded in the fourth quarter of 2017 a provisional deferred tax benefit of $2,340.4 million related to the change in Federal Corporate tax rates applicable to our deferred tax liabilities, and $1,260.0 million related to the net reversal of prior amounts accrued for taxes on unremitted earnings of certain subsidiaries. The Company also recorded a provisional income tax expense of $728.1 million related to the tax on the deemed repatriation of the deferred foreign earnings of certain non-U.S. subsidiaries (toll charge). The toll charge is payable over eight years and therefore we recorded $58.2 million in current and $669.8 million in non-current tax liabilities. The provisional estimates recorded in the 2017 consolidated financial statements are based on all available information and the Company’s initial analysis and current interpretation of the legislation under the TCJA as of the time of the filing of the Company’s Form 10-K. These estimates represent amounts for which our accounting is incomplete, but a reasonable estimate could be determined. Given the complexity of the TCJA, the proximity of the enactment date to the Company’s year end, anticipated guidance from the U.S. Treasury, and the potential for additional guidance from the Securities and Exchange Commission or the Financial Accounting Standards Board, the amounts recorded in the December 31, 2017 consolidated financial statements related to the TCJA are provisional in nature and may be adjusted during 2018. Recent Securities and Exchange Commission (“SEC”) guidance provides for a measurement period for up to one year from the enactment date of the TCJA for which adjustments to provisional amounts may be recorded as a component of tax expense or benefit in the period the adjustment is determined. The Company recorded a provisional tax expense for its toll charge based on a reasonable estimate of the tax due on the mandatory deemed repatriation of untaxed post-1986 Earnings and Profits (“E&P”) of certain non-U.S. subsidiaries. Calculating this liability involved the consideration of multiple impacting factors. Those factors include estimating the December 31, 2017 ending E&P balances of certain of the Company’s non-U.S. subsidiaries, determining which portion of that E&P was held in cash and non-cash equivalents or other assets at different prescribed measurement dates, reviewing and confirming non- U.S. taxes that would have been previously paid on those earnings, estimating other U.S. income inclusions to be considered in the E&P balances and assessing the potential impact of currently recorded uncertain tax positions. The estimated nature of these factors and their potentially significant impact on the toll charge led to the liability being recorded as a provisional amount. The final toll charge liability amount cannot be determined until the 2018 financial results of certain non-U.S. subsidiaries are finalized, the review of historical E&P and related tax data is complete and all current and future guidance from the IRS, U.S. Treasury, SEC or FASB is issued and evaluated. The Company recorded a provisional deferred tax benefit related to the net reversal of prior amounts accrued for taxes on unremitted earnings of certain non-U.S. subsidiaries. The Company had a previously recorded deferred tax liability balance for non-U.S. earnings that were not permanently reinvested. As a result of the TCJA and specifically the accrual of mandatory tax on the deemed repatriation of the same non-U.S. earnings (toll charge), the previously recorded deferred tax liability was no longer necessary and was reversed in the fourth quarter of 2017. Additionally, a deferred tax liability was recorded for the estimated taxes that would become due on the repatriation of those earnings. The calculation of this deferred tax liability is dependent on the finalization of the December 31, 2017 ending E&P balances of certain subsidiaries. The Company recorded a provisional deferred tax benefit related to the change in Federal Corporate income tax rate applicable to our deferred tax liabilities. We remeasured the net deferred tax liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. However, we are still analyzing certain aspects of the TCJA and refining our calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The Company also recognizes Due to the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the TCJA and the application of ASC 740 and are considering if deferred tax amounts should be recorded for this provision. Our accounting policies depend, in part, on analyzing our global income to determine whether we expect material tax liabilities resulting from the application of this provision, and, if so, whether and when to record related current and deferred income taxes and whether such amounts can be reasonably estimated. Anticipated further guidance from the IRS will also clarify the manner in which the GILTI tax is computed. For these reasons, we have not recorded a deferred tax expense or benefit relating to potential GILTI tax in our 2017 consolidated financial statements and have not made a policy election regarding whether to record deferred taxes on GILTI or account for the GILTI entirely as a period cost. For the years ended December 31, 2017, 2016 and 2015, foreign losses before taxes were $9,247.4 million, $1,502.8 million and $4,291.7 million, respectively. The Company’s (benefit)/provision for income taxes consisted of the following ($ in millions): Years Ended December 31, 2017 2016 2015 Current (benefit) / provision: U.S. federal $ 763.1 $ (17.5 ) $ 14.4 U.S. state (54.8 ) - 9.7 Non-U.S. 410.0 166.2 225.6 Total current (benefit) / provision 1,118.3 148.7 249.7 Deferred (benefit) / provision: U.S. federal (6,911.9 ) (1,218.5 ) (1,370.2 ) U.S. state (252.3 ) (132.1 ) (58.7 ) Non-U.S. (624.5 ) (695.1 ) (426.7 ) Total deferred (benefit) / provision (7,788.7 ) (2,045.7 ) (1,855.6 ) Total (benefit) / provision for income taxes $ (6,670.4 ) $ (1,897.0 ) $ (1,605.9 ) The reconciliations for the years ended December 31, 2017, 2016 and 2015 between the statutory Irish income tax rate for Allergan plc and the effective income tax rates were as follows: Allergan plc Years Ended December 31, 2017 2016 2015 Statutory rate (12.5 )% (12.5 )% (12.5 )% Earnings subject to U.S. taxes (1) (2) (17.8 )% (37.5 )% (18.6 )% Earnings subject to rates different than the statutory rate (1)(2) 2.5 % (18.3 )% (2.2 )% Impact of tax reform (3) (27.2 )% 0.0 % 0.0 % Tax reserves and audit outcomes 0.4 % (0.7 )% 0.3 % Non-deductible expenses 0.2 % 3.1 % 1.3 % Impact of acquisitions and reorganizations (4) (9.3 )% 3.1 % 4.0 % Tax credits and U.S. manufacturing deduction (1.5 )% (3.1 )% (0.5 )% Rate changes (5) (1.2 )% (7.4 )% 0.0 % Valuation allowances (6) 2.2 % 6.5 % (6.5 )% Other 0.0 % (0.2 )% (0.6 )% Effective income tax rate (64.2 )% (67.0 )% (35.3 )% (1) The benefit to the 2017 effective tax rate was lower as compared to 2016 due to proportionately fewer losses in jurisdictions with tax rates higher than the Irish statutory rate. (2) In 2017, the Company recorded amortization expense of $7.20 billion and impairment charges of $8.65 billion, including Teva Share Activity. A significant portion of these amounts were incurred in jurisdictions with tax rates higher than the Irish statutory rate resulting in a net $1,262.2 million favorable impact on the 2017 effective tax rate. (3) As part of the enactment of the TCJA, the Company recorded a provisional net deferred tax benefit of $2.8 billion related to the change in tax rates applicable to our deferred tax liabilities, the net reversal of amounts previously accrued for taxes on unremitted earnings of certain non-U.S. subsidiaries and the tax on the deemed repatriation of the Deferred Foreign Earnings of certain non-U.S. subsidiaries (toll charge). These provisional amounts will be finalized in 2018 or upon the finalization of the 2018 financial results. (4) In 2017, the Company recorded a tax benefit of $895.3 million for deferred taxes related to basis differences in investments expected to reverse at tax rates different than were initially recorded. This resulted in a more favorable impact on the effective tax rate as compared to 2016. (5) As a result of changes in tax rates applied to the Company’s deferred tax liabilities in France and U.S. states, the Company recorded a benefit of $128.1 million. (6) In 2017, the Company recorded a valuation allowance of $230.1 million related to capital losses and foreign tax credit carryforwards not expected to be realized. The amount was mostly offset by benefits recorded in 2017 for these capital losses and foreign tax credits. The reconciliations for the years ended December 31, 2017, 2016 and 2015 between the statutory Bermuda income tax rate for Warner Chilcott Limited and the effective income tax rates were as follows: Warner Chilcott Limited (1) Years Ended December 31, 2017 2016 2015 Statutory rate 0.0 % 0.0 % 0.0 % Earnings subject to U.S. taxes (27.9 )% (58.4 )% (29.5 )% Earnings subject to rates different than the statutory rate (0.4 )% (11.9 )% (5.0 )% Impact of tax reform (27.7 )% 0.0 % 0.0 % Tax reserves and audit outcomes 0.5 % (0.7 )% 0.3 % Non-deductible expenses 0.2 % 3.2 % 1.3 % Impact of acquisitions and reorganizations (9.5 )% 3.2 % 4.1 % Tax credits and U.S. manufacturing deduction (1.5 )% (3.2 )% (0.5 )% Rate changes (1.3 )% (7.6 )% 0.0 % Valuation allowances 2.3 % 6.7 % (6.7 )% Other (0.2 )% (0.1 )% (0.4 )% Effective income tax rate (65.5 )% (68.8 )% (36.4 )% (1) The rate reconciliation for Bermuda is largely consistent with the Irish effective tax rate reconciliations presented above. Deferred tax assets and liabilities are measured based on the difference between the financial statement and tax basis of assets and liabilities at the applicable tax rates. The significant components of the Company’s net deferred tax assets and liabilities consisted of the following (in millions): Years Ended December 31, 2017 2016 Benefits from net operating and capital losses and tax credit carryforwards $ 1,005.3 $ 702.0 Differences in financial statement and tax accounting for: Inventories, receivables and accruals 263.5 433.6 Basis differences in investments 1,088.7 - Share-based and other compensation 315.4 530.1 Other 20.4 64.0 Total deferred tax asset, gross $ 2,693.3 $ 1,729.7 Less: Valuation allowance (403.8 ) (183.9 ) Total deferred tax asset, net $ 2,289.5 $ 1,545.8 Differences in financial statement and tax accounting for: Property, equipment and intangible assets (7,519.1 ) (12,419.6 ) Outside basis differences (731.4 ) (1,793.7 ) Other (72.3 ) (68.3 ) Total deferred tax liabilities $ (8,322.8 ) $ (14,281.6 ) Total deferred taxes $ (6,033.3 ) $ (12,735.8 ) During the years ended December 31, 2017 and 2016, respectively, the Company recorded deferred tax liabilities of approximately $799.4 million and $604.9 million related to acquired entities. During the year ended December 31, 2017, the Company’s net deferred tax liability decreased by $6,702.5 million. This was predominately the result of intangible amortization and impairments and the provisional impact of the TCJA. The Company had the following carryforward tax attributes at December 31, 2017: • $824.4 million of U.S. federal net operating losses (“NOL”) and other tax attributes which begin to expire in 2019; • $368.3 million of U.S. tax credits which begin to expire in 2018; • $3,205.0 million of U.S. state NOLs which begin to expire in 2018; • $27.4 million non-U.S. NOLs which begin to expire in 2018 and $1,910.4 million non-U.S. NOLs which are not subject to expiration. Net operating loss and tax credit carryforwards of $824.4 million and $253.4 million, respectively, are subject to an annual limitation under Internal Revenue Code Section 382. The U.S. state NOLs increased by $2,146.0 million due to the expected utilization of previously unrecognized state loss carryforwards as a result of the TCJA. This was fully offset by a corresponding increase in the deferred tax liabilities for unremitted earnings. During the year ended December 31, 2017, the Company established a valuation allowance of $230.1 million related to U.S. foreign tax credit carryforwards and capital losses. As of December 31, 2017, a valuation allowance balance of $403.8 million is recorded due to the uncertainty of realizing tax credits ($223.3 million), net operating losses ($118.7 million), capital loss carryforwards ($58.2 million) and other deferred tax assets ($3.6 million). At December 31, 2017, Allergan plc (the Irish parent) is permanently reinvested in $9,358.1 million of earnings of its non-Irish subsidiaries and therefore has not provided deferred income taxes on these undistributed earnings. These amounts are intended to be indefinitely reinvested in non-Irish operations and would not be subject to significant taxes if amounts were distributed to Allergan plc. The Company has previously recorded deferred tax liabilities for specific pre-acquisition earnings of certain subsidiaries owned by entities incorporated in the U.S. As a result of the TCJA, these previously recorded deferred tax liabilities were no longer necessary and were reversed in the fourth quarter of 2017. Provisionally, the Company has recorded deferred tax liabilities of $345.5 million related to earnings of subsidiaries owned by entities incorporated in the U.S. This deferred tax liability represents the provisional estimated tax cost of a full repatriation of these earnings. The U.S. subsidiaries of Allergan plc are no longer permanently reinvested in the earnings of their non-U.S. subsidiaries as the provisions of the TCJA will allow these earnings to be remitted to the U.S. without any significant incremental tax cost. The calculation of the deferred tax liability is dependent on the finalization of the E&P balances of certain subsidiaries. Accounting for Uncertainty in Income Taxes A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in millions): Years Ended December 31, 2017 2016 2015 Balance at the beginning of the year $ 811.2 $ 781.7 $ 712.2 Increases for current year tax positions 10.1 100.7 41.2 Increases for prior year tax positions 69.2 40.5 19.7 Increases due to acquisitions 19.8 0.0 115.5 Decreases for prior year tax positions (38.7 ) (77.9 ) (41.4 ) Settlements (21.7 ) (30.8 ) (60.6 ) Lapse of applicable statute of limitations (2.9 ) (2.9 ) (3.2 ) Foreign exchange 3.3 (0.1 ) (1.7 ) Balance at the end of the year $ 850.3 $ 811.2 $ 781.7 If these benefits were subsequently recognized, $754.0 million would favorably impact the Company’s effective tax rate. The Company's continuing policy is to recognize interest and penalties related to uncertain tax positions in tax expense. During the years ended December 31, 2017, 2016 and 2015, the company recognized approximately $45.8 million, $2.0 million and $(0.5) million in interest and penalties, respectively. At December 31, 2017, 2016 and 2015, the Company had accrued $113.7 million (net of tax benefit of $25.9 million), $65.3 million (net of tax benefit of $35.4 million) and $63.3 million (net of tax benefit of $34.2 million) of interest and penalties related to uncertain tax positions, respectively. Although the company cannot determine the impact with certainty based on specific factors, it is reasonably possible that the unrecognized tax benefits may change by up to approximately $150.0 million within the next twelve months due to the resolution of certain tax examinations. The Company conducts business globally and, as a result, it files federal, state and foreign tax returns. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for amounts it believes are in accordance with the accounting standard, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations with tax authorities, identification of new issues and issuance of new legislation, regulations or case law. The Company has several concurrent audits open and pending with the Internal Revenue Service (“IRS”) as set forth below: IRS Audits Taxable Years Allergan W.C. Holding Inc. f/k/a Actavis W.C. Holding Inc. 2013 and 2014 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Allergan, Inc. 2009, 2010, 2011, 2012, 2013, 2014 and 3/7/2015 LifeCell Corporation 2014

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Shareholders’ Equity	NOTE 19 — Shareholders’ Equity Share Repurchase Program On September 25, 2017, the Company’s Board of Directors approved a $2.0 billion share repurchase program. As of December 31, 2017, the Company has repurchased $450.0 million, or 2.6 million shares under the program. During the year ended December 31, 2016, the Company’s Board of Directors approved a $5.0 billion share repurchase program which was completed in October 2016. Additionally, the Company’s Board of Directors approved a $10.0 billion accelerated share repurchase (“ASR”) program, which was initiated in November 2016. In the year ended December 31, 2017, the Company completed the ASR. As a result of the ASR, the Company repurchased 4.2 million and 61.6 million ordinary shares in the years ended December 31, 2017 and 2016, respectively. Quarterly Dividend During the year ended December 31, 2017 the Company paid a quarterly cash dividend of $0.70 per share for holders of the Company’s ordinary shares in March, June, September and December of 2017. The total amount paid in the year ended December 31, 2017 was $939.8 million. The Company also announced that its Board of Directors has approved an increase to its quarterly cash dividend for 2018 to $0.72 per ordinary share. Preferred Shares On February 24, 2015, the Company completed an offering of 5,060,000 of our 5.500% mandatorily convertible preferred shares, Series A, par value $0.0001 per share (the “Mandatory Convertible Preferred Shares”). Dividends on the Mandatory Convertible Preferred Shares will be payable on a cumulative basis when, as and if declared by our board of directors, or an authorized committee thereof, at an annual rate of 5.500% on the liquidation preference of $1,000.00 per Mandatory Convertible Preferred Share. The Company may pay declared dividends in cash, by delivery of our ordinary shares or by delivery of any combination of cash and our ordinary shares, as determined by us in our sole discretion, subject to certain limitations, on March 1, June 1, September 1 and December 1 of each year commencing June 1, 2015, to and including March 1, 2018. The net proceeds from the Mandatory Convertible Preferred Share issuance of $4,929.7 million were used to fund the Allergan Acquisition. Each Mandatory Convertible Preferred Share will automatically convert on March 1, 2018, into between 2.8345 and 3.4722 ordinary shares, subject to anti-dilution adjustments, including adjustments related to our new quarterly dividend. The number of our ordinary shares issuable on conversion of the Mandatory Convertible Preferred Shares will be determined based on the volume weighted average price per ordinary share over the 20 consecutive trading day period beginning on and including the 22nd scheduled trading day immediately preceding March 1, 2018, the mandatory conversion date. At any time prior to March 1, 2018, other than during a fundamental change conversion period as defined, holders of the Mandatory Convertible Preferred Shares may elect to convert each Mandatory Convertible Preferred Share into our ordinary shares at the minimum conversion rate of 2.8345 ordinary shares per Mandatory Convertible Preferred Share, subject to anti-dilution adjustments. In addition, holders may elect to convert any Mandatory Convertible Preferred Shares during a specified period beginning on the fundamental change effective date, in which case such Mandatory Convertible Preferred Shares will be converted into our ordinary shares at the fundamental change conversion rate and converting holders will also be entitled to receive a fundamental change dividend make-whole amount and accumulated dividend amount. In the year ended December 31, 2017, 2016 and 2015, the Company paid $278.4 million, $278.4 million and $208.1 million of dividends on preferred shares, respectively. Each preferred share will automatically convert to ordinary shares on March 1, 2018. 2015 Ordinary Shares Offering On March 2, 2015, in connection with the Allergan Acquisition, the Company issued 14,513,889 of its ordinary shares for an actual public offering price of $288.00 per share. The net proceeds of $4,071.1 million were used, in part, to finance the Allergan Acquisition. Accumulated Other Comprehensive Income / (Loss) For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive income / (loss). The effects of converting non-functional currency assets and liabilities into the functional currency are recorded as transaction gains / (losses) in general and administrative expenses in the consolidated statements of operations. Unrealized gain / (losses) net of tax primarily represent experience differentials and other actuarial charges related to the Company’s defined benefit plans as well as the mark-to-market impact of our holdings in Teva securities. The movements in accumulated other comprehensive income / (loss) for the years ended December, 2017 and 2016 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gain / (loss) net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2015 $ (564.3 ) $ 70.2 $ (494.1 ) Other comprehensive gain / (loss) before reclassifications into general and administrative (441.6 ) (48.1 ) (489.7 ) Impact of Teva Transaction 1,540.6 4.2 1,544.8 Investment in Teva ordinary shares fair value movement - (1,599.4 ) (1,599.4 ) Total other comprehensive income / (loss) 1,099.0 (1,643.3 ) (544.3 ) Balance as of December 31, 2016 $ 534.7 $ (1,573.1 ) $ (1,038.4 ) Other comprehensive gain / (loss) before reclassifications into general and administrative 1,248.0 111.7 1,359.7 Net impact of other-than-temporary loss on investment in Teva securities - 1,599.4 1,599.4 Total other comprehensive income / (loss) 1,248.0 1,711.1 2,959.1 Balance as of December 31, 2017 $ 1,782.7 $ 138.0 $ 1,920.7 As of December 31, 2017, amounts included $75.0 million

Segments

Segments	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segments	NOTE 20 — Segments The Company’s businesses are organized into the following segments: US Specialized Therapeutics, US General Medicine and International. In addition, certain revenues and shared costs, and the results of corporate initiatives, are managed outside of the three segments. The operating segments are organized as follows: • The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the U.S., including Medical Aesthetics, Medical Dermatology, Eye Care and Neuroscience and Urology therapeutic products. • The US General Medicine segment includes sales and expenses relating to branded products within the U.S. that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Diversified Brands. • The International segment includes sales and expenses relating to products sold outside the U.S. The Company evaluates segment performance based on segment contribution. Segment contribution for our segments represents net revenues less cost of sales (defined below), selling and marketing expenses, and select general and administrative expenses. Included in segment revenues for 2015 and 2016 are product sales that were sold through the Anda Distribution business once the Anda Distribution business had sold the product to a third-party customer. These sales are included in segment results and are reclassified into revenues from discontinued operations through a reduction of Corporate revenues which eliminates the sales made by the Anda Distribution business through October 3, 2016 from results of continuing operations. Cost of sales for these products in discontinued operations is equal to our average third party cost of sales for third party branded products distributed by Anda Distribution. The Company does not evaluate the following items at the segment level: • Revenues and operating expenses within cost of sales, selling and marketing expenses, and general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs. • General and administrative expenses that result from shared infrastructure, including certain expenses located within the United States. • Total assets including capital expenditures. • Other select revenues and operating expenses including R&D expenses, amortization, In-process Reseach and Development (“IPR&D”) impairments and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments. The Company defines segment net revenues as product sales and other revenue derived from branded products or licensing agreements. Cost of sales within segment contribution includes standard production and packaging costs for the products we manufacture, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements and finished goods inventory reserve charges. Cost of sales included within segment contribution does not include non-standard production costs, such as non-finished goods inventory obsolescence charges, manufacturing variances and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles. Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs. General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation and settlement costs and professional services costs which are general in nature and attributable to the segment. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Year Ended December 31, 2017 US Specialized US Therapeutics Medicine International Total Net revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 15,919.3 Operating expenses: Cost of sales (1) 495.4 843.9 478.7 1,818.0 Selling and marketing 1,369.5 1,084.1 913.8 3,367.4 General and administrative 208.2 177.3 120.6 506.1 Segment contribution $ 4,730.5 $ 3,690.9 $ 1,806.4 $ 10,227.8 Contribution margin 69.5 % 63.7 % 54.4 % 64.2 % Corporate 1,471.8 Research and development 2,100.1 Amortization 7,197.1 In-process research and development impairments 1,452.3 Asset sales and impairments, net 3,927.7 Operating (loss) $ (5,921.2 ) Operating margin (37.2 )% (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. Year Ended December 31, 2016 US Specialized US Therapeutics Medicine International Total Net revenues $ 5,811.7 $ 5,923.9 $ 2,881.3 $ 14,616.9 Operating expenses: Cost of sales (1) 290.9 879.8 418.2 1,588.9 Selling and marketing 1,137.0 1,185.7 788.2 3,110.9 General and administrative 174.2 174.9 117.2 466.3 Segment contribution $ 4,209.6 $ 3,683.5 $ 1,557.7 $ 9,450.8 Contribution margin 72.4 % 62.2 % 54.1 % 64.7 % Corporate 1,481.3 Research and development 2,575.7 Amortization 6,470.4 In-process research and development impairments 743.9 Asset sales and impairments, net 5.0 Operating (loss) $ (1,825.5 ) Operating margin (12.5 )% (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. Year Ended December 31, 2015 US Specialized US Therapeutics Medicine International Total Net revenues $ 4,309.8 $ 6,338.4 $ 2,187.3 $ 12,835.5 Operating expenses: Cost of sales(1) 235.8 909.5 350.9 1,496.2 Selling and marketing 772.8 1,194.7 569.2 2,536.7 General and administrative 68.3 105.3 107.6 281.2 Segment contribution $ 3,232.9 $ 4,128.9 $ 1,159.6 $ 8,521.4 Contribution margin 75.0 % 65.1 % 53.0 % 66.4 % Corporate 3,066.6 Research and development 2,358.5 Amortization 5,443.7 In-process research and development impairments 511.6 Asset sales and impairments, net 272.0 Operating (loss) $ (3,131.0 ) Operating margin (24.4 )% (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Years Ended December 31, 2017 2016 2015 Segment net revenues $ 15,919.3 $ 14,616.9 $ 12,835.5 Corporate revenues 21.4 (46.3 ) (147.4 ) Net revenues $ 15,940.7 $ 14,570.6 $ 12,688.1 No country outside of the United States represents ten percent or more of net revenues. The US Specialized Therapeutics and US General Medicine segments are comprised solely of sales within the United States. The following tables present global net revenues for the top products of the Company for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Year Ended December 31, 2017 US Specialized Therapeutics US General Medicine International Corporate Total Botox ® $ 2,254.4 $ - $ 914.5 $ - $ 3,168.9 Restasis ® 1,412.3 - 61.3 - 1,473.6 Juvederm ® 501.1 - 540.7 - 1,041.8 Linzess ® ® - 701.1 21.9 - 723.0 Lumigan ® ® 317.5 - 371.5 - 689.0 Bystolic ® ® - 612.2 2.2 - 614.4 Alphagan ® ® 377.3 - 175.1 - 552.4 Eye Drops 199.5 - 281.0 - 480.5 Lo Loestrin ® - 459.3 - - 459.3 Namenda XR ® - 452.8 - - 452.8 Breast Implants 242.6 - 156.9 - 399.5 Estrace ® - 366.6 - - 366.6 Viibryd ® ® - 333.2 3.1 - 336.3 Alloderm ® 321.2 - 7.5 - 328.7 Ozurdex ® 98.4 - 213.4 - 311.8 Vraylar ™ - 287.8 - - 287.8 Asacol ® ® - 195.5 50.2 - 245.7 Carafate ® ® - 235.8 2.9 - 238.7 Zenpep ® - 212.3 - - 212.3 Coolsculpting ® 150.1 - 41.6 - 191.7 Canasa ® ® - 162.7 18.3 - 181.0 Armour Thyroid - 169.1 - - 169.1 Aczone ® 166.3 - 0.5 - 166.8 Viberzi ® - 156.6 0.5 - 157.1 Saphris ® - 155.2 - - 155.2 Coolsculpting ® 106.6 - 32.1 - 138.7 Namzaric ® - 130.8 - - 130.8 Teflaro ® - 121.9 - - 121.9 Rapaflo ® 108.1 - 7.3 - 115.4 SkinMedica ® 96.8 - 3.7 - 100.5 Savella ® - 98.2 - - 98.2 Tazorac ® 65.4 - 0.7 - 66.1 Latisse ® 56.4 - 8.3 - 64.7 Minastrin ® - 61.4 - - 61.4 Avycaz ® - 61.2 - - 61.2 Kybella ® ® 49.5 - 6.8 - 56.3 Dalvance ® - 53.9 2.4 - 56.3 Lexapro ® - 51.8 - - 51.8 Liletta ® - 37.6 - - 37.6 Enablex ® - 3.6 - - 3.6 Namenda ® - 0.1 - - 0.1 Other 280.1 675.5 395.1 21.4 1,372.1 Total net revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 21.4 $ 15,940.7 ** Sales of fillers including Juvederm, Voluma and other fillers are referred to herein as the "Juvederm ® Year Ended December 31, 2016 US Specialized Therapeutics US General Medicine International Corporate Total Botox® $ 1,983.2 $ - $ 803.0 $ - $ 2,786.2 Restasis® 1,419.5 - 68.0 - 1,487.5 Juvederm® Collection ** 446.9 - 420.4 - 867.3 Lumigan®/Ganfort® 326.4 - 361.7 - 688.1 Linzess®/Constella® - 625.6 17.3 - 642.9 Bystolic® / Byvalson® - 638.8 1.7 - 640.5 Namenda XR® - 627.6 - - 627.6 Alphagan®/Combigan® 376.6 - 169.3 - 545.9 Asacol®/Delzicol® - 360.8 53.7 - 414.5 Lo Loestrin® - 403.5 - - 403.5 Estrace® Cream - 379.4 - - 379.4 Eye Drops 186.5 - 276.2 - 462.7 Breast Implants 206.0 - 149.9 - 355.9 Viibryd®/Fetzima® - 342.3 - - 342.3 Minastrin® 24 - 325.9 1.4 - 327.3 Ozurdex ® 84.4 - 179.0 - 263.4 Carafate ® / Sulcrate ® - 229.0 2.4 - 231.4 Aczone® 217.3 - - - 217.3 Zenpep® - 200.7 - - 200.7 Canasa®/Salofalk® - 178.7 17.7 - 196.4 Saphris® - 166.8 - - 166.8 Armour Thyroid - 166.5 - - 166.5 Teflaro® - 133.6 - - 133.6 Rapaflo® 116.6 - 5.8 - 122.4 SkinMedica® 108.3 - - - 108.3 Savella® - 103.2 - - 103.2 Tazorac® 95.5 - 0.8 - 96.3 Vraylar™ - 94.3 - - 94.3 Viberzi® - 93.3 - - 93.3 Latisse® 77.9 - 8.5 - 86.4 Lexapro® - 66.6 - - 66.6 Namzaric® - 57.5 - - 57.5 Kybella® / Belkyra® 50.2 - 2.3 - 52.5 Dalvance® - 39.3 - - 39.3 Avycaz® - 36.1 - - 36.1 Liletta® - 23.3 - - 23.3 Enablex® - 17.1 - - 17.1 Namenda® IR - 15.1 - - 15.1 Other 116.4 598.9 342.2 33.7 1,091.2 Less product sold through our former Anda Distribution business n.a. n.a. n.a. (80.0 ) (80.0 ) Total net revenues $ 5,811.7 $ 5,923.9 $ 2,881.3 $ (46.3 ) $ 14,570.6 ** Sales of fillers including Juvederm, Voluma and other fillers are referred to herein as the "Juvederm ® Year Ended December 31, 2015 US Specialized Therapeutics US General Medicine International Corporate Total Botox® $ 1,386.4 $ - $ 584.4 $ - $ 1,970.8 Restasis® 999.6 - 48.2 - 1,047.8 Juvederm® Collection ** 304.4 - 269.5 - 573.9 Lumigan®/Ganfort® 260.7 - 283.4 - 544.1 Linzess®/Constella® - 454.8 4.5 - 459.3 Bystolic® / Byvalson® - 644.8 1.3 - 646.1 Namenda XR® - 759.3 - - 759.3 Alphagan®/Combigan® 285.0 - 126.1 - 411.1 Asacol®/Delzicol® - 552.9 65.5 - 618.4 Lo Loestrin® - 346.5 3.1 - 349.6 Estrace® Cream - 326.2 - - 326.2 Eye Drops 177.0 - 220.6 - 397.6 Breast Implants 175.0 - 125.5 - 300.5 Viibryd®/Fetzima® - 327.6 - - 327.6 Minastrin® 24 - 272.4 0.6 - 273.0 Ozurdex ® 56.1 - 112.3 - 168.4 Carafate ® / Sulcrate ® - 213.1 - - 213.1 Aczone® 170.8 - - - 170.8 Zenpep® - 167.4 - - 167.4 Canasa®/Salofalk® - 137.1 18.5 - 155.6 Saphris® - 186.7 - - 186.7 Armour Thyroid - 130.8 - - 130.8 Teflaro® - 137.6 - - 137.6 Rapaflo® 115.2 - 10.9 - 126.1 SkinMedica® 76.6 - - - 76.6 Savella® - 106.4 - - 106.4 Tazorac® 92.3 - 1.4 - 93.7 Vraylar™ - - - - - Viberzi® - 12.3 - - 12.3 Latisse® 63.2 - 10.0 - 73.2 Lexapro® - 71.6 - - 71.6 Namzaric® - 11.2 - - 11.2 Kybella® / Belkyra® 3.2 - - - 3.2 Dalvance® - 16.8 - - 16.8 Avycaz® - 22.6 - - 22.6 Liletta® - 14.8 - - 14.8 Enablex® - 69.2 - - 69.2 Namenda® IR - 556.3 - - 556.3 Other 144.3 800.0 301.5 10.0 1,255.8 Less product sold through our former Anda Distribution business n.a. n.a. n.a. (157.4 ) (157.4 ) Total net revenues $ 4,309.8 $ 6,338.4 $ 2,187.3 $ (147.4 ) $ 12,688.1 ** Sales of fillers including Juvederm, Voluma and other fillers are referred to herein as the "Juvederm ® Unless included above, no product represents ten percent or more of total net revenues.

Business Restructuring Charges

Business Restructuring Charges	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Business Restructuring Charges	NOTE 21 — Business Restructuring Charges Restructuring activities for the year ended December 31, 2017 are as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2016 $ 68.5 $ - $ 39.7 $ 108.2 Charged to expense Cost of sales 50.4 - - 50.4 Research and development 37.1 - - 37.1 Selling and marketing 92.5 - - 92.5 General and administrative 37.5 38.8 16.3 92.6 Total expense 217.5 38.8 16.3 272.6 Cash payments (110.4 ) (31.5 ) (36.1 ) (178.0 ) Other reserve impact (9.6 ) (7.3 ) - (16.9 ) Reserve balance at December 31, 2017 $ 166.0 $ - $ 19.9 $ 185.9 In December 2017, the Company approved a new restructuring program intended to optimize and restructure its operations, while reducing costs and global headcount in anticipation of loss of exclusivity of several key revenue-generating products in 2018. As a result of this program, the Company intends to eliminate over 1,000 currently filled positions, impacting employees in commercial and other functions. Commercial reductions will primarily focus on products and categories subject to loss of exclusivity. In addition, the Company eliminated approximately 400 open positions. In the year ended December 31, 2017, the Company recorded severance and other employee related charges of $91.3 million, which includes $4.0 million of share based compensation related to this program. The Company expects that the majority of the severance costs will be paid during the 2018 fiscal year. During the year ended December 31, the Company also recorded $14.6 million of other charges relating to the program and impairments of $17.7 million primarily related to fixed assets and facilities which the Company intends to exit during the 2018 fiscal year. During the year ended December 31, 2017, the Company also initiated other restructuring programs which impacted the commercial, research and development, and global operations organizations. As a result of the commercial organization restructuring program, the Company recorded severance and other employee related charges of $16.9 million and eliminated approximately 200 filled positions and approximately 150 open positions. This initiative reduced costs in the commercial organization and primarily impacted the General Medicine sales force. As a result of the research and development restructuring program, the Company recorded severance and other employee related charges of $12.4 million and eliminated approximately 100 filled positions. This initiative intended to reduce costs as a result of prioritizing the Company’s pipeline. The majority of these severance costs were paid during the year ended December 31, 2017 and the Company does not anticipate any additional costs under these programs. As a result of the global operations restructuring program, the Company will close a manufacturing facility in December 2018 and reduce the Company’s headcount by approximately 250 employees. This program resulted in the Company recording $41.5 million of severance employee related charges and $4.2 million of accelerated depreciation. The majority of the severance costs will be paid during the year ended December 31, 2019. The Company also recorded other restructuring charges $91.7 million related to various other initiatives and the integration of acquired businesses during the year ended December 31, 2017. During 2016, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Allergan Acquisition. Restructuring activities for the year ended December 31, 2016 is as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2015 $ 94.8 $ - $ 48.6 $ 143.4 Charged to expense Cost of sales 3.9 0.5 4.9 9.3 Research and development 11.1 1.0 0.7 12.8 Selling and marketing 19.8 9.7 1.7 31.2 General and administrative 27.9 9.8 15.1 52.8 Total expense 62.7 21.0 22.4 106.1 Cash payments (81.9 ) - (33.3 ) (115.2 ) Other reserve impact (7.1 ) (21.0 ) 2.0 (26.1 ) Reserve balance at December 31, 2016 $ 68.5 $ - $ 39.7 $ 108.2 During the years ended December 31, 2017, 2016 and 2015, the Company recognized restructuring charges related to continuing operations of $272.6 million, $106.1 million and $817.6 million, respectively.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	NOTE 22 — Derivative Instruments and Hedging Activities The Company’s revenue, earnings, cash flows and fair value of its assets and liabilities can be impacted by fluctuations in foreign exchange risks and interest rates, as applicable. The Company manages the impact of foreign exchange risk and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency derivatives. As of December 31, 2017 and December 31, 2016, there were no material outstanding foreign currency instruments. Overall, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect the Company’s consolidated revenues and favorably impact operating expenses in U.S. dollars. Net Investment Hedge In the normal course of business, we manage certain foreign exchange risks through a variety of strategies, including hedging. Our hedging strategies include the use of derivatives, including net investment hedges. For net investment hedges, the effective portion of the gains and losses on the instruments arising from the effects of foreign exchange are recorded in the currency translation adjustment component of accumulated other comprehensive income / (loss), consistent with the underlying hedged item. Hedging transactions are limited to an underlying exposure. As a result, any change in the value of our hedging instruments would be substantially offset by an opposite change in the value of the underlying hedged items. We do not use derivative instruments for trading or speculative purposes. The Company is exposed to foreign exchange risk in its international operations from foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business, including the Euro Denominated Notes. In the year ended December 31, 2017, we used effective net investment hedges to partially offset the effects of foreign currency on our investments in certain of our foreign subsidiaries. The total notional amount of our instruments designated as net investment hedges was $3.6 billion as of December 31, 2017. During the year ended December 31, 2017, the impact of the net investment hedges on other comprehensive income was a loss of $208.2 million. Forward Sale of Teva Shares On November 10, 2017, the Company entered into forward sale transactions for the purpose of selling approximately 25.0 million Teva shares into the market over time, which settled on January 12, 2018 for $413.3 million. The value of the shares were based on the volume-weighted average price of Teva shares plus a premium. The movement in these shares were marked to market for a loss of $62.9 million in the year ended December 31, 2017. On February 13, 2018, the Company entered into additional forward sale transactions under which we sold approximately 25.0 million Teva shares. The value of the shares will be based on the volume weighted average price of Teva shares plus a premium and is expected to settle during the second quarter of 2018. As a result of the transaction, the Company received 80% of the proceeds, or approximately $372.0 million, with the remainder of the proceeds being delivered upon settlement.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 23 — Fair Value Measurement Assets and liabilities measured at fair value using Fair Value Leveling or disclosed at fair value on a recurring basis as of December 31, 2017 and 2016 consisted of the following ($ in millions): Fair Value Measurements as of December 31, 2017 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 1,328.1 $ 1,328.1 $ - $ - Short-term investments 2,814.4 - 2,814.4 - Deferred executive compensation investments 112.4 92.9 19.5 - Foreign currency derivatives - - - - Investment in Teva ordinary shares 1,817.7 1,817.7 - - Investments and other 72.3 72.3 - - Total assets $ 6,144.9 $ 3,311.0 $ 2,833.9 $ - Liabilities: Deferred executive compensation liabilities 113.8 94.3 19.5 - Contingent consideration obligations 476.9 - - 476.9 Total liabilities $ 590.7 $ 94.3 $ 19.5 $ 476.9 * Marketable securities with less than 90 days remaining until maturity are classified as cash equivalents. Fair Value Measurements as of December 31, 2016 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 1,238.9 $ 1,238.9 $ - $ - Short-term investments 8,062.3 - 8,062.3 - Deferred executive compensation investments 111.7 90.5 21.2 - Foreign currency derivatives 0.1 - 0.1 - Investment in Teva ordinary shares 3,439.2 - 3,439.2 - Investments and other 95.0 95.0 - - Total assets $ 12,947.2 $ 1,424.4 $ 11,522.8 $ - Liabilities: Deferred executive compensation liabilities 111.7 90.5 21.2 - Contingent consideration obligations 1,172.1 - - 1,172.1 Total liabilities $ 1,283.8 $ 90.5 $ 21.2 $ 1,172.1 * Marketable securities and investments consist of available-for-sale investments in U.S. treasury and agency securities and publicly traded equity securities for which market prices are readily available. Unrealized gains or losses on marketable securities and investments are recorded in accumulated other comprehensive (loss) / income as of December 31, 2017. Realized gains or losses on marketable securities and investments are recorded in interest income. The Company’s marketable securities and other long-term investments are classified as available-for-sale and are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non-current, as appropriate, in the Company’s consolidated balance sheets. The Company may sell certain of its marketable securities prior to their stated maturities for strategic reasons including, but not limited to, anticipation of credit deterioration and maturity management. Contingent Consideration Obligations The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions. Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Years Ended December 31, Expense / (income) 2017 2016 2015 Cost of sales $ (183.2 ) $ (17.4 ) $ 58.5 Research and development 50.0 (71.1 ) 37.7 General and administrative - 24.3 (0.5 ) Total $ (133.2 ) $ (64.2 ) $ 95.7 During the year ended December 31, 2017, the Company had net contingent consideration income in cost of sales of $183.2 million due to declines in forecasted revenues for select products. The Company had net contingent consideration expense in R&D of $50.0 million due to the advancement of the Company’s pipeline. During the year ended December 31, 2016, the Company had net contingent consideration income of $64.2 million primarily driven by ongoing R&D projects that were terminated based on clinical data acquired in the Allergan Acquisition, which was offset by additional contingent consideration expense relating to milestones achieved in connection with the AqueSys and Allergan Acquisitions. During the year ended December 31, 2015, the Company recorded additional contingent consideration of $29.8 million in connection with the approval of Viberzi™, $81.4 million in connection with the approval of Liletta ® ® The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016 ($ in millions): Balance as of December 31, 2016 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2017 Liabilities: Contingent consideration obligations $ 1,172.1 $ - $ (562.0 ) $ (133.2 ) $ 476.9 Balance at December 31, 2015 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance at December 2016 Liabilities: Contingent consideration obligations $ 868.0 $ - $ 368.3 $ (64.2 ) $ 1,172.1 The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate to reflect the internal rate of return and incremental commercial uncertainty, major risks and uncertainties associated with the successful completion of the events triggering the contingent obligation. At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. Accretion expense related to the increase in the net present value of the contingent liability is included in operating income for the period. During the year ended December 31, 2017, the following activity in contingent consideration obligations by acquisition was incurred ($ in millions): Business Acquisition Balance as of December 31, 2016 Fair Value Adjustments Payments and Other Balance as of December 31, 2017 Tobira Acquisition $ 514.4 $ 14.6 $ (301.2 ) $ 227.8 Allergan Acquisition 199.6 (70.9 ) (110.0 ) 18.7 Medicines 360 acquisition 127.5 (67.0 ) (16.1 ) 44.4 AqueSys Acquisition 103.9 (50.4 ) (25.0 ) 28.5 Oculeve Acquisition 99.5 90.6 (100.0 ) 90.1 ForSight Acquisition 65.4 (19.1 ) - 46.3 Metrogel acquisition 15.0 - (7.5 ) 7.5 Forest Acquisition 11.0 3.7 (2.0 ) 12.7 Uteron acquisition 8.2 (8.2 ) - - Other 27.6 (26.5 ) (0.2 ) 0.9 Total $ 1,172.1 $ (133.2 ) $ (562.0 ) $ 476.9

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments & Contingencies	NOTE 24 — Commitments & Contingencies The Company and its affiliates are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that is accrued. As of December 31, 2017, the Company’s consolidated balance sheet includes accrued loss contingencies of approximately $55.0 million. The Company’s legal proceedings range from cases brought by a single plaintiff to mass tort actions and class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including, but not limited to, qui tam In matters involving the assertion or defense of the Company’s intellectual property, the Company believes it has meritorious claims and intends to vigorously assert or defend the patents or other intellectual property at issue in such litigation. Similarly, in matters where the Company is a defendant, the Company believes it has meritorious defenses and intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation or, in the case of patent enforcement matters, that a generic version of the product at issue will not be launched or enjoined. Failing to prevail in a litigation could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Antitrust Litigation Asacol ® Two class action complaints were filed on June 22, 2015, and three more on September 21, 2015, in federal court in Massachusetts on behalf of a putative class of indirect purchasers. In each complaint plaintiffs allege that they paid higher prices for Warner Chilcott’s Asacol ® ® ® ® The Company has reached a tentative agreement with the direct purchaser plaintiffs to settle their claims. The Company has filed a motion for summary judgment seeking dismissal of the indirect purchaser plaintiffs’ claims. On November 9, 2017, the court issued a decision denying the Company’s summary judgment motion and granting plaintiff’s motion for class certification. Trial was set to being on January 22, 2018. However, on January 17, 2018, the Court of Appeals for the First Circuit issued an order granting the Company’s motion under Fed.R.Civ.P. 23(f) to appeal the district court’s decision to certify the proposed class. The appellate court thereafter issued a decision staying the trial in the district court. The appeal will be fully briefed by the end of March 2018. Botox ® . A class action complaint was filed in federal court in California on February 24, 2015, and amended May 29, 2015, alleging unlawful market allocation in violation of Section 1 of the Sherman Act, 15 U.S.C. §1, agreement in restraint of trade in violation of 15 U.S.C. §1 of the Sherman Act, unlawful maintenance of monopoly market power in violation of Section 2 of the Sherman Act, 15 U.S.C. §2 of the Sherman Act, violations of California’s Cartwright Act, Section 16700 et seq. of Calif. Bus. and Prof. Code, and violations of California’s unfair competition law, Section 17200 et seq. of Calif. Bus. and Prof. Code. In the complaint, plaintiffs seek an unspecified amount of treble damages. On July 19, 2016, plaintiffs filed a motion for class certification. On October 14, 2016, the Company filed an opposition to plaintiffs’ motion for class certification. Oral argument on the class certification motion was heard on January 13, 2017. On June 13, 2017, the court granted plaintiff’s motion for class certification. In September 2017, the parties filed cross motions for summary judgement, which were heard by the court on October 27, 2017. On November 30, 2017, the parties reached a tentative settlement. Loestrin ® On April 5, 2013, two putative class actions were filed in the federal district court against Warner Chilcott and certain affiliates alleging that Warner Chilcott’s 2009 patent lawsuit settlements with Watson Laboratories and Lupin related to Loestrin ® ® ® Namenda ® . On September 15, 2014, the State of New York, through the Office of the Attorney General of the State of New York, filed a lawsuit in the United States District Court for the Southern District of New York alleging that Forest was acting to prevent or delay generic competition to Forest’s immediate-release product Namenda ® ® ® Restasis ® . On October 2, 2017, Shire, which offers the dry-eye disease drug Xiidra ® ® ® ® ® ® ® Restasis ® . Between November 7, 2017, and January 17, 2018, fourteen putative class actions were filed in federal district courts against Allergan alleging that the company unlawfully harmed competition by engaging in conduct to delay the market entry of generic versions of Restasis ® ® ® ® Zymar ® ® . On February 16, 2012, Apotex Inc. and Apotex Corp. filed a complaint in the federal district court in Delaware against Senju Pharmaceuticals Co., Ltd. (“Senju”), Kyorin Pharmaceutical Co., Ltd. (“Kyorin”), and Allergan, Inc. alleging monopolization in violation of Section 2 of the Sherman Act, conspiracy to monopolize, and unreasonable restraint of trade in the market for gatifloxacin ophthalmic formulations, which includes Allergan, Inc.’s ZYMAR ® ® On June 6, 2014, a separate antitrust class action complaint was filed in the federal district court in Delaware against the same defendants as in the Apotex case. The complaint alleges that defendants unlawfully excluded or delayed generic competition in the gatifloxacin ophthalmic formulations market (generic versions of ZYMAR ® ® Commercial Litigation Celexa ® ® . Forest and certain of its affiliates have been named as defendants in multiple federal court actions relating to the promotion of Celexa ® ® ® ® ® ® ® ® On August 28, 2014, an action was filed in the federal district court in Washington seeking to certify a nationwide class of consumers and subclasses of Washington and Massachusetts consumers that purchased Celexa ® ® ® ® Generic Drug Pricing Securities and ERISA Litigation . On November 4, 2016, a class action was filed by a putative class of Allergan shareholders in federal court in California against the Company and certain of its current and former officers alleging that the Company and certain of its current and former officers made materially false and misleading statements. The complaint alleges generally that between February 2014 and November 2016, Allergan and certain of its officers made materially false and misleading statements regarding the Company’s internal controls over its financial reporting and failed to disclose that its Actavis generics unit had engaged in illegal, anticompetitive price-fixing with its generic industry peers. The complaint seeks unspecified monetary damages. On February 2, 2017, the actions were consolidated in the federal district court in New Jersey. Plaintiffs filed a consolidated amended complaint on May 1, 2017. The Company filed a motion to dismiss plaintiffs’ consolidated amended complaint on July 17, 2107. Plaintiffs filed their opposition on September 15 and the Company filed its reply on October 6, 2017. Plaintiffs filed a second amended consolidated complaint on November 28, 2017. The Company filed a motion to dismiss the second amended complaint on January 22, 2018. A complaint was filed in California state court, premised on the same alleged underlying allegations, by an individual opt-out plaintiff on February 2, 2018. The Company has not yet responded to the California state court complaint. On February 14, 2017, a separate complaint was filed in the federal district court in California that is premised on the same alleged underlying conduct that is at issue in the securities litigation but that asserts claims under the Employee Retirement Income Security Act of 1974 (“ERISA). A similar lawsuit was filed in the federal district court in New Jersey on March 7, 2017. The ERISA complaints assert claims on behalf of a putative class of individuals who participated in the Company’s retirement plans and seek an unspecified amount of damages and other injunctive relief. On June 26, 2017, the Company filed a motion to stay or transfer venue in the California ERISA matter to the District of New Jersey, after which time plaintiffs agreed to stipulate to the transfer. The Company’s motion to consolidate the matters was granted on August 21, 2017, and a consent discovery order entered. On October 23, 2017, Plaintiffs filed an amended consolidated complaint which the Company moved to dismiss on February 2, 2018. Telephone Consumer Protection Act Litigation. In October 2012, Forest and certain of its affiliates were named as defendants in a putative class action in federal court in Missouri. This suit alleges that Forest and another defendant violated the Telephone Consumer Protection Act (the “TCPA”) and was filed on behalf of a proposed class that includes all persons who, from four years prior to the filing of the action, were sent telephone facsimile messages of material advertising the commercial availability of any property, goods, or services by or on behalf of defendants, which did not display an opt-out notice compliant with a certain regulation promulgated by the FCC. On July 17, 2013, the district court granted Forest’s motion to stay the action pending the administrative proceeding initiated by the pending FCC Petition and a separate petition Forest filed. On October 31, 2015, another class action complaint was filed in Missouri state court against Allergan USA, Inc., Warner Chilcott Corporation and Actavis, Inc., now known as Allergan Finance LLC, alleging violations of the Telephone Consumer Protection Act, the Missouri Consumer Fraud and Protection Act and conversion on behalf of a putative nationwide class of plaintiffs to who defendant Warner Chilcott Corporation sent unsolicited facsimile advertisements. Defendants removed this action to the federal district court for the Western District of Missouri on December 10, 2015 and responded to the complaint on February 8, 2016. On February 17, 2016, plaintiffs voluntarily dismissed defendants Allergan USA, Inc. and Actavis, Inc. from the litigation. In the wake of the Court of Appeals decision on the Petition discussed below, the parties reached an agreement to settle the action against Warner Chilcott. In a related matter, on June 27, 2013, Forest filed a Petition for Declaratory Ruling with the FCC requesting that the FCC find that (1) the faxes at issue in the action complied, or substantially complied with the FCC regulation, and thus did not violate it, or (2) the FCC regulation was not properly promulgated under the TCPA. Warner Chilcott filed a similar petition with the FCC. On January 31, 2014, the FCC issued a Public Notice seeking comment on Forest’s and several other similar petitions. On October 30, 2014, the FCC issued a final order on the FCC Petition granting Forest and several other petitioners a retroactive waiver of the opt-out notice requirement for all faxes sent with express consent. The litigation plaintiffs, who had filed comments on the January 2014 Public Notice, have appealed the final order to the Court of Appeals for the District of Columbia. Forest and other petitioners intervened in the appeal seeking review of that portion of the FCC final order addressing the statutory basis for the opt out/express consent portion of the regulation. Oral argument before the appellate court took place on November 8, 2016. On March 31, 2017, the Court of Appeals issued a decision which held that the FCC regulation at issue was not properly promulgated under the TCPA. Plaintiffs have filed a petition for certiorari with the United States Supreme Court. Prescription Opioid Drug Abuse Litigation . The Company has been named as a defendant in approximately 290 matters relating to the promotion and sale of prescription opioid pain relievers and additional suits may be filed. On May 21, 2014, the California counties Santa Clara and Orange filed a lawsuit in California state court on behalf of the State of California against several pharmaceutical manufacturers. Plaintiffs named Actavis plc (now known as Allergan plc) in the suit. The California plaintiffs filed an amended complaint on June 9, 2014. The California complaint alleges that the manufacturer defendants engaged in a deceptive campaign to promote their products in violation of state laws. The complaint seeks an unspecified amount of monetary damages, penalties and injunctive relief. On August 27, 2015, the court stayed the action based on primary jurisdiction arguments raised in the motions to dismiss. On June 3, 2016, the California plaintiffs filed a motion to lift the stay and a motion for leave to file a third amended complaint. On July 1, 2016, the Company and co-defendants filed joint oppositions to the California plaintiffs’ motion to lift the stay and motion for leave to file a third amended complaint. On July 27, 2016, the court ordered the California plaintiffs to file another motion for leave to file an amended complaint along with a proposed amended complaint. On October 19, 2016, the court in the California litigation lifted the stay in part permitting defendants to challenge the third amended complaint and for the parties to discuss settlement and maintaining the stay in all other respects. On July 6, 2017, Santa Clara and Orange Counties filed a fourth amended complaint. On June 2, 2014, the City of Chicago also filed a complaint in Illinois state court against the same set of defendants, including Actavis plc, that were sued in the California Action. Co-defendants in the action removed the matter to the federal court in Illinois. The Chicago complaint contains similar allegations as the California complaint and also seeks unspecified monetary damages, penalties and injunctive relief. Defendants have moved to dismiss the complaints in each action. On May 8, 2015, the court granted the Company’s motion to dismiss the complaint. On August 26, 2015, the City of Chicago filed a second amended complaint. On September 29, 2016, the court in the Chicago litigation granted in part and denied in part defendants’ motion to dismiss the second amended complaint. On October 25, 2016, Chicago filed a third amended complaint. On December 15, 2016, the Company moved to dismiss the third amended complaint and filed an answer to the complaint. On December 15, 2015, the State of Mississippi filed a lawsuit in Mississippi state court against several pharmaceutical manufacturers. The Mississippi action parallels the allegations in the California and Chicago matters and seeks monetary and equitable relief. In March and April 2016, the defendants filed motions to dismiss, stay, and transfer venue in the Mississippi action. On February 13, 2017, the defendants’ motion to transfer venue was denied. On March 6, 2017, the defendants filed a petition for permission to appeal interlocutory order denying defendants’ motion to transfer venue with the Mississippi Supreme Court. On May 31, 2017, the State of Ohio filed a lawsuit in Ohio state court against several pharmaceutical manufacturers. The Ohio action parallels the allegations in the Chicago matter and seeks monetary and equitable relief. Since the filing of the complaint by the State of Ohio, additional cases have been filed, including cases filed by the States of Oklahoma and New Mexico, but mainly by political subdivisions of states (ie., counties and municipalities) in state and federal courts across the country. In addition, a putative class action was filed in the United States District Court for the Western District of Arkansas on behalf of Arkansas residents who were prescribed an opioid product or were prescribed an opioid product and were treated for an overdose or addiction against several pharmaceutical manufacturers. The claims in the additional cases The Company is aware that other states and political subdivisions are considering filing comparable actions against, among others, manufacturers and parties that promoted prescription opioid pain relievers. Testosterone Replacement Therapy Class Action . On November 24, 2014, the Company was served with a putative class action complaint filed on behalf a class of third party payers in federal court in Illinois. The suit alleges that the Company and other named pharmaceutical defendants violated various laws including the federal RICO statute and state consumer protection laws in connection with the sale and marketing of certain testosterone replacement therapy pharmaceutical products (“TRT Products”), including the Company’s Androderm ® TNS Products Litigation . On March 19, 2014, a class action complaint was filed in the federal district court in California on behalf of a putative class of consumers. The complaint alleges violations of the California Unfair Competition Law, the Consumers Legal Remedies Act, and the False Advertising Law, and deceit. On June 2, 2014, plaintiff filed a first amended complaint. On June 23, 2014, Allergan filed a motion to dismiss the first amended complaint. On September 5, 2014, the court granted-in-part and denied-in-part Allergan’s motion to dismiss. On September 8, 2014, the court set trial for September 1, 2015. On November 4, 2014, Allergan and SkinMedica filed a motion to dismiss. On January 7, 2015, Allergan and SkinMedica’s motion to dismiss was denied. On February 19, 2015 plaintiff filed a third amended complaint. On May 27, 2015, the case was stayed pending the decision of the Ninth Circuit Court of Appeals in another matter involving similar legal issues. On January 12, 2018, the parties reached a settlement. On January 16, 2018, the matter was dismissed. Xaleron Dispute. On February 5, 2016, Xaleron Pharmaceuticals, Inc. filed a lawsuit against Allergan, Inc. and Actavis, Inc., now known as Allergan Finance, LLC, in state court in New York. The complaint, filed on February 26, 2016, alleges the defendants misappropriated Xaleron’s confidential business information and asserts claims for unfair competition, tortious interference with prospective economic advantage and unjust enrichment. The Company filed a motion to dismiss the complaint on April 15, 2016. On September 13, 2016, the court issued a decision denying the Company’s motion. Defendants filed an answer to the complaint and the parties are now engaged in discovery. Zeltiq Shareholder Litigation. On March 14, 2017, a putative shareholder class action lawsuit was filed against Zeltiq Aesthetics, Inc. (“Zeltiq”) and various directors as well as Allergan entities in Delaware federal court. Plaintiffs allege that the proxy statement filed in connection with the Company’s acquisition of Zeltiq Aesthetics, Inc. misrepresented material information that prevented Zeltiq’s shareholders from making a fully informed decision on the proposed sale to Allergan, including failure to disclose GAAP reconciliation of Zeltiq’s non-GAAP projections. The Allergan entities were named under a supervisory role theory. On March 29, 2017, a similar putative shareholder class action lawsuit was filed in California federal court against Zeltiq Aesthetics, Inc. and various directors seeking a preliminary injunction. Allergan was not named as a defendant. Zeltiq filed an amendment to its Definitive Proxy Statement on April 11, 2017, which includes supplemental disclosures that address plaintiffs’ claims. On the same date, plaintiffs in the California action withdrew their motion for a preliminary injunction. On May 23, 2017, plaintiffs in the California action voluntarily dismissed their complaint, with prejudice as to the named plaintiff and without prejudice as to the class members. The parties reached an agreement to settle this dispute and plaintiffs voluntarily dismissed this action. Zeltiq Advertising Litigation . On April 26, 2017, a putative class action lawsuit was filed against Zeltiq in state court in California alleging that Zeltiq misled customers regarding the promotion of its CoolSculpting product and the product’s premarket notification clearance status. On May 30, 2017, the case was removed to the United States District Court for the Central District of California. On July 20, 2017, Plaintiffs filed an amended complaint. In August 2017, Zeltiq filed a motion to dismiss the amended complaint. Employment Litigation In July 2012, Forest was named as defendants in an action brought by certain former Company sales representatives and specialty sales representatives in the federal district court in New York. The action is a putative class and collective action, and alleges class claims under Title VII for gender discrimination with respect to pay and promotions, as well as discrimination on the basis of pregnancy, and a collective action claim under the Equal Pay Act. The proposed Title VII gender class includes all current and former female sales representatives employed by the Company throughout the U.S. from 2008 to the date of judgment, and the proposed Title VII pregnancy sub-class includes all current and former female sales representatives who have been, are, or will become pregnant while employed by the Company throughout the U.S. from 2008 to the date of judgment. The proposed Equal Pay Act collective action class includes current, former, and future female sales representatives who were not compensated equally to similarly-situated male employees during the applicable liability period. The second amended complaint also includes non-class claims on behalf of certain of the named Plaintiffs for sexual harassment and retaliation under Title VII, and for violations of the Family and Medical Leave Act. On August 14, 2014, the court issued a decision on the Company’s motion to dismiss, granting it in part and denying it in part, striking the plaintiffs’ proposed class definition and instead limiting the proposed class to a smaller set of potential class members and dismissing certain of the individual plaintiffs’ claims. Plaintiffs filed a motion for conditional certification of an Equal Pay Act collective action on May 22, 2015 which the Company has opposed. On September 2, 2015, the court granted plaintiffs motion to conditionally certify a collective action. On April 3, 2017, the parties agreed to settle this matter. On February 1, 2018, the court granted preliminary approval of the settlement and set a fairness hearing for May 4, 2018. Patent Litigation Patent Enforcement Matters Aczone ® Gel, 7.5%. In June and July 2017, Allergan, Inc. brought actions for infringement of U.S. Patent No. 9,517,219 (the “‘219 patent”) in the U.S. District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals, Inc. (collectively, “Taro”). Taro had notified Allergan in April and July 2017, that it filed an ANDA with the FDA seeking to obtain approval to market a generic version of Aczone® Gel, 7.5% before the ‘219 patent expires in November 2033. These lawsuits triggered automatic stays of approval of Taro’s ANDA that expire no earlier than October 2019 and January 2020, respectively (unless there is a final court decision adverse to Plaintiff sooner). Trial has been scheduled for February 4, 2019, assuming the parties consent to Magistrate Judge Fallon conducting all proceedings in the case. Otherwise, when the case is ready for trial the court will assign a district judge and the pre-trial and trial dates will be set depending on the district judge’s schedule. Amrix ® Bystolic ® On January 19, 2018, Allergan Sales, LLC, Allergan USA, Inc., and Forest Laboratories Holdings, Ltd. brought an action for infringement of U.S. Patent No. 6,545,040 in the United States District Court for the District of Delaware against Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd. (collectively, “Aurobindo”). Aurobindo had notified Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as the surviving entity) that Aurobindo had filed an ANDA with FDA seeking to obtain approval to market generic versions of Bystolic ® Previously, the Company had asserted the ‘040 patent in actions against Actavis, Alkem, Amerigen, Glenmark, Hetero, Indchemie and Torrent, and related subsidiaries and affiliates thereof (collectively, “the Original Defendants”), and reached settlements terminating those actions. As previously announced, under the terms of the settlement agreements, the Company will provide licenses to each of the Original Defendants that will permit them to launch their generic versions of Bystolic as of the date that is the later of (a) three calendar months prior to the expiration of the ‘040 patent, including any extensions and/or pediatric exclusivities, or (b) the date each company receives final FDA approval of its ANDA, or earlier in certain circumstances. Byvalson ® On September 18, 2017, Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as the surviving entity) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) brought an action for infringement of U.S. Patent Nos. 7,803,838 (the “‘838 patent”) and 7,838,552 (the “‘552 patent”) in the U.S. District Court for the District of New Jersey against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively, “Prinston”). Prinston notified Forest that it filed an ANDA with the FDA seeking to obtain approval to market a generic version of Byvalson ® Combigan ® . In 2012, Allergan filed a complaint against Sandoz, Alcon, Apotex and Watson in the U.S. District Court for the Eastern District of Texas, Marshall Division, alleging that their proposed products infringe U.S. Patent Number 8,133,890 (the “890 Patent”), and subsequently amended their complaint to assert infringement of U.S. Patent Number 8,354,409. In March 2013, Allergan received a Paragraph IV certification from Sandoz, contending that the ‘890 Patent is invalid and not infringed by the proposed generic product. In October 2013, Allergan filed a motion to stay and administratively close the Combigan II matter, which was granted. In April 2015, Allergan filed a stipulation of dismissal and the U.S. District Court granted the Order with respect to the Watson defendants. In October 2015, the U.S. District Court entered an order consolidating the ® matter into this matter , as lead case. A Markman Hearing was held on March 2, 2016. On May 19, 2016, Sandoz filed an opposed motion for leave to amend its answer and counterclaim seeking to add a count for declaratory judgment of invalidity of the ‘149 Patent. On July 20, 2016, Alcon and Sandoz filed motions for summary judgment of invalidity and non-infringement of claim 4 of the ‘149 Patent, and Allergan filed a motion for summary judgment of infringement of claim 4 of the ‘149 Patent and to preclude Sandoz from re-challenging the validity of that claim. On September 30, 2016, the court denied the parties’ motions for summary judgment. A bench trial concluded on October 27, 2016. On December 30, 2016, the court entered an opinion and final judgment in favor of Allergan and against Sandoz, that the asserted claims of the ‘149 Patent, and U.S. Patent Numbers 7,320,976 (“‘976 Patent”) and 8,748,425 (the “‘425 Patent”), were not invalid, and that Sandoz infringes the asserted claims of the ‘425 Patent. The court also held in favor of Sandoz and against Allergan, that Sandoz does not infringe the asserted claims of the ‘149 and ‘976 Patents. Sandoz filed a notice of appeal to U.S. Court of Appeals for the Federal Circuit on January 17, 2017, and Allergan filed a notice of cross appeal on January 27, 2017. The Federal Circuit heard oral arguments on October 2, 2017. On December 22, 2017, the Federal Circuit issued a decision affirming the district court’s finding of no invalidity of the asserted claims and non-infringement of the claims of the ‘149 and ‘976 Patents, and reversing the district court’s finding of infringement of claim 1 of the ‘425 Patent. On January 22, 2018, Allergan filed a combined petition for panel rehearing or rehearing en banc Combigan ® . On October 30, 2017, Allergan Sales, LLC and Allergan, Inc. filed a complaint against Sandoz, Inc. and Alcon Laboratories, Inc. (“Sandoz”) in the U.S. District Court for the District of New Jersey, alleging that their proposed generic versions of Combigan ® ® Delzicol ® On August 28, 2015, Warner Chilcott Company, LLC, Warner Chilcott (US), LLC, and Qualicaps Co., Ltd. (collectively, “Plaintiffs”) brought an action for infringement of U.S. Patent No. 6,649,180 (the “‘180 patent”) in the United States District Court for the Eastern District of Texas against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively, “Teva”). Teva notified Plaintiffs that it has filed an ANDA with the FDA seeking to obtain approval to market generic versions of Delzicol ® ® ) with the Teva litigation ( ) matter as the lead case. On April 1, 2016, Warner Chilcott Company, LLC, Warner Chilcott (US), LLC, Allergan Pharmaceuticals International Ltd., Allergan USA, LLC and Qualicaps Co., Ltd. (collectively, “Plaintiffs”) brought an action for infringement of the ‘180 patent in the United States District Court for the Eastern District of Texas against Zydus International Pvt. Ltd., Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, “Zydus”). Zydus notified the Company that it has filed an ANDA with the FDA seeking to obtain approval to market generic versions of Delzicol ® ® On March 31, 2017, Plaintiffs filed a motion to stay the litigation against Teva, and, on April 11, 2017, Plaintiffs filed a motion to dismiss the originally-filed action against Teva for lack of subject matter jurisdiction. On April 21, 2017, Plaintiffs brought an action for infringement of the ‘180 patent in the United States District Court for the Eastern District of Texas against Teva Pharmaceuticals USA, Inc., which had notified Plaintiffs that, on or before March 9, 2017, it had amended its ANDA seeking to obtain approval to market generic versions of Delzicol ® On December 18, 2017, Plaintiffs Allergan Sales, LLC and Qualicaps Co., Ltd. entered into a settlement agreement with Mylan and the actions with respect to Mylan were subsequently dismissed. Under the terms of the settlement agreement, Mylan may launch its generic version of Delzicol ® Delzicol ® On November 4, 2016, Mylan Pharmaceuticals Inc. (“Mylan”) filed a petition for Review (“IPR”) with the USPTO regarding U.S. Patent No. 6,649,180 (the “‘180 patent”). Qualicaps Co., Ltd.’s filed a patent owner preliminary response on February 17, 2017. On May 17, 2017, the USPTO granted Mylan’s petition to institute an IPR on certain grounds with respect to claims 1 and 4 of the ‘180 patent. On July 21, 2017, Qualicaps filed a patent owner response. September 15, 2017, Mylan filed a reply. A hearing is scheduled for January 25, 2018. On December 18, 2017, Allergan Sales, LLC and Qualicaps Co., Ltd. entered into a settlement agreement with Mylan and certain Mylan affiliates. On December 19, 2017, the USPTO granted the parties’ joint motion to terminate the IPR proceedings. Fetzima ® In September and October 2017, certain Allergan subsidiaries and Pierre Fabre Medicament received Paragraph IV certification notice letters from Amneal Pharmaceuticals LLC, Aurobindo Pharma USA, Inc., MSN Laboratories Private Limited, Prinston Pharmaceutical Inc., Torrent Pharmaceuticals Limited, West-Ward Pharmaceuticals International Limited, and Zydus Pharmaceuticals (USA) Inc. indicating that they had submitted to FDA ANDAs seeking approval to manufacture and sell generic versions of FETZIMA ® On October 30, 2017, Forest Laboratories, LLC (which later merged with and into Allergan Sales, LLC, with Allergan Sales, LLC as the surviving entity) and Forest Laboratories Holdings Limit

Warner Chilcott Limited ("WCL")

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	12 Months Ended
	Dec. 31, 2017
Warner Chilcott Acquisition [Member]
Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	NOTE 25 — Warner Chilcott Limited (“WCL”) Guarantor and Non-Guarantor Condensed Consolidating Financial Information The following financial information is presented to segregate the financial results of WCL, Allergan Funding SCS, and Allergan Finance, LLC (the issuers of the long-term notes), the guarantor subsidiaries for the long-term notes and the non-guarantor subsidiaries. The guarantors jointly and severally, and fully and unconditionally, guarantee the Company’s obligation under the long-term notes. The information includes elimination entries necessary to consolidate the guarantor and the non-guarantor subsidiaries. Investments in subsidiaries are accounted for using the equity method of accounting. The principal elimination entries eliminate investments in subsidiaries, equity and intercompany balances and transactions. WCL, Allergan Capital S.a.r.l. and Allergan Finance, LLC are guarantors of the long-term notes. The Company anticipates future legal entity structure changes which may impact the presentation of this footnote in the near future. Warner Chilcott Limited has revised its consolidating financial statements as previously presented in its balance sheet in Footnote 25 of the 2016 Annual Report on Form 10-K due to a change in the Company’s legal entity structure and other reclassifications that occurred during the year ended December 31, 2017. As a result, prior period information has been recast to conform to the current period presentation. The following financial information presents the consolidating balance sheets as of December 31, 2017 and 2016, the related statements of operations and comprehensive income / loss for the years ended December 31, 2017, 2016 and 2015 and the statements of cash flows for the years ended December 31, 2017, 2016 and 2015. Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 593.1 $ 0.1 $ - $ 1,223.0 $ - $ 1,816.3 Marketable securities - 400.2 - - 4,231.9 - 4,632.1 Accounts receivable, net - - - - 2,899.0 - 2,899.0 Receivables from Parents - 4,223.5 - - 1,573.9 - 5,797.4 Inventories - - - - 904.5 - 904.5 Intercompany receivables - 8,118.7 5,507.6 19.6 25,417.0 (39,062.9 ) - Prepaid expenses and other current assets - - - 85.0 1,038.0 - 1,123.0 Total current assets 0.1 13,335.5 5,507.7 104.6 37,287.3 (39,062.9 ) 17,172.3 Property, plant and equipment, net - - - - 1,785.4 - 1,785.4 Investments and other assets - - - - 267.9 - 267.9 Investment in subsidiaries 81,282.1 87,530.6 - 110,114.8 - (278,927.5 ) - Non current intercompany receivables - 27,518.7 20,985.0 - 30,544.0 (79,047.7 ) - Non current receivables from Parents - - - - 3,964.0 - 3,964.0 Non current assets held for sale - - - - 81.6 - 81.6 Deferred tax assets - - - - 316.0 - 316.0 Product rights and other intangibles - - - - 54,648.3 - 54,648.3 Goodwill - - - - 49,862.9 - 49,862.9 Total assets $ 81,282.2 $ 128,384.8 $ 26,492.7 $ 110,219.4 $ 178,757.4 $ (397,038.1 ) $ 128,098.4 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.6 202.9 89.3 5,222.8 - 5,515.6 Intercompany payables - 12,186.2 1,828.5 11,402.3 13,645.9 (39,062.9 ) - Payables to Parents - - - - 2,340.6 - 2,340.6 Income taxes payable - - - - 74.9 - 74.9 Current portion of long-term debt and capital leases - - 3,475.4 - 756.4 - 4,231.8 Total current liabilities - 12,186.8 5,506.8 11,491.6 22,040.6 (39,062.9 ) 12,162.9 Long-term debt and capital leases - - 20,985.0 2,130.1 2,728.4 - 25,843.5 Other long-term liabilities - 0.2 - - 886.7 - 886.9 Long-term intercompany payables - 30,395.0 - 149.0 48,503.7 (79,047.7 ) - Other taxes payable - - - - 1,573.5 - 1,573.5 Deferred tax liabilities - 0.2 - - 6,349.2 - 6,349.4 Total liabilities - 42,582.2 26,491.8 13,770.7 82,082.1 (118,110.6 ) 46,816.2 Total equity / (deficit) 81,282.2 85,802.6 0.9 96,448.7 96,675.3 (278,927.5 ) 81,282.2 Total liabilities and equity $ 81,282.2 $ 128,384.8 $ 26,492.7 $ 110,219.4 $ 178,757.4 $ (397,038.1 ) $ 128,098.4 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2016 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 513.9 $ - $ - $ 1,199.2 $ - $ 1,713.2 Marketable securities - 6,351.8 - - 5,149.7 - 11,501.5 Accounts receivable, net - - - - 2,531.0 - 2,531.0 Receivables from Parents - 4,196.9 - - 5,092.3 - 9,289.2 Inventories - - - - 718.0 - 718.0 Intercompany receivables - 24,348.6 3,343.5 81.6 66,840.8 (94,614.5 ) - Prepaid expenses and other current assets - 14.2 - 42.7 1,325.2 - 1,382.1 Total current assets 0.1 35,425.4 3,343.5 124.3 82,856.2 (94,614.5 ) 27,135.0 Property, plant and equipment, net - - - - 1,611.3 - 1,611.3 Investments and other assets - - - 15.8 266.3 - 282.1 Investment in subsidiaries 88,093.4 89,219.0 - 108,902.4 - (286,214.8 ) - Non current intercompany receivables - 27,706.6 22,540.1 - 9,686.6 (59,933.3 ) - Non current receivables from Parents - - - - 3,964.0 - 3,964.0 Non current assets held for sale - - - - 27.0 - 27.0 Deferred tax assets - - - - 233.3 - 233.3 Product rights and other intangibles - - - - 62,618.6 - 62,618.6 Goodwill - - - - 46,356.1 - 46,356.1 Total assets $ 88,093.5 $ 152,351.0 $ 25,883.6 $ 109,042.5 $ 207,619.4 $ (440,762.6 ) $ 142,227.4 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - - 208.9 - 4,784.4 - 4,993.3 Intercompany payables - 55,828.8 1,652.9 9,359.1 27,773.7 (94,614.5 ) - Payables to Parents - 334.1 - - 1,038.7 - 1,372.8 Income taxes payable - - - - 57.8 - 57.8 Current portion of long-term debt and capital leases - - 1,478.1 1,197.4 122.4 - 2,797.9 Total current liabilities - 56,162.9 3,339.9 10,556.5 33,777.0 (94,614.5 ) 9,221.8 Long-term debt and capital leases - - 22,540.1 3,079.0 4,351.7 - 29,970.8 Other long-term liabilities - - - - 1,086.0 - 1,086.0 Long-term intercompany payables - 9,537.6 - 149.0 50,246.7 (59,933.3 ) - Other taxes payable - - - - 886.2 - 886.2 Deferred tax liabilities - - - - 12,969.1 - 12,969.1 Total liabilities - 65,700.5 25,880.0 13,784.5 103,316.7 (154,547.8 ) 54,133.9 Total equity / (deficit) 88,093.5 86,650.5 3.6 95,258.0 104,302.7 (286,214.8 ) 88,093.5 Total liabilities and equity $ 88,093.5 $ 152,351.0 $ 25,883.6 $ 109,042.5 $ 207,619.4 $ (440,762.6 ) $ 142,227.4 Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 15,940.7 $ - $ 15,940.7 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,168.0 - 2,168.0 Research and development - - - - 2,100.1 - 2,100.1 Selling and marketing - - - - 3,514.8 - 3,514.8 General and administrative - - 8.6 1.1 1,392.6 - 1,402.3 Amortization - - - - 7,197.1 - 7,197.1 In-process research and development impairments - - - - 1,452.3 - 1,452.3 Asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Total operating expenses - - 8.6 1.1 21,752.6 - 21,762.3 Operating income / (loss) - - (8.6 ) (1.1 ) (5,811.9 ) - (5,821.6 ) Non-operating income / (expense): Interest income / (expense), net - 845.5 116.6 (131.2 ) (1,760.2 ) - (929.3 ) Other income / (expense), net - - (110.4 ) (66.7 ) (3,260.2 ) - (3,437.3 ) Total other income / (expense), net - 845.5 6.2 (197.9 ) (5,020.4 ) - (4,366.6 ) Income / (loss) before income taxes and noncontrolling interest - 845.5 (2.4 ) (199.0 ) (10,832.3 ) - (10,188.2 ) Provision / (benefit) for income taxes - 5.0 0.3 (177.3 ) (6,498.4 ) - (6,670.4 ) (Earnings) / losses of equity interest subsidiaries 3,927.3 4,841.4 - 610.6 - (9,379.3 ) - Net income / (loss) from continuing operations, net of tax (3,927.3 ) (4,000.9 ) (2.7 ) (632.3 ) (4,333.9 ) 9,379.3 (3,517.8 ) (Loss) from discontinued operations, net of tax - - - - (402.9 ) - (402.9 ) Net income / (loss) (3,927.3 ) (4,000.9 ) (2.7 ) (632.3 ) (4,736.8 ) 9,379.3 (3,920.7 ) (Income) attributable to noncontrolling interest - - - - (6.6 ) - (6.6 ) Net income / (loss) attributable to members (3,927.3 ) (4,000.9 ) (2.7 ) (632.3 ) (4,743.4 ) 9,379.3 (3,927.3 ) Other comprehensive (loss) / income, net of tax 2,959.1 3,153.0 - 1,823.0 2,959.1 (7,935.1 ) 2,959.1 Comprehensive income / (loss) attributable to members $ (968.2 ) $ (847.9 ) $ (2.7 ) $ 1,190.7 $ (1,784.3 ) $ 1,444.2 $ (968.2 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2016 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 14,570.6 $ - $ 14,570.6 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,860.8 - 1,860.8 Research and development - - - - 2,575.7 - 2,575.7 Selling and marketing - - - - 3,266.4 - 3,266.4 General and administrative - - - 19.8 1,330.6 - 1,350.4 Amortization - - - - 6,470.4 - 6,470.4 In-process research and development impairments - - - - 743.9 - 743.9 Asset sales and impairments, net - - - - 5.0 - 5.0 Total operating expenses - - - 19.8 16,252.8 - 16,272.6 Operating income / (loss) - - - (19.8 ) (1,682.2 ) - (1,702.0 ) Non-operating income / (expense): Interest income / (expense), net - 2,255.3 3.4 (157.1 ) (3,286.1 ) - (1,184.5 ) Other income / (expense), net - - - - 172.2 - 172.2 Total other income / (expense), net - 2,255.3 3.4 (157.1 ) (3,113.9 ) - (1,012.3 ) Income / (loss) before income taxes and noncontrolling interest - 2,255.3 3.4 (176.9 ) (4,796.1 ) - (2,714.3 ) Provision / (benefit) for income taxes - - 0.1 66.3 (1,963.4 ) - (1,897.0 ) (Earnings) / losses of equity interest subsidiaries (15,091.1 ) (9,342.8 ) - (18,837.8 ) - 43,271.7 - Net income / (loss) from continuing operations, net of tax 15,091.1 11,598.1 3.3 18,594.6 (2,832.7 ) (43,271.7 ) (817.3 ) Income from discontinued operations, net of tax - - - - 15,914.5 - 15,914.5 Net income / (loss) 15,091.1 11,598.1 3.3 18,594.6 13,081.8 (43,271.7 ) 15,097.2 (Income) attributable to noncontrolling interest - - - - (6.1 ) - (6.1 ) Net income / (loss) attributable to members 15,091.1 11,598.1 3.3 18,594.6 13,075.7 (43,271.7 ) 15,091.1 Other comprehensive (loss) / income, net of tax (544.3 ) (419.9 ) - (2,822.2 ) (544.3 ) 3,786.4 (544.3 ) Comprehensive income / (loss) attributable to members $ 14,546.8 $ 11,178.2 $ 3.3 $ 15,772.4 $ 12,531.4 $ (39,485.3 ) $ 14,546.8 Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 12,688.1 - 12,688.1 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,751.8 - 2,751.8 Research and development - - - - 2,358.5 - 2,358.5 Selling and marketing - - - - 2,765.1 - 2,765.1 General and administrative - 212.1 16.1 - 1,352.8 - 1,581.0 Amortization - - - - 5,443.7 - 5,443.7 In-process research and development impairments - - - - 511.6 - 511.6 Asset sales and impairments, net - - - - 272.0 - 272.0 Total operating expenses - 212.1 16.1 - 15,455.5 - 15,683.7 Operating income / (loss) - (212.1 ) (16.1 ) - (2,767.4 ) - (2,995.6 ) Non-operating income / (expense): Interest income / (expense), net - 1,572.4 (14.6 ) (168.5 ) (2,572.0 ) - (1,182.7 ) Other income / (expense), net - (265.4 ) 31.0 - 0.6 - (233.8 ) Total other income / (expense), net - 1,307.0 16.4 (168.5 ) (2,571.4 ) - (1,416.5 ) Income / (loss) before income taxes and noncontrolling interest - 1,094.9 0.3 (168.5 ) (5,338.8 ) - (4,412.1 ) Provision / (benefit) for income taxes - - - (58.3 ) (1,547.6 ) - (1,605.9 ) (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (3,412.3 ) - 11,799.4 - Net income / (loss) from continuing operations, net of tax 4,050.6 5,431.4 0.3 3,302.1 (3,791.2 ) (11,799.4 ) (2,806.2 ) Income from discontinued operations, net of tax - - - - 6,861.0 - 6,861.0 Net income / (loss) 4,050.6 5,431.4 0.3 3,302.1 3,069.8 (11,799.4 ) 4,054.8 (Income) attributable to noncontrolling interest - - - - (4.2 ) - (4.2 ) Net income / (loss) attributable to members 4,050.6 5,431.4 0.3 3,302.1 3,065.6 (11,799.4 ) 4,050.6 Other comprehensive (loss) / income, net of tax (28.7 ) 24.5 - (28.7 ) (28.7 ) 32.9 (28.7 ) Comprehensive income / (loss) attributable to members $ 4,021.9 $ 5,455.9 $ 0.3 $ 3,273.4 $ 3,036.9 $ (11,766.5 ) $ 4,021.9 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ (3,927.3 ) $ (4,000.9 ) $ (2.7 ) $ (632.3 ) $ (4,736.8 ) $ 9,379.3 $ (3,920.7 ) Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries 3,927.3 4,841.4 - 610.6 - (9,379.3 ) - Depreciation - - - - 171.5 - 171.5 Amortization - - - - 7,197.1 - 7,197.1 Provision for inventory reserve - - - - 102.2 - 102.2 Share-based compensation - - - - 293.3 - 293.3 Deferred income tax benefit - - - - (7,783.1 ) - (7,783.1 ) In-process research and development impairments - - - - 1,452.3 - 1,452.3 Loss / (gain) on asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Net income impact of other-than-temporary loss on investment in Teva securities - - - - 3,273.5 - 3,273.5 Charge to settle Teva related matters - - - - 387.4 - 387.4 Loss on forward sale of Teva shares - - - - 62.9 - 62.9 Amortization of inventory step-up - - - - 131.7 - 131.7 Non-cash extinguishment of debt - - 17.6 12.2 (45.5 ) - (15.7 ) Amortization of deferred financing costs - - 23.3 4.5 - - 27.8 Contingent consideration adjustments, including accretion - - - - (133.2 ) - (133.2 ) Dividends from subsidiaries 1,668.2 - - - - (1,668.2 ) - Other, net - (10.0 ) - - (27.0 ) - (37.0 ) Changes in assets and liabilities (net of effects of acquisitions) - (4,228.1 ) (241.5 ) 2,148.3 3,207.3 - 886.0 Net cash provided by / (used in) operating activities 1,668.2 (3,397.6 ) (203.3 ) 2,143.3 7,481.3 (1,668.2 ) 6,023.7 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (349.9 ) - (349.9 ) Additions to product rights and other intangibles - - - - (614.3 ) - (614.3 ) Additions to investments - (4,389.6 ) - - (5,394.2 ) - (9,783.8 ) Proceeds from sale of investments and other assets - 7,866.4 - - 7,286.9 - 15,153.3 Proceeds from sales of property, plant and equipment - - - - 7.1 - 7.1 Acquisitions of businesses, net of cash acquired - - - - (5,290.4 ) - (5,290.4 ) Net cash (used in) / provided by investing activities - 3,476.8 - - (4,354.8 ) - (878.0 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - 3,020.9 - 529.1 - 3,550.0 Debt issuance and other financing costs - - (17.5 ) - (3.1 ) - (20.6 ) Payments on debt, including capital lease obligations and credit facility - - (2,800.0 ) (2,143.3 ) (1,470.3 ) - (6,413.6 ) Payments of contingent consideration and other financing - - - - (511.6 ) - (511.6 ) Dividends to Parents (1,668.2 ) - - - (1,668.2 ) 1,668.2 (1,668.2 ) Net cash (used in) / provided by financing activities (1,668.2 ) - 203.4 (2,143.3 ) (3,124.1 ) 1,668.2 (5,064.0 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 21.4 - 21.4 Net increase / (decrease) in cash and cash equivalents - 79.2 0.1 - 23.8 - 103.1 Cash and cash equivalents at beginning of period 0.1 513.9 - - 1,199.2 - 1,713.2 Cash and cash equivalents at end of period $ 0.1 $ 593.1 $ 0.1 $ - $ 1,223.0 $ - $ 1,816.3 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2016 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 15,091.1 $ 11,598.1 $ 3.3 $ 18,594.6 $ 13,081.8 $ (43,271.7 ) $ 15,097.2 Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries (15,091.1 ) (9,342.8 ) - (18,837.8 ) - 43,271.7 - Depreciation - - - - 155.8 - 155.8 Amortization - - - - 6,475.2 - 6,475.2 Provision for inventory reserve - - - - 181.4 - 181.4 Share-based compensation - - - - 334.5 - 334.5 Deferred income tax benefit - - - - (1,443.9 ) - (1,443.9 ) Pre-tax gain on sale of businesses to Teva - - - - (24,511.1 ) - (24,511.1 ) Non-cash tax effect of gain on sale of businesses to Teva - - - - 5,285.2 - 5,285.2 In-process research and development impairments - - - - 743.9 - 743.9 Loss / (gain) on asset sales and impairments, net - - - - 5.0 - 5.0 Amortization of inventory step-up - - - - 42.4 - 42.4 Amortization of deferred financing costs - 23.5 23.3 4.2 - - 51.0 Contingent consideration adjustments, including accretion - - - - (66.8 ) - (66.8 ) Dividends from subsidiaries 2,034.8 - - - - (2,034.8 ) - Other, net - - - - (59.9 ) - (59.9 ) Changes in assets and liabilities (net of effects of acquisitions) 0.1 16,536.2 473.4 237.0 (17,957.6 ) - (710.9 ) Net cash provided by / (used in) operating activities 2,034.9 18,815.0 500.0 (2.0 ) (17,734.1 ) (2,034.8 ) 1,579.0 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (331.4 ) - (331.4 ) Additions to product rights and other intangibles - - - - (2.0 ) - (2.0 ) Sale of businesses to Teva - - - - 33,804.2 - 33,804.2 Additions to investments - (6,351.8 ) - - (9,391.7 ) - (15,743.5 ) Proceeds from sale of investments and other assets - - - - 7,771.6 - 7,771.6 Loans to Parents - (4,196.9 ) - - (9,035.3 ) - (13,232.2 ) Proceeds from sales of property, plant and equipment - - - - 33.3 - 33.3 Acquisitions of businesses, net of cash acquired - - - - (1,198.9 ) - (1,198.9 ) Net cash (used in) / provided by investing activities - (10,548.7 ) - - 21,649.8 - 11,101.1 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 1,050.0 - - - - 1,050.0 Payments on debt, including capital lease obligations and credit facility - (8,815.9 ) (500.0 ) - (1,532.8 ) - (10,848.7 ) Payments of contingent consideration and other financing - - - - (161.1 ) - (161.1 ) Dividends to Parents (2,034.8 ) - - - (2,034.8 ) 2,034.8 (2,034.8 ) Net cash (used in) / provided by financing activities (2,034.8 ) (7,765.9 ) (500.0 ) - (3,728.7 ) 2,034.8 (11,994.6 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - (8.5 ) - (8.5 ) Net increase / (decrease) in cash and cash equivalents 0.1 500.4 - (2.0 ) 178.5 - 677.0 Cash and cash equivalents at beginning of period - 13.5 - 2.0 1,020.7 - 1,036.2 Cash and cash equivalents at end of period $ 0.1 $ 513.9 $ - $ - $ 1,199.2 $ - $ 1,713.2 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 4,050.6 $ 5,431.4 $ 0.3 $ 3,302.1 $ 3,069.8 $ (11,799.4 ) $ 4,054.8 Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (3,412.3 ) - 11,799.4 - Depreciation - - - 0.2 218.1 - 218.3 Amortization - - - - 5,777.0 - 5,777.0 Provision for inventory reserve - - - - 140.9 - 140.9 Share-based compensation - - - 51.6 638.8 - 690.4 Deferred income tax benefit - - - - (7,380.1 ) - (7,380.1 ) In-process research and development impairments - - - - 511.6 - 511.6 Loss / (gain) on asset sales and impairments, net - - - - 334.4 334.4 Amortization of inventory step-up - - - - 1,192.9 - 1,192.9 Amortization of deferred financing costs - 272.5 20.9 4.1 0.8 - 298.3 Contingent consideration adjustments, including accretion - - - - 108.8 - 108.8 Dividends from subsidiaries 208.1 208.1 - - - (416.2 ) - Other, net - - - - 66.4 - 66.4 Changes in assets and liabilities (net of effects of acquisitions) (0.1 ) (370.6 ) 122.5 97.7 (1,199.2 ) - (1,349.7 ) Net cash provided by / (used in) operating activities 208.0 1,204.9 143.7 43.4 3,480.2 (416.2 ) 4,664.0 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - (42.9 ) (412.0 ) - (454.9 ) Additions to product rights and other intangibles - - - - (154.7 ) - (154.7 ) Additions to investments (9,000.8 ) (9,000.8 ) - - (24.3 ) 18,001.6 (24.3 ) Proceeds from sale of investments and other assets - - - - 883.0 - 883.0 Proceeds from sales of property, plant and equipment - - - - 140.1 - 140.1 Acquisitions of businesses, net of cash acquired - - - - (37,510.1 ) - (37,510.1 ) Net cash (used in) / provided by investing activities (9,000.8 ) (9,000.8 ) - (42.9 ) (37,078.0 ) 18,001.6 (37,120.9 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 9,110.0 20,955.6 - 72.1 - 30,137.7 Financing structure and other activity with affiliates - (5,500.0 ) (20,955.6 ) - 26,455.6 - - Debt issuance and other financing costs - (167.1 ) (143.7 ) - - - (310.8 ) Payments on debt, including capital lease obligations and credit facility - (4,431.7 ) - - (702.5 ) - (5,134.2 ) Payments of contingent consideration and other financing - - - - (230.1 ) - (230.1 ) Dividends to Parents (208.1 ) (208.1 ) - - (208.1 ) 416.2 (208.1 ) Contributions from Parents 9,000.8 9,000.8 - - 9,000.8 (18,001.6 ) 9,000.8 Net cash provided by / (used in) financing activities 8,792.7 7,803.9 (143.7 ) - 34,387.8 (17,585.4 ) 33,255.3 Effect of currency exchange rate changes on cash and cash equivalents - - - - (6.5 ) - (6.5 ) Net increase / (decrease) in cash and cash equivalents (0.1 ) 8.0 - 0.5 783.5 - 791.9 Cash and cash equivalents at beginning of period 0.1 5.5 - 1.5 237.2 - 244.3 Cash and cash equivalents at end of period $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2

Compensation

Compensation	12 Months Ended
	Dec. 31, 2017
Compensation Related Costs [Abstract]
Compensation	NOTE 26 — Compensation The following table represents compensation costs for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Year Ended December 31, 2017 2016 2015 Wages and salaries $ 1,892.8 $ 2,108.7 $ 2,252.3 Stock-based compensation 308.0 396.1 925.7 Pensions 82.7 156.8 99.9 Social welfare 150.4 165.0 185.1 Other benefits 265.1 321.0 271.6 Total $ 2,699.0 $ 3,147.6 $ 3,734.6 Amount included in continuing operations $ 2,699.0 $ 2,578.4 $ 2,597.7 Amount included in discontinued operations $ - $ 569.2 $ 1,136.9

Concentration

Concentration	12 Months Ended
	Dec. 31, 2017
Risks And Uncertainties [Abstract]
Concentration	NOTE 27 — Concentration The Company considers there to be a concentration risk for customers that account for 10% or more of their third party revenues. The following table illustrates any customer which accounted for 10% or more of our annual revenues within the U.S. and Canada in any of the past three fiscal years and the respective percentage of our revenues for which they account for each of the last three years: Customer 2017 2016 2015 McKesson Corporation 23 % 23 % 27 % Cardinal Health, Inc. 19 % 18 % 20 % AmerisourceBergen Corporation 19 % 18 % 19 % Changes in the mix of concentration amongst the Company’s largest customers are due, in part, to the impact of acquisitions as well as changes in the supply chain of our indirect customers. No other country outside the U.S. and Canada had 10% or more of global sales. The Company’s accounts receivable primarily arise from product sales in North America and Europe and primarily represent amounts due from wholesalers, distributors, drug store chains and service providers in the health care and pharmaceutical industries, public hospitals and other government entities. Approximately 58% and 59% of the gross accounts receivable balance are concentrated among the Company’s three largest customers as of December 31, 2017 and 2016, respectively. The Company performs ongoing credit evaluations of its customers and maintains an allowance for potential uncollectible accounts. Actual losses from uncollectible accounts have been minimal. Outside of the U.S., concentrations of credit risk with respect to accounts receivable are limited due to the wide variety of customers and markets using the Company’s products, as well as their dispersion across many different geographic areas. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The Company does not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on its financial position, liquidity or results of operations. Certain of the Company’s finished products and raw materials are obtained from single source suppliers. Although the Company seeks to identify more than one source for its various finished products and raw materials, loss of a single source supplier could have an adverse effect on the Company’s results of operations, financial condition and cash flows. Further, a second source supplier may not be able to produce the same volumes of inventory as the Company’s primary supplier. No third party manufacturer accounted for 10% or more of the Company’s products sold based on third-party revenues for the year ended December 31, 2017.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 28 — Subsequent Events Elastagen Pty Ltd On February 6, 2018, the Company completed the acquisition of Elastagen Pty Ltd for approximately $95.0 million, which was accounted for as an asset acquisition and expensed as a component of R&D during the first quarter of 2018. Under the terms of the agreement, Elastagen Pty Ltd is eligible to receive additional consideration of up to $165.0 million. Repros Therapeutics, Inc. On January 31, 2018, the Company completed the acquisition of Repros Therapeutics, Inc. for approximately $31.0 million, which was accounted for as an asset acquisition and expensed as a component of R&D during the first quarter of 2018.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Valuation And Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II Allergan plc Warner Chilcott Limited Valuation and Qualifying Accounts Years Ended December 31, 2017, 2016 and 2015 ($ in millions) Balance at Beginning of Period Charged to Costs and Expenses Deductions/ Write-offs Other* Balance at End of Period Allowance for doubtful accounts: Year ended December 31, 2017 $ 75.7 $ 11.6 $ (1.7 ) $ 7.4 $ 93.0 Year ended December 31, 2016 $ 80.6 $ 3.5 $ (8.4 ) $ - $ 75.7 Year ended December 31, 2015 $ 4.8 $ 8.4 $ (7.3 ) $ 74.7 $ 80.6 Tax valuation allowance: Year ended December 31, 2017 $ 183.9 $ 230.1 $ - $ (10.2 ) $ 403.8 Year ended December 31, 2016 $ 196.2 $ 183.8 $ - $ (196.1 ) $ 183.9 Year ended December 31, 2015 $ 474.0 $ (335.6 ) $ - $ 57.8 $ 196.2 *Includes opening balances of businesses acquired in the period and reclasses to assets held for sale.

Supplementary Data

Supplementary Data	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Supplementary Data	SUPPLEMENTARY DATA (UNAUDITED) Selected unaudited quarterly consolidated financial data and market price information are shown below ($ in millions except per share data): For Three Month Periods Ended Year Ended 12/31/2017 Dec. 31, 2017 Sept. 30, 2017 June 30, 2017 Mar. 31, 2017 Net revenues $ 15,940.7 $ 4,326.1 $ 4,034.3 $ 4,007.4 $ 3,572.9 Net income/(loss) $ (4,118.9 ) $ 3,123.2 $ (3,954.0 ) $ (723.9 ) $ (2,564.2 ) Basic earnings per share (13.19 ) 9.21 (12.07 ) (2.37 ) (7.86 ) Diluted earnings per share (13.19 ) 8.88 (12.07 ) (2.37 ) (7.86 ) Market price per share: High $ 210.98 $ 256.15 $ 248.91 $ 249.32 Low $ 163.58 $ 202.66 $ 218.73 $ 210.80 For Three Month Periods Ended Year Ended 12/31/2016 Dec. 31, 2016 Sept. 30, 2016 June 30, 2016 Mar. 31, 2016 Net revenues $ 14,570.6 $ 3,864.3 $ 3,622.2 $ 3,684.8 $ 3,399.3 Net income/(loss) $ 14,979.5 $ 1.2 $ 15,221.8 $ (499.9 ) $ 256.4 Basic earnings per share 38.18 (0.20 ) 38.58 (1.44 ) 0.47 Diluted earnings per share 38.18 (0.20 ) 38.58 (1.44 ) 0.47 Market price per share: High $ 244.66 $ 261.27 $ 277.96 $ 310.83 Low $ 184.50 $ 228.68 $ 195.50 $ 261.60

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented. The Company’s consolidated financial statements include the financial results of all acquired companies subsequent to the acquisition date.
Reclassifications	Reclassifications In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Effective January 1, 2017, the Company prospectively adopted the guidance and as a result of implementation, the Company reduced previously reported Retained Earnings by $62.4 million and increased previously reported Additional-Paid-In-Capital by $62.4 million. In addition, the Company decreased its net Deferred Tax Liabilities and increased Retained Earnings by $20.8 million for the tax impact of this change. The Company also revised its presentation of previously reported cash flows by eliminating the presentation of “Excess tax benefit from stock-based compensation” which raised operating cash flows and reduced financing cash flows for the year ended December 31, 2016 by $20.4 million.
Use of Estimates	Use of Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to the determination of SRAs (defined below) included within either accounts receivable or accrued liabilities, the valuation of inventory balances, the determination of useful lives for intangible assets, pension and other post-retirement benefit plan assumptions, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment and recognition and measurement of assets acquired and liabilities assumed in business combinations at fair value. The estimation process required to prepare the Company’s consolidated financial statements requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. The Company’s actual results could differ materially from those estimates.
Foreign Currency Translation	Foreign Currency Translation For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive (loss) / income. The effects of revaluing non-functional currency assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. The Company realizes foreign currency gains / (losses) in the normal course of business based on movement in the applicable exchange rates. These transactional gains / (losses) are included as a component of general and administrative expenses.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in banks, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Fair Value of Other Financial Instruments	Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, investments, trade accounts payable, and long-term debt, including the current portion. The carrying amounts of cash and cash equivalents, marketable securities, accounts and other receivables and trade accounts payable are representative of their respective fair values due to their relatively short maturities. The fair values of investments in companies that are publicly traded and not accounted for under the equity method are based on quoted market prices. The Company estimates the fair value of its fixed rate long-term obligations based on quoted market rates.
Inventories	Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventory includes brand pharmaceutical and medical aesthetic products which represent Food and Drug Administration (“FDA”) approved or likely to be approved indications. Inventory valuation reserves are established based on a number of factors/situations including, but not limited to, raw materials, work in process or finished goods not meeting product specifications, product obsolescence, or application of the lower of cost (first-in, first-out method) or market (net realizable value) concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. Assumptions utilized in our quantification of inventory reserves include, but are not limited to, estimates of future product demand, consideration of current and future market conditions, product net selling price, anticipated product launch dates, potential product obsolescence and other events relating to special circumstances surrounding certain products. No material adjustments have been required to our inventory reserve estimates for the periods presented. Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Major renewals and improvements are capitalized, while routine maintenance and repairs are expensed as incurred. The Company capitalizes interest on qualified construction projects. At the time property, plant and equipment are retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is computed principally on the straight-line method, over the estimated useful lives of the related assets. The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years The Company assesses property, plant and equipment for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable.
Investments	Investments The Company’s equity investments are accounted for under the equity method of accounting when the Company can exert significant influence and the Company’s ownership interest does not exceed 50%. The Company records equity method investments at cost and adjusts for the appropriate share of investee net earnings or losses. Investments in which the Company owns less than a 20% interest and cannot exert significant influence are accounted for using the cost method if the fair value of such investments is not readily determinable.
Marketable Securities	Marketable Securities The Company’s marketable securities consist of U.S. treasury and agency securities and debt and equity securities of publicly-held companies. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices. Unrealized temporary adjustments to fair value were included on the balance sheet in a separate component of shareholders’ equity as unrealized gains and losses and are reported as a component of accumulated other comprehensive income / (loss) as of December 31, 2017. No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Product Rights and Other Definite-Lived Intangible Assets	Product Rights and Other Definite-Lived Intangible Assets Our product rights and other definite-lived intangible assets are stated at cost, less accumulated amortization, and are amortized using the economic benefit model or the straight-line method, if results are materially aligned, over their estimated useful lives. We determine amortization periods for product rights and other definite-lived intangible assets based on our assessment of various factors impacting estimated useful lives and cash flows. Such factors include the product’s position in its life cycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in a reduction in the intangibles useful life and an acceleration of related amortization expense, which could cause our net results to decline. Product rights and other definite-lived intangible assets are tested periodically for impairment when events or changes in circumstances indicate that an asset’s carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in net (loss) / income in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Our projections of discounted cash flows use a discount rate determined by our management to be commensurate with the risk inherent in our business model. Our estimates of future cash flows attributable to our other definite-lived intangible assets require significant judgment based on our historical and anticipated results and are subject to many factors. Different assumptions and judgments could materially affect the calculation of the fair value of the other definite-lived intangible assets which could trigger impairment.
Goodwill and Intangible Assets with Indefinite Lives	Goodwill and Intangible Assets with Indefinite-Lives The Company tests goodwill and intangible assets with indefinite-lives for impairment annually in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income and this could result in a material impact to net income / (loss) and income / (loss) per share. Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to acquired research and development projects that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that the Company has acquired with respect to products and/or processes that have not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired, if there is no future alternative use or no market for which to sell the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, R&D costs, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. Changes in these assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of the product, we will make a separate determination of the useful life of the intangible, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life.
Contingent Consideration	Contingent Consideration Contingent consideration is recorded at the acquisition date estimated fair value of the contingent payment for all applicable acquisitions. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statements of operations. (Refer to “NOTE 23 — Fair Value Measurement” for additional details regarding the fair value of contingent consideration.)
Revenue Recognition	Revenue Recognition General During the years ended December 31, 2017, 2016 and 2015, revenue from product sales was recognized when title and risk of loss to the product transfers to the customer, which is based on the transaction shipping terms. Recognition of revenue also requires reasonable assurance of collection of sales proceeds, the seller’s price to the buyer to be fixed or determinable and the completion of all performance obligations. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, sales returns and allowances, commercial and government rebates, customer loyalty programs and fee-for-service arrangements with certain distributors, which we refer to in the aggregate as “SRA”. Royalty and commission revenue is recognized as a component of net revenues in accordance with the terms of their respective contractual agreements when collectability is reasonably assured and when revenue can be reasonably measured.
Provisions for SRAs	Provisions for SRAs As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes gross revenue from the sale of products, an estimate of SRA is recorded, which reduces the product revenues. Accounts receivable and/or accrued liabilities are also reduced and/or increased by the SRA amount depending on whether we have the right of offset with the customer. These provisions are estimated based on historical payment experience, historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material revenue adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback payments. We continually monitor current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states / authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for the cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, promotional allowances, and loyalty cards. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are not permitted. Customer returns of product are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes which may impact future expected returns. Promotional allowances are credits that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Loyalty cards allow the end user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2014 $ 28.0 $ 995.8 $ 255.2 $ 16.3 $ 1,295.3 Add: Allergan Acquisition 14.1 306.4 100.4 8.6 429.5 Provision related to sales in 2015 649.9 4,035.7 659.9 275.6 5,621.1 Credits and payments (613.8 ) (3,993.5 ) (648.0 ) (275.4 ) (5,530.7 ) Balance at December 31, 2015 $ 78.2 $ 1,344.4 $ 367.5 $ 25.1 $ 1,815.2 Provision related to sales in 2016 1,003.2 4,338.7 1,390.1 306.5 7,038.5 Credits and payments (967.2 ) (4,069.1 ) (1,341.7 ) (296.9 ) (6,674.9 ) Balance at December 31, 2016 $ 114.2 $ 1,614.0 $ 415.9 $ 34.7 $ 2,178.8 Provision related to sales in 2017 1,098.7 4,891.4 1,799.3 330.6 8,120.0 Credits and payments (1,135.7 ) (4,710.4 ) (1,734.7 ) (328.8 ) (7,909.6 ) Add: LifeCell and Zeltiq Acquisitions - 4.2 37.1 - 41.3 Balance at December 31, 2017 $ 77.2 $ 1,799.2 $ 517.6 $ 36.5 $ 2,430.5 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): As of December 31, 2017 2016 Accounts receivable $ 250.6 $ 287.4 Accounts payable and accrued expenses 2,179.9 1,891.4 $ 2,430.5 $ 2,178.8 The provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Years Ended December 31, Gross Product Sales Chargebacks Rebates Returns and Other Allowances Cash Discounts Net Product Sales Percentage of Gross Product Sales 2015 $ 18,125.1 $ 649.9 $ 4,035.7 $ 659.9 $ 275.6 $ 12,504.0 69.0 % 2016 $ 21,398.6 $ 1,003.2 $ 4,338.7 $ 1,390.1 $ 306.5 $ 14,360.1 67.1 % 2017 $ 23,688.4 $ 1,098.7 $ 4,891.4 $ 1,799.3 $ 330.6 $ 15,568.4 65.7 % The following table summarizes the activity from discontinued operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2014 $ 536.9 $ 750.8 $ 356.9 $ 44.4 $ 1,689.0 Provision related to sales in 2015 5,907.2 1,991.9 729.4 277.3 8,905.8 Credits and payments (5,825.1 ) (2,011.7 ) (757.7 ) (261.6 ) (8,856.1 ) Balance at December 31, 2015 $ 619.0 $ 731.0 $ 328.6 $ 60.1 $ 1,738.7 Provision related to sales in 2016 3,525.4 1,290.4 583.0 159.1 5,557.9 Credits and payments (3,655.0 ) (1,350.0 ) (496.3 ) (155.4 ) (5,656.7 ) Disposal of businesses (489.4 ) (671.4 ) (415.3 ) (63.8 ) (1,639.9 ) Balance at December 31, 2016 $ - $ - $ - $ - $ - The Company’s divested generics business also had the following type of SRAs: • Pricing adjustments, included shelf stock adjustments which are credits issued to reflect price decreases in selling prices charged to the Company’s direct customers. Shelf stock adjustments are based upon the amount of product our customers have in their inventory at the time of an agreed-upon price reduction. The provision for shelf stock adjustments was based upon specific terms with the Company’s customers and includes estimates of existing customer inventory levels based upon their historical purchasing patterns. • Billback adjustments are credits that are issued to certain customers who purchase directly from us as well as indirectly through a wholesaler. These credits are issued in the event there was a difference between the customer’s direct and indirect contract price. The provision for billbacks was estimated based upon historical purchasing patterns of qualified customers who purchase product directly from us and supplement their purchases indirectly through our wholesale customers.
Litigation and Contingencies	Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with FASB Accounting Standards Codification (“ASC”) Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts progress or as additional information becomes available. Acquired contingencies in business combinations are recorded at fair value to the extent determinable, otherwise in accordance with ASC 450. Refer to “NOTE 24 — Commitments and Contingencies” for more information.
R&D Activities	R&D Activities R&D activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and acquisition and license related milestone payments, if any. As of December 31, 2017, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including the following: Product Therapeutic Area Indication Expected Launch Year Phase Esmya Women's Health Uterine Fibroids 2018 Review Cariprazine CNS Bipolar Depression 2019 III Ubrogepant CNS Acute Migraine 2020 III Abicipar Eye Care Age Related Macular Degeneration 2020 III Bimatoprost SR Eye Care Glaucoma 2020 III Rapastinel CNS Depression 2021 III Cenicriviroc Gastrointestinal NASH 2021 III Relamorelin Gastrointestinal Gastroparesis 2023 III Pilo/Oxy Eye Care Presbyopia 2021 II RORyT Medical Aesthetics Psoriasis 2022 II Atogepant CNS Migraine Prevention 2022 II Abicipar Eye Care Diabetic Macular Edema 2023 II Brazikumab Gastrointestinal Crohn's Disease 2024 II Botox Medical Aesthetics Platysma/Masseter 2025/2023 II Brazikumab Gastrointestinal Ulcerative Colitis 2025 I We also have a number of products in development as part of our life-cycle management strategy for our existing product portfolio.
Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed	Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed We account for acquired businesses using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values as determined using a market participant concept. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The most material line items impacted by the allocation of acquisition fair values are: • Intangible assets (including IPR&D assets upon successful completion of the project and approval of the product) which are amortized to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected future net cash flow streams, the timing of approvals and the probability of success for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the future useful lives. For these and other reasons, actual results may vary significantly from estimated results. • Inventory is recorded at fair market value factoring in selling price and costs to dispose. Inventory acquired is typically valued higher than replacement cost.
Income Taxes	Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax basis of assets and liabilities at the applicable tax rates. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets by assessing its valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in applicable tax jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company’s effective tax rate on future earnings. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first financial reporting period in which that threshold is no longer met. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within the consolidated statements of operations as income tax expense. The income tax effects of the TCJA have been initially accounted for on a provisional basis pursuant to the guidance in Staff Accouting Bulletin (“SAB”) 118. Reasonable estimates for all material tax effects of the TCJA (other than amounts related to accounting policy elections) have been provided and adjustments to provisional amounts will be made in subsequent reporting periods as information becomes available to complete provisional computations. The provisional impact of the TCJA for the Federal tax rate change and the resulting deferred tax liability for unremitted earnings will be completed in subsequent measurement periods when the required computations for the 2017 tax year and the related tax returns for the relevant entities have been completed. The final amount for the toll charge is dependent on amounts that cannot be determined until the 2018 financial results of certain non-US subsidiaries are completed. In addition, the IRS continues to issue interpretive guidance on the computation of the tax on deferred foreign earnings and therefore the computations cannot be finalized until all relevant IRS guidance has been promulgated and its impact assessed. The TCJA introduced an additional U.S. tax on certain non-U.S. subsidiaries’ earnings which are considered to be Global Intangible Low Taxed Income (referred to as “GILTI”). Under this provision, the amount of GILTI included by a U.S. shareholder will be taxed at a rate of 10.5% for tax years beginning after December 31, 2017 (increasing to 13.125% for tax years beginning after December 31, 2025) with a partial offset for foreign tax credits. Due to the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the TCJA and the application of ASC 740 and are considering if deferred tax amounts should be recorded for this provision. Our accounting policies depend, in part, on analyzing our global income to determine whether we expect material tax liabilities resulting from the application of this provision, and, if so, whether and when to record related current and deferred income taxes and whether such amounts can be reasonably estimated. Anticipated further guidance from the IRS will also clarify the manner in which the GILTI tax is computed. For these reasons, we have not recorded a deferred tax expense or benefit relating to potential GILTI tax in our 2017 consolidated financial statements and have not made a policy election regarding whether to record deferred taxes on GILTI or account for the GILTI entirely as a period cost.
Comprehensive Income / (Loss)	Comprehensive Income / (Loss) Comprehensive income / (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income / (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income / (loss), but excluded from net income / (loss) as these amounts are recorded directly as an adjustment to shareholders’ equity. The Company’s other comprehensive income / (loss) is comprised of unrealized gains / (losses) on certain holdings of publicly traded equity and debt securities, investments in U.S. treasury and agency securities and actuarial gains / (losses), and foreign currency translation adjustments.
Earnings Per Share ("EPS")	Earnings Per Share (“EPS”) The Company computes EPS in accordance with ASC Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) / income by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Diluted EPS also includes the impact of ordinary share equivalents to be issued upon the mandatory conversion of the Company’s preferred shares. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive to continuing operations. A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following ($ in millions, except per share amounts): Years Ended December 31, 2017 2016 2015 Net (loss) / income: Net (loss) attributable to ordinary shareholders excluding (loss) / income from discontinued operations, net of tax $ (4,001.0 ) $ (1,219.5 ) $ (3,177.8 ) (Loss) / income from discontinued operations, net of tax (402.9 ) 15,914.5 6,861.0 Net (loss) / income attributable to ordinary shareholders $ (4,403.9 ) $ 14,695.0 $ 3,683.2 Basic weighted average ordinary shares outstanding 333.8 384.9 367.8 Basic EPS: Continuing operations $ (11.99 ) $ (3.17 ) $ (8.64 ) Discontinued operations $ (1.20 ) $ 41.35 $ 18.65 Net (loss) / income per share $ (13.19 ) $ 38.18 $ 10.01 Dividends per ordinary share $ 2.80 $ - $ - Diluted weighted average ordinary shares outstanding 333.8 384.9 367.8 Diluted EPS: Continuing operations $ (11.99 ) $ (3.17 ) $ (8.64 ) Discontinued operations $ (1.20 ) $ 41.35 $ 18.65 Net (loss) / income per share $ (13.19 ) $ 38.18 $ 10.01 Stock awards to purchase 3.8 million, 4.7 million, and 5.2 million ordinary shares for the years ended December 31, 2017, 2016 and 2015, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations was also anti-dilutive. The weighted average impact of ordinary share equivalents of 17.8 million, 17.6 million and 13.6 million for years ended December 31, 2017, 2016 and 2015, respectively, which are anticipated to result from the mandatory conversion of the Company’s preferred shares were not included in the calculation of diluted EPS as their impact would be anti-dilutive.
Employee Benefits	Employee Benefits Defined Contribution Plans The Company has defined contribution plans that are post-employment benefit plans under which the Company pays fixed contributions to a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to the defined contribution plans are recognized as an employee benefit expense in the consolidated statement of operations in the periods during which the related services were rendered. Defined Benefit Plans The Company recognizes the overfunded or underfunded status of each of its defined benefit plans as an asset or liability on its consolidated balance sheets. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. The estimates of the obligation and related expense of these plans recorded in the financial statements are based on certain assumptions. The most significant assumptions relate to discount rate and expected return on plan assets. Other assumptions used may include employee demographic factors such as compensation rate increases, retirement patterns, expected employee turnover and participant mortality rates. The difference between these assumptions and actual experience results in the recognition of an asset or liability based upon a net actuarial (gain) / loss. If the total net actuarial (gain) / loss included in accumulated other comprehensive income / (loss) exceeds a threshold of 10% of the greater of the projected benefit obligation or the market related value of plan assets, it is subject to amortization and recorded as a component of net periodic pension cost over the average remaining service lives of the employees participating in the pension plan. Net periodic benefit costs are recognized in the consolidated statement of operations.
Share-based Compensation	Share-based Compensation The Company has adopted several equity award plans which authorize the granting of options, restricted shares, restricted stock units and other forms of equity awards of the Company’s ordinary shares, subject to certain conditions. The Company grants awards with the following features: • Time-based vesting restricted stock and restricted stock units awards; • Performance-based restricted stock unit awards measured to performance-based targets defined by the Company, including, but not limited to, total shareholder return metrics, R&D milestones and EBITDA, as defined by the Company; • Non-qualified options to purchase outstanding shares; and • Cash-settled awards recorded as a liability. These cash settled awards are based on pre-established total shareholder returns metrics. The Company recognizes share-based compensation expense for the granted awards over the applicable vesting period.
Restructuring Costs	Restructuring Costs The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also incurs costs with contract terminations and costs of transferring products as part of restructuring activities. Refer to “NOTE 21 — Business Restructuring Charges” for more information.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (Topic 606) "Revenue from Contracts with Customers." Topic 606 supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, “Revenue Recognition”, and requires entities to recognize revenue when they transfer control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company will adopt Topic 606 as of January 1, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. Upon adoption, the Company will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings, the impact of which is not significant. Prior periods will not be retrospectively adjusted. The Company has assessed our revenue recognition practices with respect to the agreements for which the Company currently recognizes revenues and has concluded that there is no material impact from the new revenue recognition standard. Under Topic 606, the Company will apply the practical expedient to recognize the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs will be included in selling, general, and administrative expenses which are consistent with current accounting prior to the adoption of Topic 606. The Company will also elect to use the practical expedient to not adjust the promised amount of consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is equal to one year or less. In January 2016, the FASB issued ASU No. 2016-01, which changes the requirement to require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The adoption of this guidance on January 1, 2018 resulted in a reduction of other comprehensive income, net of tax, of approximately $63.0 million with a corresponding increase to retained earnings. In February 2016, the FASB issued ASU No. 2016-02, which states that a lessee should recognize the assets and liabilities that arise from leases. This update is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating the impact that this pronouncement will have on our financial position and results of operations. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application will be permitted for all organizations for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is evaluating the impact, if any, that this pronouncement will have on our financial position and results of operations. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Current GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. This prohibition on recognition is an exception to the principle of comprehensive recognition of current and deferred income taxes in GAAP. The amendment to the guidance eliminates the exception for an intra-entity transfer of an asset other than inventory and requires an entity to recognize the income tax consequences when the transfer occurs. Two common examples of assets included in the scope of the amendment are intellectual property and property, plant, and equipment. The amendment is effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The amendment should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of the guidance on January 1, 2018 resulted in an increase to retained earnings of $356.2 million and a corresponding reduction in net tax liabilities. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments to the guidance are intended to help companies evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. When substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. This amendment introduces an initial required screening that, if met, eliminates the need for further assessment. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. To be a business without outputs, there will need to be an organized workforce. The ASU also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. These amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The changes to the definition of a business may result in more acquisitions being accounted for as asset acquisitions. In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments to the guidance eliminate Step 2 from the goodwill impairment test. The goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. These amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment. These amendments should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. These amendments are effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of these amendments are not anticipated to have a material impact on the Company’s financial position or results of operations. In March 2017, the FASB issued ASU No. 2017-07, Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The amendments to the guidance require that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. If a separate line item or items are used to present the other components of net benefit cost, that line item or items must be appropriately described. If a separate line item or items are not used, the line item or items used in the income statement to present the other components of net benefit cost must be disclosed. In addition, the amendments also allow only the service cost component to be eligible for capitalization when applicable. The amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company does not anticipate the standard having a material impact on our financial position and results of operations. In March 2017, The FASB issued Accounting Standards Update (ASU) No. 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities. The ASU shortens the amortization period for certain callable debt securities held at a premium and requires the premium to be amortized to the earliest call date, but does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The amendments are effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Entities are required to apply the amendments on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The entity is required to provide disclosures about a change in accounting principle in the period of adoption. The Company is evaluating the impact these amendments will have on our financial position and results of operations. In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718) — Scope of Modification Accounting. ASU No. 2017-09 applies to entities that change the terms or conditions of a share-based payment award. The amendments to the guidance in ASU No. 2017-09 include guidance on determining changes to the terms and conditions of share-based payment awards and require an entity to apply modification accounting under Topic 718 unless all of the following conditions are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 and should be applied prospectively to an award modified on or after the adoption date. The adoption of these amendments are not anticipated to have a material impact on the Company’s financial position or results of operations. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) — Targeted Improvements to Accounting for Hedging Activities. The amendments to the guidance will better align an entity’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To meet that objective, the amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The amendments also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted in any interim period or fiscal years before the effective date of the amendments. For cash flow and net investment hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate measurement of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year that an entity adopts the amendments. The amended presentation and disclosure guidance is required only prospectively. The guidance may have an impact on the Company’s future financial positions and results of operations.

Reconciliation of Warner Chil39

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results (Tables)	12 Months Ended
	Dec. 31, 2017
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc	December 31, 2017 December 31, 2016 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 1,817.2 $ 1,816.3 $ 0.9 $ 1,724.0 $ 1,713.2 $ 10.8 Prepaid expenses and other current assets 1,123.9 1,123.0 0.9 1,383.4 1,382.1 1.3 Deferred tax assets 319.1 316.0 3.1 233.3 233.3 - Accounts payable and accrued liabilities 5,541.4 5,515.6 25.8 5,019.0 4,993.3 25.7 Other long-term liabilities 886.9 886.9 - 1,085.0 1,086.0 (1.0 ) Other taxes payables 1,573.9 1,573.5 0.4 886.2 886.2 - Deferred tax liabilities 6,352.4 6,349.4 3.0 12,969.1 12,969.1 -
Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc	Year Ended December 31, 2017 Year Ended December 31, 2016 Year Ended December 31, 2015 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 1,501.9 $ 1,402.3 $ 99.6 $ 1,473.9 $ 1,350.4 $ 123.5 $ 1,716.4 $ 1,581.0 $ 135.4 Operating (loss) (5,921.2 ) (5,821.6 ) (99.6 ) (1,825.5 ) (1,702.0 ) (123.5 ) (3,131.0 ) (2,995.6 ) (135.4 ) Interest Income 67.7 166.3 (98.6 ) 69.9 111.1 (41.2 ) 10.6 10.6 - Other income / (expense), net (3,437.3 ) (3,437.3 ) - 219.2 172.2 47.0 (233.8 ) (233.8 ) - (Loss) before income taxes and noncontrolling interest (10,386.4 ) (10,188.2 ) (198.2 ) (2,832.0 ) (2,714.3 ) (117.7 ) (4,547.5 ) (4,412.1 ) (135.4 ) Net (loss) from continuing operations, net of tax (3,716.0 ) (3,517.8 ) (198.2 ) (935.0 ) (817.3 ) (117.7 ) (2,941.6 ) (2,806.2 ) (135.4 ) Net (loss) / income (4,118.9 ) (3,920.7 ) (198.2 ) 14,979.5 15,097.2 (117.7 ) 3,919.4 4,054.8 (135.4 ) Dividends on preferred shares 278.4 - 278.4 278.4 - 278.4 232.0 - 232.0 Net (loss) / income attributable to ordinary shareholders/members (4,403.9 ) (3,927.3 ) (476.6 ) 14,695.0 15,091.1 (396.1 ) 3,683.2 4,050.6 (367.4 )

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Property and Equipment	The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years
Schedule of Balance Sheet Classification of SRA Reserves	The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): As of December 31, 2017 2016 Accounts receivable $ 250.6 $ 287.4 Accounts payable and accrued expenses 2,179.9 1,891.4 $ 2,430.5 $ 2,178.8
Summary of Activity in Gross-to-Net Revenue Excluding Discontinued Operations	The provisions recorded to reduce gross product sales to net product sales, excluding discontinued operations, were as follows ($ in millions): Years Ended December 31, Gross Product Sales Chargebacks Rebates Returns and Other Allowances Cash Discounts Net Product Sales Percentage of Gross Product Sales 2015 $ 18,125.1 $ 649.9 $ 4,035.7 $ 659.9 $ 275.6 $ 12,504.0 69.0 % 2016 $ 21,398.6 $ 1,003.2 $ 4,338.7 $ 1,390.1 $ 306.5 $ 14,360.1 67.1 % 2017 $ 23,688.4 $ 1,098.7 $ 4,891.4 $ 1,799.3 $ 330.6 $ 15,568.4 65.7 %
Summary of Products Which Utilize Novel Drug Delivery Systems through Combination of Internal and Collaborative Programs	As of December 31, 2017, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including the following: Product Therapeutic Area Indication Expected Launch Year Phase Esmya Women's Health Uterine Fibroids 2018 Review Cariprazine CNS Bipolar Depression 2019 III Ubrogepant CNS Acute Migraine 2020 III Abicipar Eye Care Age Related Macular Degeneration 2020 III Bimatoprost SR Eye Care Glaucoma 2020 III Rapastinel CNS Depression 2021 III Cenicriviroc Gastrointestinal NASH 2021 III Relamorelin Gastrointestinal Gastroparesis 2023 III Pilo/Oxy Eye Care Presbyopia 2021 II RORyT Medical Aesthetics Psoriasis 2022 II Atogepant CNS Migraine Prevention 2022 II Abicipar Eye Care Diabetic Macular Edema 2023 II Brazikumab Gastrointestinal Crohn's Disease 2024 II Botox Medical Aesthetics Platysma/Masseter 2025/2023 II Brazikumab Gastrointestinal Ulcerative Colitis 2025 I
Earnings Per Share	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following ($ in millions, except per share amounts): Years Ended December 31, 2017 2016 2015 Net (loss) / income: Net (loss) attributable to ordinary shareholders excluding (loss) / income from discontinued operations, net of tax $ (4,001.0 ) $ (1,219.5 ) $ (3,177.8 ) (Loss) / income from discontinued operations, net of tax (402.9 ) 15,914.5 6,861.0 Net (loss) / income attributable to ordinary shareholders $ (4,403.9 ) $ 14,695.0 $ 3,683.2 Basic weighted average ordinary shares outstanding 333.8 384.9 367.8 Basic EPS: Continuing operations $ (11.99 ) $ (3.17 ) $ (8.64 ) Discontinued operations $ (1.20 ) $ 41.35 $ 18.65 Net (loss) / income per share $ (13.19 ) $ 38.18 $ 10.01 Dividends per ordinary share $ 2.80 $ - $ - Diluted weighted average ordinary shares outstanding 333.8 384.9 367.8 Diluted EPS: Continuing operations $ (11.99 ) $ (3.17 ) $ (8.64 ) Discontinued operations $ (1.20 ) $ 41.35 $ 18.65 Net (loss) / income per share $ (13.19 ) $ 38.18 $ 10.01
Continuing Operations [Member]
Provisions for Sales Returns and Allowances from Continuing Operations Activity	The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2014 $ 28.0 $ 995.8 $ 255.2 $ 16.3 $ 1,295.3 Add: Allergan Acquisition 14.1 306.4 100.4 8.6 429.5 Provision related to sales in 2015 649.9 4,035.7 659.9 275.6 5,621.1 Credits and payments (613.8 ) (3,993.5 ) (648.0 ) (275.4 ) (5,530.7 ) Balance at December 31, 2015 $ 78.2 $ 1,344.4 $ 367.5 $ 25.1 $ 1,815.2 Provision related to sales in 2016 1,003.2 4,338.7 1,390.1 306.5 7,038.5 Credits and payments (967.2 ) (4,069.1 ) (1,341.7 ) (296.9 ) (6,674.9 ) Balance at December 31, 2016 $ 114.2 $ 1,614.0 $ 415.9 $ 34.7 $ 2,178.8 Provision related to sales in 2017 1,098.7 4,891.4 1,799.3 330.6 8,120.0 Credits and payments (1,135.7 ) (4,710.4 ) (1,734.7 ) (328.8 ) (7,909.6 ) Add: LifeCell and Zeltiq Acquisitions - 4.2 37.1 - 41.3 Balance at December 31, 2017 $ 77.2 $ 1,799.2 $ 517.6 $ 36.5 $ 2,430.5
Discontinued Operations [Member]
Provisions for Sales Returns and Allowances from Continuing Operations Activity	The following table summarizes the activity from discontinued operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2014 $ 536.9 $ 750.8 $ 356.9 $ 44.4 $ 1,689.0 Provision related to sales in 2015 5,907.2 1,991.9 729.4 277.3 8,905.8 Credits and payments (5,825.1 ) (2,011.7 ) (757.7 ) (261.6 ) (8,856.1 ) Balance at December 31, 2015 $ 619.0 $ 731.0 $ 328.6 $ 60.1 $ 1,738.7 Provision related to sales in 2016 3,525.4 1,290.4 583.0 159.1 5,557.9 Credits and payments (3,655.0 ) (1,350.0 ) (496.3 ) (155.4 ) (5,656.7 ) Disposal of businesses (489.4 ) (671.4 ) (415.3 ) (63.8 ) (1,639.9 ) Balance at December 31, 2016 $ - $ - $ - $ - $ -

Business Development (Tables)

Business Development (Tables)	12 Months Ended
	Dec. 31, 2017
Pro Forma Results of Businesses Acquired	The unaudited pro forma results of the businesses acquired that materially impacted the reported results of the Company are as follows ($ in millions except per share information): Year Ended December 31, 2015 (unaudited) As reported Allergan Acquisition Pro Forma Net revenues $ 12,688.1 $ 1,523.0 $ 14,211.1 Net income attributable to ordinary shareholders $ 3,683.2 $ 377.7 $ 4,060.9 Net income per share Basic $ 10.01 $ 10.32 Diluted $ 10.01 $ 10.32
Zeltiq Aesthetics, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Preliminary Valuation as of December 31, 2017 Cash and cash equivalents $ 36.7 Accounts receivable 47.0 Inventories 59.3 Property, plant and equipment 12.4 Intangible assets 1,185.0 Goodwill 1,200.6 Other assets 17.1 Accounts payable and accrued expenses (93.6 ) Deferred revenue (10.6 ) Deferred taxes, net (47.2 ) Other liabilities (1.3 ) Net assets acquired $ 2,405.4
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite-lived assets Consumables $ 985.0 6.7 System 43.0 3.7 Total CMP 1,028.0 Customer Relationships 157.0 6.6 Total definite-lived assets $ 1,185.0
LifeCell Corporation [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Valuation as of December 31, 2017 Cash and cash equivalents $ 8.7 Accounts receivable 50.8 Inventories 175.4 Property, plant and equipment, net 53.7 Currently marketed products ("CMP") intangible assets 2,010.0 In-process research and development ("IPR&D") intangible assets 10.0 Goodwill 1,449.1 Accounts payable and accrued expenses (149.6 ) Deferred tax liabilities, net (746.2 ) Other 21.2 Net assets acquired $ 2,883.1
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite-lived assets Alloderm ® $ 1,385.0 6.9 Revolve ® 80.0 7.1 Strattice ® 320.0 5.1 Artia ® 115.0 8.8 Other 10.0 2.8 Total CMP 1,910.0 Customer Relationships 100.0 6.3 Total definite-lived assets 2,010.0 In-process research and development Other 10.0 Total IPR&D 10.0 Total intangible assets $ 2,020.0
Tobira Therapeutics Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): December 31, 2016 Preliminary Valuation Measurement Period Adjustments December 31, 2017 Final Valuation Cash and cash equivalents $ 21.3 $ - $ 21.3 IPR&D intangible assets 1,357.0 - 1,357.0 Goodwill 112.7 (14.1 ) 98.6 Indebtedness (15.9 ) - (15.9 ) Contingent consideration (479.0 ) - (479.0 ) Deferred tax liabilities, net (395.9 ) 14.1 (381.8 ) Other assets and liabilities (30.1 ) - (30.1 ) Net assets acquired $ 570.1 $ - $ 570.1
Vitae Pharmaceuticals Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): December 31, 2016 Preliminary Valuation Measurement Period Adjustments December 31, 2017 Final Valuation Cash and cash equivalents $ 44.7 $ - $ 44.7 Marketable securities 20.2 - 20.2 Property, plant and equipment, net 5.0 - 5.0 IPR&D intangible assets 686.0 - 686.0 Assets held for sale 22.5 - 22.5 Goodwill 34.4 (3.8 ) 30.6 Other assets and liabilities (20.7 ) - (20.7 ) Deferred tax liabilities, net (170.7 ) 3.8 (166.9 ) Net assets acquired $ 621.4 $ - $ 621.4
ForSight VISION 5 [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): December 31, 2016 Preliminary Valuation Measurement Period Adjustments December 31, 2017 Final Valuation Cash and cash equivalents $ 1.0 $ - $ 1.0 IPR&D intangible assets 158.0 - 158.0 Goodwill 51.6 (1.1 ) 50.5 Current liabilities (14.8 ) - (14.8 ) Contingent consideration (79.8 ) - (79.8 ) Deferred tax liabilities, net (38.3 ) 1.1 (37.2 ) Other assets and liabilities (3.2 ) - (3.2 ) Net assets acquired $ 74.5 $ - $ 74.5
AqueSys [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 6.2 Current assets 1.2 IPR&D intangible assets 302.0 Intangible assets 221.0 Goodwill 138.5 Current liabilities (6.9 ) Contingent consideration (193.5 ) Deferred tax liabilities, net (169.6 ) Net assets acquired $ 298.9
Kythera Biopharmaceuticals, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 78.1 Marketable securities 79.9 Inventories 18.2 Other current assets 14.5 IPR&D intangible assets 320.0 Intangible assets 2,120.0 Goodwill 328.7 Other current liabilities (48.6 ) Deferred tax, net (766.7 ) Outstanding indebtedness (54.6 ) Net assets acquired $ 2,089.5
Oculeve, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 1.6 IPR&D intangible assets 286.0 Goodwill 33.3 Other assets and liabilities (1.9 ) Contingent consideration (90.0 ) Deferred tax liabilities, net (94.5 ) Net assets acquired $ 134.5
Allergan, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Amount Cash and cash equivalents $ 5,424.5 Accounts receivable 948.7 Inventories 1,218.6 Other current assets 318.8 Property, plant and equipment, net 1,214.5 Other long-term assets 196.1 IPR&D intangible assets 9,700.0 Intangible assets 45,050.5 Goodwill 27,088.9 Current liabilities (1,222.1 ) Contingent consideration (383.7 ) Deferred tax liabilities, net (11,880.1 ) Other taxes payable (111.3 ) Other long-term liabilities (622.0 ) Outstanding indebtedness (2,183.5 ) Net assets acquired $ 74,757.9
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite-lived assets Restasis ® $ 3,970.0 4.0 Refresh ® ® 2,720.0 7.6 Other Eye Care Products 6,690.0 4.2 Botox ® 22,600.0 8.0 Aczone ® 160.0 1.3 Other Skin Products 820.0 5.0 Other Aesthetics 6,350.0 6.0 Total CMP 43,310.0 6.7 Trade name 690.0 4.5 Customer relationships 1,050.5 3.4 Total definite-lived assets 45,050.5 6.6 In-process research and development Eye Care 5,500.0 Botox ® 810.0 Aesthetics 2,270.0 Other 1,120.0 Total IPR&D 9,700.0 Total intangible assets $ 54,750.5
Summary of Transaction and Integration Costs for Acquisition	As a result of the acquisition, the Company incurred the following transaction and integration costs for the year of acquisition (year ended December 31, 2015) and the comparable first full year (year ended December 31, 2016) ($ in millions): Years Ended December 31, 2016 2015 Cost of sales Stock-based compensation acquired for Legacy Allergan employees $ 9.6 $ 22.5 Acquisition, integration and restructuring related charges 18.1 14.9 Research and development Stock-based compensation acquired for Legacy Allergan employees 43.0 124.8 Acquisition, integration and restructuring related charges 11.8 83.5 Selling and marketing Stock-based compensation acquired for Legacy Allergan employees 65.3 110.0 Acquisition, integration and restructuring related charges 24.7 75.7 General and administrative Stock-based compensation acquired for Legacy Allergan employees 33.6 258.9 Acquisition, integration and restructuring related charges 197.4 364.1 Other (expense) / income Bridge loan facilities expense - (264.9 ) Interest rate locks - 30.9 Total transaction and integration costs $ 403.5 $ 1,288.4

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2017
Discontinued Operations And Disposal Groups [Abstract]
Schedule of Reconciliation of Proceeds Received in Sale of Generics Business and Anda Distribution Business to Gain Recognized in Income from Discontinued Operations	The Company notes the following reconciliation of the proceeds received in the combined transaction to the gain recognized in income from discontinued operations in 2016 ($ in millions): Net cash proceeds received $ 33,804.2 August 2, 2016 fair value of Teva shares 5,038.6 Total Proceeds $ 38,842.8 Net assets sold to Teva, excluding cash (12,487.7 ) Other comprehensive income disposed (1,544.8 ) Deferral of proceeds relating to additional elements of agreements with Teva (299.2 ) Pre-tax gain on sale of generics business and Anda Distribution business $ 24,511.1 Income taxes (8,578.9 ) Net gain on sale of generics business and Anda Distribution business $ 15,932.2
Summary of Teva Share Activity	During the year ended December 31, 2017, the Company recorded the following movements in its investment in Teva securities (defined herein as "Teva Share Activity") as follows ($ in millions except per share information): in million except per share amounts Shares Cost Basis Market Price Discount Movement in the Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income Gain / (Loss) Recognized in Other Income (Expense), Net Teva securities as of December 31, 2016 100.3 $ 53.39 $ 36.25 5.4 % $ 3,439.2 $ (1,599.4 ) $ - Other-than-temporary impairment recognized at March 31, 2017 100.3 $ 32.09 $ 32.09 4.9 % $ (378.6 ) $ 1,599.4 $ (1,978.0 ) Other-than-temporary impairment recognized at September 30, 2017 100.3 $ 17.60 $ 17.60 0.0 % $ (1,295.5 ) $ - $ (1,295.5 ) Sales during the twelve months ended December 31, 2017 (4.4 ) n.a. n.a. 0.0 % $ (76.7 ) $ - $ 4.2 Other fair value movements in the twelve months ended December 31, 2017 95.9 $ 17.60 $ 18.95 0.0 % $ 129.3 $ 129.3 $ - Teva securities as of and for the twelve months ended December 31, 2017 95.9 $ 17.60 $ 18.95 0.0 % $ 1,817.7 $ 129.3 $ (3,269.3 )
Summary of Key Financial Results of Businesses Income from Discontinued Operations, Net of Tax	The following table presents key financial results of the global generics business and the Anda Distribution business included in “(Loss) / income from discontinued operations, net of tax” for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Years Ended December 31, 2017 2016 2015 Net revenues $ - $ 4,504.3 $ 8,499.0 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - 2,798.3 4,847.5 Research and development - 269.4 422.2 Selling and marketing - 352.9 706.6 General and administrative 18.8 425.8 702.2 Amortization - 4.8 333.3 Asset sales and impairments, net 1.2 - 62.4 Total operating expenses 20.0 3,851.2 7,074.2 Operating (loss) / income (20.0 ) 653.1 1,424.8 Other (expense) / income, net (470.4 ) 15,932.2 (7.1 ) (Benefit) / provision for income taxes (87.5 ) 670.8 (5,443.3 ) (Loss) / income from discontinued operations, net of tax $ (402.9 ) $ 15,914.5 $ 6,861.0
Schedule of Depreciation Amortization and Significant Operating and Investing Noncash Items of Discontinued Operations	Years Ended December 31, 2017 2016 2015 Depreciation from discontinued operations $ - $ 2.1 $ 93.7 Amortization from discontinued operations - 4.8 333.3 Capital expenditures - 85.3 234.5 Deferred income tax expense - 6,038.5 (5,568.8 )

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model	Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2017 Grants 2016 Grants 2015 Grants 2015 Acquired Awards Dividend yield 1.2 % 0 % 0 % 0 % Expected volatility 27.0 % 27.0 % 26.0 - 29.0% 26.0 - 27.0% Risk-free interest rate 2.0-2.3% 1.3 - 2.4% 1.9 - 2.1% 0.1 - 2.1% Expected term (years) 7.0 7.0 - 7.5 7.0 - 7.5 up to 6.9
Share-Based Compensation Expense Recognized in Company's Results of Operations	Share-based compensation expense recognized in the Company’s results of operations, including discontinued operations, for the years ended December 31, 2017, 2016 and 2015 was as follows ($ in millions): Year Ended December 31, 2017 2016 2015 Equity-based compensation awards $ 293.3 $ 334.5 $ 690.4 Cash-settled awards in connection with the Zeltiq Acquisition 31.5 - - Cash-settled awards in connection with the Tobira Acquisition - 27.0 - Cash-settled awards in connection with the Vitae Acquisition - 18.6 - Cash-settled awards in connection with the ForSight Acquisition - 3.1 - Cash-settled awards in connection with the Allergan Acquisition - - 127.1 Cash-settled awards in connection with the Kythera Acquisition - - 9.6 Non equity-settled awards other (16.8 ) - 98.6 Total stock-based compensation expense $ 308.0 $ 383.2 $ 925.7
Summary of Impact of Accelerations and Step-ups Relating to Acquisition Accounting Treatment of Outstanding Awards	Included in the stock-based compensation awards for the years ended December 31, 2017, 2016 and 2015 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Zeltiq, Allergan, Forest and Kythera Acquisitions ($ in millions) Year Ended December 31, 2017 2016 2015 Zeltiq Acquisition $ 47.8 $ - $ - Allergan Acquisition 47.1 108.9 314.8 Forest Acquisition 10.1 45.2 109.7 Kythera Acquisition - - 64.4 Total $ 105.0 $ 154.1 $ 488.9
Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units	The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2016 through December 31, 2017: (in millions, except per share data) Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2016 1.5 $ 251.88 1.6 $ 388.0 Granted 1.2 232.18 278.6 Assumed as part of the Zeltiq Acquisition* 0.2 213.15 41.8 Vested (0.5 ) (238.39 ) (127.0 ) Forfeited (0.4 ) (265.26 ) (97.3 ) Restricted shares / units outstanding at December 31, 2017 2.0 $ 237.72 1.8 $ 484.1
Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares	The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2016 through December 31, 2017: (in millions, except per share data) Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2016 9.0 $ 113.77 5.9 $ 861.7 Granted 0.3 239.33 Exercised (1.8 ) (92.71 ) Cancelled (0.2 ) (137.80 ) Outstanding, vested and expected to vest at December 31, 2017 7.3 $ 120.94 5.2 $ 312.7

Pension and Other Postretirem44

Pension and Other Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Summary of Net Periodic Benefit (Income) Cost of Defined Benefit Plans for Continuing Operations	The net periodic benefit (income) cost of the defined benefit plans for continuing operations for the years ended December 31, 2017, 2016 and 2015 was as follows ($ in millions): Year Ended December 31, 2017 2016 2015 Service cost $ 5.5 $ 5.0 $ 5.0 Interest cost 40.7 44.5 35.0 Expected Return on plan assets (54.5 ) (53.0 ) (46.4 ) Settlement (0.1 ) (1.8 ) (4.3 ) Net periodic benefit (income) cost $ (8.4 ) $ (5.3 ) $ (10.7 )
Schedule of Benefit Obligation and Asset Data for Defined Benefit Plans for Continuing Operations	Benefit obligation and asset data for the defined benefit plans for continuing operations, were as follows ($ in millions): Year Ended December 31, 2017 2016 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,093.9 $ 1,051.1 Employer contribution 15.2 37.4 Return on plan assets 117.2 116.8 Benefits paid (36.0 ) (32.5 ) Settlements (5.3 ) (47.7 ) Effects of exchange rate changes and other 50.2 (31.2 ) Fair value of plan assets at end of year $ 1,235.2 $ 1,093.9 Year Ended December 31, 2017 2016 Change in Benefit Obligation Benefit obligation at beginning of the year $ 1,234.1 $ 1,188.5 Service cost 5.5 5.0 Interest cost 40.7 44.5 Actuarial loss / (gain) 36.9 108.0 Curtailments (8.1 ) - Settlements and other (5.3 ) (46.9 ) Benefits paid (36.0 ) (32.5 ) Effects of exchange rate changes and other 62.2 (32.5 ) Benefit obligation at end of year $ 1,330.0 $ 1,234.1 Funded status at end of year $ (94.8 ) $ (140.2 )
Schedule of Funded Status Amount Recognized in Consolidated Balance Sheet	The following table outlines the funded actuarial amounts recognized ($ in millions): As of December 31, 2017 2016 Noncurrent assets $ 21.9 $ 9.4 Current liabilities (0.8 ) (0.7 ) Noncurrent liabilities (115.9 ) (148.9 ) $ (94.8 ) $ (140.2 )
Schedule of Fair Values of Pension Plan Assets by Asset Category	The fair values of the Company’s pension plan assets at December 31, 2017 by asset category are as follows ($ in millions): Quoted Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 33.5 $ - $ - $ 33.5 International equities 265.5 - - 265.5 Other equity securities 70.5 - - 70.5 Equity securities $ 369.5 $ - $ - $ 369.5 U.S. Treasury bonds $ - $ 96.9 $ - $ 96.9 Bonds and bond funds - 745.7 - 745.7 Other debt securities - 21.2 - 21.2 Debt securities $ - $ 863.8 $ - $ 863.8 Other investments Other - 1.9 - 1.9 Total assets $ 369.5 $ 865.7 $ - $ 1,235.2 The fair values of the Company’s pension plan assets at December 31, 2016 by asset category are as follows ($ in millions): Quoted Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 41.5 $ - $ - $ 41.5 International equities 244.4 - - 244.4 Other equity securities 87.4 - - 87.4 Equity securities $ 373.3 $ - $ - $ 373.3 U.S. Treasury bonds $ - $ 23.6 $ - $ 23.6 Bonds and bond funds - 684.8 - 684.8 Other debt securities - 8.3 - 8.3 Debt securities $ - $ 716.7 $ - $ 716.7 Other investments Other - 3.9 - 3.9 Total assets $ 373.3 $ 720.6 $ - $ 1,093.9
Schedule of Allocated Target Investment Portfolio of Pension Plans for Continuing Operations	The target investment portfolio of the Company’s continuing operations pension plans is allocated as follows: Target Allocation as of December 31, 2017 2016 Bonds 68.8 % 68.3 % Equity securities 31.2 % 31.5 % Other investments 0.0 % 0.2 %
Schedule of Expected Benefit Payments of Pension Plans	Total expected benefit payments for the Company’s pension plans are as follows ($ in millions): Expected Benefit Payments 2018 $ 34.6 2019 36.7 2020 38.9 2021 41.3 2022 43.4 Thereafter 1,135.1 Total liability $ 1,330.0
Schedule of Defined Benefit Plans with Accumulated Benefit Obligation in Excess of Plan Assets	Information for defined benefit plans with an accumulated benefit obligation in excess of plan assets is presented below ($ in millions): Defined Benefit as of December 31, 2017 2016 Projected benefit obligations $ 1,330.0 $ 1,234.1 Accumulated benefit obligations $ 1,324.7 $ 1,220.1 Plan assets $ 1,235.2 $ 1,093.9
Schedule of Balances Recognized within Accumulated Other Comprehensive Income / (Loss) Excluding the Impact of Taxes	Balances recognized within accumulated other comprehensive income/(loss) excluding the impact of taxes that have not been recognized as components of net periodic benefit costs are as follows ($ in millions): Defined Benefit Balance as of December 31, 2015 $ 70.4 Net actuarial loss (46.0 ) Balance as of December 31, 2016 $ 24.4 Net actuarial loss 33.8 Balance as of December 31, 2017 $ 58.2
Weighted Average Assumptions Used to Calculate Projected Benefit Obligations and Net Periodic Benefit Cost	The weighted average assumptions used to calculate the projected benefit obligations of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2017 2016 Discount rate 2.9 % 3.3 % Salary growth rate 3.0 % 3.0 % The weighted average assumptions used to calculate the net periodic benefit cost of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2017 2016 Discount rate 3.3 % 3.8 % Expected rate of return on plan assets 5.0 % 5.1 % Salary growth rate 3.0 % 3.0 %
Schedule of Accumulated Benefit Obligation for Defined Benefit Plans	Accumulated benefit obligationfor the defined benefit plans, were as follows ($ in millions): Accumulated Benefit Obligation Accumulated benefit obligation as of December 31, 2015 $ 50.1 Service cost 0.3 Interest cost 2.1 Actuarial charge 3.6 Benefits paid (3.4 ) Accumulated benefit obligation as of December 31, 2016 $ 52.7 Service cost - Interest cost 2.0 Actuarial charge (5.0 ) Benefits paid (2.9 ) Accumulated benefit obligation as of December 31, 2017 $ 46.8

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	12 Months Ended
	Dec. 31, 2017
Other Income And Expenses [Abstract]
Components of Income (Expense), Net	Other income / (expense), net consisted of the following ($ in millions): Years Ended December 31, 2017 2016 2015 Teva Share Activity (3,269.3 ) - - Debt extinguishment costs as part of the debt tender offer (161.6 ) - - Debt extinguishment other (27.6 ) - - Other-than-temporary impairments (26.1 ) - - Dividend income 85.2 68.2 - Naurex recovery 20.0 - - Forward sale of Teva shares (62.9 ) - - Pfizer termination fee (Allergan plc only) - 150.0 - Bridge loan commitment fee - - (264.9 ) Interest rate locks - - 31.0 Other (expense) / income, net 5.0 1.0 0.1 Other (expense) / income , net $ (3,437.3 ) $ 219.2 $ (233.8 )

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following ($ in millions): December 31, December 31, 2017 2016 Raw materials $ 326.9 $ 297.1 Work-in-process 158.1 145.4 Finished goods 527.8 357.7 1,012.8 800.2 Less: inventory reserves 108.3 82.2 Total Inventories $ 904.5 $ 718.0

Accounts Payable and Accrued 47

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following ($ in millions): December 31, 2017 December 31, 2016 Accrued expenses: Accrued third-party rebates $ 1,804.1 $ 1,595.5 Contractual commitments (including amount due to Teva) 705.4 264.9 Accrued payroll and related benefits 635.6 581.1 Accrued returns 375.8 295.9 Interest payable 245.9 294.2 Royalties payable 189.2 146.6 Accrued pharmaceutical fees 186.4 221.3 Accrued R&D expenditures 165.9 154.0 Accrued severance, retention and other shutdown costs 132.8 86.2 Litigation-related reserves and legal fees 78.3 101.1 Accrued non-provision taxes 76.5 55.0 Current portion of contingent consideration obligations 56.2 511.0 Accrued selling and marketing expenditures 53.0 95.9 Dividends payable 24.6 23.2 Other accrued expenses 487.2 368.2 Total accrued expenses $ 5,216.9 $ 4,794.1 Accounts payable 324.5 224.9 Total accounts payable and accrued expenses $ 5,541.4 $ 5,019.0

Property, plant and equipment48

Property, plant and equipment, net (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net consisted of the following as of December 31, 2017 and 2016 ($ in millions): Machinery and Equipment Research and Laboratory Equipment Transportation / Other Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2016 $ 437.1 $ 48.8 $ 381.4 $ 705.3 $ 446.1 $ 2,018.7 Additions 20.7 8.3 34.1 14.6 280.6 358.3 Additions due to acquisitions 14.3 0.7 18.6 31.2 1.3 66.1 Disposals/transfers/other 64.8 (1.2 ) 38.1 104.1 (224.3 ) (18.5 ) Assets held for sale - - - (49.7 ) - (49.7 ) Currency translation 8.4 2.4 3.1 9.4 3.3 26.6 At December 31, 2017 $ 545.3 $ 59.0 $ 475.3 $ 814.9 $ 507.0 $ 2,401.5 Accumulated depreciation At December 31, 2016 $ 148.4 $ 24.0 $ 164.5 $ 70.5 $ - $ 407.4 Additions 61.5 7.8 65.0 37.2 - 171.5 Disposals/transfers/impairments/other 7.2 5.3 - 18.0 - 30.5 Assets held for sale - - - (0.7 ) - (0.7 ) Currency translation 2.2 1.4 2.9 0.9 - 7.4 At December 31, 2017 $ 219.3 $ 38.5 $ 232.4 $ 125.9 $ - $ 616.1 Property, plant and equipment, net At December 31, 2017 $ 326.0 $ 20.5 $ 242.9 $ 689.0 $ 507.0 $ 1,785.4

Prepaid Expenses, Investments49

Prepaid Expenses, Investments and Other Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Investments All Other Investments [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following ($ in millions): December 31, 2017 December 31, 2016 Prepaid taxes $ 690.9 $ 957.4 Prepaid insurance 20.9 25.7 Royalty receivables 80.1 94.3 Sales and marketing 31.9 42.5 Other 300.1 263.5 Total prepaid expenses and other current assets $ 1,123.9 $ 1,383.4
Marketable Securities, Including Cash and Cash Equivalents, Other Investments and Other Assets	Investments in marketable securities, including those classified in cash and cash equivalents due to the maturity term of the instrument, other investments and other assets consisted of the following ($ in millions): December 31, 2017 December 31, 2016 Marketable securities: Short-term investments $ 2,814.4 $ 8,062.3 Teva shares 1,817.7 3,439.2 Total marketable securities $ 4,632.1 $ 11,501.5 Investments and other assets: Legacy Allergan Deferred executive compensation investments $ 112.4 $ 111.7 Equity method investments 11.5 12.8 Cost method investments - 15.0 Other long-term investments 60.8 67.2 Taxes receivable 32.1 36.0 Other assets 51.1 39.4 Total investments and other assets $ 267.9 $ 282.1
Investments in Securities	Investments in securities as of December 31, 2017 and 2016 included the following ($ in millions): Investments in Securities as of December 31, 2017: Level 1 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 1,328.1 $ - $ - $ 1,328.1 $ 1,328.1 $ - Investment in Teva ordinary shares 1,688.0 129.3 - 1,817.7 - 1,817.7 Total $ 3,016.1 $ 129.3 $ - $ 3,145.8 $ 1,328.1 $ 1,817.7 Level 2 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Commercial paper and other $ 1,248.9 $ - $ (0.7 ) $ 1,248.2 $ - $ 1,248.2 Certificates of deposit 1,566.2 - - 1,566.2 - 1,566.2 Total $ 2,815.1 $ - $ (0.7 ) $ 2,814.4 $ - $ 2,814.4 Investments in Securities as of December 31, 2016: Level 1 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Money market funds $ 1,238.9 $ - $ - $ 1,238.9 $ 1,238.9 $ - Total $ 1,238.9 $ - $ - $ 1,238.9 $ 1,238.9 $ - Level 2 Carrying amount Unrecognized gain Unrecognized loss Estimated fair value Cash & cash equivalents Marketable securities Commercial paper and other $ 3,909.7 $ 0.2 $ - $ 3,909.9 $ - $ 3,909.9 Investment in Teva ordinary shares 5,038.6 - (1,599.4 ) 3,439.2 - 3,439.2 Certificates of deposit 4,152.4 - - 4,152.4 - 4,152.4 Total $ 13,100.7 $ 0.2 $ (1,599.4 ) $ 11,501.5 $ - $ 11,501.5
Summary of Long-term Investments	The movements in long-term investments were as follows ($ in millions): Equity Method Investments Cost Method and Other Long-term Investments Balance at December 31, 2016 $ 12.8 $ 82.2 Additions - - Other-than-temporary impairments - (26.1 ) Other (1.3 ) 4.7 Balance at December 31, 2017 $ 11.5 $ 60.8

Goodwill, Product Rights and 50

Goodwill, Product Rights and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Specialized Therapeutics US General Medicine International Total Balance as of December 31, 2016 $ 18,433.2 $ 21,426.6 $ 6,496.3 $ 46,356.1 Additions through acquisitions 2,456.0 - 245.9 2,701.9 Measurement period adjustments (29.6 ) (14.1 ) - (43.7 ) Held for sale - (12.8 ) - (12.8 ) Foreign exchange and other adjustments - - 861.4 861.4 Balance as of December 31, 2017 $ 20,859.6 $ 21,399.7 $ 7,603.6 $ 49,862.9
Schedule of Cost Basis on Product Rights and Other Intangible Assets	Product rights and other intangible assets consisted of the following for the years ended December 31, 2017 and 2016 ($ in millions): Cost Basis Balance as of December 31, 2016 Acquisitions Impairments IPR&D to CMP Transfers Disposals/ Held Sale/ Other Foreign Currency Translation Balance as of December 31, 2017 Intangibles with definite lives: Product rights and other intangibles $ 67,801.4 $ 3,876.9 $ - $ 1,444.0 $ (34.0 ) $ 804.2 $ 73,892.5 Trade name 690.0 - - - - - 690.0 Total definite-lived intangible assets $ 68,491.4 $ 3,876.9 $ - $ 1,444.0 $ (34.0 ) $ 804.2 $ 74,582.5 Intangibles with indefinite lives: IPR&D $ 8,758.3 $ 10.0 $ (1,452.3 ) $ (1,444.0 ) $ (6.6 ) $ 8.7 $ 5,874.1 Total indefinite- lived intangible assets $ 8,758.3 $ 10.0 $ (1,452.3 ) $ (1,444.0 ) $ (6.6 ) $ 8.7 $ 5,874.1 Total product rights and other intangibles $ 77,249.7 $ 3,886.9 $ (1,452.3 ) $ - $ (40.6 ) $ 812.9 $ 80,456.6 Accumulated Amortization Balance as of December 31, 2016 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2017 Intangibles with definite lives: Product rights and other intangibles $ (14,493.9 ) $ (7,119.6 ) $ (3,879.1 ) $ 24.8 $ (125.8 ) $ (25,593.6 ) Trade name (137.2 ) (77.5 ) - - - (214.7 ) Total definite-lived intangible assets $ (14,631.1 ) $ (7,197.1 ) $ (3,879.1 ) $ 24.8 $ (125.8 ) $ (25,808.3 ) Total product rights and other intangibles $ (14,631.1 ) $ (7,197.1 ) $ (3,879.1 ) $ 24.8 $ (125.8 ) $ (25,808.3 ) Net Product Rights and Other Intangibles $ 62,618.6 $ 54,648.3 Product rights and other intangible assets consisted of the following for the years ended December 31, 2016 and 2015 ($ in millions): Cost Basis Balance as of December 31, 2015 Acquisitions Impairments IPR&D Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2016 Intangibles with definite lives: Product rights and other intangibles $ 64,366.0 $ 43.6 $ - $ 3,809.9 $ (194.6 ) $ (223.5 ) $ 67,801.4 Trade name 690 - - - - - 690.0 Total definite-lived intangible assets $ 65,056.0 $ 43.6 $ - $ 3,809.9 $ (194.6 ) $ (223.5 ) $ 68,491.4 Intangibles with indefinite lives: IPR&D $ 11,128.2 $ 2,223.5 $ (743.9 ) $ (3,809.9 ) $ (22.5 ) $ (17.1 ) $ 8,758.3 Total indefinite- lived intangible assets $ 11,128.2 $ 2,223.5 $ (743.9 ) $ (3,809.9 ) $ (22.5 ) $ (17.1 ) $ 8,758.3 Total product rights and other intangibles $ 76,184.2 $ 2,267.1 $ (743.9 ) $ - $ (217.1 ) $ (240.6 ) $ 77,249.7 Accumulated Amortization Balance as of December 31, 2015 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2016 Intangibles with definite lives: Product rights and other intangibles $ (8,288.5 ) $ (6,392.7 ) $ (28.9 ) $ 176.8 $ 39.4 $ (14,493.9 ) Trade name (59.5 ) (77.7 ) - - - (137.2 ) Total definite-lived intangible assets $ (8,348.0 ) $ (6,470.4 ) $ (28.9 ) $ 176.8 $ 39.4 $ (14,631.1 ) Total product rights and other intangibles $ (8,348.0 ) $ (6,470.4 ) $ (28.9 ) $ 176.8 $ 39.4 $ (14,631.1 ) Net Product Rights and Other Intangibles $ 67,836.2 $ 62,618.6
Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, continuing operations related to annual amortization expense on product rights and other related intangibles as of December 31, 2017 over each of the next five years is estimated to be as follows ($ in millions): Amortization 2018 $ 6,438.3 2019 $ 6,039.4 2020 $ 5,717.4 2021 $ 4,778.2 2022 $ 4,414.8

Long-Term Debt and Capital Le51

Long-Term Debt and Capital Leases (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-Term Debt and Capital Leases	Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of Issuance Date / Acquisition Date Interest Payments December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due March 12, 2018 * March 4, 2015 Quarterly $ 500.0 $ 500.0 $ 500.6 $ 502.5 $500.0 million floating rate notes due March 12, 2020 ** March 4, 2015 Quarterly 500.0 500.0 508.1 509.4 1,000.0 1,000.0 1,008.7 1,011.9 Fixed Rate Notes $1,000.0 million 1.850% notes due March 1, 2017 March 4, 2015 Semi-annually - 1,000.0 - 1,001.1 $500.0 million 1.300% notes due June 15, 2017 June 10, 2014 Semi-annually - 500.0 - 499.7 $1,200.0 million 1.875% notes due October 1, 2017 October 2, 2012 Semi-annually - 1,200.0 - 1,202.5 $3,000.0 million 2.350% notes due March 12, 2018 March 4, 2015 Semi-annually 3,000.0 3,000.0 3,001.9 3,018.0 $250.0 million 1.350% notes due March 15, 2018 March 17, 2015 Semi-annually 250.0 250.0 249.7 248.4 $1,050.0 million 4.375% notes due February 1, 2019 July 1, 2014 Semi-annually - 1,050.0 - 1,090.0 $500.0 million 2.450% notes due June 15, 2019 June 10, 2014 Semi-annually 500.0 500.0 499.7 501.2 $400.0 million 6.125% notes due August 15, 2019 August 24, 2009 Semi-annually - 400.0 - 437.7 $3,500.0 million 3.000% notes due March 12, 2020 March 4, 2015 Semi-annually 3,500.0 3,500.0 3,528.4 3,541.8 $650.0 million 3.375% notes due September 15, 2020 March 17, 2015 Semi-annually 650.0 650.0 661.3 663.6 $750.0 million 4.875% notes due February 15, 2021 July 1, 2014 Semi-annually 450.0 750.0 474.3 803.3 $1,200.0 million 5.000% notes due December 15, 2021 July 1, 2014 Semi-annually 1,200.0 1,200.0 1,282.6 1,297.7 $3,000.0 million 3.450% notes due March 15, 2022 March 4, 2015 Semi-annually 3,000.0 3,000.0 3,044.5 3,030.7 $1,700.0 million 3.250% notes due October 1, 2022 October 2, 2012 Semi-annually 1,700.0 1,700.0 1,703.0 1,693.1 $350.0 million 2.800% notes due March 15, 2023 March 17, 2015 Semi-annually 350.0 350.0 341.6 335.6 $1,200.0 million 3.850% notes due June 15, 2024 June 10, 2014 Semi-annually 1,200.0 1,200.0 1,232.3 1,211.7 $4,000.0 million 3.800% notes due March 15, 2025 March 4, 2015 Semi-annually 4,000.0 4,000.0 4,067.1 3,995.6 $2,500.0 million 4.550% notes due March 15, 2035 March 4, 2015 Semi-annually 2,500.0 2,500.0 2,631.9 2,458.5 $1,000.0 million 4.625% notes due October 1, 2042 October 2, 2012 Semi-annually 456.7 1,000.0 471.2 967.6 $1,500.0 million 4.850% notes due June 15, 2044 June 10, 2014 Semi-annually 1,500.0 1,500.0 1,606.2 1,496.4 $2,500.0 million 4.750% notes due March 15, 2045 March 4, 2015 Semi-annually 1,200.0 2,500.0 1,277.3 2,466.9 25,456.7 31,750.0 26,073.0 31,961.1 Euro Denominated Notes €750.0 million 0.500% notes due June 1, 2021 May 26, 2017 Annually 900.4 - 895.8 - €700.0 million 1.250% notes due June 1, 2024 May 26, 2017 Annually 840.4 - 831.1 - €550.0 million 2.125% notes due June 1, 2029 May 26, 2017 Annually 660.3 - 657.8 - €700.0 million floating rate notes due June 1, 2019*** May 26, 2017 Quarterly 840.4 - 837.2 - 3,241.5 - 3,221.9 - Total Senior Notes Gross 29,698.2 32,750.0 30,303.6 32,973.0 Unamortized premium 88.9 171.2 - - Unamortized discount (81.7 ) (95.8 ) - - Total Senior Notes Net 29,705.4 32,825.4 30,303.6 32,973.0 Other Indebtedness Debt Issuance Costs (121.5 ) (144.6 ) Margin Loan 459.0 - Other 29.7 85.5 Total Other Borrowings 367.2 (59.1 ) Capital Leases 2.7 2.4 Total Indebtedness $ 30,075.3 $ 32,768.7 * Interest on the 2018 floating rate note is three month USD ** Interest on the 2020 floating rate note is three month USD *** Interest on the €700.0 million floating rate notes is the three month EURIBOR plus 0.350% per annum
Schedule of Annual Debt Maturities	As of December 31, 2017, annual debt maturities were as follows ($ in millions): Total Payments 2018 $ 3,750.0 2019 1,340.4 2020 4,650.0 2021 2,550.4 2022 4,700.0 2023 and after 12,707.4 Total senior notes gross $ 29,698.2 Capital leases 2.7 Debt issuance costs (121.5 ) Other short-term borrowings 488.7 Unamortized premium 88.9 Unamortized discount (81.7 ) Total Indebtedness $ 30,075.3
Schedule of Future Minimum Lease Payments under Capital and Operating Leases	The future minimum lease payments under both capital and operating leases that have remaining terms in excess of one year are ($ in millions): Total Payments 2018 $ 53.5 2019 59.1 2020 46.5 2021 44.9 2022 42.9 Thereafter 206.1 Total minimum lease payments $ 453.0

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Other Liabilities Disclosure [Abstract]
Summary of Other Long-Term Liabilities	Other long-term liabilities consisted of the following ($ in millions): December 31, December 31, 2017 2016 Acquisition related contingent consideration liabilities $ 420.7 $ 661.1 Long-term pension and post retirement liability 162.7 201.6 Legacy Allergan deferred executive compensation 113.8 111.7 Long-term severance and restructuring liabilities 53.1 22.0 Deferred revenue 37.9 15.7 Product warranties 28.7 28.1 Long-term contractual obligations 45.2 25.3 Other long-term liabilities 24.8 19.5 Total other long-term liabilities $ 886.9 $ 1,085.0

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule of (Benefit)/Provision for Income Taxes	The Company’s (benefit)/provision for income taxes consisted of the following ($ in millions): Years Ended December 31, 2017 2016 2015 Current (benefit) / provision: U.S. federal $ 763.1 $ (17.5 ) $ 14.4 U.S. state (54.8 ) - 9.7 Non-U.S. 410.0 166.2 225.6 Total current (benefit) / provision 1,118.3 148.7 249.7 Deferred (benefit) / provision: U.S. federal (6,911.9 ) (1,218.5 ) (1,370.2 ) U.S. state (252.3 ) (132.1 ) (58.7 ) Non-U.S. (624.5 ) (695.1 ) (426.7 ) Total deferred (benefit) / provision (7,788.7 ) (2,045.7 ) (1,855.6 ) Total (benefit) / provision for income taxes $ (6,670.4 ) $ (1,897.0 ) $ (1,605.9 )
Schedule of Components Company's Net Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities are measured based on the difference between the financial statement and tax basis of assets and liabilities at the applicable tax rates. The significant components of the Company’s net deferred tax assets and liabilities consisted of the following (in millions): Years Ended December 31, 2017 2016 Benefits from net operating and capital losses and tax credit carryforwards $ 1,005.3 $ 702.0 Differences in financial statement and tax accounting for: Inventories, receivables and accruals 263.5 433.6 Basis differences in investments 1,088.7 - Share-based and other compensation 315.4 530.1 Other 20.4 64.0 Total deferred tax asset, gross $ 2,693.3 $ 1,729.7 Less: Valuation allowance (403.8 ) (183.9 ) Total deferred tax asset, net $ 2,289.5 $ 1,545.8 Differences in financial statement and tax accounting for: Property, equipment and intangible assets (7,519.1 ) (12,419.6 ) Outside basis differences (731.4 ) (1,793.7 ) Other (72.3 ) (68.3 ) Total deferred tax liabilities $ (8,322.8 ) $ (14,281.6 ) Total deferred taxes $ (6,033.3 ) $ (12,735.8 )
Schedule of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in millions): Years Ended December 31, 2017 2016 2015 Balance at the beginning of the year $ 811.2 $ 781.7 $ 712.2 Increases for current year tax positions 10.1 100.7 41.2 Increases for prior year tax positions 69.2 40.5 19.7 Increases due to acquisitions 19.8 0.0 115.5 Decreases for prior year tax positions (38.7 ) (77.9 ) (41.4 ) Settlements (21.7 ) (30.8 ) (60.6 ) Lapse of applicable statute of limitations (2.9 ) (2.9 ) (3.2 ) Foreign exchange 3.3 (0.1 ) (1.7 ) Balance at the end of the year $ 850.3 $ 811.2 $ 781.7
Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS	The Company has several concurrent audits open and pending with the Internal Revenue Service (“IRS”) as set forth below: IRS Audits Taxable Years Allergan W.C. Holding Inc. f/k/a Actavis W.C. Holding Inc. 2013 and 2014 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Allergan, Inc. 2009, 2010, 2011, 2012, 2013, 2014 and 3/7/2015 LifeCell Corporation 2014
Irish Income Tax Authority [Member]
Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate	The reconciliations for the years ended December 31, 2017, 2016 and 2015 between the statutory Irish income tax rate for Allergan plc and the effective income tax rates were as follows: Allergan plc Years Ended December 31, 2017 2016 2015 Statutory rate (12.5 )% (12.5 )% (12.5 )% Earnings subject to U.S. taxes (1) (2) (17.8 )% (37.5 )% (18.6 )% Earnings subject to rates different than the statutory rate (1)(2) 2.5 % (18.3 )% (2.2 )% Impact of tax reform (3) (27.2 )% 0.0 % 0.0 % Tax reserves and audit outcomes 0.4 % (0.7 )% 0.3 % Non-deductible expenses 0.2 % 3.1 % 1.3 % Impact of acquisitions and reorganizations (4) (9.3 )% 3.1 % 4.0 % Tax credits and U.S. manufacturing deduction (1.5 )% (3.1 )% (0.5 )% Rate changes (5) (1.2 )% (7.4 )% 0.0 % Valuation allowances (6) 2.2 % 6.5 % (6.5 )% Other 0.0 % (0.2 )% (0.6 )% Effective income tax rate (64.2 )% (67.0 )% (35.3 )% (1) The benefit to the 2017 effective tax rate was lower as compared to 2016 due to proportionately fewer losses in jurisdictions with tax rates higher than the Irish statutory rate. (2) In 2017, the Company recorded amortization expense of $7.20 billion and impairment charges of $8.65 billion, including Teva Share Activity. A significant portion of these amounts were incurred in jurisdictions with tax rates higher than the Irish statutory rate resulting in a net $1,262.2 million favorable impact on the 2017 effective tax rate. (3) As part of the enactment of the TCJA, the Company recorded a provisional net deferred tax benefit of $2.8 billion related to the change in tax rates applicable to our deferred tax liabilities, the net reversal of amounts previously accrued for taxes on unremitted earnings of certain non-U.S. subsidiaries and the tax on the deemed repatriation of the Deferred Foreign Earnings of certain non-U.S. subsidiaries (toll charge). These provisional amounts will be finalized in 2018 or upon the finalization of the 2018 financial results. (4) In 2017, the Company recorded a tax benefit of $895.3 million for deferred taxes related to basis differences in investments expected to reverse at tax rates different than were initially recorded. This resulted in a more favorable impact on the effective tax rate as compared to 2016. (5) As a result of changes in tax rates applied to the Company’s deferred tax liabilities in France and U.S. states, the Company recorded a benefit of $128.1 million. (6) In 2017, the Company recorded a valuation allowance of $230.1 million related to capital losses and foreign tax credit carryforwards not expected to be realized. The amount was mostly offset by benefits recorded in 2017 for these capital losses and foreign tax credits.
Bermuda Income Tax Authority [Member] | Warner Chilcott Limited [Member]
Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate	The reconciliations for the years ended December 31, 2017, 2016 and 2015 between the statutory Bermuda income tax rate for Warner Chilcott Limited and the effective income tax rates were as follows: Warner Chilcott Limited (1) Years Ended December 31, 2017 2016 2015 Statutory rate 0.0 % 0.0 % 0.0 % Earnings subject to U.S. taxes (27.9 )% (58.4 )% (29.5 )% Earnings subject to rates different than the statutory rate (0.4 )% (11.9 )% (5.0 )% Impact of tax reform (27.7 )% 0.0 % 0.0 % Tax reserves and audit outcomes 0.5 % (0.7 )% 0.3 % Non-deductible expenses 0.2 % 3.2 % 1.3 % Impact of acquisitions and reorganizations (9.5 )% 3.2 % 4.1 % Tax credits and U.S. manufacturing deduction (1.5 )% (3.2 )% (0.5 )% Rate changes (1.3 )% (7.6 )% 0.0 % Valuation allowances 2.3 % 6.7 % (6.7 )% Other (0.2 )% (0.1 )% (0.4 )% Effective income tax rate (65.5 )% (68.8 )% (36.4 )% (1) The rate reconciliation for Bermuda is largely consistent with the Irish effective tax rate reconciliations presented above.

Shareholders_ Equity (Tables)

Shareholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Movements in Accumulated Other Comprehensive (Loss)	Unrealized gain / (losses) net of tax primarily represent experience differentials and other actuarial charges related to the Company’s defined benefit plans as well as the mark-to-market impact of our holdings in Teva securities. The movements in accumulated other comprehensive income / (loss) for the years ended December, 2017 and 2016 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gain / (loss) net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2015 $ (564.3 ) $ 70.2 $ (494.1 ) Other comprehensive gain / (loss) before reclassifications into general and administrative (441.6 ) (48.1 ) (489.7 ) Impact of Teva Transaction 1,540.6 4.2 1,544.8 Investment in Teva ordinary shares fair value movement - (1,599.4 ) (1,599.4 ) Total other comprehensive income / (loss) 1,099.0 (1,643.3 ) (544.3 ) Balance as of December 31, 2016 $ 534.7 $ (1,573.1 ) $ (1,038.4 ) Other comprehensive gain / (loss) before reclassifications into general and administrative 1,248.0 111.7 1,359.7 Net impact of other-than-temporary loss on investment in Teva securities - 1,599.4 1,599.4 Total other comprehensive income / (loss) 1,248.0 1,711.1 2,959.1 Balance as of December 31, 2017 $ 1,782.7 $ 138.0 $ 1,920.7

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment	Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Year Ended December 31, 2017 US Specialized US Therapeutics Medicine International Total Net revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 15,919.3 Operating expenses: Cost of sales (1) 495.4 843.9 478.7 1,818.0 Selling and marketing 1,369.5 1,084.1 913.8 3,367.4 General and administrative 208.2 177.3 120.6 506.1 Segment contribution $ 4,730.5 $ 3,690.9 $ 1,806.4 $ 10,227.8 Contribution margin 69.5 % 63.7 % 54.4 % 64.2 % Corporate 1,471.8 Research and development 2,100.1 Amortization 7,197.1 In-process research and development impairments 1,452.3 Asset sales and impairments, net 3,927.7 Operating (loss) $ (5,921.2 ) Operating margin (37.2 )% (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. Year Ended December 31, 2016 US Specialized US Therapeutics Medicine International Total Net revenues $ 5,811.7 $ 5,923.9 $ 2,881.3 $ 14,616.9 Operating expenses: Cost of sales (1) 290.9 879.8 418.2 1,588.9 Selling and marketing 1,137.0 1,185.7 788.2 3,110.9 General and administrative 174.2 174.9 117.2 466.3 Segment contribution $ 4,209.6 $ 3,683.5 $ 1,557.7 $ 9,450.8 Contribution margin 72.4 % 62.2 % 54.1 % 64.7 % Corporate 1,481.3 Research and development 2,575.7 Amortization 6,470.4 In-process research and development impairments 743.9 Asset sales and impairments, net 5.0 Operating (loss) $ (1,825.5 ) Operating margin (12.5 )% (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. Year Ended December 31, 2015 US Specialized US Therapeutics Medicine International Total Net revenues $ 4,309.8 $ 6,338.4 $ 2,187.3 $ 12,835.5 Operating expenses: Cost of sales(1) 235.8 909.5 350.9 1,496.2 Selling and marketing 772.8 1,194.7 569.2 2,536.7 General and administrative 68.3 105.3 107.6 281.2 Segment contribution $ 3,232.9 $ 4,128.9 $ 1,159.6 $ 8,521.4 Contribution margin 75.0 % 65.1 % 53.0 % 66.4 % Corporate 3,066.6 Research and development 2,358.5 Amortization 5,443.7 In-process research and development impairments 511.6 Asset sales and impairments, net 272.0 Operating (loss) $ (3,131.0 ) Operating margin (24.4 )% (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
Schedule of Reconciliation of Net Revenues for Operating Segments	The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Years Ended December 31, 2017 2016 2015 Segment net revenues $ 15,919.3 $ 14,616.9 $ 12,835.5 Corporate revenues 21.4 (46.3 ) (147.4 ) Net revenues $ 15,940.7 $ 14,570.6 $ 12,688.1
Schedule Of Revenue Classified By Products	The following tables present global net revenues for the top products of the Company for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Year Ended December 31, 2017 US Specialized Therapeutics US General Medicine International Corporate Total Botox ® $ 2,254.4 $ - $ 914.5 $ - $ 3,168.9 Restasis ® 1,412.3 - 61.3 - 1,473.6 Juvederm ® 501.1 - 540.7 - 1,041.8 Linzess ® ® - 701.1 21.9 - 723.0 Lumigan ® ® 317.5 - 371.5 - 689.0 Bystolic ® ® - 612.2 2.2 - 614.4 Alphagan ® ® 377.3 - 175.1 - 552.4 Eye Drops 199.5 - 281.0 - 480.5 Lo Loestrin ® - 459.3 - - 459.3 Namenda XR ® - 452.8 - - 452.8 Breast Implants 242.6 - 156.9 - 399.5 Estrace ® - 366.6 - - 366.6 Viibryd ® ® - 333.2 3.1 - 336.3 Alloderm ® 321.2 - 7.5 - 328.7 Ozurdex ® 98.4 - 213.4 - 311.8 Vraylar ™ - 287.8 - - 287.8 Asacol ® ® - 195.5 50.2 - 245.7 Carafate ® ® - 235.8 2.9 - 238.7 Zenpep ® - 212.3 - - 212.3 Coolsculpting ® 150.1 - 41.6 - 191.7 Canasa ® ® - 162.7 18.3 - 181.0 Armour Thyroid - 169.1 - - 169.1 Aczone ® 166.3 - 0.5 - 166.8 Viberzi ® - 156.6 0.5 - 157.1 Saphris ® - 155.2 - - 155.2 Coolsculpting ® 106.6 - 32.1 - 138.7 Namzaric ® - 130.8 - - 130.8 Teflaro ® - 121.9 - - 121.9 Rapaflo ® 108.1 - 7.3 - 115.4 SkinMedica ® 96.8 - 3.7 - 100.5 Savella ® - 98.2 - - 98.2 Tazorac ® 65.4 - 0.7 - 66.1 Latisse ® 56.4 - 8.3 - 64.7 Minastrin ® - 61.4 - - 61.4 Avycaz ® - 61.2 - - 61.2 Kybella ® ® 49.5 - 6.8 - 56.3 Dalvance ® - 53.9 2.4 - 56.3 Lexapro ® - 51.8 - - 51.8 Liletta ® - 37.6 - - 37.6 Enablex ® - 3.6 - - 3.6 Namenda ® - 0.1 - - 0.1 Other 280.1 675.5 395.1 21.4 1,372.1 Total net revenues $ 6,803.6 $ 5,796.2 $ 3,319.5 $ 21.4 $ 15,940.7 ** Sales of fillers including Juvederm, Voluma and other fillers are referred to herein as the "Juvederm ® Year Ended December 31, 2016 US Specialized Therapeutics US General Medicine International Corporate Total Botox® $ 1,983.2 $ - $ 803.0 $ - $ 2,786.2 Restasis® 1,419.5 - 68.0 - 1,487.5 Juvederm® Collection ** 446.9 - 420.4 - 867.3 Lumigan®/Ganfort® 326.4 - 361.7 - 688.1 Linzess®/Constella® - 625.6 17.3 - 642.9 Bystolic® / Byvalson® - 638.8 1.7 - 640.5 Namenda XR® - 627.6 - - 627.6 Alphagan®/Combigan® 376.6 - 169.3 - 545.9 Asacol®/Delzicol® - 360.8 53.7 - 414.5 Lo Loestrin® - 403.5 - - 403.5 Estrace® Cream - 379.4 - - 379.4 Eye Drops 186.5 - 276.2 - 462.7 Breast Implants 206.0 - 149.9 - 355.9 Viibryd®/Fetzima® - 342.3 - - 342.3 Minastrin® 24 - 325.9 1.4 - 327.3 Ozurdex ® 84.4 - 179.0 - 263.4 Carafate ® / Sulcrate ® - 229.0 2.4 - 231.4 Aczone® 217.3 - - - 217.3 Zenpep® - 200.7 - - 200.7 Canasa®/Salofalk® - 178.7 17.7 - 196.4 Saphris® - 166.8 - - 166.8 Armour Thyroid - 166.5 - - 166.5 Teflaro® - 133.6 - - 133.6 Rapaflo® 116.6 - 5.8 - 122.4 SkinMedica® 108.3 - - - 108.3 Savella® - 103.2 - - 103.2 Tazorac® 95.5 - 0.8 - 96.3 Vraylar™ - 94.3 - - 94.3 Viberzi® - 93.3 - - 93.3 Latisse® 77.9 - 8.5 - 86.4 Lexapro® - 66.6 - - 66.6 Namzaric® - 57.5 - - 57.5 Kybella® / Belkyra® 50.2 - 2.3 - 52.5 Dalvance® - 39.3 - - 39.3 Avycaz® - 36.1 - - 36.1 Liletta® - 23.3 - - 23.3 Enablex® - 17.1 - - 17.1 Namenda® IR - 15.1 - - 15.1 Other 116.4 598.9 342.2 33.7 1,091.2 Less product sold through our former Anda Distribution business n.a. n.a. n.a. (80.0 ) (80.0 ) Total net revenues $ 5,811.7 $ 5,923.9 $ 2,881.3 $ (46.3 ) $ 14,570.6 ** Sales of fillers including Juvederm, Voluma and other fillers are referred to herein as the "Juvederm ® Year Ended December 31, 2015 US Specialized Therapeutics US General Medicine International Corporate Total Botox® $ 1,386.4 $ - $ 584.4 $ - $ 1,970.8 Restasis® 999.6 - 48.2 - 1,047.8 Juvederm® Collection ** 304.4 - 269.5 - 573.9 Lumigan®/Ganfort® 260.7 - 283.4 - 544.1 Linzess®/Constella® - 454.8 4.5 - 459.3 Bystolic® / Byvalson® - 644.8 1.3 - 646.1 Namenda XR® - 759.3 - - 759.3 Alphagan®/Combigan® 285.0 - 126.1 - 411.1 Asacol®/Delzicol® - 552.9 65.5 - 618.4 Lo Loestrin® - 346.5 3.1 - 349.6 Estrace® Cream - 326.2 - - 326.2 Eye Drops 177.0 - 220.6 - 397.6 Breast Implants 175.0 - 125.5 - 300.5 Viibryd®/Fetzima® - 327.6 - - 327.6 Minastrin® 24 - 272.4 0.6 - 273.0 Ozurdex ® 56.1 - 112.3 - 168.4 Carafate ® / Sulcrate ® - 213.1 - - 213.1 Aczone® 170.8 - - - 170.8 Zenpep® - 167.4 - - 167.4 Canasa®/Salofalk® - 137.1 18.5 - 155.6 Saphris® - 186.7 - - 186.7 Armour Thyroid - 130.8 - - 130.8 Teflaro® - 137.6 - - 137.6 Rapaflo® 115.2 - 10.9 - 126.1 SkinMedica® 76.6 - - - 76.6 Savella® - 106.4 - - 106.4 Tazorac® 92.3 - 1.4 - 93.7 Vraylar™ - - - - - Viberzi® - 12.3 - - 12.3 Latisse® 63.2 - 10.0 - 73.2 Lexapro® - 71.6 - - 71.6 Namzaric® - 11.2 - - 11.2 Kybella® / Belkyra® 3.2 - - - 3.2 Dalvance® - 16.8 - - 16.8 Avycaz® - 22.6 - - 22.6 Liletta® - 14.8 - - 14.8 Enablex® - 69.2 - - 69.2 Namenda® IR - 556.3 - - 556.3 Other 144.3 800.0 301.5 10.0 1,255.8 Less product sold through our former Anda Distribution business n.a. n.a. n.a. (157.4 ) (157.4 ) Total net revenues $ 4,309.8 $ 6,338.4 $ 2,187.3 $ (147.4 ) $ 12,688.1 ** Sales of fillers including Juvederm, Voluma and other fillers are referred to herein as the "Juvederm ®

Business Restructuring Charges

Business Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities	Restructuring activities for the year ended December 31, 2017 are as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2016 $ 68.5 $ - $ 39.7 $ 108.2 Charged to expense Cost of sales 50.4 - - 50.4 Research and development 37.1 - - 37.1 Selling and marketing 92.5 - - 92.5 General and administrative 37.5 38.8 16.3 92.6 Total expense 217.5 38.8 16.3 272.6 Cash payments (110.4 ) (31.5 ) (36.1 ) (178.0 ) Other reserve impact (9.6 ) (7.3 ) - (16.9 ) Reserve balance at December 31, 2017 $ 166.0 $ - $ 19.9 $ 185.9 During 2016, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Allergan Acquisition. Restructuring activities for the year ended December 31, 2016 is as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2015 $ 94.8 $ - $ 48.6 $ 143.4 Charged to expense Cost of sales 3.9 0.5 4.9 9.3 Research and development 11.1 1.0 0.7 12.8 Selling and marketing 19.8 9.7 1.7 31.2 General and administrative 27.9 9.8 15.1 52.8 Total expense 62.7 21.0 22.4 106.1 Cash payments (81.9 ) - (33.3 ) (115.2 ) Other reserve impact (7.1 ) (21.0 ) 2.0 (26.1 ) Reserve balance at December 31, 2016 $ 68.5 $ - $ 39.7 $ 108.2

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or on Recurring Basis	Assets and liabilities measured at fair value using Fair Value Leveling or disclosed at fair value on a recurring basis as of December 31, 2017 and 2016 consisted of the following ($ in millions): Fair Value Measurements as of December 31, 2017 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 1,328.1 $ 1,328.1 $ - $ - Short-term investments 2,814.4 - 2,814.4 - Deferred executive compensation investments 112.4 92.9 19.5 - Foreign currency derivatives - - - - Investment in Teva ordinary shares 1,817.7 1,817.7 - - Investments and other 72.3 72.3 - - Total assets $ 6,144.9 $ 3,311.0 $ 2,833.9 $ - Liabilities: Deferred executive compensation liabilities 113.8 94.3 19.5 - Contingent consideration obligations 476.9 - - 476.9 Total liabilities $ 590.7 $ 94.3 $ 19.5 $ 476.9 * Marketable securities with less than 90 days remaining until maturity are classified as cash equivalents. Fair Value Measurements as of December 31, 2016 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents * $ 1,238.9 $ 1,238.9 $ - $ - Short-term investments 8,062.3 - 8,062.3 - Deferred executive compensation investments 111.7 90.5 21.2 - Foreign currency derivatives 0.1 - 0.1 - Investment in Teva ordinary shares 3,439.2 - 3,439.2 - Investments and other 95.0 95.0 - - Total assets $ 12,947.2 $ 1,424.4 $ 11,522.8 $ - Liabilities: Deferred executive compensation liabilities 111.7 90.5 21.2 - Contingent consideration obligations 1,172.1 - - 1,172.1 Total liabilities $ 1,283.8 $ 90.5 $ 21.2 $ 1,172.1 *
Change in Fair Value of Contingent Consideration Obligations	Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Years Ended December 31, Expense / (income) 2017 2016 2015 Cost of sales $ (183.2 ) $ (17.4 ) $ 58.5 Research and development 50.0 (71.1 ) 37.7 General and administrative - 24.3 (0.5 ) Total $ (133.2 ) $ (64.2 ) $ 95.7
Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016 ($ in millions): Balance as of December 31, 2016 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of December 31, 2017 Liabilities: Contingent consideration obligations $ 1,172.1 $ - $ (562.0 ) $ (133.2 ) $ 476.9 Balance at December 31, 2015 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance at December 2016 Liabilities: Contingent consideration obligations $ 868.0 $ - $ 368.3 $ (64.2 ) $ 1,172.1
Schedule of Contingent Consideration Obligations by Acquisitions	During the year ended December 31, 2017, the following activity in contingent consideration obligations by acquisition was incurred ($ in millions): Business Acquisition Balance as of December 31, 2016 Fair Value Adjustments Payments and Other Balance as of December 31, 2017 Tobira Acquisition $ 514.4 $ 14.6 $ (301.2 ) $ 227.8 Allergan Acquisition 199.6 (70.9 ) (110.0 ) 18.7 Medicines 360 acquisition 127.5 (67.0 ) (16.1 ) 44.4 AqueSys Acquisition 103.9 (50.4 ) (25.0 ) 28.5 Oculeve Acquisition 99.5 90.6 (100.0 ) 90.1 ForSight Acquisition 65.4 (19.1 ) - 46.3 Metrogel acquisition 15.0 - (7.5 ) 7.5 Forest Acquisition 11.0 3.7 (2.0 ) 12.7 Uteron acquisition 8.2 (8.2 ) - - Other 27.6 (26.5 ) (0.2 ) 0.9 Total $ 1,172.1 $ (133.2 ) $ (562.0 ) $ 476.9

Warner Chilcott Limited ("WCL58

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information (Tables) - Warner Chilcott Acquisition [Member]	12 Months Ended
	Dec. 31, 2017
Consolidating Balance Sheets	Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 593.1 $ 0.1 $ - $ 1,223.0 $ - $ 1,816.3 Marketable securities - 400.2 - - 4,231.9 - 4,632.1 Accounts receivable, net - - - - 2,899.0 - 2,899.0 Receivables from Parents - 4,223.5 - - 1,573.9 - 5,797.4 Inventories - - - - 904.5 - 904.5 Intercompany receivables - 8,118.7 5,507.6 19.6 25,417.0 (39,062.9 ) - Prepaid expenses and other current assets - - - 85.0 1,038.0 - 1,123.0 Total current assets 0.1 13,335.5 5,507.7 104.6 37,287.3 (39,062.9 ) 17,172.3 Property, plant and equipment, net - - - - 1,785.4 - 1,785.4 Investments and other assets - - - - 267.9 - 267.9 Investment in subsidiaries 81,282.1 87,530.6 - 110,114.8 - (278,927.5 ) - Non current intercompany receivables - 27,518.7 20,985.0 - 30,544.0 (79,047.7 ) - Non current receivables from Parents - - - - 3,964.0 - 3,964.0 Non current assets held for sale - - - - 81.6 - 81.6 Deferred tax assets - - - - 316.0 - 316.0 Product rights and other intangibles - - - - 54,648.3 - 54,648.3 Goodwill - - - - 49,862.9 - 49,862.9 Total assets $ 81,282.2 $ 128,384.8 $ 26,492.7 $ 110,219.4 $ 178,757.4 $ (397,038.1 ) $ 128,098.4 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.6 202.9 89.3 5,222.8 - 5,515.6 Intercompany payables - 12,186.2 1,828.5 11,402.3 13,645.9 (39,062.9 ) - Payables to Parents - - - - 2,340.6 - 2,340.6 Income taxes payable - - - - 74.9 - 74.9 Current portion of long-term debt and capital leases - - 3,475.4 - 756.4 - 4,231.8 Total current liabilities - 12,186.8 5,506.8 11,491.6 22,040.6 (39,062.9 ) 12,162.9 Long-term debt and capital leases - - 20,985.0 2,130.1 2,728.4 - 25,843.5 Other long-term liabilities - 0.2 - - 886.7 - 886.9 Long-term intercompany payables - 30,395.0 - 149.0 48,503.7 (79,047.7 ) - Other taxes payable - - - - 1,573.5 - 1,573.5 Deferred tax liabilities - 0.2 - - 6,349.2 - 6,349.4 Total liabilities - 42,582.2 26,491.8 13,770.7 82,082.1 (118,110.6 ) 46,816.2 Total equity / (deficit) 81,282.2 85,802.6 0.9 96,448.7 96,675.3 (278,927.5 ) 81,282.2 Total liabilities and equity $ 81,282.2 $ 128,384.8 $ 26,492.7 $ 110,219.4 $ 178,757.4 $ (397,038.1 ) $ 128,098.4 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2016 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 513.9 $ - $ - $ 1,199.2 $ - $ 1,713.2 Marketable securities - 6,351.8 - - 5,149.7 - 11,501.5 Accounts receivable, net - - - - 2,531.0 - 2,531.0 Receivables from Parents - 4,196.9 - - 5,092.3 - 9,289.2 Inventories - - - - 718.0 - 718.0 Intercompany receivables - 24,348.6 3,343.5 81.6 66,840.8 (94,614.5 ) - Prepaid expenses and other current assets - 14.2 - 42.7 1,325.2 - 1,382.1 Total current assets 0.1 35,425.4 3,343.5 124.3 82,856.2 (94,614.5 ) 27,135.0 Property, plant and equipment, net - - - - 1,611.3 - 1,611.3 Investments and other assets - - - 15.8 266.3 - 282.1 Investment in subsidiaries 88,093.4 89,219.0 - 108,902.4 - (286,214.8 ) - Non current intercompany receivables - 27,706.6 22,540.1 - 9,686.6 (59,933.3 ) - Non current receivables from Parents - - - - 3,964.0 - 3,964.0 Non current assets held for sale - - - - 27.0 - 27.0 Deferred tax assets - - - - 233.3 - 233.3 Product rights and other intangibles - - - - 62,618.6 - 62,618.6 Goodwill - - - - 46,356.1 - 46,356.1 Total assets $ 88,093.5 $ 152,351.0 $ 25,883.6 $ 109,042.5 $ 207,619.4 $ (440,762.6 ) $ 142,227.4 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - - 208.9 - 4,784.4 - 4,993.3 Intercompany payables - 55,828.8 1,652.9 9,359.1 27,773.7 (94,614.5 ) - Payables to Parents - 334.1 - - 1,038.7 - 1,372.8 Income taxes payable - - - - 57.8 - 57.8 Current portion of long-term debt and capital leases - - 1,478.1 1,197.4 122.4 - 2,797.9 Total current liabilities - 56,162.9 3,339.9 10,556.5 33,777.0 (94,614.5 ) 9,221.8 Long-term debt and capital leases - - 22,540.1 3,079.0 4,351.7 - 29,970.8 Other long-term liabilities - - - - 1,086.0 - 1,086.0 Long-term intercompany payables - 9,537.6 - 149.0 50,246.7 (59,933.3 ) - Other taxes payable - - - - 886.2 - 886.2 Deferred tax liabilities - - - - 12,969.1 - 12,969.1 Total liabilities - 65,700.5 25,880.0 13,784.5 103,316.7 (154,547.8 ) 54,133.9 Total equity / (deficit) 88,093.5 86,650.5 3.6 95,258.0 104,302.7 (286,214.8 ) 88,093.5 Total liabilities and equity $ 88,093.5 $ 152,351.0 $ 25,883.6 $ 109,042.5 $ 207,619.4 $ (440,762.6 ) $ 142,227.4
Consolidating Statements of Operations and Comprehensive Income / (Loss)	Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 15,940.7 $ - $ 15,940.7 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,168.0 - 2,168.0 Research and development - - - - 2,100.1 - 2,100.1 Selling and marketing - - - - 3,514.8 - 3,514.8 General and administrative - - 8.6 1.1 1,392.6 - 1,402.3 Amortization - - - - 7,197.1 - 7,197.1 In-process research and development impairments - - - - 1,452.3 - 1,452.3 Asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Total operating expenses - - 8.6 1.1 21,752.6 - 21,762.3 Operating income / (loss) - - (8.6 ) (1.1 ) (5,811.9 ) - (5,821.6 ) Non-operating income / (expense): Interest income / (expense), net - 845.5 116.6 (131.2 ) (1,760.2 ) - (929.3 ) Other income / (expense), net - - (110.4 ) (66.7 ) (3,260.2 ) - (3,437.3 ) Total other income / (expense), net - 845.5 6.2 (197.9 ) (5,020.4 ) - (4,366.6 ) Income / (loss) before income taxes and noncontrolling interest - 845.5 (2.4 ) (199.0 ) (10,832.3 ) - (10,188.2 ) Provision / (benefit) for income taxes - 5.0 0.3 (177.3 ) (6,498.4 ) - (6,670.4 ) (Earnings) / losses of equity interest subsidiaries 3,927.3 4,841.4 - 610.6 - (9,379.3 ) - Net income / (loss) from continuing operations, net of tax (3,927.3 ) (4,000.9 ) (2.7 ) (632.3 ) (4,333.9 ) 9,379.3 (3,517.8 ) (Loss) from discontinued operations, net of tax - - - - (402.9 ) - (402.9 ) Net income / (loss) (3,927.3 ) (4,000.9 ) (2.7 ) (632.3 ) (4,736.8 ) 9,379.3 (3,920.7 ) (Income) attributable to noncontrolling interest - - - - (6.6 ) - (6.6 ) Net income / (loss) attributable to members (3,927.3 ) (4,000.9 ) (2.7 ) (632.3 ) (4,743.4 ) 9,379.3 (3,927.3 ) Other comprehensive (loss) / income, net of tax 2,959.1 3,153.0 - 1,823.0 2,959.1 (7,935.1 ) 2,959.1 Comprehensive income / (loss) attributable to members $ (968.2 ) $ (847.9 ) $ (2.7 ) $ 1,190.7 $ (1,784.3 ) $ 1,444.2 $ (968.2 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2016 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 14,570.6 $ - $ 14,570.6 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,860.8 - 1,860.8 Research and development - - - - 2,575.7 - 2,575.7 Selling and marketing - - - - 3,266.4 - 3,266.4 General and administrative - - - 19.8 1,330.6 - 1,350.4 Amortization - - - - 6,470.4 - 6,470.4 In-process research and development impairments - - - - 743.9 - 743.9 Asset sales and impairments, net - - - - 5.0 - 5.0 Total operating expenses - - - 19.8 16,252.8 - 16,272.6 Operating income / (loss) - - - (19.8 ) (1,682.2 ) - (1,702.0 ) Non-operating income / (expense): Interest income / (expense), net - 2,255.3 3.4 (157.1 ) (3,286.1 ) - (1,184.5 ) Other income / (expense), net - - - - 172.2 - 172.2 Total other income / (expense), net - 2,255.3 3.4 (157.1 ) (3,113.9 ) - (1,012.3 ) Income / (loss) before income taxes and noncontrolling interest - 2,255.3 3.4 (176.9 ) (4,796.1 ) - (2,714.3 ) Provision / (benefit) for income taxes - - 0.1 66.3 (1,963.4 ) - (1,897.0 ) (Earnings) / losses of equity interest subsidiaries (15,091.1 ) (9,342.8 ) - (18,837.8 ) - 43,271.7 - Net income / (loss) from continuing operations, net of tax 15,091.1 11,598.1 3.3 18,594.6 (2,832.7 ) (43,271.7 ) (817.3 ) Income from discontinued operations, net of tax - - - - 15,914.5 - 15,914.5 Net income / (loss) 15,091.1 11,598.1 3.3 18,594.6 13,081.8 (43,271.7 ) 15,097.2 (Income) attributable to noncontrolling interest - - - - (6.1 ) - (6.1 ) Net income / (loss) attributable to members 15,091.1 11,598.1 3.3 18,594.6 13,075.7 (43,271.7 ) 15,091.1 Other comprehensive (loss) / income, net of tax (544.3 ) (419.9 ) - (2,822.2 ) (544.3 ) 3,786.4 (544.3 ) Comprehensive income / (loss) attributable to members $ 14,546.8 $ 11,178.2 $ 3.3 $ 15,772.4 $ 12,531.4 $ (39,485.3 ) $ 14,546.8 Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 12,688.1 - 12,688.1 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 2,751.8 - 2,751.8 Research and development - - - - 2,358.5 - 2,358.5 Selling and marketing - - - - 2,765.1 - 2,765.1 General and administrative - 212.1 16.1 - 1,352.8 - 1,581.0 Amortization - - - - 5,443.7 - 5,443.7 In-process research and development impairments - - - - 511.6 - 511.6 Asset sales and impairments, net - - - - 272.0 - 272.0 Total operating expenses - 212.1 16.1 - 15,455.5 - 15,683.7 Operating income / (loss) - (212.1 ) (16.1 ) - (2,767.4 ) - (2,995.6 ) Non-operating income / (expense): Interest income / (expense), net - 1,572.4 (14.6 ) (168.5 ) (2,572.0 ) - (1,182.7 ) Other income / (expense), net - (265.4 ) 31.0 - 0.6 - (233.8 ) Total other income / (expense), net - 1,307.0 16.4 (168.5 ) (2,571.4 ) - (1,416.5 ) Income / (loss) before income taxes and noncontrolling interest - 1,094.9 0.3 (168.5 ) (5,338.8 ) - (4,412.1 ) Provision / (benefit) for income taxes - - - (58.3 ) (1,547.6 ) - (1,605.9 ) (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (3,412.3 ) - 11,799.4 - Net income / (loss) from continuing operations, net of tax 4,050.6 5,431.4 0.3 3,302.1 (3,791.2 ) (11,799.4 ) (2,806.2 ) Income from discontinued operations, net of tax - - - - 6,861.0 - 6,861.0 Net income / (loss) 4,050.6 5,431.4 0.3 3,302.1 3,069.8 (11,799.4 ) 4,054.8 (Income) attributable to noncontrolling interest - - - - (4.2 ) - (4.2 ) Net income / (loss) attributable to members 4,050.6 5,431.4 0.3 3,302.1 3,065.6 (11,799.4 ) 4,050.6 Other comprehensive (loss) / income, net of tax (28.7 ) 24.5 - (28.7 ) (28.7 ) 32.9 (28.7 ) Comprehensive income / (loss) attributable to members $ 4,021.9 $ 5,455.9 $ 0.3 $ 3,273.4 $ 3,036.9 $ (11,766.5 ) $ 4,021.9
Consolidating Statements of Cash Flows	Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2017 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ (3,927.3 ) $ (4,000.9 ) $ (2.7 ) $ (632.3 ) $ (4,736.8 ) $ 9,379.3 $ (3,920.7 ) Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries 3,927.3 4,841.4 - 610.6 - (9,379.3 ) - Depreciation - - - - 171.5 - 171.5 Amortization - - - - 7,197.1 - 7,197.1 Provision for inventory reserve - - - - 102.2 - 102.2 Share-based compensation - - - - 293.3 - 293.3 Deferred income tax benefit - - - - (7,783.1 ) - (7,783.1 ) In-process research and development impairments - - - - 1,452.3 - 1,452.3 Loss / (gain) on asset sales and impairments, net - - - - 3,927.7 - 3,927.7 Net income impact of other-than-temporary loss on investment in Teva securities - - - - 3,273.5 - 3,273.5 Charge to settle Teva related matters - - - - 387.4 - 387.4 Loss on forward sale of Teva shares - - - - 62.9 - 62.9 Amortization of inventory step-up - - - - 131.7 - 131.7 Non-cash extinguishment of debt - - 17.6 12.2 (45.5 ) - (15.7 ) Amortization of deferred financing costs - - 23.3 4.5 - - 27.8 Contingent consideration adjustments, including accretion - - - - (133.2 ) - (133.2 ) Dividends from subsidiaries 1,668.2 - - - - (1,668.2 ) - Other, net - (10.0 ) - - (27.0 ) - (37.0 ) Changes in assets and liabilities (net of effects of acquisitions) - (4,228.1 ) (241.5 ) 2,148.3 3,207.3 - 886.0 Net cash provided by / (used in) operating activities 1,668.2 (3,397.6 ) (203.3 ) 2,143.3 7,481.3 (1,668.2 ) 6,023.7 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (349.9 ) - (349.9 ) Additions to product rights and other intangibles - - - - (614.3 ) - (614.3 ) Additions to investments - (4,389.6 ) - - (5,394.2 ) - (9,783.8 ) Proceeds from sale of investments and other assets - 7,866.4 - - 7,286.9 - 15,153.3 Proceeds from sales of property, plant and equipment - - - - 7.1 - 7.1 Acquisitions of businesses, net of cash acquired - - - - (5,290.4 ) - (5,290.4 ) Net cash (used in) / provided by investing activities - 3,476.8 - - (4,354.8 ) - (878.0 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - 3,020.9 - 529.1 - 3,550.0 Debt issuance and other financing costs - - (17.5 ) - (3.1 ) - (20.6 ) Payments on debt, including capital lease obligations and credit facility - - (2,800.0 ) (2,143.3 ) (1,470.3 ) - (6,413.6 ) Payments of contingent consideration and other financing - - - - (511.6 ) - (511.6 ) Dividends to Parents (1,668.2 ) - - - (1,668.2 ) 1,668.2 (1,668.2 ) Net cash (used in) / provided by financing activities (1,668.2 ) - 203.4 (2,143.3 ) (3,124.1 ) 1,668.2 (5,064.0 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 21.4 - 21.4 Net increase / (decrease) in cash and cash equivalents - 79.2 0.1 - 23.8 - 103.1 Cash and cash equivalents at beginning of period 0.1 513.9 - - 1,199.2 - 1,713.2 Cash and cash equivalents at end of period $ 0.1 $ 593.1 $ 0.1 $ - $ 1,223.0 $ - $ 1,816.3 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2016 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 15,091.1 $ 11,598.1 $ 3.3 $ 18,594.6 $ 13,081.8 $ (43,271.7 ) $ 15,097.2 Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries (15,091.1 ) (9,342.8 ) - (18,837.8 ) - 43,271.7 - Depreciation - - - - 155.8 - 155.8 Amortization - - - - 6,475.2 - 6,475.2 Provision for inventory reserve - - - - 181.4 - 181.4 Share-based compensation - - - - 334.5 - 334.5 Deferred income tax benefit - - - - (1,443.9 ) - (1,443.9 ) Pre-tax gain on sale of businesses to Teva - - - - (24,511.1 ) - (24,511.1 ) Non-cash tax effect of gain on sale of businesses to Teva - - - - 5,285.2 - 5,285.2 In-process research and development impairments - - - - 743.9 - 743.9 Loss / (gain) on asset sales and impairments, net - - - - 5.0 - 5.0 Amortization of inventory step-up - - - - 42.4 - 42.4 Amortization of deferred financing costs - 23.5 23.3 4.2 - - 51.0 Contingent consideration adjustments, including accretion - - - - (66.8 ) - (66.8 ) Dividends from subsidiaries 2,034.8 - - - - (2,034.8 ) - Other, net - - - - (59.9 ) - (59.9 ) Changes in assets and liabilities (net of effects of acquisitions) 0.1 16,536.2 473.4 237.0 (17,957.6 ) - (710.9 ) Net cash provided by / (used in) operating activities 2,034.9 18,815.0 500.0 (2.0 ) (17,734.1 ) (2,034.8 ) 1,579.0 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (331.4 ) - (331.4 ) Additions to product rights and other intangibles - - - - (2.0 ) - (2.0 ) Sale of businesses to Teva - - - - 33,804.2 - 33,804.2 Additions to investments - (6,351.8 ) - - (9,391.7 ) - (15,743.5 ) Proceeds from sale of investments and other assets - - - - 7,771.6 - 7,771.6 Loans to Parents - (4,196.9 ) - - (9,035.3 ) - (13,232.2 ) Proceeds from sales of property, plant and equipment - - - - 33.3 - 33.3 Acquisitions of businesses, net of cash acquired - - - - (1,198.9 ) - (1,198.9 ) Net cash (used in) / provided by investing activities - (10,548.7 ) - - 21,649.8 - 11,101.1 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 1,050.0 - - - - 1,050.0 Payments on debt, including capital lease obligations and credit facility - (8,815.9 ) (500.0 ) - (1,532.8 ) - (10,848.7 ) Payments of contingent consideration and other financing - - - - (161.1 ) - (161.1 ) Dividends to Parents (2,034.8 ) - - - (2,034.8 ) 2,034.8 (2,034.8 ) Net cash (used in) / provided by financing activities (2,034.8 ) (7,765.9 ) (500.0 ) - (3,728.7 ) 2,034.8 (11,994.6 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - (8.5 ) - (8.5 ) Net increase / (decrease) in cash and cash equivalents 0.1 500.4 - (2.0 ) 178.5 - 677.0 Cash and cash equivalents at beginning of period - 13.5 - 2.0 1,020.7 - 1,036.2 Cash and cash equivalents at end of period $ 0.1 $ 513.9 $ - $ - $ 1,199.2 $ - $ 1,713.2 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 4,050.6 $ 5,431.4 $ 0.3 $ 3,302.1 $ 3,069.8 $ (11,799.4 ) $ 4,054.8 Reconciliation to net cash provided by / (used in) operating activities: (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (3,412.3 ) - 11,799.4 - Depreciation - - - 0.2 218.1 - 218.3 Amortization - - - - 5,777.0 - 5,777.0 Provision for inventory reserve - - - - 140.9 - 140.9 Share-based compensation - - - 51.6 638.8 - 690.4 Deferred income tax benefit - - - - (7,380.1 ) - (7,380.1 ) In-process research and development impairments - - - - 511.6 - 511.6 Loss / (gain) on asset sales and impairments, net - - - - 334.4 334.4 Amortization of inventory step-up - - - - 1,192.9 - 1,192.9 Amortization of deferred financing costs - 272.5 20.9 4.1 0.8 - 298.3 Contingent consideration adjustments, including accretion - - - - 108.8 - 108.8 Dividends from subsidiaries 208.1 208.1 - - - (416.2 ) - Other, net - - - - 66.4 - 66.4 Changes in assets and liabilities (net of effects of acquisitions) (0.1 ) (370.6 ) 122.5 97.7 (1,199.2 ) - (1,349.7 ) Net cash provided by / (used in) operating activities 208.0 1,204.9 143.7 43.4 3,480.2 (416.2 ) 4,664.0 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - (42.9 ) (412.0 ) - (454.9 ) Additions to product rights and other intangibles - - - - (154.7 ) - (154.7 ) Additions to investments (9,000.8 ) (9,000.8 ) - - (24.3 ) 18,001.6 (24.3 ) Proceeds from sale of investments and other assets - - - - 883.0 - 883.0 Proceeds from sales of property, plant and equipment - - - - 140.1 - 140.1 Acquisitions of businesses, net of cash acquired - - - - (37,510.1 ) - (37,510.1 ) Net cash (used in) / provided by investing activities (9,000.8 ) (9,000.8 ) - (42.9 ) (37,078.0 ) 18,001.6 (37,120.9 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 9,110.0 20,955.6 - 72.1 - 30,137.7 Financing structure and other activity with affiliates - (5,500.0 ) (20,955.6 ) - 26,455.6 - - Debt issuance and other financing costs - (167.1 ) (143.7 ) - - - (310.8 ) Payments on debt, including capital lease obligations and credit facility - (4,431.7 ) - - (702.5 ) - (5,134.2 ) Payments of contingent consideration and other financing - - - - (230.1 ) - (230.1 ) Dividends to Parents (208.1 ) (208.1 ) - - (208.1 ) 416.2 (208.1 ) Contributions from Parents 9,000.8 9,000.8 - - 9,000.8 (18,001.6 ) 9,000.8 Net cash provided by / (used in) financing activities 8,792.7 7,803.9 (143.7 ) - 34,387.8 (17,585.4 ) 33,255.3 Effect of currency exchange rate changes on cash and cash equivalents - - - - (6.5 ) - (6.5 ) Net increase / (decrease) in cash and cash equivalents (0.1 ) 8.0 - 0.5 783.5 - 791.9 Cash and cash equivalents at beginning of period 0.1 5.5 - 1.5 237.2 - 244.3 Cash and cash equivalents at end of period $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2

Compensation (Tables)

Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Compensation Related Costs [Abstract]
Schedule of Compensation Charges	The following table represents compensation costs for the years ended December 31, 2017, 2016 and 2015 ($ in millions): Year Ended December 31, 2017 2016 2015 Wages and salaries $ 1,892.8 $ 2,108.7 $ 2,252.3 Stock-based compensation 308.0 396.1 925.7 Pensions 82.7 156.8 99.9 Social welfare 150.4 165.0 185.1 Other benefits 265.1 321.0 271.6 Total $ 2,699.0 $ 3,147.6 $ 3,734.6 Amount included in continuing operations $ 2,699.0 $ 2,578.4 $ 2,597.7 Amount included in discontinued operations $ - $ 569.2 $ 1,136.9

Concentration (Tables)

Concentration (Tables)	12 Months Ended
	Dec. 31, 2017
Risks And Uncertainties [Abstract]
Schedule of Concentration on Revenues	The following table illustrates any customer which accounted for 10% or more of our annual revenues within the U.S. and Canada in any of the past three fiscal years and the respective percentage of our revenues for which they account for each of the last three years: Customer 2017 2016 2015 McKesson Corporation 23 % 23 % 27 % Cardinal Health, Inc. 19 % 18 % 20 % AmerisourceBergen Corporation 19 % 18 % 19 %

Supplementary Data (Tables)

Supplementary Data (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Consolidated Financial Data and Market Price Information	Selected unaudited quarterly consolidated financial data and market price information are shown below ($ in millions except per share data): For Three Month Periods Ended Year Ended 12/31/2017 Dec. 31, 2017 Sept. 30, 2017 June 30, 2017 Mar. 31, 2017 Net revenues $ 15,940.7 $ 4,326.1 $ 4,034.3 $ 4,007.4 $ 3,572.9 Net income/(loss) $ (4,118.9 ) $ 3,123.2 $ (3,954.0 ) $ (723.9 ) $ (2,564.2 ) Basic earnings per share (13.19 ) 9.21 (12.07 ) (2.37 ) (7.86 ) Diluted earnings per share (13.19 ) 8.88 (12.07 ) (2.37 ) (7.86 ) Market price per share: High $ 210.98 $ 256.15 $ 248.91 $ 249.32 Low $ 163.58 $ 202.66 $ 218.73 $ 210.80 For Three Month Periods Ended Year Ended 12/31/2016 Dec. 31, 2016 Sept. 30, 2016 June 30, 2016 Mar. 31, 2016 Net revenues $ 14,570.6 $ 3,864.3 $ 3,622.2 $ 3,684.8 $ 3,399.3 Net income/(loss) $ 14,979.5 $ 1.2 $ 15,221.8 $ (499.9 ) $ 256.4 Basic earnings per share 38.18 (0.20 ) 38.58 (1.44 ) 0.47 Diluted earnings per share 38.18 (0.20 ) 38.58 (1.44 ) 0.47 Market price per share: High $ 244.66 $ 261.27 $ 277.96 $ 310.83 Low $ 184.50 $ 228.68 $ 195.50 $ 261.60

Description of Business - Addit

Description of Business - Additional Information (Detail) shares in Millions, $ in Millions	Aug. 02, 2016USD ($)shares	Dec. 31, 2017USD ($)CountryManufacturer	Dec. 31, 2016USD ($)	Jan. 31, 2018USD ($)	Oct. 31, 2016USD ($)	Oct. 03, 2016USD ($)
Segment Reporting Information [Line Items]
Number of operating countries | Country		100
Number of manufacturers | Manufacturer		0
Teva [Member]
Segment Reporting Information [Line Items]
Ordinary shares received from divestiture of businesses | shares	100.3
Working capital balance reserve proposed adjustment					$ 1,400
Revised estimated adjustment to the closing date working capital balance					$ 1,500
Pre-tax charge recorded		$ 466
Teva [Member] | Subsequent Event [Member]
Segment Reporting Information [Line Items]
Working capital one-time settlement payable				$ 700
Teva [Member] | Anda Distribution Business [Member]
Segment Reporting Information [Line Items]
Number of manufacturers | Manufacturer		300
Consideration amount on sale of business						$ 500
Allergan Global Generic Pharmaceuticals Business and Certain Other Assets | Teva [Member]
Segment Reporting Information [Line Items]
Proceeds Received From Divestiture of Businesses	$ 33,300
Ordinary shares received from divestiture of businesses | shares	100.3
Stock value received in divestiture of businesses	$ 5,000
Discounted rate due to lack of marketability in divestiture of business	5.90%
Deferred liabilities relating to other elements of arrangements			$ 299.2
Allergan Global Generic Pharmaceuticals Business and Certain Other Assets | Teva [Member] | Anda Distribution Business [Member]
Segment Reporting Information [Line Items]
Gain on sale of business			$ 15,932.2

Formation of the Company - Addi

Formation of the Company - Additional Information (Detail) $ / shares in Units, shares in Millions, $ in Billions	Mar. 17, 2015USD ($)shares	Oct. 01, 2013Ratio	Dec. 31, 2017$ / shares	Dec. 31, 2016$ / shares
Business Acquisition [Line Items]
Date of incorporation as a private limited company			May 16, 2013
Effective date of re-registration as a public limited company			Sep. 20, 2013
Ordinary shares, par value | $ / shares			$ 0.0001	$ 0.0001
Class A [Member]
Business Acquisition [Line Items]
Ordinary shares, par value | $ / shares			$ 0.0033
Allergan Finance, LLC [Member]
Business Acquisition [Line Items]
Ordinary share, conversion ratio | Ratio		1
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, consideration transferred	$ 77
Outstanding indebtedness	2.2
Payments to acquire business, cash	40.1
Equity consideration	$ 34.7
Business acquisition date			Mar. 17, 2015
Shares issued to acquire entity | shares	111.2
Allergan, Inc. [Member] | Non-qualified Options [Member]
Business Acquisition [Line Items]
Shares issued to acquire entity | shares	7
Allergan, Inc. [Member] | Restricted Stock Units (RSUs) [Member]
Business Acquisition [Line Items]
Shares issued to acquire entity | shares	0.5

Reconciliation of Warner Chil64

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	$ 1,817.2	$ 1,724	$ 1,096	$ 250
Prepaid expenses and other current assets	1,123.9	1,383.4
Deferred tax assets	319.1	233.3
Accounts payable and accrued liabilities	5,541.4	5,019
Other long-term liabilities	886.9	1,085
Other taxes payables	1,573.9	886.2
Deferred tax liabilities	6,352.4	12,969.1
Material Reconciling Items [Member] | Allergan, Inc. [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	1,817.2	1,724
Prepaid expenses and other current assets	1,123.9	1,383.4
Deferred tax assets	319.1	233.3
Accounts payable and accrued liabilities	5,541.4	5,019
Other long-term liabilities	886.9	1,085
Other taxes payables	1,573.9	886.2
Deferred tax liabilities	6,352.4	12,969.1
Material Reconciling Items [Member] | Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	1,816.3	1,713.2
Prepaid expenses and other current assets	1,123	1,382.1
Deferred tax assets	316	233.3
Accounts payable and accrued liabilities	5,515.6	4,993.3
Other long-term liabilities	886.9	1,086
Other taxes payables	1,573.5	886.2
Deferred tax liabilities	6,349.4	12,969.1
Material Reconciling Items [Member] | Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	0.9	10.8
Prepaid expenses and other current assets	0.9	1.3
Deferred tax assets	3.1
Accounts payable and accrued liabilities	25.8	25.7
Other long-term liabilities		$ (1)
Other taxes payables	0.4
Deferred tax liabilities	$ 3

Reconciliation of Warner Chil65

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									$ 1,501.9	$ 1,473.9	$ 1,716.4
Operating (loss)									(5,921.2)	(1,825.5)	(3,131)
Interest Income									67.7	69.9	10.6
Other income / (expense), net									(3,437.3)	219.2	(233.8)
(Loss) before income taxes and noncontrolling interest									(10,386.4)	(2,832)	(4,547.5)
Net (loss) from continuing operations, net of tax									(3,716)	(935)	(2,941.6)
Net (loss) / income	$ 3,123.2	$ (3,954)	$ (723.9)	$ (2,564.2)	$ 1.2	$ 15,221.8	$ (499.9)	$ 256.4	(4,118.9)	14,979.5	3,919.4
Dividends on preferred shares									278.4	278.4	232
Net (loss) / income attributable to ordinary shareholders/members									(4,403.9)	14,695	3,683.2
Material Reconciling Items [Member] | Allergan, Inc. [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									1,501.9	1,473.9	1,716.4
Operating (loss)									(5,921.2)	(1,825.5)	(3,131)
Interest Income									67.7	69.9	10.6
Other income / (expense), net									(3,437.3)	219.2	(233.8)
(Loss) before income taxes and noncontrolling interest									(10,386.4)	(2,832)	(4,547.5)
Net (loss) from continuing operations, net of tax									(3,716)	(935)	(2,941.6)
Net (loss) / income									(4,118.9)	14,979.5	3,919.4
Dividends on preferred shares									278.4	278.4	232
Net (loss) / income attributable to ordinary shareholders/members									(4,403.9)	14,695	3,683.2
Material Reconciling Items [Member] | Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									1,402.3	1,350.4	1,581
Operating (loss)									(5,821.6)	(1,702)	(2,995.6)
Interest Income									166.3	111.1	10.6
Other income / (expense), net									(3,437.3)	172.2	(233.8)
(Loss) before income taxes and noncontrolling interest									(10,188.2)	(2,714.3)	(4,412.1)
Net (loss) from continuing operations, net of tax									(3,517.8)	(817.3)	(2,806.2)
Net (loss) / income									(3,920.7)	15,097.2	4,054.8
Net (loss) / income attributable to ordinary shareholders/members									(3,927.3)	15,091.1	4,050.6
Material Reconciling Items [Member] | Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									99.6	123.5	135.4
Operating (loss)									(99.6)	(123.5)	(135.4)
Interest Income									(98.6)	(41.2)
Other income / (expense), net										47
(Loss) before income taxes and noncontrolling interest									(198.2)	(117.7)	(135.4)
Net (loss) from continuing operations, net of tax									(198.2)	(117.7)	(135.4)
Net (loss) / income									(198.2)	(117.7)	(135.4)
Dividends on preferred shares									278.4	278.4	232
Net (loss) / income attributable to ordinary shareholders/members									$ (476.6)	$ (396.1)	$ (367.4)

Reconciliation of Warner Chil66

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Interest income	$ (67.7)	$ (69.9)	$ (10.6)
Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Receivable from Parents	5,797.4	9,289.2
Non current receivables from Parents	3,964	3,964
Interest income	(166.3)	(111.1)	$ (10.6)
Material Reconciling Items [Member] | Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Interest income	$ 98.6	$ 41.2

Summary of Significant Accoun67

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Millions	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Maximum percentage of ownership for equity method accounting		50.00%
Ownership percentage in cost method investments		20.00%
Gains or losses on marketable securities		$ 0
Estimated increase tax rate for global intangible low taxed income including foreign credits for beginning after December 31, 2025		13.125%
Maximum percentage of actuarial gain or loss in excess of greater of projected benefit obligation or market related value of plan assets		10.00%
Increase in retained earnings		$ 12,957,200,000	$ 18,342,500,000
Stock Awards [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS		3.8	4.7	5.2
Subsequent Event [Member]
Summary Of Significant Accounting Policies [Line Items]
Tax rate for global intangible low taxed income including foreign credits	10.50%
Ordinary Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS		17.8	17.6	13.6
ASU No. 2016-09 [Member]
Summary Of Significant Accounting Policies [Line Items]
Impact of reclassification adjustment on net deferred tax liabilities and retained earnings due to adoption of new accounting pronouncement		$ 20,800,000
Impact of reclassification adjustment on financing cash flows due to adoption of new accounting pronouncement			$ (20,400,000)
ASU No. 2016-09 [Member] | Retained Earnings [Member]
Summary Of Significant Accounting Policies [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement		(62,400,000)
ASU No. 2016-09 [Member] | Additional Paid-in Capital [Member]
Summary Of Significant Accounting Policies [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement		62,400,000
ASU No. 2016-01 [Member]
Summary Of Significant Accounting Policies [Line Items]
Impact of reclassification adjustment on net deferred tax liabilities and retained earnings due to adoption of new accounting pronouncement		$ 63,000,000
ASU No. 2016-01 [Member] | Subsequent Event [Member] | Revenue from Contracts with Customers (Topic 606) [Member]
Summary Of Significant Accounting Policies [Line Items]
Increase in retained earnings	$ 63,000,000
ASU No. 2016-16 [Member] | Subsequent Event [Member] | Net Tax Liabilities [Member]
Summary Of Significant Accounting Policies [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement	$ (356,200,000)

Summary of Significant Accoun68

Summary of Significant Accounting Policies - Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2017
Computer Software / Hardware (Including Internally Developed) [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Computer Software / Hardware (Including Internally Developed) [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	15 years
Research and Laboratory Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Research and Laboratory Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	10 years
Buildings, Improvements, Leasehold Improvements and Other [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	4 years
Buildings, Improvements, Leasehold Improvements and Other [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	50 years
Transportation Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Transportation Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	20 years

Summary of Significant Accoun69

Summary of Significant Accounting Policies - Provisions for Sales Returns and Allowances from Continuing Operations Activity (Detail) - Continuing Operations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$ 2,178.8	$ 1,815.2	$ 1,295.3
Provision related to sales	8,120	7,038.5	5,621.1
Credits and payments	(7,909.6)	(6,674.9)	(5,530.7)
Balance at end of period	2,430.5	2,178.8	1,815.2
Allergan Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			429.5
Life Cell and Zeltiq Acquisitions [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	41.3
Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	114.2	78.2	28
Provision related to sales	1,098.7	1,003.2	649.9
Credits and payments	(1,135.7)	(967.2)	(613.8)
Balance at end of period	77.2	114.2	78.2
Chargebacks [Member] | Allergan Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			14.1
Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	1,614	1,344.4	995.8
Provision related to sales	4,891.4	4,338.7	4,035.7
Credits and payments	(4,710.4)	(4,069.1)	(3,993.5)
Balance at end of period	1,799.2	1,614	1,344.4
Rebates [Member] | Allergan Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			306.4
Rebates [Member] | Life Cell and Zeltiq Acquisitions [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	4.2
Returns and Other Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	415.9	367.5	255.2
Provision related to sales	1,799.3	1,390.1	659.9
Credits and payments	(1,734.7)	(1,341.7)	(648)
Balance at end of period	517.6	415.9	367.5
Returns and Other Allowances [Member] | Allergan Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			100.4
Returns and Other Allowances [Member] | Life Cell and Zeltiq Acquisitions [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	37.1
Cash Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	34.7	25.1	16.3
Provision related to sales	330.6	306.5	275.6
Credits and payments	(328.8)	(296.9)	(275.4)
Balance at end of period	$ 36.5	$ 34.7	25.1
Cash Discounts [Member] | Allergan Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			$ 8.6

Summary of Significant Accoun70

Summary of Significant Accounting Policies - Summarizes The Balance Sheet Classification of Our SRA Reserves (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Sales Return Allowance Reserve [Line Items]
Accounts receivable	$ 2,899	$ 2,531
Accounts payable and accrued expenses	5,541.4	5,019
Sales Return and Allowances [Member]
Sales Return Allowance Reserve [Line Items]
Accounts receivable	250.6	287.4
Accounts payable and accrued expenses	2,179.9	1,891.4
Net of accounts receivable and payables	$ 2,430.5	$ 2,178.8

Summary of Significant Accoun71

Summary of Significant Accounting Policies - Summary of Activity in Gross-to-Net Revenue Excluding Discontinued Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Gross Product Sales	$ 23,688.4	$ 21,398.6	$ 18,125.1
Chargebacks	1,098.7	1,003.2	649.9
Rebates	4,891.4	4,338.7	4,035.7
Returns and Other Allowances	1,799.3	1,390.1	659.9
Cash Discounts	330.6	306.5	275.6
Net Product Sales	$ 15,568.4	$ 14,360.1	$ 12,504
Product Concentration Risk [Member] | Sales Revenue, Net [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Percentage of Gross Product Sales	65.70%	67.10%	69.00%

Summary of Significant Accoun72

Summary of Significant Accounting Policies - Provisions for Sales Returns and Allowances from Discontinued Operations Activity (Detail) - Discontinued Operations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$ 1,738.7	$ 1,689
Provision related to sales	5,557.9	8,905.8
Credits and payments	(5,656.7)	(8,856.1)
Disposal of businesses	(1,639.9)
Balance at end of period		1,738.7
Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	619	536.9
Provision related to sales	3,525.4	5,907.2
Credits and payments	(3,655)	(5,825.1)
Disposal of businesses	(489.4)
Balance at end of period		619
Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	731	750.8
Provision related to sales	1,290.4	1,991.9
Credits and payments	(1,350)	(2,011.7)
Disposal of businesses	(671.4)
Balance at end of period		731
Returns and Other Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	328.6	356.9
Provision related to sales	583	729.4
Credits and payments	(496.3)	(757.7)
Disposal of businesses	(415.3)
Balance at end of period		328.6
Cash Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	60.1	44.4
Provision related to sales	159.1	277.3
Credits and payments	(155.4)	(261.6)
Disposal of businesses	$ (63.8)
Balance at end of period		$ 60.1

Summary of Significant Accoun73

Summary of Significant Accounting Policies - Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net (loss) / income:
Net (loss) attributable to ordinary shareholders excluding (loss) / income from discontinued operations, net of tax									$ (4,001)	$ (1,219.5)	$ (3,177.8)
(Loss) / income from discontinued operations, net of tax									(402.9)	15,914.5	6,861
Net (loss) / income attributable to ordinary shareholders									$ (4,403.9)	$ 14,695	$ 3,683.2
Basic weighted average ordinary shares outstanding									333.8	384.9	367.8
Basic EPS:
Continuing operations									$ (11.99)	$ (3.17)	$ (8.64)
Discontinued operations									(1.20)	41.35	18.65
Net (loss) / income per share - basic	$ 9.21	$ (12.07)	$ (2.37)	$ (7.86)	$ (0.20)	$ 38.58	$ (1.44)	$ 0.47	(13.19)	$ 38.18	$ 10.01
Dividends per ordinary share									$ 2.80
Diluted weighted average ordinary shares outstanding									333.8	384.9	367.8
Diluted EPS:
Continuing operations									$ (11.99)	$ (3.17)	$ (8.64)
Discontinued operations									(1.20)	41.35	18.65
Net (loss) / income per share - diluted	$ 8.88	$ (12.07)	$ (2.37)	$ (7.86)	$ (0.20)	$ 38.58	$ (1.44)	$ 0.47	$ (13.19)	$ 38.18	$ 10.01

Business Development - Pro Form

Business Development - Pro Forma Results of Businesses Acquired (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Net revenues	$ 4,326.1	$ 4,034.3	$ 4,007.4	$ 3,572.9	$ 3,864.3	$ 3,622.2	$ 3,684.8	$ 3,399.3	$ 15,940.7	$ 14,570.6	$ 12,688.1
Net income attributable to ordinary shareholders									$ (4,403.9)	$ 14,695	$ 3,683.2
Net income per share
Basic	$ 9.21	$ (12.07)	$ (2.37)	$ (7.86)	$ (0.20)	$ 38.58	$ (1.44)	$ 0.47	$ (13.19)	$ 38.18	$ 10.01
Diluted	$ 8.88	$ (12.07)	$ (2.37)	$ (7.86)	$ (0.20)	$ 38.58	$ (1.44)	$ 0.47	$ (13.19)	$ 38.18	$ 10.01
Pro Forma [Member]
Business Acquisition [Line Items]
Net revenues											$ 14,211.1
Net income attributable to ordinary shareholders											$ 4,060.9
Net income per share
Basic											$ 10.32
Diluted											$ 10.32
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Net revenues											$ 1,523
Net income attributable to ordinary shareholders											$ 377.7

Business Development - Addition

Business Development - Additional Information (Detail) $ / shares in Units, € in Millions, £ in Millions

Sep. 08, 2017USD ($)

Jul. 31, 2017USD ($)

Jun. 23, 2017

Apr. 28, 2017USD ($)

Mar. 14, 2017USD ($)

Feb. 01, 2017USD ($)

Jan. 09, 2017USD ($)

Dec. 15, 2016USD ($)

Nov. 22, 2016USD ($)

Nov. 01, 2016USD ($)Program$ / shares

Oct. 25, 2016USD ($)

Oct. 02, 2016USD ($)

Sep. 23, 2016USD ($)

Sep. 06, 2016USD ($)

Aug. 26, 2016USD ($)

Apr. 21, 2016USD ($)

Apr. 06, 2016USD ($)

Jan. 06, 2016USD ($)

Nov. 04, 2015USD ($)

Oct. 27, 2015EUR (€)

Oct. 16, 2015USD ($)

Oct. 01, 2015USD ($)$ / shares

Aug. 28, 2015USD ($)

Aug. 10, 2015USD ($)

May 29, 2015USD ($)

May 29, 2015GBP (£)

Mar. 17, 2015USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Mar. 02, 2015USD ($)

Dec. 31, 2014USD ($)

Business Acquisition [Line Items]

Goodwill

$ 49,862,900,000

$ 46,356,100,000

Research and development

2,100,100,000

2,575,700,000

$ 2,358,500,000

Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)

2,168,000,000

1,860,800,000

2,751,800,000

Sale of assets

22,500,000

Impairments of intangible assets

1,452,300,000

743,900,000

511,600,000

Reduction of acquired contingent consideration

(133,200,000)

(64,200,000)

95,700,000

Defined benefit pension obligation

1,330,000,000

1,234,100,000

1,188,500,000

Payments to acquire intangible assets

614,300,000

2,000,000

154,700,000

Respiratory Therapeutic Area [Member]

Business Acquisition [Line Items]

Asset held for sale

$ 734,000,000

Goodwill

$ 309,100,000

Incremental charge in cost of sales relating to inventory

35,300,000

R&D Expense [Member]

Business Acquisition [Line Items]

Reduction of acquired contingent consideration

50,000,000

(71,100,000)

37,700,000

Migraine License Acquisition [Member]

Business Acquisition [Line Items]

Payment for license upfront fees

100,000,000

Migraine License Acquisition [Member] | R&D Expense [Member]

Business Acquisition [Line Items]

Upfront charge

250,000,000

Saint Regis Mohawk Tribe [Member]

Business Acquisition [Line Items]

Upfront payment of agreement

$ 13,800,000

Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)

13,800,000

AstraZeneca [Member]

Business Acquisition [Line Items]

Consideration amount on sale of business

$ 600,000,000

Additional consideration amount on sale of business

$ 100,000,000

AstraZeneca [Member] | Other (Expense) Income [Member]

Business Acquisition [Line Items]

Gain (loss) on sale of business

$ (5,300,000)

US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

20,859,600,000

18,433,200,000

International [Member]

Business Acquisition [Line Items]

Goodwill

7,603,600,000

6,496,300,000

US General Medicine [Member]

Business Acquisition [Line Items]

Goodwill

21,399,700,000

21,426,600,000

Payments to acquire intangible assets

574,000,000

Maximum [Member] | Migraine License Acquisition [Member]

Business Acquisition [Line Items]

Contingent payment based on commercial and development milestones

965,000,000

Maximum [Member] | Saint Regis Mohawk Tribe [Member]

Business Acquisition [Line Items]

Annual royalties payable in 2018

$ 15,000,000

Keller Medical, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Jun. 23, 2017

Zeltiq Aesthetics, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Apr. 28, 2017

Payments to acquire business, cash

$ 2,405,400,000

Goodwill

1,200,600,000

Step-up in the value of inventories

22,900,000

Amortization of inventory step-up to cost of sales

22,900,000

Zeltiq Aesthetics, Inc. [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

954,700,000

Zeltiq Aesthetics, Inc. [Member] | International [Member]

Business Acquisition [Line Items]

Goodwill

$ 245,900,000

Zeltiq Aesthetics, Inc. [Member] | IPR&D [Member] | Minimum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

10.00%

Zeltiq Aesthetics, Inc. [Member] | IPR&D [Member] | Maximum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

11.00%

LifeCell Corporation [Member]

Business Acquisition [Line Items]

Business acquisition date

Feb. 1, 2017

Goodwill

1,449,100,000

Step-up in the value of inventories

$ 108,400,000

Acquisition purchase price

2,883,100,000

LifeCell Corporation [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

$ 1,449,100,000

LifeCell Corporation [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

7.50%

Lyndra, Inc [Member] | Ultra-long-acting Oral Products [Member]

Business Acquisition [Line Items]

Business acquisition date

Jul. 31, 2017

Payment for license upfront fees

$ 15,000,000

Research and development

15,000,000

Lyndra, Inc [Member] | Maximum [Member] | Ultra-long-acting Oral Products [Member]

Business Acquisition [Line Items]

Research and development

85,000,000

Editas Medicine Inc [Member] | Eye Care [Member]

Business Acquisition [Line Items]

Business acquisition date

Mar. 14, 2017

Payment for license upfront fees

$ 90,000,000

Research and development

90,000,000

Assembly Biosciences, Inc [Member]

Business Acquisition [Line Items]

Business acquisition date

Jan. 9, 2017

Payment for license upfront fees

$ 50,000,000

Research and development

50,000,000

Assembly Biosciences, Inc [Member] | Maximum [Member]

Business Acquisition [Line Items]

Research and development

2,771,000,000

Lysosomal Therapeutics, Inc [Member]

Business Acquisition [Line Items]

Business acquisition date

Jan. 9, 2017

Research and development

145,000,000

Lysosomal Therapeutics, Inc [Member] | Option Right [Member]

Business Acquisition [Line Items]

Research and development

$ 150,000,000

Tobira Therapeutics Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Nov. 1, 2016

Goodwill

98,600,000

Acquisition purchase price

$ 570,100,000

Maximum amount of contingent consideration

1,101,300,000

Payments of contingent consideration

303,100,000

Contingent consideration liability

$ 479,000,000

479,000,000

Number of differentiated, complementary development programs added | Program

1

Tobira Therapeutics Inc. [Member] | US General Medicine [Member]

Business Acquisition [Line Items]

Goodwill

$ 98,600,000

Tobira Therapeutics Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Contingent consideration for acquisition CVRs per share value | $ / shares

$ 49.84

Tobira Therapeutics Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

11.50%

Topokine Therapeutics, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Apr. 21, 2016

Payments to acquire business, cash

303,100,000

Payment for license upfront fees

$ 85,800,000

Research and development

85,000,000

Contingent consideration liability

$ 479,000,000

Contingent payment based on commercial and development milestones

$ 260,000,000

Topokine Therapeutics, Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 1,101,300,000

Vitae Pharmaceuticals Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 25, 2016

Goodwill

30,600,000

Acquisition purchase price

$ 621,400,000

Asset held for sale

22,500,000

Vitae Pharmaceuticals Inc. [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

$ 30,600,000

Vitae Pharmaceuticals Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

9.50%

ForSight VISION 5 [Member]

Business Acquisition [Line Items]

Business acquisition date

Sep. 23, 2016

Payments to acquire business, cash

$ 95,000,000

Goodwill

50,500,000

Acquisition purchase price

74,500,000

Contingent consideration liability

79,800,000

79,800,000

15,000,000

Payment of outstanding indebtedness

14,800,000

ForSight VISION 5 [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

50,500,000

ForSight VISION 5 [Member] | Maximum [Member]

Business Acquisition [Line Items]

Acquisition purchase price

125,000,000

Contingent consideration liability

$ 125,000,000

ForSight VISION 5 [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

13.00%

Impairments of intangible assets

$ 33,000,000

33,000,000

Reduction of acquired contingent consideration

$ (15,000,000)

Motus Therapeutics, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Dec. 15, 2016

Payment for license upfront fees

$ 200,000,000

Research and development

199,500,000

Chase Pharmaceuticals Corporation [Member]

Business Acquisition [Line Items]

Business acquisition date

Nov. 22, 2016

Payment for license upfront fees

$ 125,000,000

Research and development

122,900,000

Potential regulatory and commercial milestones payments

$ 875,000,000

AstraZeneca [Member]

Business Acquisition [Line Items]

Research and development

250,000,000

Maximum amount of contingent consideration

$ 1,270,000,000

License fees for development and commercialization

$ 250,000,000

RetroSense Therapeutics, LLC [Member]

Business Acquisition [Line Items]

Business acquisition date

Sep. 6, 2016

Payment for license upfront fees

$ 60,000,000

Research and development

59,700,000

Contingent payment based on commercial and development milestones

$ 495,000,000

Akarna Therapeutics, Ltd [Member]

Business Acquisition [Line Items]

Business acquisition date

Aug. 26, 2016

Payment for license upfront fees

$ 50,000,000

Research and development

39,600,000

48,200,000

Contingent payment based on commercial and development milestones

$ 1,015,000,000

Heptares Therapeutics Ltd. [Member]

Business Acquisition [Line Items]

Business acquisition date

Apr. 6, 2016

Payment for license upfront fees

$ 125,000,000

Research and development

15,000,000

125,000,000

Contingent payment based on commercial and development milestones

665,000,000

Aggregate payments contingent upon achieving certain annual sales threshold milestones

$ 2,575,000,000

Anterios, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Jan. 6, 2016

Research and development

89,200,000

Contingent payment based on commercial and development milestones

$ 387,500,000

Upfront payment

$ 90,000,000

AqueSys, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 16, 2015

Goodwill

$ 138,500,000

Acquisition purchase price

298,900,000

Contingent consideration liability

$ 193,500,000

Intangible assets amortizable period

12 years 2 months 12 days

AqueSys, Inc. [Member] | Milestone Payment [Member]

Business Acquisition [Line Items]

Payments of contingent consideration

25,000,000

100,000,000

AqueSys, Inc. [Member] | CMP and IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

21.00%

AqueSys, Inc. [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

$ 50,500,000

AqueSys, Inc. [Member] | International [Member]

Business Acquisition [Line Items]

Goodwill

$ 88,000,000

Kythera Biopharmaceuticals, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 1, 2015

Goodwill

$ 328,700,000

Acquisition purchase price

$ 2,089,500,000

Intangible assets amortizable period

17 years 3 months 18 days

Business combination cash consideration for each share | $ / shares

$ 75

Kythera Biopharmaceuticals, Inc. [Member] | CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

8.50%

Kythera Biopharmaceuticals, Inc. [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

$ 208,700,000

Kythera Biopharmaceuticals, Inc. [Member] | International [Member]

Business Acquisition [Line Items]

Goodwill

$ 120,000,000

Kythera Biopharmaceuticals, Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

9.50%

Oculeve, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Aug. 10, 2015

Goodwill

$ 33,300,000

Acquisition purchase price

134,500,000

Contingent consideration liability

90,000,000

Payment of contingent consideration liability

100,000,000

Oculeve, Inc. [Member] | Milestone Payment [Member]

Business Acquisition [Line Items]

Payment of contingent consideration liability

$ 100,000,000

Oculeve, Inc. [Member] | US Specialized Therapeutics [Member]

Business Acquisition [Line Items]

Goodwill

33,300,000

Oculeve, Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Future contingent payments

$ 300,000,000

Oculeve, Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

11.00%

Auden Mckenzie Holdings Limited [Member]

Business Acquisition [Line Items]

Business acquisition date

May 29, 2015

Payments to acquire business, cash

$ 495,900,000

£ 323.7

Allergan, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Mar. 17, 2015

Payments to acquire business, cash

$ 40,100,000,000

Goodwill

27,088,900,000

Step-up in the value of inventories

923,900,000

Amortization of inventory step-up to cost of sales

21,600,000

$ 902,300,000

Acquisition purchase price

77,000,000,000

Contingent consideration liability

383,700,000

Cash and equity consideration

74,800,000,000

Value of equity shares outstanding

33,900,000,000

Portion of equity awards deemed to have been earned

800,000,000

Portion of equity awards deemed not to have been earned

843,100,000

Portion of equity awards deemed expense

$ 77,200,000

151,500,000

$ 516,200,000

Defined benefit plans, net liability

302,600,000

Defined benefit pension obligation

60,200,000

Allergan, Inc. [Member] | R&D Expense [Member]

Business Acquisition [Line Items]

Reduction of acquired contingent consideration

64,200,000

Allergan, Inc. [Member] | Migraine License Acquisition [Member]

Business Acquisition [Line Items]

Impairments of intangible assets

$ 106,000,000

Allergan, Inc. [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

1,042,000,000

Allergan, Inc. [Member] | Other Benefit Obligation [Member]

Business Acquisition [Line Items]

Fair value of assets

117,100,000

Fair value of liabilities

120,000,000

Allergan, Inc. [Member] | Cash and Cash Equivalents [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

13,600,000

Allergan, Inc. [Member] | Equity Securities [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

480,100,000

Allergan, Inc. [Member] | Fixed Income Securities [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

$ 548,300,000

Allergan, Inc. [Member] | CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

10.00%

Allergan, Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Impairments of intangible assets

140,000,000

Allergan, Inc. [Member] | IPR&D [Member] | Minimum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

10.00%

Allergan, Inc. [Member] | IPR&D [Member] | Maximum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

11.00%

Mimetogen Pharmaceuticals [Member]

Business Acquisition [Line Items]

Payment for license upfront fees

$ 50,000,000

Almirall [Member]

Business Acquisition [Line Items]

Payments to acquire intangible assets | €

€ 60

Naurex, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Aug. 28, 2015

Aug. 28, 2015

Upfront charge of acquired rights recognized as research and development expense

$ 571,700,000

Amount received from purchase price reduction

$ 20,000,000

Naurex, Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Future contingent payments

$ 1,150,000,000

Business Development - Summary

Business Development - Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date and Purchase Accounting Adjustments Subsequent to Acquisition Date (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Feb. 01, 2017	Dec. 31, 2016	Nov. 01, 2016	Sep. 23, 2016	Oct. 16, 2015	Oct. 01, 2015	Aug. 10, 2015	Mar. 17, 2015
Business Acquisition [Line Items]
Goodwill	$ 49,862.9		$ 46,356.1
Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	36.7
Accounts receivable	47
Inventories	59.3
Property, plant and equipment, net	12.4
Intangible assets	1,185
Goodwill	1,200.6
Other assets	17.1
Accounts payable and accrued expenses	(93.6)
Deferred revenue	(10.6)
Deferred tax liabilities, net	(47.2)
Other liabilities	(1.3)
Net assets acquired	2,405.4
LifeCell Corporation [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	8.7
Accounts receivable	50.8
Inventories	175.4
Property, plant and equipment, net	53.7
Intangible assets	2,020	$ 2,020
Goodwill	1,449.1
Accounts payable and accrued expenses	(149.6)
Deferred tax liabilities, net	(746.2)
Other long-term liabilities	(21.2)
Other	21.2
Net assets acquired	2,883.1
LifeCell Corporation [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets		$ 10
Intangible assets	10
LifeCell Corporation [Member] | Currently Marketed Products ("CMP") [Member]
Business Acquisition [Line Items]
Intangible assets	2,010
Tobira Therapeutics Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	21.3
Goodwill	98.6
Indebtedness	(15.9)
Contingent consideration	(479)			$ (479)
Deferred tax liabilities, net	(381.8)
Other assets and liabilities	(30.1)
Net assets acquired	570.1
Tobira Therapeutics Inc. [Member] | Previously Reported Preliminary Valuation [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			21.3
Goodwill			112.7
Indebtedness			(15.9)
Contingent consideration			(479)
Deferred tax liabilities, net			(395.9)
Other assets and liabilities			(30.1)
Net assets acquired			570.1
Tobira Therapeutics Inc. [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Goodwill	(14.1)
Deferred tax liabilities, net	14.1
Tobira Therapeutics Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets	1,357		1,357
Tobira Therapeutics Inc. [Member] | IPR&D [Member] | Previously Reported Preliminary Valuation [Member]
Business Acquisition [Line Items]
IPR&D intangible assets			1,357
Vitae Pharmaceuticals Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	44.7
Marketable securities	20.2
Property, plant and equipment, net	5
Assets held for sale	22.5
Goodwill	30.6
Deferred tax liabilities, net	(166.9)
Other assets and liabilities	(20.7)
Net assets acquired	621.4
Vitae Pharmaceuticals Inc. [Member] | Previously Reported Preliminary Valuation [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			44.7
Marketable securities			20.2
Property, plant and equipment, net			5
Assets held for sale			22.5
Goodwill			34.4
Deferred tax liabilities, net			(170.7)
Other assets and liabilities			(20.7)
Net assets acquired			621.4
Vitae Pharmaceuticals Inc. [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Goodwill	(3.8)
Deferred tax liabilities, net	3.8
Vitae Pharmaceuticals Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets	686		686
Vitae Pharmaceuticals Inc. [Member] | IPR&D [Member] | Previously Reported Preliminary Valuation [Member]
Business Acquisition [Line Items]
IPR&D intangible assets			686
ForSight VISION 5 [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	1
Goodwill	50.5
Current liabilities	(14.8)
Contingent consideration	(79.8)		(15)		$ (79.8)
Deferred tax liabilities, net	(37.2)
Other assets and liabilities	(3.2)
Net assets acquired	74.5
ForSight VISION 5 [Member] | Previously Reported Preliminary Valuation [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			1
Goodwill			51.6
Current liabilities			(14.8)
Contingent consideration			(79.8)
Deferred tax liabilities, net			(38.3)
Other assets and liabilities			(3.2)
Net assets acquired			74.5
ForSight VISION 5 [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Goodwill	(1.1)
Deferred tax liabilities, net	1.1
ForSight VISION 5 [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets	$ 158		158
ForSight VISION 5 [Member] | IPR&D [Member] | Previously Reported Preliminary Valuation [Member]
Business Acquisition [Line Items]
IPR&D intangible assets			$ 158
AqueSys, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents						$ 6.2
Current assets						1.2
Intangible assets						221
Goodwill						138.5
Current liabilities						(6.9)
Contingent consideration						(193.5)
Deferred tax liabilities, net						(169.6)
Net assets acquired						298.9
AqueSys, Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets						$ 302
Kythera Biopharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents							$ 78.1
Inventories							18.2
Marketable securities							79.9
Other current assets							14.5
Intangible assets							2,120
Goodwill							328.7
Other current liabilities							(48.6)
Deferred tax liabilities, net							(766.7)
Outstanding indebtedness							(54.6)
Net assets acquired							2,089.5
Kythera Biopharmaceuticals, Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets							$ 320
Oculeve, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents								$ 1.6
Goodwill								33.3
Contingent consideration								(90)
Deferred tax liabilities, net								(94.5)
Other assets and liabilities								(1.9)
Net assets acquired								134.5
Oculeve, Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets								$ 286
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents									$ 5,424.5
Accounts receivable									948.7
Inventories									1,218.6
Other current assets									318.8
Property, plant and equipment, net									1,214.5
Other long-term assets									196.1
Intangible assets									54,750.5
Goodwill									27,088.9
Current liabilities									(1,222.1)
Contingent consideration									(383.7)
Deferred tax liabilities, net									(11,880.1)
Other taxes payable									(111.3)
Other long-term liabilities									(622)
Outstanding indebtedness									(2,183.5)
Other									622
Net assets acquired									74,757.9
Allergan, Inc. [Member] | Currently Marketed Products ("CMP") [Member]
Business Acquisition [Line Items]
Intangible assets									45,050.5
Allergan, Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
IPR&D intangible assets									$ 9,700

Business Development - Summar77

Business Development - Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets (Detail) - USD ($) $ in Millions	Apr. 28, 2017	Feb. 01, 2017	Dec. 31, 2015	Dec. 31, 2017	Mar. 17, 2015
Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 1,185
Intangible Assets, Amount recognized as of the acquisition date				$ 1,185
LifeCell Corporation [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 2,010
Intangible Assets, Amount recognized as of the acquisition date		2,020		2,020
LifeCell Corporation [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date		10
Intangible Assets, Amount recognized as of the acquisition date				$ 10
LifeCell Corporation [Member] | IPR&D [Member] | Other Products [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date		10
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					$ 45,050.5
Intangible Assets, Amount recognized as of the acquisition date					54,750.5
Weighted average useful lives (years)			6 years 7 months 6 days
Allergan, Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date					9,700
Allergan, Inc. [Member] | IPR&D [Member] | Other Products [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date					1,120
Allergan, Inc. [Member] | IPR&D [Member] | Botox [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date					810
Allergan, Inc. [Member] | IPR&D [Member] | Eye Care [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date					5,500
Allergan, Inc. [Member] | IPR&D [Member] | Aesthetics [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date					2,270
CMP [Member] | Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	1,028
CMP [Member] | Zeltiq Aesthetics, Inc. [Member] | Consumables [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 985
Weighted average useful lives (years)	6 years 8 months 12 days
CMP [Member] | Zeltiq Aesthetics, Inc. [Member] | System [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 43
Weighted average useful lives (years)	3 years 8 months 12 days
CMP [Member] | LifeCell Corporation [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		1,910
CMP [Member] | LifeCell Corporation [Member] | Alloderm [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 1,385
Weighted average useful lives (years)		6 years 10 months 24 days
CMP [Member] | LifeCell Corporation [Member] | Revolve [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 80
Weighted average useful lives (years)		7 years 1 month 6 days
CMP [Member] | LifeCell Corporation [Member] | Strattice [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 320
Weighted average useful lives (years)		5 years 1 month 6 days
CMP [Member] | LifeCell Corporation [Member] | Artia [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 115
Weighted average useful lives (years)		8 years 9 months 18 days
CMP [Member] | LifeCell Corporation [Member] | Other Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 10
Weighted average useful lives (years)		2 years 9 months 18 days
CMP [Member] | Allergan, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					43,310
Weighted average useful lives (years)			6 years 8 months 12 days
CMP [Member] | Allergan, Inc. [Member] | Restasis [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					3,970
Weighted average useful lives (years)			4 years
CMP [Member] | Allergan, Inc. [Member] | Refresh Optive [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					2,720
Weighted average useful lives (years)			7 years 7 months 6 days
CMP [Member] | Allergan, Inc. [Member] | Other Eye Care Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					6,690
Weighted average useful lives (years)			4 years 2 months 12 days
CMP [Member] | Allergan, Inc. [Member] | Botox [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					22,600
Weighted average useful lives (years)			8 years
CMP [Member] | Allergan, Inc. [Member] | Aczone [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					160
Weighted average useful lives (years)			1 year 3 months 18 days
CMP [Member] | Allergan, Inc. [Member] | Other Skin Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					820
Weighted average useful lives (years)			5 years
CMP [Member] | Allergan, Inc. [Member] | Other Aesthetics [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					6,350
Weighted average useful lives (years)			6 years
Customer Relationships [Member] | Zeltiq Aesthetics, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 157
Weighted average useful lives (years)	6 years 7 months 6 days
Customer Relationships [Member] | LifeCell Corporation [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 100
Weighted average useful lives (years)		6 years 3 months 18 days
Customer Relationships [Member] | Allergan, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					1,050.5
Weighted average useful lives (years)			3 years 4 months 24 days
Trade Name [Member] | Allergan, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date					$ 690
Weighted average useful lives (years)			4 years 6 months

Business Development - Summar78

Business Development - Summary of Transaction and Integration Costs for Acquisition (Detail) - Legacy Allergan [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Total transaction and integration costs	$ 403.5	$ 1,288.4
Acquisition, Integration and Restructuring Related Charges [Member] | Cost of Sales [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	18.1	14.9
Acquisition, Integration and Restructuring Related Charges [Member] | Research and Development Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	11.8	83.5
Acquisition, Integration and Restructuring Related Charges [Member] | Selling and Marketing Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	24.7	75.7
Acquisition, Integration and Restructuring Related Charges [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	197.4	364.1
Bridge Loan Facilities Expense [Member] | Other (Expense) Income [Member]
Business Acquisition [Line Items]
Total transaction and integration costs		(264.9)
Interest Rate Lock [Member] | Other (Expense) Income [Member]
Business Acquisition [Line Items]
Total transaction and integration costs		30.9
Stock Compensation Plan [Member] | Cost of Sales [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	9.6	22.5
Stock Compensation Plan [Member] | Research and Development Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	43	124.8
Stock Compensation Plan [Member] | Selling and Marketing Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	65.3	110
Stock Compensation Plan [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	$ 33.6	$ 258.9

Collaborations - Additional Inf

Collaborations - Additional Information (Detail) - USD ($) $ in Millions	Aug. 13, 2014	Dec. 02, 2013	May 09, 2013	Sep. 30, 2007	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Collaborations And License Agreements [Line Items]
Reduction of acquired contingent consideration					$ (133.2)	$ (64.2)	$ 95.7
Amgen, Inc. [Member] | Collaborative Arrangement [Member]
Collaborations And License Agreements [Line Items]
Co-development costs					107.2
Research and Development Expense [Member]
Collaborations And License Agreements [Line Items]
Reduction of acquired contingent consideration					50	(71.1)	$ 37.7
Apollo Endosurgery, Inc [Member]
Collaborations And License Agreements [Line Items]
Payments to acquire business, cash		$ 75
Equity consideration					$ 15
Business acquisition date					Dec. 2, 2013
Other than temporary impairment on investments					$ 15
LiRIS Biomedical, Inc. [Member]
Collaborations And License Agreements [Line Items]
Business acquisition upfront payment	$ 67.5
Aggregate payments contingent upon achieving certain future development milestones	295
Aggregate payments contingent upon achieving certain future commercial milestones	225
Fair Value of contingent consideration	$ 169.6
Impairment due to clinical data						210
LiRIS Biomedical, Inc. [Member] | Research and Development Expense [Member]
Collaborations And License Agreements [Line Items]
Reduction of acquired contingent consideration						(186)
Trevena [Member]
Collaborations And License Agreements [Line Items]
Other than temporary impairment on investments					11.2
Purchases of preferred stock			$ 30
Purchases of common stock			$ 3
Fair Value of acquired common stock					$ 5.4	$ 20
Ironwood Collaboration Agreement [Member]
Collaborations And License Agreements [Line Items]
Acquisition related contingent milestone payments				$ 100

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - USD ($) $ in Millions	Oct. 03, 2016	Aug. 02, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 31, 2018	Oct. 31, 2016
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Pre-tax charge sale of business				$ 24,511.1
Deferred tax (benefit) expense related to investment in certain subsidiaries				(462.2)	$ 5,738.8
Deferred income tax benefit			$ (7,783.1)	(1,443.9)	$ (7,380.1)
Anda Distribution Business and Global Generics Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on sale of business				15,932.2
Pre-tax charge sale of business				24,511.1
Teva [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Working capital balance reserve proposed adjustment							$ 1,400
Revised estimated adjustment to the closing date working capital balance							$ 1,500
Pre-tax charge sale of business			$ 466
Deferred income tax benefit				5,276.6
Teva [Member] | Allergan Global Generic Pharmaceuticals Business and Certain Other Assets
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discounted rate due to lack of marketability in divestiture of business		5.90%
Teva [Member] | Subsequent Event [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Working capital one-time settlement payable						$ 700
Teva [Member] | Anda Distribution Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued operations definite sale agreement date	Oct. 3, 2016
Consideration amount on sale of business	$ 500
Teva [Member] | Anda Distribution Business [Member] | Allergan Global Generic Pharmaceuticals Business and Certain Other Assets
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on sale of business				$ 15,932.2

Discontinued Operations - Sched

Discontinued Operations - Schedule of Reconciliation of Proceeds Received in Sale of Generics Business and Anda Distribution Business to Gain Recognized in Income from Discontinued Operations (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Net cash proceeds received	$ 33,804.2
Pre-tax gain on sale of generics business and Anda Distribution business	24,511.1
Generics Business and Anda Distribution Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Net cash proceeds received	33,804.2
August 2, 2016 fair value of Teva shares	5,038.6
Total Proceeds	38,842.8
Net assets sold to Teva, excluding cash	(12,487.7)
Other comprehensive income disposed	(1,544.8)
Deferral of proceeds relating to additional elements of agreements with Teva	(299.2)
Pre-tax gain on sale of generics business and Anda Distribution business	24,511.1
Income taxes	(8,578.9)
Net gain on sale of generics business and Anda Distribution business	$ 15,932.2

Discontinued Operations - Summa

Discontinued Operations - Summary of Teva Share Activity (Detail) - Teva [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended		12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Securities Financing Transaction [Line Items]
Shares			95.9	100.3
Cost Basis			$ 17.60	$ 53.39
Market Price			$ 18.95	$ 36.25
Discount			0.00%	5.40%
Movement in the Value of Marketable Securities			$ 1,817.7	$ 3,439.2
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income			129.3	$ (1,599.4)
Gain / (Loss) Recognized in Other Income (Expense), Net			$ (3,269.3)
Other-than-temporary Impairment [Member]
Securities Financing Transaction [Line Items]
Shares	100.3	100.3
Cost Basis	$ 17.60	$ 32.09
Market Price	$ 17.60	$ 32.09
Discount	0.00%	4.90%
Movement in the Value of Marketable Securities	$ (1,295.5)	$ (378.6)
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income		1,599.4
Gain / (Loss) Recognized in Other Income (Expense), Net	$ (1,295.5)	$ (1,978)
Sales [Member]
Securities Financing Transaction [Line Items]
Shares			(4.4)
Discount			0.00%
Movement in the Value of Marketable Securities			$ (76.7)
Gain / (Loss) Recognized in Other Income (Expense), Net			$ 4.2
Other Fair Value [Member]
Securities Financing Transaction [Line Items]
Shares			95.9
Cost Basis			$ 17.60
Market Price			$ 18.95
Discount			0.00%
Movement in the Value of Marketable Securities			$ 129.3
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income			$ 129.3

Discontinued Operations - Sum83

Discontinued Operations - Summary of Key Financial Results of Global Generics Business Income from Discontinued Operations , Net of Tax (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Discontinued Operations And Disposal Groups [Abstract]
Net revenues		$ 4,504.3	$ 8,499
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		2,798.3	4,847.5
Research and development		269.4	422.2
Selling and marketing		352.9	706.6
General and administrative	$ 18.8	425.8	702.2
Amortization		4.8	333.3
Asset sales and impairments, net	1.2		62.4
Total operating expenses	20	3,851.2	7,074.2
Operating (loss) / income	(20)	653.1	1,424.8
Other (expense) / income, net	(470.4)	15,932.2	(7.1)
(Benefit) / provision for income taxes	(87.5)	670.8	(5,443.3)
(Loss) / income from discontinued operations, net of tax	$ (402.9)	$ 15,914.5	$ 6,861

Discontinued Operations - Sch84

Discontinued Operations - Schedule of Depreciation Amortization and Significant Operating and Investing Noncash Items of Discontinued Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Discontinued Operations And Disposal Groups [Abstract]
Depreciation from discontinued operations	$ 2.1	$ 93.7
Amortization from discontinued operations	4.8	333.3
Capital expenditures	85.3	234.5
Deferred income tax expense	$ 6,038.5	$ (5,568.8)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	10 years
Restricted stock awards restrictions eliminated period	After one year
Share-based compensation expense included as discontinued operations		$ 12.9	$ 36.4
Share-based compensation and related tax benefits	$ 105	$ 131.8	285.9
Unrecognized future share-based compensation expense	$ 404.7
Remaining weighted average period (years)	1 year 6 months
Zeltiq Aesthetics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized future share-based compensation expense	$ 25.2
Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized future share-based compensation expense	28.7
Non Equity-Settled Awards Other [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Income in non-equity settled awards other due to actuarial reversal based on total shareholder return metrics	$ (16.8)		$ 98.6
Minimum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period	3 years
Minimum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	1 year
Maximum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period	5 years
Maximum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	4 years

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
2017 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	1.20%
Expected volatility	27.00%
Risk-free interest rate, Minimum	2.00%
Risk-free interest rate, Maximum	2.30%
Expected term	7 years
2016 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield		0.00%
Expected volatility		27.00%
Risk-free interest rate, Minimum		1.30%
Risk-free interest rate, Maximum		2.40%
2016 Grants [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term		7 years 6 months
2016 Grants [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term		7 years
2015 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield			0.00%
Expected volatility, Minimum			26.00%
Expected volatility, Maximum			29.00%
Risk-free interest rate, Minimum			1.90%
Risk-free interest rate, Maximum			2.10%
2015 Grants [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term			7 years 6 months
2015 Grants [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term			7 years
2015 Acquired Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield			0.00%
Expected volatility, Minimum			26.00%
Expected volatility, Maximum			27.00%
Risk-free interest rate, Minimum			0.10%
Risk-free interest rate, Maximum			2.10%
2015 Acquired Awards [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term			6 years 10 months 24 days

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense Recognized in Company's Results of Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 308	$ 383.2	$ 925.7
Equity Based Compensation Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	293.3	334.5	690.4
Cash-Settled Equity Awards [Member] | Zeltiq Aesthetics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	31.5
Cash-Settled Equity Awards [Member] | Tobira Therapeutics Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		27
Cash-Settled Equity Awards [Member] | Vitae Pharmaceuticals Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		18.6
Cash-Settled Equity Awards [Member] | ForSight VISION 5 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		$ 3.1
Cash-Settled Equity Awards [Member] | Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense			127.1
Cash-Settled Equity Awards [Member] | Kythera Biopharmaceuticals, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense			9.6
Non Equity-Settled Awards Other [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense (benefit)	$ (16.8)		$ 98.6

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Impact of Accelerations and Step-ups Relating to Acquisition Accounting Treatment of Outstanding Awards (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	$ 105	$ 154.1	$ 488.9
Zeltiq Aesthetics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	47.8
Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	47.1	108.9	314.8
Forest Laboratories, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	$ 10.1	$ 45.2	109.7
Kythera Biopharmaceuticals, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired			$ 64.4

Share-Based Compensation - Su89

Share-Based Compensation - Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units (Detail) - Restricted Stock [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares / units outstanding, beginning balance	1.5
Shares, Granted	1.2
Shares, Vested	(0.5)
Shares, Forfeited	(0.4)
Restricted shares / units outstanding, ending balance	2	1.5
Weighted Average Grant Date Fair Value, outstanding, beginning balance	$ 251.88
Weighted Average Grant Date Fair Value, Granted	232.18
Weighted Average Grant Date Fair Value, Vested	(238.39)
Weighted Average Grant Date Fair Value, Forfeited	(265.26)
Weighted Average Grant Date Fair Value, outstanding, ending balance	$ 237.72	$ 251.88
Weighted Average Remaining Contractual Term (Years)	1 year 9 months 18 days	1 year 7 months 6 days
Aggregate Grant Date Fair Value, outstanding, beginning balance	$ 388
Aggregate Grant Date Fair Value, Granted	278.6
Aggregate Grant Date Fair Value, Vested	(127)
Aggregate Grant Date Fair Value, Forfeited	(97.3)
Aggregate Grant Date Fair Value, outstanding, ending balance	$ 484.1	$ 388
Zeltiq Aesthetics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Assumed as part of the Zeltiq Acquisition	0.2
Weighted Average Grant Date Fair Value, Assumed as part of the Zeltiq Acquisition	$ 213.15
Aggregate Grant Date Fair Value, Assumed as part of the Zeltiq Acquisition	$ 41.8

Share-Based Compensation - Su90

Share-Based Compensation - Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares (Detail) - Non-qualified Options [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Outstanding, Beginning Balance	9
Options, Granted	0.3
Options, Exercised	(1.8)
Options, Cancelled	(0.2)
Options, Outstanding, Ending Balance	7.3	9
Options, vested and expected to vest	7.3
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 113.77
Weighted Average Exercise Price, Granted	239.33
Weighted Average Exercise Price, Exercised	(92.71)
Weighted Average Exercise Price, Cancelled	(137.80)
Weighted Average Exercise Price, Outstanding, Ending Balance	120.94	$ 113.77
Weighted Average Exercise Price, vested and expected to vest	$ 120.94
Weighted Average Remaining Contractual Term (Years), Outstanding	5 years 2 months 12 days	5 years 10 months 24 days
Weighted Average Remaining Contractual Term (Years), vested and expected to vest	5 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 312.7	$ 861.7
Aggregate Intrinsic Value, vested and expected to vest	$ 312.7

Pension and Other Postretirem91

Pension and Other Postretirement Benefit Plans - Summary of Net Periodic Benefit (Income) Cost of Defined Benefit Plans for Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Service cost	$ 5.5	$ 5	$ 5
Interest cost	40.7	44.5	35
Expected Return on plan assets	(54.5)	(53)	(46.4)
Settlement	(0.1)	(1.8)	(4.3)
Net periodic benefit (income) cost	$ (8.4)	$ (5.3)	$ (10.7)

Pension and Other Postretirem92

Pension and Other Postretirement Benefit Plans - Schedule of Benefit Obligation and Asset Data for Defined Benefit Plans for Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Change in Plan Assets
Fair value of plan assets at beginning of year	$ 1,093.9	$ 1,051.1
Employer contribution	15.2	37.4
Return on plan assets	117.2	116.8
Benefits paid	(36)	(32.5)
Settlements	(5.3)	(47.7)
Effects of exchange rate changes and other	50.2	(31.2)
Fair value of plan assets at end of year	1,235.2	1,093.9	$ 1,051.1
Change in Benefit Obligation
Benefit obligation at beginning of the year	1,234.1	1,188.5
Service cost	5.5	5	5
Interest cost	40.7	44.5	35
Actuarial loss / (gain)	36.9	108
Curtailments	(8.1)
Settlements and other	(5.3)	(46.9)
Benefits paid	(36)	(32.5)
Effects of exchange rate changes and other	62.2	(32.5)
Fair value of plan assets at end of year	1,235.2	1,093.9	1,051.1
Benefit obligation at end of year	1,330	1,234.1	$ 1,188.5
Funded status at end of year	$ (94.8)	$ (140.2)

Pension and Other Postretirem93

Pension and Other Postretirement Benefit Plans - Schedule of Funded Status Amount Recognized in Consolidated Balance Sheet (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Amounts Recognized In Balance Sheet [Abstract]
Noncurrent assets	$ 21.9	$ 9.4
Current liabilities	(0.8)	(0.7)
Noncurrent liabilities	(115.9)	(148.9)
Funded status at end of year	$ (94.8)	$ (140.2)

Pension and Other Postretirem94

Pension and Other Postretirement Benefit Plans - Schedule of Fair Values of Pension Plan Assets by Asset Category (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	$ 1,235.2	$ 1,093.9	$ 1,051.1
Investment Funds [Member] | Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	369.5	373.3
Investment Funds [Member] | Equity Securities [Member] | U.S. Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	33.5	41.5
Investment Funds [Member] | Equity Securities [Member] | International Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	265.5	244.4
Investment Funds [Member] | Equity Securities [Member] | Other Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	70.5	87.4
Investment Funds [Member] | Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	863.8	716.7
Investment Funds [Member] | Debt Securities [Member] | U.S. Treasury Bonds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	96.9	23.6
Investment Funds [Member] | Debt Securities [Member] | Bonds and Bond Funds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	745.7	684.8
Investment Funds [Member] | Debt Securities [Member] | Other Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	21.2	8.3
Other Investments [Member] | Other [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	1.9	3.9
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	369.5	373.3
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	369.5	373.3
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member] | U.S. Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	33.5	41.5
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member] | International Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	265.5	244.4
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment Funds [Member] | Equity Securities [Member] | Other Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	70.5	87.4
Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	865.7	720.6
Significant Other Observable Inputs (Level 2) [Member] | Investment Funds [Member] | Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	863.8	716.7
Significant Other Observable Inputs (Level 2) [Member] | Investment Funds [Member] | Debt Securities [Member] | U.S. Treasury Bonds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	96.9	23.6
Significant Other Observable Inputs (Level 2) [Member] | Investment Funds [Member] | Debt Securities [Member] | Bonds and Bond Funds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	745.7	684.8
Significant Other Observable Inputs (Level 2) [Member] | Investment Funds [Member] | Debt Securities [Member] | Other Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	21.2	8.3
Significant Other Observable Inputs (Level 2) [Member] | Other Investments [Member] | Other [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of pension plan assets	$ 1.9	$ 3.9

Pension and Other Postretirem95

Pension and Other Postretirement Benefit Plans - Schedule of Allocated Target Investment Portfolio of Pension Plans for Continuing Operations (Detail)	Dec. 31, 2017	Dec. 31, 2016
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	31.20%	31.50%
Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	68.80%	68.30%
Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	0.00%	0.20%

Pension and Other Postretirem96

Pension and Other Postretirement Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Continuing Operations [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions to pension plans in next fiscal year	$ 11.7
Continuing Operations [Member] | Savings Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	$ 89.1	$ 75.6	$ 26.6
Discontinued Operations [Member] | Savings Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions			$ 23.6

Pension and Other Postretirem97

Pension and Other Postretirement Benefit Plans - Schedule of Expected Benefit Payments of Pension Plans (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Estimated Future Benefit Payments [Abstract]
2,018	$ 34.6
2,019	36.7
2,020	38.9
2,021	41.3
2,022	43.4
Thereafter	1,135.1
Total liability	$ 1,330	$ 1,234.1	$ 1,188.5

Pension and Other Postretirem98

Pension and Other Postretirement Benefit Plans - Schedule of Defined Benefit Plans with Accumulated Benefit Obligation in Excess of Plan Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets [Abstract]
Projected benefit obligations	$ 1,330	$ 1,234.1
Accumulated benefit obligations	1,324.7	1,220.1
Plan assets	$ 1,235.2	$ 1,093.9

Pension and Other Postretirem99

Pension and Other Postretirement Benefit Plans - Schedule of Balances Recognized within Accumulated Other Comprehensive Income / (Loss) Excluding the Impact of Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income [Abstract]
Beginning balance	$ 24.4	$ 70.4
Net actuarial loss	33.8	(46)
Ending Balance	$ 58.2	$ 24.4

Pension and Other Postretire100

Pension and Other Postretirement Benefit Plans - Weighted Average Assumptions Used to Calculate Projected Benefit Obligations and Net Periodic Benefit Cost (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Weighted Average Assumptions Used In Calculating Benefit Obligation [Abstract]
Projected benefit obligations, Discount rate	2.90%	3.30%
Projected benefit obligations, Salary growth rate	3.00%	3.00%
Net periodic benefit cost, Discount Rate	3.30%	3.80%
Net periodic benefit cost, Expected rate of return on plan assets	5.00%	5.10%
Net periodic benefit cost, Salary growth rate	3.00%	3.00%

Pension and Other Postretire101

Pension and Other Postretirement Benefit Plans - Schedule of Accumulated Benefit Obligation for Defined Benefit Plans (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Pension Plan With Accumulated Benefit Obligation In Excess Of Fair Value Of Plan Assets [Line Items]
Service cost	$ 5.5	$ 5	$ 5
Actuarial charge	(36.9)	(108)
Benefits paid	(36)	(32.5)
Allergan and Forest Acquisitions [Member] | Other Benefit Obligation [Member]
Defined Benefit Pension Plan With Accumulated Benefit Obligation In Excess Of Fair Value Of Plan Assets [Line Items]
Accumulated benefit obligation, Beginning balance	52.7	50.1
Service cost		0.3
Interest cost	2	2.1
Actuarial charge	(5)	3.6
Benefits paid	(2.9)	(3.4)
Accumulated benefit obligation, Ending balance	$ 46.8	$ 52.7	$ 50.1

Other Income (Expense), Net - C

Other Income (Expense), Net - Components of Income (Expense), Net (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Non Operating Income Expense [Line Items]
Other-than-temporary impairments	$ (26.1)
Dividend income	85.2	$ 68.2
Naurex recovery	20
Pfizer termination fee (Allergan plc only)		150
Bridge loan commitment fee			$ (264.9)
Interest rate locks			31
Other (expense) / income, net	5	1	0.1
Other (expense) / income , net	(3,437.3)	$ 219.2	$ (233.8)
Teva [Member]
Other Non Operating Income Expense [Line Items]
Net income impact of other-than-temporary loss on investment	(3,269.3)
Forward sale of shares	(62.9)
Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Debt extinguishment costs	(161.6)
Other Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Debt extinguishment costs	$ (27.6)

Other Income (Expense), Net - A

Other Income (Expense), Net - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	Feb. 13, 2018	Jan. 12, 2018	Aug. 02, 2016	Aug. 28, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 10, 2017
Other Non Operating Income Expense [Line Items]
Other-than-temporary impairment charges on other equity and cost investments					$ 26.1
Dividend income					85.2	$ 68.2
Pfizer termination fee						150
Bridge loan financing and commitment costs							$ 264.9
Interest rate lock income							31
Interest Rate Lock [Member]
Other Non Operating Income Expense [Line Items]
Interest rate lock income							31
Interest Rate Lock [Member] | Allergan Acquisition [Member]
Other Non Operating Income Expense [Line Items]
Debt issued on business combination							$ 21,000
Naurex, Inc. [Member]
Other Non Operating Income Expense [Line Items]
Business acquisition date				Aug. 28, 2015			Aug. 28, 2015
Amount received from purchase price reduction					20
Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Early repayment of senior notes					2,843.3
Gain (loss) on extinguishment of debt					(161.6)
Redeemable premium interest					170.5
Other Debt Tender Offer [Member]
Other Non Operating Income Expense [Line Items]
Early repayment of senior notes					750
Gain (loss) on extinguishment of debt					(27.6)
Redeemable premium interest					35.1
Teva [Member]
Other Non Operating Income Expense [Line Items]
Net income impact of other-than-temporary loss on investment in Teva securities					3,273.5
Ordinary shares received from divestiture of businesses			100.3
Dividend income					85.2	$ 68.2
Loss on forward sale of investment					$ 62.9
Acelerated share repurchase transaction					25			25
Teva [Member] | Subsequent Event [Member]
Other Non Operating Income Expense [Line Items]
Loss on forward sale of investment		$ 413.3
Accelerated share repurchases settlement date		Jan. 12, 2018
Percentage of proceeds from forward sale received	80.00%
Proceeds from forward sale received	$ 372
Forward sale of investment shares	25

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 326.9	$ 297.1
Work-in-process	158.1	145.4
Finished goods	527.8	357.7
Inventories, gross	1,012.8	800.2
Less: inventory reserves	108.3	82.2
Total Inventories	$ 904.5	$ 718

Accounts Payable and Accrued105

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued expenses:
Accrued third-party rebates	$ 1,804.1	$ 1,595.5
Contractual commitments (including amount due to Teva)	705.4	264.9
Accrued payroll and related benefits	635.6	581.1
Accrued returns	375.8	295.9
Interest payable	245.9	294.2
Royalties payable	189.2	146.6
Accrued pharmaceutical fees	186.4	221.3
Accrued R&D expenditures	165.9	154
Accrued severance, retention and other shutdown costs	132.8	86.2
Litigation-related reserves and legal fees	78.3	101.1
Accrued non-provision taxes	76.5	55
Current portion of contingent consideration obligations	56.2	511
Accrued selling and marketing expenditures	53	95.9
Dividends payable	24.6	23.2	$ 24
Other accrued expenses	487.2	368.2
Total accrued expenses	5,216.9	4,794.1
Accounts payable	324.5	224.9
Total accounts payable and accrued expenses	$ 5,541.4	$ 5,019

Property, Plant and Equipmen106

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Beginning balance	$ 2,018.7
Additions	358.3
Additions due to acquisitions	66.1
Disposals/transfers/other	(18.5)
Assets held for sale	(49.7)
Currency translation	26.6
Ending balance	2,401.5	$ 2,018.7
Accumulated depreciation
Accumulated depreciation, beginning balance	407.4
Additions	171.5	155.8	$ 218.3
Disposals/transfers/impairments/other	30.5
Assets held for sale	(0.7)
Currency translation	7.4
Accumulated depreciation, ending balance	616.1	407.4
Property, plant and equipment, net	1,785.4	1,611.3
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Beginning balance	437.1
Additions	20.7
Additions due to acquisitions	14.3
Disposals/transfers/other	64.8
Currency translation	8.4
Ending balance	545.3	437.1
Accumulated depreciation
Accumulated depreciation, beginning balance	148.4
Additions	61.5
Disposals/transfers/impairments/other	7.2
Currency translation	2.2
Accumulated depreciation, ending balance	219.3	148.4
Property, plant and equipment, net	326
Research and Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Beginning balance	48.8
Additions	8.3
Additions due to acquisitions	0.7
Disposals/transfers/other	(1.2)
Currency translation	2.4
Ending balance	59	48.8
Accumulated depreciation
Accumulated depreciation, beginning balance	24
Additions	7.8
Disposals/transfers/impairments/other	5.3
Currency translation	1.4
Accumulated depreciation, ending balance	38.5	24
Property, plant and equipment, net	20.5
Transportation / Other [Member]
Property Plant And Equipment [Line Items]
Beginning balance	381.4
Additions	34.1
Additions due to acquisitions	18.6
Disposals/transfers/other	38.1
Currency translation	3.1
Ending balance	475.3	381.4
Accumulated depreciation
Accumulated depreciation, beginning balance	164.5
Additions	65
Currency translation	2.9
Accumulated depreciation, ending balance	232.4	164.5
Property, plant and equipment, net	242.9
Land, Buildings and Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Beginning balance	705.3
Additions	14.6
Additions due to acquisitions	31.2
Disposals/transfers/other	104.1
Assets held for sale	(49.7)
Currency translation	9.4
Ending balance	814.9	705.3
Accumulated depreciation
Accumulated depreciation, beginning balance	70.5
Additions	37.2
Disposals/transfers/impairments/other	18
Assets held for sale	(0.7)
Currency translation	0.9
Accumulated depreciation, ending balance	125.9	70.5
Property, plant and equipment, net	689
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Beginning balance	446.1
Additions	280.6
Additions due to acquisitions	1.3
Disposals/transfers/other	(224.3)
Currency translation	3.3
Ending balance	507	$ 446.1
Accumulated depreciation
Property, plant and equipment, net	$ 507

Property, Plant and Equipmen107

Property, Plant and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Depreciation expense	$ 171.5	$ 155.8	$ 218.3
Continuing Operations [Member]
Property Plant And Equipment [Line Items]
Depreciation expense	$ 171.5	$ 153.7	$ 124.6

Prepaid Expenses, Investment108

Prepaid Expenses, Investments and Other Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Prepaid taxes	$ 690.9	$ 957.4
Prepaid insurance	20.9	25.7
Royalty receivables	80.1	94.3
Sales and marketing	31.9	42.5
Other	300.1	263.5
Total prepaid expenses and other current assets	$ 1,123.9	$ 1,383.4

Prepaid Expenses, Investment109

Prepaid Expenses, Investments and Other Assets - Marketable Securities, Including Cash and Cash Equivalents, Other Investments and Other Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Total marketable securities	$ 4,632.1	$ 11,501.5
Investments and other assets:
Legacy Allergan Deferred executive compensation investments	112.4	111.7
Equity method investments	11.5	12.8
Cost method investments		15
Other long-term investments	60.8	67.2
Taxes receivable	32.1	36
Other assets	51.1	39.4
Total investments and other assets	267.9	282.1
Short-term Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Total marketable securities	2,814.4	8,062.3
Teva [Member]
Schedule Of Available For Sale Securities [Line Items]
Total marketable securities	$ 1,817.7	$ 3,439.2

Prepaid Expenses, Investment110

Prepaid Expenses, Investments and Other Assets - Additional Information (Detail) - Teva [Member] - USD ($) shares in Millions, $ in Millions	1 Months Ended
	Feb. 16, 2018	Feb. 13, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Number of shares owned			95.9
Subsequent Event [Member]
Schedule Of Available For Sale Securities [Line Items]
Number of shares owned		40
Number of additional ordinary shares sold	6.3
Number of additional ordinary shares sold, value	$ 127.9

Prepaid Expenses, Investment111

Prepaid Expenses, Investments and Other Assets - Investments in Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Marketable securities	$ 4,632.1	$ 11,501.5
Investment In Teva Ordinary Shares [Member]
Schedule Of Available For Sale Securities [Line Items]
Estimated fair value	1,817.7	3,439.2
Level 1 [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	3,016.1	1,238.9
Unrecognized gain	129.3
Estimated fair value	3,145.8	1,238.9
Cash & cash equivalents	1,328.1	1,238.9
Marketable securities	1,817.7
Level 1 [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	1,328.1	1,238.9
Estimated fair value	1,328.1	1,238.9
Cash & cash equivalents	1,328.1	1,238.9
Level 1 [Member] | Investment In Teva Ordinary Shares [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	1,688
Unrecognized gain	129.3
Estimated fair value	1,817.7
Marketable securities	1,817.7
Level 2 [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	2,815.1	13,100.7
Unrecognized gain		0.2
Unrecognized loss	(0.7)	(1,599.4)
Estimated fair value	2,814.4	11,501.5
Marketable securities	2,814.4	11,501.5
Level 2 [Member] | Investment In Teva Ordinary Shares [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount		5,038.6
Unrecognized loss		(1,599.4)
Estimated fair value		3,439.2
Marketable securities		3,439.2
Level 2 [Member] | Commercial Paper and Other [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	1,248.9	3,909.7
Unrecognized gain		0.2
Unrecognized loss	(0.7)
Estimated fair value	1,248.2	3,909.9
Marketable securities	1,248.2	3,909.9
Level 2 [Member] | Certificates of Deposit [Member]
Schedule Of Available For Sale Securities [Line Items]
Carrying amount	1,566.2	4,152.4
Estimated fair value	1,566.2	4,152.4
Marketable securities	$ 1,566.2	$ 4,152.4

Prepaid Expenses, Investment112

Prepaid Expenses, Investments and Other Assets - Summary of Long-term Investments (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Long Term Investments [Abstract]
Equity Method Investments, beginning balance	$ 12.8
Equity Method Investments, Other	(1.3)
Equity Method Investments, ending balance	11.5
Cost Method and Other Long-term Investments, beginning balance	82.2
Cost Method and Other Long-term Investments, Other-than-temporary impairment	(26.1)
Cost Method and Other Long-term Investments, Other	4.7
Cost Method and Other Long-term Investments, ending balance	$ 60.8

Goodwill, Product Rights and113

Goodwill, Product Rights and Other Intangible Assets - Schedule of Goodwill (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Goodwill [Line Items]
Balance as of December 31, 2016	$ 46,356.1
Additions through acquisitions	2,701.9
Measurement period adjustments	(43.7)
Held for sale	(12.8)
Foreign exchange and other adjustments	861.4
Balance as of December 31, 2017	49,862.9
US Specialized Therapeutics [Member]
Goodwill [Line Items]
Balance as of December 31, 2016	18,433.2
Additions through acquisitions	2,456
Measurement period adjustments	(29.6)
Balance as of December 31, 2017	20,859.6
US General Medicine [Member]
Goodwill [Line Items]
Balance as of December 31, 2016	21,426.6
Measurement period adjustments	(14.1)
Held for sale	(12.8)
Balance as of December 31, 2017	21,399.7
International [Member]
Goodwill [Line Items]
Balance as of December 31, 2016	6,496.3
Additions through acquisitions	245.9
Foreign exchange and other adjustments	861.4
Balance as of December 31, 2017	$ 7,603.6

Goodwill, Product Rights and114

Goodwill, Product Rights and Other Intangible Assets - Additional Information (Detail) $ in Millions	Sep. 23, 2016USD ($)	Dec. 31, 2017USD ($)Patent	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Feb. 01, 2017USD ($)	Nov. 01, 2016USD ($)	Mar. 17, 2015USD ($)
Goodwill Product Rights And Other Intangible Assets [Line Items]
Gross balance of goodwill		$ 49,880.2	$ 46,373.4
Addition to goodwill		2,701.9
Reacquired aggregate value of intangible assets		614.3	2	$ 154.7
In-process research and development impairments		1,452.3	743.9	$ 511.6
Women's Healthcare Research and Development Project [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments		$ 91.3	24
Total Gastrointestinal (GI) [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			42
Osteoarthritis Research and Development Project [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			190
International Eye Care Pipeline Project [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			35
Botox Premature Ejaculation Product [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			40
Restasis [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Number of patents | Patent		4
Impairment of intangible Assets		$ 3,230
US General Medicine [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Reacquired aggregate value of intangible assets		574
LifeCell Corporation [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Addition to goodwill		1,449.1
Intangible assets		2,020			$ 2,020
LifeCell Corporation [Member] | IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Intangible assets		10
IPR&D intangible assets					$ 10
Zeltiq [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Addition to goodwill		1,200.6
Zeltiq Acquisition Inc. [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Intangible assets		1,185
Allergan, Inc. [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Intangible assets							$ 54,750.5
Contingent consideration liability							383.7
Allergan, Inc. [Member] | Migraine License Acquisition [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			106
Allergan, Inc. [Member] | Urology [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			210
Contingent consideration liability			186
Allergan, Inc. [Member] | IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments		140
IPR&D intangible assets							$ 9,700
Allergan, Inc. [Member] | IPR&D [Member] | CNS [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments		486
Allergan, Inc. [Member] | IPR&D [Member] | Eye Care Project [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments		209
Allergan, Inc. [Member] | IPR&D [Member] | Medical Aesthetics [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments		29
Allergan, Inc. [Member] | IPR&D [Member] | Other Dry Eye [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments		170
Allergan, Inc. [Member] | IPR&D [Member] | Aczone [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Impairment of intangible Assets		646
Warner Chilcott [Member] | IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments		278
Tobira [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Contingent consideration liability		479				$ 479
Tobira [Member] | IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
IPR&D intangible assets		1,357	1,357
Vitae [Member] | Atopic Dermatitis Pipeline Candidate [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			46
Vitae [Member] | IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
IPR&D intangible assets		686	686
ForSight [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Contingent consideration liability	$ 79.8	79.8	15
ForSight [Member] | IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments	$ 33		33
IPR&D intangible assets		$ 158	$ 158

Goodwill, Product Rights and115

Goodwill, Product Rights and Other Intangible Assets - Schedule of Cost Basis on Product Rights and Other Intangible Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, gross, Amortization	$ (7,197.1)	$ (6,470.4)	$ (5,443.7)
Intangibles with indefinite lives, Impairments	(1,452.3)	(743.9)	(511.6)
Product rights and other intangibles	54,648.3	62,618.6	67,836.2
Cost Basis [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	68,491.4	65,056
Intangibles with definite lives, Acquisitions	3,876.9	43.6
Intangibles with definite lives, IPR&D to CMP Transfers	1,444	3,809.9
Intangibles with definite lives, Disposals/Held for Sale/Other	(34)	(194.6)
Intangibles assets, gross, Foreign Currency Translation	812.9	(240.6)
Intangibles with definite lives, Foreign Currency Translation	804.2	(223.5)
Intangibles with definite lives, Ending balance	74,582.5	68,491.4	65,056
Intangibles with indefinite lives, Beginning balance	8,758.3	11,128.2
Intangibles with indefinite lives, Acquisitions	10	2,223.5
Intangibles with indefinite lives, Impairments	(1,452.3)	(743.9)
Intangibles with indefinite lives, IPR&D to CMP Transfers	(1,444)	(3,809.9)
Intangibles with indefinite lives, Disposals/Held for Sale/Other	(6.6)	(22.5)
Intangibles with indefinite lives, Foreign Currency Translation	8.7	(17.1)
Intangibles with indefinite lives, Ending balance	5,874.1	8,758.3	11,128.2
Intangible assets, gross, Beginning balance	77,249.7	76,184.2
Intangible assets, gross, Acquisitions	3,886.9	2,267.1
Intangible assets, gross, Impairments	(1,452.3)	(743.9)
Intangibles assets, Disposals/Held for Sale/Other	(40.6)	(217.1)
Intangible assets, gross, Ending balance	80,456.6	77,249.7	76,184.2
Cost Basis [Member] | Product Rights and Other Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	67,801.4	64,366
Intangibles with definite lives, Acquisitions	3,876.9	43.6
Intangibles with definite lives, IPR&D to CMP Transfers	1,444	3,809.9
Intangibles with definite lives, Disposals/Held for Sale/Other	(34)	(194.6)
Intangibles with definite lives, Foreign Currency Translation	804.2	(223.5)
Intangibles with definite lives, Ending balance	73,892.5	67,801.4	64,366
Cost Basis [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	690	690
Intangibles with definite lives, Ending balance	690	690	690
Cost Basis [Member] | IPR&D [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Beginning balance	8,758.3	11,128.2
Intangibles with indefinite lives, Acquisitions	10	2,223.5
Intangibles with indefinite lives, Impairments	(1,452.3)	(743.9)
Intangibles with indefinite lives, IPR&D to CMP Transfers	(1,444)	(3,809.9)
Intangibles with indefinite lives, Disposals/Held for Sale/Other	(6.6)	(22.5)
Intangibles with indefinite lives, Foreign Currency Translation	8.7	(17.1)
Intangibles with indefinite lives, Ending balance	5,874.1	8,758.3	11,128.2
Accumulated Amortization [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(14,631.1)	(8,348)
Intangible assets, gross, Amortization	(7,197.1)	(6,470.4)
Intangibles with definite lives, Impairments	(3,879.1)	(28.9)
Intangible assets gross, Disposals/Held for Sale/Other	24.8	176.8
Intangibles with definite lives, Disposals/Held for Sale/Other	24.8	176.8
Intangibles assets, gross, Foreign Currency Translation	(125.8)	39.4
Intangibles with definite lives, Foreign Currency Translation	(125.8)	39.4
Intangible assets, Accumulated Amortization, Ending balance	(25,808.3)	(14,631.1)	(8,348)
Intangible assets, gross, Impairments	(3,879.1)	(28.9)
Accumulated Amortization [Member] | Product Rights and Other Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(14,493.9)	(8,288.5)
Intangible assets, gross, Amortization	(7,119.6)	(6,392.7)
Intangibles with definite lives, Impairments	(3,879.1)	(28.9)
Intangibles with definite lives, Disposals/Held for Sale/Other	24.8	176.8
Intangibles with definite lives, Foreign Currency Translation	(125.8)	39.4
Intangible assets, Accumulated Amortization, Ending balance	(25,593.6)	(14,493.9)	(8,288.5)
Accumulated Amortization [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(137.2)	(59.5)
Intangible assets, gross, Amortization	(77.5)	(77.7)
Intangible assets, Accumulated Amortization, Ending balance	$ (214.7)	$ (137.2)	$ (59.5)

Goodwill, Product Rights and116

Goodwill, Product Rights and Other Intangible Assets - Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles (Detail) - Product Rights and Other Related Intangibles [Member] $ in Millions	Dec. 31, 2017USD ($)
Finite Lived Intangible Assets [Line Items]
2,018	$ 6,438.3
2,019	6,039.4
2,020	5,717.4
2,021	4,778.2
2,022	$ 4,414.8

Long-Term Debt and Capital L117

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 29,698.2	$ 32,750
Unamortized premium	88.9	171.2
Unamortized discount	(81.7)	(95.8)
Total Senior Notes Net	29,705.4	32,825.4
Senior Notes, Fair Market Value	30,303.6	32,973
Debt Issuance Costs	(121.5)	(144.6)
Total Other Borrowings	367.2	(59.1)
Total Indebtedness	30,075.3	32,768.7
Margin Loan [Member]
Debt Instrument [Line Items]
Total Other Borrowings	459
Capital Leases [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	2.7	2.4
Floating Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,000	1,000
Senior Notes, Fair Market Value	1,008.7	1,011.9
Floating Rate Notes [Member] | Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	$ 500.6	502.5
Issuance Date	Mar. 4, 2015
Interest Payments	Quarterly
Acquisition Date	Mar. 4, 2015
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 500	500
Senior Notes, Fair Market Value	$ 508.1	509.4
Issuance Date	Mar. 4, 2015
Interest Payments	Quarterly
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 25,456.7	31,750
Senior Notes, Fair Market Value	$ 26,073	31,961.1
Fixed Rate Notes [Member] | 1.850% Notes Due March 1, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		1,000
Senior Notes, Fair Market Value		1,001.1
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 1.300% Notes Due June 15, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		500
Senior Notes, Fair Market Value		499.7
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date	Jun. 10, 2014
Fixed Rate Notes [Member] | 1.875% Notes Due October 1, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		1,200
Senior Notes, Fair Market Value		1,202.5
Issuance Date	Oct. 2, 2012
Interest Payments	Semi-annually
Acquisition Date	Oct. 2, 2012
Fixed Rate Notes [Member] | 2.350% Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 3,000	3,000
Senior Notes, Fair Market Value	$ 3,001.9	3,018
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 250	250
Senior Notes, Fair Market Value	$ 249.7	248.4
Issuance Date	Mar. 17, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 17, 2015
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		1,050
Senior Notes, Fair Market Value		1,090
Issuance Date	Jul. 1, 2014
Interest Payments	Semi-annually
Acquisition Date	Jul. 1, 2014
Fixed Rate Notes [Member] | 2.450% Notes Due June 15, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 500	500
Senior Notes, Fair Market Value	$ 499.7	501.2
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date	Jun. 10, 2014
Fixed Rate Notes [Member] | 6.125% Senior Notes Due August 15, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		400
Senior Notes, Fair Market Value		437.7
Issuance Date	Aug. 24, 2009
Interest Payments	Semi-annually
Acquisition Date	Aug. 24, 2009
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 3,500	3,500
Senior Notes, Fair Market Value	$ 3,528.4	3,541.8
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 650	650
Senior Notes, Fair Market Value	$ 661.3	663.6
Issuance Date	Mar. 17, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 17, 2015
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 450	750
Senior Notes, Fair Market Value	$ 474.3	803.3
Issuance Date	Jul. 1, 2014
Interest Payments	Semi-annually
Acquisition Date	Jul. 1, 2014
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,200	1,200
Senior Notes, Fair Market Value	$ 1,282.6	1,297.7
Issuance Date	Jul. 1, 2014
Interest Payments	Semi-annually
Acquisition Date	Jul. 1, 2014
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 3,000	3,000
Senior Notes, Fair Market Value	$ 3,044.5	3,030.7
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,700	1,700
Senior Notes, Fair Market Value	$ 1,703	1,693.1
Issuance Date	Oct. 2, 2012
Interest Payments	Semi-annually
Acquisition Date	Oct. 2, 2012
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 350	350
Senior Notes, Fair Market Value	$ 341.6	335.6
Issuance Date	Mar. 17, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 17, 2015
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,200	1,200
Senior Notes, Fair Market Value	$ 1,232.3	1,211.7
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date	Jun. 10, 2014
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 4,000	4,000
Senior Notes, Fair Market Value	$ 4,067.1	3,995.6
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 2,500	2,500
Senior Notes, Fair Market Value	$ 2,631.9	2,458.5
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 456.7	1,000
Senior Notes, Fair Market Value	$ 471.2	967.6
Issuance Date	Oct. 2, 2012
Interest Payments	Semi-annually
Acquisition Date	Oct. 2, 2012
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,500	1,500
Senior Notes, Fair Market Value	$ 1,606.2	1,496.4
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date	Jun. 10, 2014
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,200	2,500
Senior Notes, Fair Market Value	$ 1,277.3	2,466.9
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Euro Denominated Notes [Member] | 0.500% Notes Due June 1, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 900.4
Senior Notes, Fair Market Value	$ 895.8
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date	May 26, 2017
Euro Denominated Notes [Member] | 1.250% Notes Due June 1, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 840.4
Senior Notes, Fair Market Value	$ 831.1
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date	May 26, 2017
Euro Denominated Notes [Member] | 2.125% Notes Due June 1, 2029 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 660.3
Senior Notes, Fair Market Value	$ 657.8
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date	May 26, 2017
Euro Denominated Notes [Member] | Notes Due June 1, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 840.4
Senior Notes, Fair Market Value	$ 837.2
Issuance Date	May 26, 2017
Interest Payments	Quarterly
Acquisition Date	May 26, 2017
Euro Denominated Notes [Member] | Notes Due June 1, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 3,241.5
Senior Notes, Fair Market Value	3,221.9
Other [Member]
Debt Instrument [Line Items]
Total Other Borrowings	$ 29.7	$ 85.5

Long-Term Debt and Capital L118

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 13, 2017	Nov. 30, 2017
Floating Rate Notes [Member] | Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2018	Mar. 12, 2018
Percentage of margin	1.08%	1.08%
Debt instrument variable rate basis	Three month USD LIBOR	Three month USD LIBOR
Interest payment terms	Interest on the 2018 floating rate note is three month USD LIBOR plus 1.080% per annum	Interest on the 2018 floating rate note is three month USD LIBOR plus 1.080% per annum
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2020	Mar. 12, 2020
Percentage of margin	1.255%	1.255%
Debt instrument variable rate basis	Three month USD LIBOR	Three month USD LIBOR
Interest payment terms	Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum	Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum
Fixed Rate Notes [Member] | 1.850% Notes Due March 1, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 1, 2017	Mar. 1, 2017
Senior notes, interest rate	1.85%	1.85%
Fixed Rate Notes [Member] | 1.300% Notes Due June 15, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2017	Jun. 15, 2017
Senior notes, interest rate	1.30%	1.30%
Fixed Rate Notes [Member] | 1.875% Notes Due October 1, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Oct. 1, 2017	Oct. 1, 2017
Senior notes, interest rate	1.875%	1.875%
Fixed Rate Notes [Member] | 2.350% Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2018	Mar. 12, 2018
Senior notes, interest rate	2.35%	2.35%
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2018	Mar. 15, 2018
Senior notes, interest rate	1.35%	1.35%
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Feb. 1, 2019	Feb. 1, 2019
Senior notes, interest rate	4.375%	4.375%	4.375%
Fixed Rate Notes [Member] | 2.450% Notes Due June 15, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2019	Jun. 15, 2019
Senior notes, interest rate	2.45%	2.45%
Fixed Rate Notes [Member] | 6.125% Senior Notes Due August 15, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Aug. 15, 2019	Aug. 15, 2019
Senior notes, interest rate	6.125%	6.125%		6.125%
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2020	Mar. 12, 2020
Senior notes, interest rate	3.00%	3.00%
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Sep. 15, 2020	Sep. 15, 2020
Senior notes, interest rate	3.375%	3.375%
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Feb. 15, 2021	Feb. 15, 2021
Senior notes, interest rate	4.875%	4.875%
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Dec. 15, 2021	Dec. 15, 2021
Senior notes, interest rate	5.00%	5.00%
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2022	Mar. 15, 2022
Senior notes, interest rate	3.45%	3.45%
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Oct. 1, 2022	Oct. 1, 2022
Senior notes, interest rate	3.25%	3.25%
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2023	Mar. 15, 2023
Senior notes, interest rate	2.80%	2.80%
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2024	Jun. 15, 2024
Senior notes, interest rate	3.85%	3.85%
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2025	Mar. 15, 2025
Senior notes, interest rate	3.80%	3.80%
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2035	Mar. 15, 2035
Senior notes, interest rate	4.55%	4.55%
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Oct. 1, 2042	Oct. 1, 2042
Senior notes, interest rate	4.625%	4.625%
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2044	Jun. 15, 2044
Senior notes, interest rate	4.85%	4.85%
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2045	Mar. 15, 2045
Senior notes, interest rate	4.75%	4.75%
Euro Denominated Notes [Member] | 0.500% Notes Due June 1, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2021	Jun. 1, 2021
Senior notes, interest rate	0.50%	0.50%
Euro Denominated Notes [Member] | 1.250% Notes Due June 1, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2024	Jun. 1, 2024
Senior notes, interest rate	1.25%	1.25%
Euro Denominated Notes [Member] | 2.125% Notes Due June 1, 2029 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2029	Jun. 1, 2029
Senior notes, interest rate	2.125%	2.125%
Euro Denominated Notes [Member] | Notes Due June 1, 2019 [Member]
Debt Instrument [Line Items]
Percentage of margin	0.35%	0.35%
Debt instrument variable rate basis	Three month EURIBOR	Three month EURIBOR
Interest payment terms	Interest on the €700.0 million floating rate notes is the three month EURIBOR plus 0.350% per annum	Interest on the €700.0 million floating rate notes is the three month EURIBOR plus 0.350% per annum

Long-Term Debt and Capital L119

Long-Term Debt and Capital Leases - Floating Rate Notes - Additional Information (Detail) - Floating Rate Notes [Member] - Notes Due September 1, 2016 [Member]	12 Months Ended
	Dec. 31, 2017
Debt Instrument [Line Items]
Percentage of margin	0.875%
Debt instrument variable rate basis	Three-month LIBOR

Long-Term Debt and Capital L120

Long-Term Debt and Capital Leases - Acquired Allergan Notes - Additional Information (Detail) - USD ($) $ in Millions	Mar. 17, 2015	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total Senior Notes Gross		$ 29,698.2	$ 32,750
Senior Notes, Fair Market Value		30,303.6	32,973
Unamortized premium		88.9	171.2
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		25,456.7	31,750
Senior Notes, Fair Market Value		$ 26,073	$ 31,961.1
Fixed Rate Notes [Member] | Allergan Acquisition [Member]
Debt Instrument [Line Items]
Senior Notes, Fair Market Value	$ 2,087.5
Unamortized premium	$ 37.5
Fixed Rate Notes [Member] | Allergan Acquisition [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	5.75%
Senior notes, maturity date	Apr. 1, 2016
Senior notes redeemed date	Apr. 1, 2016
Total Senior Notes Gross	$ 800

Long-Term Debt and Capital L121

Long-Term Debt and Capital Leases - Acquired Forest Notes - Additional Information (Detail) $ in Millions	Jul. 01, 2014USD ($)
Fixed Rate Notes [Member] | Forest Laboratories, Inc. [Member]
Debt Instrument [Line Items]
Acquisition premium on indebtedness	$ 260.3

Long-Term Debt and Capital L122

Long-Term Debt and Capital Leases - Credit Facility Indebtedness - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Interest expense on outstanding indebtedness	$ 116.2	$ 147.3

Long-Term Debt and Capital L123

Long-Term Debt and Capital Leases - Marginal Loan - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2017	Nov. 10, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Aggregate principal amount	$ 29,698.2		$ 32,750
Marginal Loan [Member]
Debt Instrument [Line Items]
Single draw end date	Dec. 22, 2017
Amount drew down	$ 525
Amount repaid	$ 66
Maximum [Member] | Marginal Loan [Member]
Debt Instrument [Line Items]
Aggregate principal amount		$ 550

Long-Term Debt and Capital L124

Long-Term Debt and Capital Leases - Revolving Credit Facility - Additional Information (Detail) - Revolver Agreement [Member] - USD ($) $ in Millions	Jun. 14, 2017	Dec. 31, 2017
Line Of Credit Facility [Line Items]
Revolving credit facility, term	5 years
Maximum borrowing capacity	$ 1,500
Ability to increase the revolving credit facility	500
Borrowing capacity	$ 2,000
Customary affirmative covenants		The Revolver Agreement contains customary affirmative covenants for facilities of this type, including, among others, covenants pertaining to the delivery of financial statements, notices of default, maintenance of corporate existence and compliance with laws, as well as customary negative covenants for facilities of this type, including, among others, limitations on secured indebtedness, non-guarantor subsidiary indebtedness, mergers and certain other fundamental changes and passive holding company status. The Revolver Agreement also contains a financial covenant requiring maintenance of a maximum consolidated leverage ratio.
Borrowings outstanding		$ 28.6
Letters of credit outstanding		$ 28.6
Minimum [Member]
Line Of Credit Facility [Line Items]
Credit facility unused portion commitment fee percentage	0.07%
Minimum [Member] | Base Rate [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	0.00%
Minimum [Member] | Eurodollar [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	0.875%
Maximum [Member]
Line Of Credit Facility [Line Items]
Credit facility unused portion commitment fee percentage	0.25%
Maximum [Member] | Base Rate [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	1.00%
Maximum [Member] | Eurodollar [Member]
Line Of Credit Facility [Line Items]
Percentage of margin	2.00%

Long-Term Debt and Capital L125

Long-Term Debt and Capital Leases - Cash Bridge Loan Facility - Additional Information (Detail)	Apr. 09, 2015USD ($)
Cash Bridge Loan Facility [Member]
Debt Instrument [Line Items]
Facility repayment	$ 2,800,000,000

Long-Term Debt and Capital L126

Long-Term Debt and Capital Leases - 2017 Repayments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 13, 2017	May 30, 2017
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	4.875%	4.875%
Senior notes, maturity date	Feb. 15, 2021	Feb. 15, 2021
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	4.625%	4.625%
Senior notes, maturity date	Oct. 1, 2042	Oct. 1, 2042
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	4.375%	4.375%	4.375%
Senior notes, maturity date	Feb. 1, 2019	Feb. 1, 2019
Tender Offer [Member]
Debt Instrument [Line Items]
Senior notes, repurchase date	May 30, 2017
Senior notes, repurchase amount				$ 3,013.8
Senior notes early tender payment				170.5
Senior notes, net expense				161.6
Tender Offer [Member] | Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, repurchase amount				300
Senior notes, face amount				$ 750
Senior notes, interest rate				4.875%
Senior notes, maturity date	Feb. 15, 2021
Tender Offer [Member] | Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Senior notes, repurchase amount				$ 543.3
Senior notes, face amount				$ 1,000
Senior notes, interest rate				4.625%
Senior notes, maturity date	Oct. 1, 2042
Tender Offer [Member] | Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, repurchase amount				$ 700
Senior notes, face amount				$ 1,050
Senior notes, interest rate				4.375%
Senior notes, maturity date	Feb. 1, 2019
Tender Offer [Member] | Fixed Rate Notes [Member] | Notes Due March 15, 2045 [Member]
Debt Instrument [Line Items]
Senior notes, repurchase amount				$ 1,300
Senior notes, face amount				$ 2,500
Senior notes, interest rate				4.75%
Senior notes, maturity date	Mar. 15, 2045

Long-Term Debt and Capital L127

Long-Term Debt and Capital Leases - Other Prepayments - Additional Information (Detail) - Fixed Rate Notes [Member] - USD ($) $ in Millions	Dec. 13, 2017	Nov. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
6.125% Senior Notes Due August 15, 2019 [Member]
Debt Instrument [Line Items]
Early repayment of senior notes		$ 400
Senior notes, interest rate		6.125%	6.125%	6.125%
Senior notes, maturity date			Aug. 15, 2019	Aug. 15, 2019
Prepayments of senior notes including early tender payment		$ 426.8
Senior notes early tender payment		$ 26.8
4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Early repayment of senior notes	$ 350
Senior notes, interest rate	4.375%		4.375%	4.375%
Senior notes, maturity date			Feb. 1, 2019	Feb. 1, 2019

Long-Term Debt and Capital L128

Long-Term Debt and Capital Leases - Schedule of Annual Debt Maturities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2,018	$ 3,750
2,019	1,340.4
2,020	4,650
2,021	2,550.4
2,022	4,700
2023 and after	12,707.4
Total senior notes gross	29,698.2
Capital leases	2.7
Debt issuance costs	(121.5)
Other short-term borrowings	488.7
Unamortized premium	88.9	$ 171.2
Unamortized discount	(81.7)	(95.8)
Total Indebtedness	$ 30,075.3	$ 32,768.7

Long-Term Debt and Capital L129

Long-Term Debt and Capital Leases - 2009 Notes Issuance and Lease Commitments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Rent expenses for operating leases	$ 72	$ 47.7	$ 49.9

Long-Term Debt and Capital L130

Long-Term Debt and Capital Leases - Schedule of Future Minimum Lease Payments under Capital and Operating Leases (Detail) $ in Millions	Dec. 31, 2017USD ($)
Debt Disclosure [Abstract]
2,018	$ 53.5
2,019	59.1
2,020	46.5
2,021	44.9
2,022	42.9
Thereafter	206.1
Total minimum lease payments	$ 453

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities Disclosure [Abstract]
Acquisition related contingent consideration liabilities	$ 420.7	$ 661.1
Long-term pension and post retirement liability	162.7	201.6
Legacy Allergan deferred executive compensation	113.8	111.7
Long-term severance and restructuring liabilities	53.1	22
Deferred revenue	37.9	15.7
Product warranties	28.7	28.1
Long-term contractual obligations	45.2	25.3
Other long-term liabilities	24.8	19.5
Total other long-term liabilities	$ 886.9	$ 1,085

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	Jan. 01, 2019	Jan. 01, 2018	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Repatriation tax payable period			8 years	8 years
U.S.federal corporate income tax rate						35.00%
Estimated increase tax rate for global intangible low taxed income including foreign credits for beginning after December 31, 2025						13.125%
Decrease to deferred tax liabilities				$ 2,340,400,000
Partial reversal of prior amounts accrued for taxes on unremitted earnings				1,260,000,000
Income tax expense related to repatriation of foreign earnings				728,100,000
Deferred tax liabilities, current				58,200,000		$ 58,200,000
Deferred tax liabilities, non current				669,800,000		669,800,000
Foreign losses before taxes						9,247,400,000	$ 1,502,800,000	$ 4,291,700,000
Deferred tax liabilities related to acquired entities				799,400,000		799,400,000	604,900,000
Decreased in net deferred tax liabilities						6,702,500,000
Net operating loss carryforward				1,005,300,000		1,005,300,000	702,000,000
Net operating loss carryforwards				824,400,000		824,400,000
Tax credit carryforwards				253,400,000		253,400,000
Valuation allowance				403,800,000		403,800,000	183,900,000
Net operating income (losses)						(5,921,200,000)	(1,825,500,000)	(3,131,000,000)
Other deferred tax assets				20,400,000		20,400,000	64,000,000
Undistributed earnings of foreign subsidiaries				9,358,100,000		9,358,100,000
Undistributed earnings of domestic subsidiaries				0		0
Deferred tax liabilities				6,033,300,000		6,033,300,000	12,735,800,000
Unrecognized amount that would favorably affect Company's effective tax rate				754,000,000		754,000,000
Interest and penalties related to uncertain tax positions recognized in tax expense						45,800,000	2,000,000	(500,000)
Interest and penalties related to tax positions accrued				113,700,000		113,700,000	65,300,000	63,300,000
Tax benefit on penalties and interest accrued				25,900,000		25,900,000	$ 35,400,000	$ 34,200,000
Reasonably possible change in unrecognized tax benefits				150,000,000		150,000,000
Valuation Allowance on U.S. Capital Loss Carryforwards [Member]
Income Tax [Line Items]
Tax expense recorded related to change in valuation allowance						230,100,000
Tax Valuation Allowance [Member]
Income Tax [Line Items]
Net operating income (losses)						(118,700,000)
Tax credits				223,300,000		223,300,000
Capital loss carryforwards				58,200,000		58,200,000
Other deferred tax assets				3,600,000		3,600,000
U.S. [Member]
Income Tax [Line Items]
Net operating loss carryforward				824,400,000		824,400,000
Tax credits, expire in 2018				368,300,000		368,300,000
Tax net operating losses, expire in 2018				3,205,000,000		3,205,000,000
Increase to net operating loss						2,146,000,000
Deferred tax liabilities				345,500,000		345,500,000
Non-U.S. [Member]
Income Tax [Line Items]
Tax net operating losses, expire in 2018				27,400,000		27,400,000
Tax net operating losses, not subject to expiration				$ 1,910,400,000		$ 1,910,400,000
Subsequent Event [Member]
Income Tax [Line Items]
Tax rate for global intangible low taxed income including foreign credits		10.50%
Income tax deductible interest expense percent		30.00%
Minimum base erosion anti-abuse tax		5.00%
Scenario Forecast [Member]
Income Tax [Line Items]
U.S.federal corporate income tax rate					21.00%
Minimum base erosion anti-abuse tax	10.00%

Income Taxes - Schedule of (Ben

Income Taxes - Schedule of (Benefit)/Provision for Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current (benefit) / provision:
Current (benefit) / provision, U.S. federal	$ 763.1	$ (17.5)	$ 14.4
Current (benefit) / provision, U.S. state	(54.8)		9.7
Current (benefit) / provision, Non-U.S.	410	166.2	225.6
Total current (benefit) / provision	1,118.3	148.7	249.7
Deferred (benefit) / provision:
Deferred (benefit) / provision, U.S. federal	(6,911.9)	(1,218.5)	(1,370.2)
Deferred (benefit) / provision, U.S. state	(252.3)	(132.1)	(58.7)
Deferred (benefit) / provision, Non-U.S.	(624.5)	(695.1)	(426.7)
Total deferred (benefit) / provision	(7,788.7)	(2,045.7)	(1,855.6)
Total (benefit) / provision for income taxes	$ (6,670.4)	$ (1,897)	$ (1,605.9)

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Statutory rate	(35.00%)
Irish [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Statutory rate	(12.50%)	(12.50%)	(12.50%)
Earnings subject to U.S. taxes	(17.80%)	(37.50%)	(18.60%)
Earnings subject to rates different than the statutory rate	2.50%	(18.30%)	(2.20%)
Impact of tax reform	(27.20%)	0.00%	0.00%
Tax reserves and audit outcomes	0.40%	(0.70%)	0.30%
Non-deductible expenses	0.20%	3.10%	1.30%
Impact of acquisitions and reorganizations	(9.30%)	3.10%	4.00%
Tax credits and U.S. manufacturing deduction	(1.50%)	(3.10%)	(0.50%)
Rate changes	(1.20%)	(7.40%)	0.00%
Valuation allowances	2.20%	6.50%	(6.50%)
Other	0.00%	(0.20%)	(0.60%)
Effective income tax rate	(64.20%)	(67.00%)	(35.30%)
Bermuda [Member] | Warner Chilcott Limited [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Statutory rate	(0.00%)	(0.00%)	(0.00%)
Earnings subject to U.S. taxes	(27.90%)	(58.40%)	(29.50%)
Earnings subject to rates different than the statutory rate	(0.40%)	(11.90%)	(5.00%)
Impact of tax reform	(27.70%)	0.00%	0.00%
Tax reserves and audit outcomes	0.50%	(0.70%)	0.30%
Non-deductible expenses	0.20%	3.20%	1.30%
Impact of acquisitions and reorganizations	(9.50%)	3.20%	4.10%
Tax credits and U.S. manufacturing deduction	(1.50%)	(3.20%)	(0.50%)
Rate changes	(1.30%)	(7.60%)	0.00%
Valuation allowances	2.30%	6.70%	(6.70%)
Other	(0.20%)	(0.10%)	(0.40%)
Effective income tax rate	(65.50%)	(68.80%)	(36.40%)

Income Taxes - Schedule of R135

Income Taxes - Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Amortization expense	$ 7,197.1	$ 6,470.4	$ 5,443.7
Impairment charges, including Teva share activity	8,650
Impact on effective tax rate	1,262.2
TCJA change in tax rate income tax expense benefit	2,800
Income tax benefit related to basis differences in investments	895.3
Income tax benefit of income rate changes in U.S. and France	128.1
Valuation Allowance on U.S. Capital Loss Carryforwards [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Tax expense recorded related to change in valuation allowance	$ 230.1

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components Company's Net Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Benefits from net operating and capital losses and tax credit carryforwards	$ 1,005.3	$ 702
Differences in financial statement and tax accounting for:
Inventories, receivables and accruals	263.5	433.6
Basis differences in investments	1,088.7
Share-based and other compensation	315.4	530.1
Other	20.4	64
Total deferred tax asset, gross	2,693.3	1,729.7
Less: Valuation allowance	(403.8)	(183.9)
Total deferred tax asset, net	2,289.5	1,545.8
Differences in financial statement and tax accounting for:
Property, equipment and intangible assets	(7,519.1)	(12,419.6)
Outside basis differences	(731.4)	(1,793.7)
Other	(72.3)	(68.3)
Total deferred tax liabilities	(8,322.8)	(14,281.6)
Total deferred taxes	$ (6,033.3)	$ (12,735.8)

Income Taxes - Schedule of R137

Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 811.2	$ 781.7	$ 712.2
Increases for current year tax positions	10.1	100.7	41.2
Increases for prior year tax positions	69.2	40.5	19.7
Increases due to acquisitions	19.8	0	115.5
Decreases for prior year tax positions	(38.7)	(77.9)	(41.4)
Settlements	(21.7)	(30.8)	(60.6)
Lapse of applicable statute of limitations	(2.9)	(2.9)	(3.2)
Foreign exchange		(0.1)	(1.7)
Foreign exchange	3.3
Balance at the end of the year	$ 850.3	$ 811.2	$ 781.7

Income Taxes - Summary of Acqui

Income Taxes - Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS (Detail) - U.S. Federal Income Tax Authority [Member]	12 Months Ended
	Dec. 31, 2017
Allergan W.C. Holding Inc. [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Allergan W.C. Holding Inc. [Member] | Tax Year 2014 [Member]
Income Tax Examination [Line Items]
Tax Years	2,014
Warner Chilcott Corporation [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Warner Chilcott Corporation [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Warner Chilcott Corporation [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Warner Chilcott Corporation [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Forest Laboratories, Inc. [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Forest Laboratories, Inc. [Member] | Tax Year 2014 [Member]
Income Tax Examination [Line Items]
Tax Years	2,014
Forest Laboratories, Inc. [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Forest Laboratories, Inc. [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Forest Laboratories, Inc. [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Allergan, Inc. [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Allergan, Inc. [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Allergan, Inc. [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Allergan, Inc. [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Allergan, Inc. [Member] | Tax Year 2009 [Member]
Income Tax Examination [Line Items]
Tax Years	2,009
Allergan, Inc. [Member] | Tax Year 2015 [Member]
Income Tax Examination [Line Items]
Tax Years	2,015
LifeCell Corporation [Member] | Tax Year 2014 [Member]
Income Tax Examination [Line Items]
Tax Years	2,014

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($)	Mar. 02, 2015	Feb. 24, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 25, 2017
Shareholders Equity [Line Items]
Share repurchase program, Approved amount				$ 5,000,000,000		$ 2,000,000,000
Amount of shares repurchased under the program			$ 43,000,000	76,400,000	$ 118,000,000
Number of shares repurchased under program			2,600,000
Accelerated share repurchase agreement additional purchase amount				$ 10,000,000,000
Share repurchased during period			4,200,000	61,600,000
Quarterly cash dividends paid			$ 0.70
Dividends on ordinary shares			$ 939,800,000
Increase in quarterly cash dividend per share for 2018			$ 0.72
Preferred shares, shares issued			5,100,000	5,100,000
Preferred shares, par value			$ 0.0001	$ 0.0001
Proceeds from the issuance of Mandatory Convertible Preferred Shares					4,929,700,000
Convertible Preferred Share, conversion date			Mar. 1, 2018
Dividends on preferred shares			$ 278,400,000	$ 278,400,000	208,100,000
Ordinary shares, per share	$ 288
Proceeds from issuance of ordinary shares					$ 4,071,100,000
Pension and other post retirement plans included in unrealized gain (loss) net of tax			75,000,000
ASU No. 2016-01 [Member]
Shareholders Equity [Line Items]
Impact of recent accounting pronouncements			$ 63,000,000
Ordinary Shares [Member]
Shareholders Equity [Line Items]
Share repurchased during period			100,000	300,000	400,000
Ordinary shares, shares issued	14,513,889
Allergan, Inc. [Member]
Shareholders Equity [Line Items]
Proceeds from issuance of ordinary shares	$ 4,071,100,000
Mandatory Convertible Preferred Shares [Member]
Shareholders Equity [Line Items]
Preferred shares, shares issued		5,060,000
Preferred shares, dividend rate percentage		5.50%
Preferred shares, par value		$ 0.0001
Preferred shares, liquidation preference per share		$ 1,000
Preferred stock, dividend payment terms				The Company may pay declared dividends in cash, by delivery of our ordinary shares or by delivery of any combination of cash and our ordinary shares, as determined by us in our sole discretion, subject to certain limitations, on March 1, June 1, September 1 and December 1 of each year commencing June 1, 2015, to and including March 1, 2018.
Convertible Preferred Share, conversion date				Mar. 1, 2018
Convertible Preferred Share, terms of conversion				The number of our ordinary shares issuable on conversion of the Mandatory Convertible Preferred Shares will be determined based on the volume weighted average price per ordinary share over the 20 consecutive trading day period beginning on and including the 22nd scheduled trading day immediately preceding March 1, 2018, the mandatory conversion date.
Mandatory Convertible Preferred Shares [Member] | Minimum [Member]
Shareholders Equity [Line Items]
Convertible Preferred Share issued upon conversion subject to anti-dilution adjustments		2.8345
Mandatory Convertible Preferred Shares [Member] | Maximum [Member]
Shareholders Equity [Line Items]
Convertible Preferred Share issued upon conversion subject to anti-dilution adjustments		3.4722
Mandatory Convertible Preferred Shares [Member] | Allergan, Inc. [Member]
Shareholders Equity [Line Items]
Proceeds from the issuance of Mandatory Convertible Preferred Shares		$ 4,929,700,000
Share Repurchase Program [Member]
Shareholders Equity [Line Items]
Amount of shares repurchased under the program			$ 450,000,000

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Movements in Accumulated Other Comprehensive (Loss) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	$ 76,192.7	$ 76,591.4	$ 28,331.1
Other comprehensive gain / (loss) before reclassifications into general and administrative	1,359.7	(489.7)
Investment in Teva ordinary shares fair value movement	(111.7)	1,647.5	(101.2)
Total other comprehensive income / (loss), net of tax	2,959.1	(544.3)	(28.7)
Balance	73,821.1	76,192.7	76,591.4
Teva [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Impact of Teva Transaction		1,544.8
Investment in Teva ordinary shares fair value movement		(1,599.4)
Net impact of other-than-temporary loss on investment in Teva securities	1,599.4
Foreign Currency Translation Items [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	534.7	(564.3)
Other comprehensive gain / (loss) before reclassifications into general and administrative	1,248	(441.6)
Total other comprehensive income / (loss), net of tax	1,248	1,099
Balance	1,782.7	534.7	(564.3)
Foreign Currency Translation Items [Member] | Teva [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Impact of Teva Transaction		1,540.6
Unrealized Gains/(Loss) Net of Tax [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	(1,573.1)	70.2
Other comprehensive gain / (loss) before reclassifications into general and administrative	111.7	(48.1)
Total other comprehensive income / (loss), net of tax	1,711.1	(1,643.3)
Balance	138	(1,573.1)	70.2
Unrealized Gains/(Loss) Net of Tax [Member] | Teva [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Impact of Teva Transaction		4.2
Investment in Teva ordinary shares fair value movement		(1,599.4)
Net impact of other-than-temporary loss on investment in Teva securities	1,599.4
Accumulated Other Comprehensive Income / (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	(1,038.4)	(494.1)	(465.4)
Balance	$ 1,920.7	(1,038.4)	$ (494.1)
Accumulated Other Comprehensive Income / (Loss) [Member] | Teva [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Impact of Teva Transaction		$ 1,544.8

Segments - Additional Informati

Segments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017Segment
Segment Reporting [Abstract]
Number of operating segments	3

Segments - Schedule of Net Reve

Segments - Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net revenues	$ 4,326.1	$ 4,034.3	$ 4,007.4	$ 3,572.9	$ 3,864.3	$ 3,622.2	$ 3,684.8	$ 3,399.3	$ 15,940.7	$ 14,570.6	$ 12,688.1
Operating expenses:
Cost of sales									2,168	1,860.8	2,751.8
Selling and marketing									3,514.8	3,266.4	2,765.1
General and administrative									1,501.9	1,473.9	1,716.4
Research and development									2,100.1	2,575.7	2,358.5
Amortization									7,197.1	6,470.4	5,443.7
In-process research and development impairments									1,452.3	743.9	511.6
Asset sales and impairments, net									3,927.7	5	272
Operating (loss)									(5,921.2)	(1,825.5)	(3,131)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues									15,919.3	14,616.9	12,835.5
Operating expenses:
Cost of sales									1,818	1,588.9	1,496.2
Selling and marketing									3,367.4	3,110.9	2,536.7
General and administrative									506.1	466.3	281.2
Segment contribution									$ 10,227.8	$ 9,450.8	$ 8,521.4
Contribution margin									64.20%	64.70%	66.40%
Corporate									$ 1,471.8	$ 1,481.3	$ 3,066.6
Research and development									2,100.1	2,575.7	2,358.5
Amortization									7,197.1	6,470.4	5,443.7
In-process research and development impairments									1,452.3	743.9	511.6
Asset sales and impairments, net									3,927.7	5	272
Operating (loss)									$ (5,921.2)	$ (1,825.5)	$ (3,131)
Operating margin									(37.20%)	(12.50%)	(24.40%)
Operating Segments [Member] | US Specialized Therapeutics [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 6,803.6	$ 5,811.7	$ 4,309.8
Operating expenses:
Cost of sales									495.4	290.9	235.8
Selling and marketing									1,369.5	1,137	772.8
General and administrative									208.2	174.2	68.3
Segment contribution									$ 4,730.5	$ 4,209.6	$ 3,232.9
Contribution margin									69.50%	72.40%	75.00%
Operating Segments [Member] | US General Medicine [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 5,796.2	$ 5,923.9	$ 6,338.4
Operating expenses:
Cost of sales									843.9	879.8	909.5
Selling and marketing									1,084.1	1,185.7	1,194.7
General and administrative									177.3	174.9	105.3
Segment contribution									$ 3,690.9	$ 3,683.5	$ 4,128.9
Contribution margin									63.70%	62.20%	65.10%
Operating Segments [Member] | International [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 3,319.5	$ 2,881.3	$ 2,187.3
Operating expenses:
Cost of sales									478.7	418.2	350.9
Selling and marketing									913.8	788.2	569.2
General and administrative									120.6	117.2	107.6
Segment contribution									$ 1,806.4	$ 1,557.7	$ 1,159.6
Contribution margin									54.40%	54.10%	53.00%

Segments - Reconciliation of Ne

Segments - Reconciliation of Net Revenues for Operating Segments (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net revenues	$ 4,326.1	$ 4,034.3	$ 4,007.4	$ 3,572.9	$ 3,864.3	$ 3,622.2	$ 3,684.8	$ 3,399.3	$ 15,940.7	$ 14,570.6	$ 12,688.1
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues									15,919.3	14,616.9	12,835.5
Corporate Revenues [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 21.4	$ (46.3)	$ (147.4)

Segments - Presents of Global N

Segments - Presents of Global Net Revenues by Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 4,326.1	$ 4,034.3	$ 4,007.4	$ 3,572.9	$ 3,864.3	$ 3,622.2	$ 3,684.8	$ 3,399.3	$ 15,940.7	$ 14,570.6	$ 12,688.1
Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									15,919.3	14,616.9	12,835.5
Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									6,803.6	5,811.7	4,309.8
Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									5,796.2	5,923.9	6,338.4
Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3,319.5	2,881.3	2,187.3
Corporate Non Segment [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									21.4	(46.3)	(147.4)
Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3,168.9	2,786.2	1,970.8
Botox [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2,254.4	1,983.2	1,386.4
Botox [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									914.5	803	584.4
Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,473.6	1,487.5	1,047.8
Restasis [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,412.3	1,419.5	999.6
Restasis [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									61.3	68	48.2
Juvederm Collection [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,041.8	867.3	573.9
Juvederm Collection [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									501.1	446.9	304.4
Juvederm Collection [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									540.7	420.4	269.5
Namenda XR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									452.8	627.6	759.3
Namenda XR [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									452.8	627.6	759.3
Bystolic/Byvalson [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									614.4	640.5	646.1
Bystolic/Byvalson [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									612.2	638.8	644.8
Bystolic/Byvalson [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2.2	1.7	1.3
Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									245.7	414.5	618.4
Asacol/Delzicol [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									195.5	360.8	552.9
Asacol/Delzicol [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									50.2	53.7	65.5
Namenda IR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									0.1	15.1	556.3
Namenda IR [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									0.1	15.1	556.3
Lumigan And Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									689	688.1	544.1
Lumigan And Ganfort [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									317.5	326.4	260.7
Lumigan And Ganfort [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									371.5	361.7	283.4
Linzess/Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									723	642.9	459.3
Linzess/Constella [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									701.1	625.6	454.8
Linzess/Constella [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									21.9	17.3	4.5
Alphagan And Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									552.4	545.9	411.1
Alphagan And Combigan [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									377.3	376.6	285
Alphagan And Combigan [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									175.1	169.3	126.1
Eye Drops [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									480.5	462.7	397.6
Eye Drops [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									199.5	186.5	177
Eye Drops [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									281	276.2	220.6
Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									459.3	403.5	349.6
Lo Loestrin [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									459.3	403.5	346.5
Lo Loestrin [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues											3.1
Breast Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									399.5	355.9	300.5
Breast Implants [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									242.6	206	175
Breast Implants [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									156.9	149.9	125.5
Viibryd/Fetzima [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									336.3	342.3	327.6
Viibryd/Fetzima [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									333.2	342.3	327.6
Viibryd/Fetzima [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3.1
Estrace Cream [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									366.6	379.4	326.2
Estrace Cream [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									366.6	379.4	326.2
Minastrin 24 [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									61.4	327.3	273
Minastrin 24 [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									61.4	325.9	272.4
Minastrin 24 [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										1.4	0.6
Ozurdex [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									311.8	263.4	168.4
Ozurdex [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									98.4	84.4	56.1
Ozurdex [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									213.4	179	112.3
Carafate And Sulcrate [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									238.7	231.4	213.1
Carafate And Sulcrate [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									235.8	229	213.1
Carafate And Sulcrate [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2.9	2.4
Aczone [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									166.8	217.3	170.8
Aczone [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									166.3	217.3	170.8
Aczone [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									0.5
Zenpep [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									212.3	200.7	167.4
Zenpep [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									212.3	200.7	167.4
Canasa/Salofalk [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									181	196.4	155.6
Canasa/Salofalk [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									162.7	178.7	137.1
Canasa/Salofalk [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									18.3	17.7	18.5
Saphris [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									155.2	166.8	186.7
Saphris [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									155.2	166.8	186.7
Armour Thyroid [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									169.1	166.5	130.8
Armour Thyroid [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									169.1	166.5	130.8
Teflaro [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									121.9	133.6	137.6
Teflaro [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									121.9	133.6	137.6
Rapaflo [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									115.4	122.4	126.1
Rapaflo [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									108.1	116.6	115.2
Rapaflo [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									7.3	5.8	10.9
SkinMedica Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									100.5	108.3	76.6
SkinMedica Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									96.8	108.3	76.6
SkinMedica Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3.7
Savella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									98.2	103.2	106.4
Savella [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									98.2	103.2	106.4
Tazorac [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									66.1	96.3	93.7
Tazorac [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									65.4	95.5	92.3
Tazorac [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									0.7	0.8	1.4
Vraylar [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									287.8	94.3
Vraylar [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									287.8	94.3
Viberzi [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									157.1	93.3	12.3
Viberzi [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									156.6	93.3	12.3
Viberzi [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									0.5
Latisse [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									64.7	86.4	73.2
Latisse [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									56.4	77.9	63.2
Latisse [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									8.3	8.5	10
Lexapro [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									51.8	66.6	71.6
Lexapro [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									51.8	66.6	71.6
Namzaric [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									130.8	57.5	11.2
Namzaric [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									130.8	57.5	11.2
Kybella/Belkyra [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									56.3	52.5	3.2
Kybella/Belkyra [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									49.5	50.2	3.2
Kybella/Belkyra [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									6.8	2.3
Dalvance [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									56.3	39.3	16.8
Dalvance [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									53.9	39.3	16.8
Dalvance [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2.4
Avycaz [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									61.2	36.1	22.6
Avycaz [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									61.2	36.1	22.6
Liletta [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									37.6	23.3	14.8
Liletta [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									37.6	23.3	14.8
Enablex [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3.6	17.1	69.2
Enablex [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3.6	17.1	69.2
Alloderm [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									328.7
Alloderm [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									321.2
Alloderm [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									7.5
Coolsculpting Consumables [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									191.7
Coolsculpting Consumables [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									150.1
Coolsculpting Consumables [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									41.6
Coolsculpting Systems & Add On Applicators [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									138.7
Coolsculpting Systems & Add On Applicators [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									106.6
Coolsculpting Systems & Add On Applicators [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									32.1
Other [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,372.1	1,091.2	1,255.8
Other [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									280.1	116.4	144.3
Other [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									675.5	598.9	800
Other [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									395.1	342.2	301.5
Other [Member] | Corporate Non Segment [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									$ 21.4	33.7	10
Product Sold By Anda Distribution | Discontinued Operations [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										(80)	(157.4)
Product Sold By Anda Distribution | Corporate Non Segment [Member] | Discontinued Operations [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues										$ (80)	$ (157.4)

Business Restructuring Charg145

Business Restructuring Charges - Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	$ 108.2	$ 143.4
Charged to expense	272.6	106.1	$ 817.6
Cash payments	(178)	(115.2)
Other reserve impact	(16.9)	(26.1)
Reserve ending balance	185.9	108.2	143.4
Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	50.4	9.3
Research and Development Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	37.1	12.8
Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	92.5	31.2
General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	92.6	52.8
Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	68.5	94.8
Charged to expense	217.5	62.7
Cash payments	(110.4)	(81.9)
Other reserve impact	(9.6)	(7.1)
Reserve ending balance	166	68.5	94.8
Severance and Retention [Member] | Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	50.4	3.9
Severance and Retention [Member] | Research and Development Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	37.1	11.1
Severance and Retention [Member] | Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	92.5	19.8
Severance and Retention [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	37.5	27.9
Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	38.8	21
Cash payments	(31.5)
Other reserve impact	(7.3)	(21)
Share-Based Compensation [Member] | Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		0.5
Share-Based Compensation [Member] | Research and Development Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		1
Share-Based Compensation [Member] | Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		9.7
Share-Based Compensation [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	38.8	9.8
Other [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	39.7	48.6
Charged to expense	16.3	22.4
Cash payments	(36.1)	(33.3)
Other reserve impact		2
Reserve ending balance	19.9	39.7	$ 48.6
Other [Member] | Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		4.9
Other [Member] | Research and Development Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		0.7
Other [Member] | Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		1.7
Other [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense	$ 16.3	$ 15.1

Business Restructuring Charg146

Business Restructuring Charges - Additional Information (Detail) $ in Millions	Feb. 17, 2018USD ($)	Dec. 31, 2017USD ($)Employee	Dec. 31, 2017USD ($)Employee	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Restructuring Cost And Reserve [Line Items]
Severance and other employee related charges		$ 91.3
Share based compensation related to business restructuring		4
Other restructuring charges		$ 14.6
Severance and other employee related charges recorded			$ 12.4
Restructuring charges related to various other initiatives and integration of acquired businesses			91.7
Restructuring charges recognized			$ 272.6	$ 106.1	$ 817.6
Filled Positions [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions expected to be eliminated | Employee			100
Open Positions [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions expected to be eliminated | Employee		400
Scenario Forecast [Member]
Restructuring Cost And Reserve [Line Items]
Impairment charges related to fixed assets and facilities	$ 17.7
Commercial and Other Functions [Member] | Filled Positions [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions expected to be eliminated | Employee		1,000
Commercial Organization Restructuring [Member]
Restructuring Cost And Reserve [Line Items]
Severance and other employee related charges			$ 16.9
Commercial Organization Restructuring [Member] | Filled Positions [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions expected to be eliminated | Employee			200
Commercial Organization Restructuring [Member] | Open Positions [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions expected to be eliminated | Employee			150
Manufacturing Facility [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions expected to be eliminated | Employee			250
Severance and other employee related charges			$ 41.5
Accelerated depreciation related to restructuring			$ 4.2

Derivative Instruments and H147

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	Feb. 13, 2018	Jan. 12, 2018	Dec. 31, 2017	Nov. 10, 2017
Teva [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Acelerated share repurchase transaction			25	25
Loss on forward sale of investment			$ 62.9
Accelerated Share Repurchases, adjustments loss			62.9
Teva [Member] | Subsequent Event [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Loss on forward sale of investment		$ 413.3
Accelerated share repurchases settlement date		Jan. 12, 2018
Forward sale of investment shares	25
Percentage of proceeds from forward sale received	80.00%
Proceeds from forward sale received	$ 372
Designated as Hedging Instrument [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative notional amount			3,600
Gain (Loss) on Derivative Used in Net Investment Hedge, Net of Tax			$ 208.2

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or on Recurring Basis (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
ASSETS
Short-term investments	$ 2,814.4	$ 8,062.3
Deferred executive compensation investments	112.4	111.7
Foreign currency derivatives		0.1
Investments and other	72.3	95
Total assets	6,144.9	12,947.2
Liabilities:
Deferred executive compensation liabilities	113.8	111.7
Contingent consideration obligations	476.9	1,172.1
Total liabilities	590.7	1,283.8
Investment In Teva Ordinary Shares [Member]
ASSETS
Investment in Teva ordinary shares	1,817.7	3,439.2
Cash Equivalents [Member]
ASSETS
Cash & cash equivalents	1,328.1	1,238.9
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
ASSETS
Cash & cash equivalents	1,328.1	1,238.9
Deferred executive compensation investments	92.9	90.5
Investments and other	72.3	95
Total assets	3,311	1,424.4
Liabilities:
Deferred executive compensation liabilities	94.3	90.5
Total liabilities	94.3	90.5
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Investment In Teva Ordinary Shares [Member]
ASSETS
Investment in Teva ordinary shares	1,817.7
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Cash Equivalents [Member]
ASSETS
Cash & cash equivalents	1,328.1	1,238.9
Significant Other Observable Inputs (Level 2) [Member]
ASSETS
Short-term investments	2,814.4	8,062.3
Deferred executive compensation investments	19.5	21.2
Foreign currency derivatives		0.1
Total assets	2,833.9	11,522.8
Liabilities:
Deferred executive compensation liabilities	19.5	21.2
Total liabilities	19.5	21.2
Significant Other Observable Inputs (Level 2) [Member] | Investment In Teva Ordinary Shares [Member]
ASSETS
Investment in Teva ordinary shares		3,439.2
Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	476.9	1,172.1
Total liabilities	$ 476.9	$ 1,172.1

Fair Value Measurement - Sch149

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or on Recurring Basis (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities remaining maturity period	90 days	90 days

Fair Value Measurement - Change

Fair Value Measurement - Change in Fair Value of Contingent Consideration Obligations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ (133.2)	$ (64.2)	$ 95.7
Cost of Sales [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	(183.2)	(17.4)	58.5
R&D Expense [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ 50	(71.1)	37.7
General and Administrative Expense [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation		$ 24.3	$ (0.5)

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income	$ (133.2)	$ (64.2)	$ 95.7
Contingent consideration	476.9	1,172.1
R&D Expense [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income	50	(71.1)	37.7
Cost of Sales [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income	(183.2)	(17.4)	58.5
Furiex Pharmaceuticals, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			29.8
Medicines 360 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			81.4
Durata Therapeutics Inc [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			6.4
Forest Laboratories, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain on contingent consideration fair value adjustment			32.3
Allergan, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain on contingent consideration fair value adjustment			$ 8.2
Allergan, Inc. [Member] | R&D Expense [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income		$ 64.2
Net contingent consideration expense	50
Allergan, Inc. [Member] | Cost of Sales [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Net contingent consideration income	183.2
Net contingent consideration expense	$ 50

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) - Contingent Consideration Obligations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1,172.1	$ 868
Purchases, settlements, and other net	(562)	368.3
Net accretion and fair value adjustments	(133.2)	(64.2)
Ending balance	$ 476.9	$ 1,172.1

Fair Value Measurement - Sch153

Fair Value Measurement - Schedule of Contingent Consideration Obligations by Acquisitions (Detail) - Contingent Consideration Obligations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Beginning balance	$ 1,172.1	$ 868
Fair Value Adjustments and Accretion	(133.2)	(64.2)
Payments and Other	(562)
Ending balance	476.9	1,172.1
Tobira [Member]
Business Acquisition [Line Items]
Beginning balance	514.4
Fair Value Adjustments and Accretion	14.6
Payments and Other	(301.2)
Ending balance	227.8	514.4
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	199.6
Fair Value Adjustments and Accretion	(70.9)
Payments and Other	(110)
Ending balance	18.7	199.6
Medicines 360 Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	127.5
Fair Value Adjustments and Accretion	(67)
Payments and Other	(16.1)
Ending balance	44.4	127.5
AqueSys Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	103.9
Fair Value Adjustments and Accretion	(50.4)
Payments and Other	(25)
Ending balance	28.5	103.9
Oculeve Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	99.5
Fair Value Adjustments and Accretion	90.6
Payments and Other	(100)
Ending balance	90.1	99.5
ForSight [Member]
Business Acquisition [Line Items]
Beginning balance	65.4
Fair Value Adjustments and Accretion	(19.1)
Ending balance	46.3	65.4
Metrogel Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	15
Payments and Other	(7.5)
Ending balance	7.5	15
Forest Laboratories, Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	11
Fair Value Adjustments and Accretion	3.7
Payments and Other	(2)
Ending balance	12.7	11
Uteron Pharma, SA [Member]
Business Acquisition [Line Items]
Beginning balance	8.2
Fair Value Adjustments and Accretion	(8.2)
Ending balance		8.2
Other Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	27.6
Fair Value Adjustments and Accretion	(26.5)
Payments and Other	(0.2)
Ending balance	$ 0.9	$ 27.6

Commitments & Contingencies - A

Commitments & Contingencies - Additional Information (Detail) $ in Millions

Mar. 16, 2017Claim

Mar. 14, 2017Litigation

Feb. 23, 2017Claim

Feb. 16, 2017Claim

Nov. 04, 2016Claim

Feb. 05, 2016Cases

Jan. 05, 2016

Sep. 21, 2015Litigation

Aug. 24, 2015

Jun. 22, 2015Litigation

Jun. 08, 2015Litigation

May 29, 2015Litigation

Feb. 24, 2015Litigation

Apr. 05, 2013Litigation

Jan. 31, 2016

Jan. 17, 2018LitigationCases

Dec. 31, 2017USD ($)Defendant

Loss Contingencies [Line Items]

Accrued loss contingencies | $

$ 55

Number of plaintiffs | Claim

1

2

2

Saphris [Member]

Loss Contingencies [Line Items]

Trial date

2016-10

End-payors [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

9

Direct Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

5

Number of cases dismissed | Cases

1

Apotex [Member]

Loss Contingencies [Line Items]

Settlement agreement date

February 11, 2016

Apotex [Member] | Restasis [Member]

Loss Contingencies [Line Items]

Trial date

2017-08

Settlement agreement date

December 15, 2015

Apotex [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Settlement agreement date

April 10, 2017

TNS Products Litigation [Member] | Prescription Drug Abuse Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

Jan. 16, 2018

Zydus [Member]

Loss Contingencies [Line Items]

Settlement agreement date

November 28, 2016

Mylan [Member]

Loss Contingencies [Line Items]

Settlement agreement date

November 16, 2015

Mylan [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 18, 2017

Alembic Global holding SA [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

Jan. 5, 2018

Amerigen [Member]

Loss Contingencies [Line Items]

Settlement agreement date

October 20, 2015

Lupin [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 22, 2015

Teva [Member]

Loss Contingencies [Line Items]

Trial commencement date

Feb. 16, 2016

Sandoz [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

Apr. 13, 2017

Rapaflo [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Trial date

2019-09

Famy Care [Member] | Restasis [Member]

Loss Contingencies [Line Items]

Settlement agreement date

August 28, 2017

Innopharma [Member] | Restasis [Member]

Loss Contingencies [Line Items]

Settlement agreement date

October 12, 2017

Argentum [Member] | Restasis [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 7, 2016

Asacol Litigation [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

2

Number of additional putative class actions filed

3

Trial date

2018-01

Botox [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Tentative settlement date

Nov. 30, 2017

Loestrin 24 [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

2

Loestrin Twenty Four Direct Payors [Member] | Antitrust Litigation [Member]

Loss Contingencies [Line Items]

Number of cases pending

2

Namenda Litigation Direct Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Namenda Litigation Indirect Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Restasis [Member] | Subsequent Event [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

14

Zymar/Zymaxid [Member] | Apotex [Member]

Loss Contingencies [Line Items]

Tentative settlement date

Oct. 18, 2017

Settlement agreement date

March 27, 2017

Dismissal date

Apr. 26, 2017

Generic Drug Pricing Securities Litigation [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed | Claim

1

Prescription Drug Abuse Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

May 8, 2015

Prescription Drug Abuse Litigation [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of cases pending | Defendant

290

Xaleron Pharmaceuticals, Inc [Member]

Loss Contingencies [Line Items]

Number of lawsuit filed | Cases

1

Zeltiq [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Forest Laboratories, Inc. [Member] | Employment Litigation [Member]

Loss Contingencies [Line Items]

Settlement agreement date

April 3, 2017

Forest Laboratories, Inc. [Member] | Ranbaxy [Member]

Loss Contingencies [Line Items]

Settlement agreement date

May 1, 2015

Forest Laboratories, Inc. [Member] | Accord [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 14, 2016

Delzicol [Member] | Patent Litigation [Member]

Loss Contingencies [Line Items]

Trial date

2017-10

Lastacaft [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Trial date

2019-07

Sun and Certain Sun Affiliates [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 2,018

Namenda XR [Member] | Patent Litigation [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 13, 2015

Namenda XR [Member] | Patent Litigation [Member] | Anchen and Par [Member]

Loss Contingencies [Line Items]

Settlement agreement terms

Under the terms of the settlement agreement, and subject to review of the settlement terms by the U.S. Federal Trade Commission, Plaintiffs will provide a license to Wockhardt that will permit it to launch its generic version of Namenda XR® as of the date that is the later of (a) two (2) calendar months prior to the expiration date of the last to expire of the ‘703 patent, the ‘209 patent, the ‘708 patent, the ‘379 patent, the ‘752 patent, the ‘085 patent, and the ‘233 patent, including any extensions and/or pediatric exclusivities; or (b) the date that Wockhardt obtains final FDA approval of its ANDA, or earlier in certain circumstances.

Namzaric [Member] | Patent Litigation [Member]

Loss Contingencies [Line Items]

Trial date

2017-10

Namzaric [Member] | Amerigen [Member]

Loss Contingencies [Line Items]

Settlement agreement date

October 21, 2016

Namzaric [Member] | Accord [Member]

Loss Contingencies [Line Items]

Settlement agreement date

July 20, 2016

Namzaric [Member] | Amneal [Member]

Loss Contingencies [Line Items]

Settlement agreement date

August 30, 2016

Viibryd [Member] | Patent Litigation [Member]

Loss Contingencies [Line Items]

Trial date

2018-01

Viibryd [Member] | Patent Litigation [Member] | Alembic [Member]

Loss Contingencies [Line Items]

Settlement agreement date

April 20, 2017

Viibryd [Member] | Patent Litigation [Member] | Accord [Member]

Loss Contingencies [Line Items]

Settlement agreement date

May 15, 2017

Viibryd [Member] | Patent Litigation [Member] | Teva [Member]

Loss Contingencies [Line Items]

Settlement agreement date

June 29, 2017

Viibryd [Member] | Patent Litigation [Member] | Apotex [Member]

Loss Contingencies [Line Items]

Settlement agreement date

July 28, 2017

Viibryd [Member] | Patent Litigation [Member] | InvaGen [Member]

Loss Contingencies [Line Items]

Settlement agreement date

October 23, 2017

Dismissal date

Oct. 24, 2017

Commitments & Contingencies 155

Commitments & Contingencies - Additional Information 1 (Detail) $ in Millions	Mar. 16, 2017Claim	Feb. 23, 2017Claim	Feb. 16, 2017Claim	Dec. 28, 2015Claim	Dec. 31, 2017PatentLitigationClaimCasesDefendantTrademarkPlaintiff	Jan. 31, 2018USD ($)	Apr. 19, 2017Cases	Oct. 31, 2016USD ($)
Loss Contingencies [Line Items]
Number of plaintiffs | Claim	1	2	2
Teva [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Working capital one-time settlement payable | $						$ 700
Restasis [Member]
Loss Contingencies [Line Items]
Number of patents acquired | Patent					4
Saint Regis Mohawk Tribe [Member] | Restasis [Member]
Loss Contingencies [Line Items]
Number of patents acquired | Patent					6
Dermavita Limited Partnership [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of trademark opposition and cancellation pending | Trademark					150
Working Capital Dispute [Member] | Teva [Member]
Loss Contingencies [Line Items]
Proposed estimated adjustment to the closing date working capital balance | $								$ 1,400
Revised estimated adjustment to the closing date working capital balance | $								$ 1,500
Juvederm [Member] | KBC [Member]
Loss Contingencies [Line Items]
Settlement agreement date					June 2,017
Actonel Litigation [Member] | Warner Chilcott Limited [Member]
Loss Contingencies [Line Items]
Number of cases pending | Claim					379
Number of defendant cases | Defendant					165
Number of plaintiffs | Plaintiff					545
Actonel Litigation [Member] | Product Liability Litigation [Member] | Warner Chilcott Limited [Member]
Loss Contingencies [Line Items]
Number of plaintiffs | Plaintiff					2
AlloDerm Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of lawsuit filed | Litigation					335
Number of cases dismissed							332
AlloDerm Litigation [Member] | Product Liability Litigation [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending							1
Celexa/Lexapro Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of defendant cases | Defendant					166
Celexa/Lexapro Litigation [Member] | Product Liability Litigation [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending					5
RepliForm Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of defendant cases					250
Testosterone Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending					546
Putative Class of Private Payers [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed | Claim				1
Dismissal date					Jan. 18, 2017

Warner Chilcott Limited ("WC156

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Balance Sheets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,817.2	$ 1,724	$ 1,096	$ 250
Marketable securities	4,632.1	11,501.5
Accounts receivable, net	2,899	2,531
Inventories	904.5	718
Prepaid expenses and other current assets	1,123.9	1,383.4
Total current assets	11,376.7	17,857.9
Property, plant and equipment, net	1,785.4	1,611.3
Investments and other assets	267.9	282.1
Non current assets held for sale	81.6	27
Deferred tax assets	319.1	233.3
Product rights and other intangibles	54,648.3	62,618.6	67,836.2
Goodwill	49,862.9	46,356.1
Total assets	118,341.9	128,986.3
Current liabilities:
Accounts payable and accrued expenses	5,541.4	5,019
Income taxes payable	74.9	57.8
Current portion of long-term debt and capital leases	4,231.8	2,797.9
Total current liabilities	9,848.1	7,874.7
Long-term debt and capital leases	25,843.5	29,970.8
Other long-term liabilities	886.9	1,085
Other taxes payable	1,573.9	886.2
Deferred tax liabilities	6,352.4	12,969.1
Total liabilities	44,504.8	52,785.8
Total equity / (deficit)	73,837.1	76,200.5
Total liabilities and equity	118,341.9	128,986.3
Warner Chilcott Limited Parent Guarantor [Member]
Current assets:
Cash and cash equivalents	0.1	0.1		0.1
Total current assets	0.1	0.1
Investment in subsidiaries	81,282.1	88,093.4
Total assets	81,282.2	88,093.5
Current liabilities:
Total equity / (deficit)	81,282.2	88,093.5
Total liabilities and equity	81,282.2	88,093.5
Allergan Capital S.a.r.l. (Guarantor) [Member]
Current assets:
Cash and cash equivalents	593.1	513.9	13.5	5.5
Marketable securities	400.2	6,351.8
Receivables from Parents	4,223.5	4,196.9
Intercompany receivables	8,118.7	24,348.6
Prepaid expenses and other current assets		14.2
Total current assets	13,335.5	35,425.4
Investment in subsidiaries	87,530.6	89,219
Non current intercompany receivables	27,518.7	27,706.6
Total assets	128,384.8	152,351
Current liabilities:
Accounts payable and accrued expenses	0.6
Intercompany payables	12,186.2	55,828.8
Payables to Parents		334.1
Total current liabilities	12,186.8	56,162.9
Other long-term liabilities	0.2
Long-term intercompany payables	30,395	9,537.6
Deferred tax liabilities	0.2
Total liabilities	42,582.2	65,700.5
Total equity / (deficit)	85,802.6	86,650.5
Total liabilities and equity	128,384.8	152,351
Allergan Funding SCS (Issuer) [Member]
Current assets:
Cash and cash equivalents	0.1
Intercompany receivables	5,507.6	3,343.5
Total current assets	5,507.7	3,343.5
Non current intercompany receivables	20,985	22,540.1
Total assets	26,492.7	25,883.6
Current liabilities:
Accounts payable and accrued expenses	202.9	208.9
Intercompany payables	1,828.5	1,652.9
Current portion of long-term debt and capital leases	3,475.4	1,478.1
Total current liabilities	5,506.8	3,339.9
Long-term debt and capital leases	20,985	22,540.1
Total liabilities	26,491.8	25,880
Total equity / (deficit)	0.9	3.6
Total liabilities and equity	26,492.7	25,883.6
Allergan Finance LLC (Issuer and Guarantor) [Member]
Current assets:
Cash and cash equivalents			2	1.5
Intercompany receivables	19.6	81.6
Prepaid expenses and other current assets	85	42.7
Total current assets	104.6	124.3
Investments and other assets		15.8
Investment in subsidiaries	110,114.8	108,902.4
Total assets	110,219.4	109,042.5
Current liabilities:
Accounts payable and accrued expenses	89.3
Intercompany payables	11,402.3	9,359.1
Current portion of long-term debt and capital leases		1,197.4
Total current liabilities	11,491.6	10,556.5
Long-term debt and capital leases	2,130.1	3,079
Long-term intercompany payables	149	149
Total liabilities	13,770.7	13,784.5
Total equity / (deficit)	96,448.7	95,258
Total liabilities and equity	110,219.4	109,042.5
Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	1,223	1,199.2	1,020.7	237.2
Marketable securities	4,231.9	5,149.7
Accounts receivable, net	2,899	2,531
Receivables from Parents	1,573.9	5,092.3
Inventories	904.5	718
Intercompany receivables	25,417	66,840.8
Prepaid expenses and other current assets	1,038	1,325.2
Total current assets	37,287.3	82,856.2
Property, plant and equipment, net	1,785.4	1,611.3
Investments and other assets	267.9	266.3
Non current intercompany receivables	30,544	9,686.6
Non current receivables from Parents	3,964	3,964
Non current assets held for sale	81.6	27
Deferred tax assets	316	233.3
Product rights and other intangibles	54,648.3	62,618.6
Goodwill	49,862.9	46,356.1
Total assets	178,757.4	207,619.4
Current liabilities:
Accounts payable and accrued expenses	5,222.8	4,784.4
Intercompany payables	13,645.9	27,773.7
Payables to Parents	2,340.6	1,038.7
Income taxes payable	74.9	57.8
Current portion of long-term debt and capital leases	756.4	122.4
Total current liabilities	22,040.6	33,777
Long-term debt and capital leases	2,728.4	4,351.7
Other long-term liabilities	886.7	1,086
Long-term intercompany payables	48,503.7	50,246.7
Other taxes payable	1,573.5	886.2
Deferred tax liabilities	6,349.2	12,969.1
Total liabilities	82,082.1	103,316.7
Total equity / (deficit)	96,675.3	104,302.7
Total liabilities and equity	178,757.4	207,619.4
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	1,816.3	1,713.2	$ 1,036.2	$ 244.3
Marketable securities	4,632.1	11,501.5
Accounts receivable, net	2,899	2,531
Receivables from Parents	5,797.4	9,289.2
Inventories	904.5	718
Prepaid expenses and other current assets	1,123	1,382.1
Total current assets	17,172.3	27,135
Property, plant and equipment, net	1,785.4	1,611.3
Investments and other assets	267.9	282.1
Non current receivables from Parents	3,964	3,964
Non current assets held for sale	81.6	27
Deferred tax assets	316	233.3
Product rights and other intangibles	54,648.3	62,618.6
Goodwill	49,862.9	46,356.1
Total assets	128,098.4	142,227.4
Current liabilities:
Accounts payable and accrued expenses	5,515.6	4,993.3
Payables to Parents	2,340.6	1,372.8
Income taxes payable	74.9	57.8
Current portion of long-term debt and capital leases	4,231.8	2,797.9
Total current liabilities	12,162.9	9,221.8
Long-term debt and capital leases	25,843.5	29,970.8
Other long-term liabilities	886.9	1,086
Other taxes payable	1,573.5	886.2
Deferred tax liabilities	6,349.4	12,969.1
Total liabilities	46,816.2	54,133.9
Total equity / (deficit)	81,282.2	88,093.5
Total liabilities and equity	128,098.4	142,227.4
Eliminations [Member]
Current assets:
Intercompany receivables	(39,062.9)	(94,614.5)
Total current assets	(39,062.9)	(94,614.5)
Investment in subsidiaries	(278,927.5)	(286,214.8)
Non current intercompany receivables	(79,047.7)	(59,933.3)
Total assets	(397,038.1)	(440,762.6)
Current liabilities:
Intercompany payables	(39,062.9)	(94,614.5)
Total current liabilities	(39,062.9)	(94,614.5)
Long-term intercompany payables	(79,047.7)	(59,933.3)
Total liabilities	(118,110.6)	(154,547.8)
Total equity / (deficit)	(278,927.5)	(286,214.8)
Total liabilities and equity	$ (397,038.1)	$ (440,762.6)

Warner Chilcott Limited ("WC157

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statements of Operations and Comprehensive Income / (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Income Statements Captions [Line Items]
Net revenues	$ 4,326.1	$ 4,034.3	$ 4,007.4	$ 3,572.9	$ 3,864.3	$ 3,622.2	$ 3,684.8	$ 3,399.3	$ 15,940.7	$ 14,570.6	$ 12,688.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									2,168	1,860.8	2,751.8
Research and development									2,100.1	2,575.7	2,358.5
Selling and marketing									3,514.8	3,266.4	2,765.1
General and administrative									1,501.9	1,473.9	1,716.4
Amortization									7,197.1	6,470.4	5,443.7
Asset sales and impairments, net									3,927.7	5	272
Total operating expenses									21,861.9	16,396.1	15,819.1
Operating (loss)									(5,921.2)	(1,825.5)	(3,131)
Non-operating income / (expense):
Other income / (expense), net									(3,437.3)	219.2	(233.8)
Total other income (expense), net									(4,465.2)	(1,006.5)	(1,416.5)
Income / (loss) before income taxes and noncontrolling interest									(10,386.4)	(2,832)	(4,547.5)
(Benefit) for income taxes									(6,670.4)	(1,897)	(1,605.9)
Net income / (loss) from continuing operations, net of tax									(3,716)	(935)	(2,941.6)
(Loss) / income from discontinued operations, net of tax									(402.9)	15,914.5	6,861
Net (loss) / income	$ 3,123.2	$ (3,954)	$ (723.9)	$ (2,564.2)	$ 1.2	$ 15,221.8	$ (499.9)	$ 256.4	(4,118.9)	14,979.5	3,919.4
(Income) attributable to noncontrolling interest									(6.6)	(6.1)	(4.2)
Net (loss) / income attributable to shareholders									(4,125.5)	14,973.4	3,915.2
Other comprehensive (loss) / income, net of tax									2,959.1	(544.3)	(28.7)
Comprehensive (loss) / income attributable to ordinary shareholders									(1,166.4)	14,429.1	3,886.5
Warner Chilcott Limited Parent Guarantor [Member]
Non-operating income / (expense):
(Earnings) / losses of equity interest subsidiaries									3,927.3	(15,091.1)	(4,050.6)
Net income / (loss) from continuing operations, net of tax									(3,927.3)	15,091.1	4,050.6
Net (loss) / income									(3,927.3)	15,091.1	4,050.6
Net (loss) / income attributable to shareholders									(3,927.3)	15,091.1	4,050.6
Other comprehensive (loss) / income, net of tax									2,959.1	(544.3)	(28.7)
Comprehensive (loss) / income attributable to ordinary shareholders									(968.2)	14,546.8	4,021.9
Allergan Capital S.a.r.l. (Guarantor) [Member]
Operating expenses:
General and administrative											212.1
Total operating expenses											212.1
Operating (loss)											(212.1)
Non-operating income / (expense):
Interest income / (expense), net									845.5	2,255.3	1,572.4
Other income / (expense), net											(265.4)
Total other income (expense), net									845.5	2,255.3	1,307
Income / (loss) before income taxes and noncontrolling interest									845.5	2,255.3	1,094.9
(Benefit) for income taxes									5
(Earnings) / losses of equity interest subsidiaries									4,841.4	(9,342.8)	(4,336.5)
Net income / (loss) from continuing operations, net of tax									(4,000.9)	11,598.1	5,431.4
Net (loss) / income									(4,000.9)	11,598.1	5,431.4
Net (loss) / income attributable to shareholders									(4,000.9)	11,598.1	5,431.4
Other comprehensive (loss) / income, net of tax									3,153	(419.9)	24.5
Comprehensive (loss) / income attributable to ordinary shareholders									(847.9)	11,178.2	5,455.9
Allergan Funding SCS (Issuer) [Member]
Operating expenses:
General and administrative									8.6		16.1
Total operating expenses									8.6		16.1
Operating (loss)									(8.6)		(16.1)
Non-operating income / (expense):
Interest income / (expense), net									116.6	3.4	(14.6)
Other income / (expense), net									(110.4)		31
Total other income (expense), net									6.2	3.4	16.4
Income / (loss) before income taxes and noncontrolling interest									(2.4)	3.4	0.3
(Benefit) for income taxes									0.3	0.1
Net income / (loss) from continuing operations, net of tax									(2.7)	3.3	0.3
Net (loss) / income									(2.7)	3.3	0.3
Net (loss) / income attributable to shareholders									(2.7)	3.3	0.3
Comprehensive (loss) / income attributable to ordinary shareholders									(2.7)	3.3	0.3
Allergan Finance LLC (Issuer and Guarantor) [Member]
Operating expenses:
General and administrative									1.1	19.8
Total operating expenses									1.1	19.8
Operating (loss)									(1.1)	(19.8)
Non-operating income / (expense):
Interest income / (expense), net									(131.2)	(157.1)	(168.5)
Other income / (expense), net									(66.7)
Total other income (expense), net									(197.9)	(157.1)	(168.5)
Income / (loss) before income taxes and noncontrolling interest									(199)	(176.9)	(168.5)
(Benefit) for income taxes									(177.3)	66.3	(58.3)
(Earnings) / losses of equity interest subsidiaries									610.6	(18,837.8)	(3,412.3)
Net income / (loss) from continuing operations, net of tax									(632.3)	18,594.6	3,302.1
Net (loss) / income									(632.3)	18,594.6	3,302.1
Net (loss) / income attributable to shareholders									(632.3)	18,594.6	3,302.1
Other comprehensive (loss) / income, net of tax									1,823	(2,822.2)	(28.7)
Comprehensive (loss) / income attributable to ordinary shareholders									1,190.7	15,772.4	3,273.4
Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Net revenues									15,940.7	14,570.6	12,688.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									2,168	1,860.8	2,751.8
Research and development									2,100.1	2,575.7	2,358.5
Selling and marketing									3,514.8	3,266.4	2,765.1
General and administrative									1,392.6	1,330.6	1,352.8
Amortization									7,197.1	6,470.4	5,443.7
In-process research and development impairments									1,452.3	743.9	511.6
Asset sales and impairments, net									3,927.7	5	272
Total operating expenses									21,752.6	16,252.8	15,455.5
Operating (loss)									(5,811.9)	(1,682.2)	(2,767.4)
Non-operating income / (expense):
Interest income / (expense), net									(1,760.2)	(3,286.1)	(2,572)
Other income / (expense), net									(3,260.2)	172.2	0.6
Total other income (expense), net									(5,020.4)	(3,113.9)	(2,571.4)
Income / (loss) before income taxes and noncontrolling interest									(10,832.3)	(4,796.1)	(5,338.8)
(Benefit) for income taxes									(6,498.4)	(1,963.4)	(1,547.6)
Net income / (loss) from continuing operations, net of tax									(4,333.9)	(2,832.7)	(3,791.2)
(Loss) / income from discontinued operations, net of tax									(402.9)	15,914.5	6,861
Net (loss) / income									(4,736.8)	13,081.8	3,069.8
(Income) attributable to noncontrolling interest									(6.6)	(6.1)	(4.2)
Net (loss) / income attributable to shareholders									(4,743.4)	13,075.7	3,065.6
Other comprehensive (loss) / income, net of tax									2,959.1	(544.3)	(28.7)
Comprehensive (loss) / income attributable to ordinary shareholders									(1,784.3)	12,531.4	3,036.9
Warner Chilcott Limited [Member]
Condensed Income Statements Captions [Line Items]
Net revenues									15,940.7	14,570.6	12,688.1
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									2,168	1,860.8	2,751.8
Research and development									2,100.1	2,575.7	2,358.5
Selling and marketing									3,514.8	3,266.4	2,765.1
General and administrative									1,402.3	1,350.4	1,581
Amortization									7,197.1	6,470.4	5,443.7
In-process research and development impairments									1,452.3	743.9	511.6
Asset sales and impairments, net									3,927.7	5	272
Total operating expenses									21,762.3	16,272.6	15,683.7
Operating (loss)									(5,821.6)	(1,702)	(2,995.6)
Non-operating income / (expense):
Interest income / (expense), net									(929.3)	(1,184.5)	(1,182.7)
Other income / (expense), net									(3,437.3)	172.2	(233.8)
Total other income (expense), net									(4,366.6)	(1,012.3)	(1,416.5)
Income / (loss) before income taxes and noncontrolling interest									(10,188.2)	(2,714.3)	(4,412.1)
(Benefit) for income taxes									(6,670.4)	(1,897)	(1,605.9)
Net income / (loss) from continuing operations, net of tax									(3,517.8)	(817.3)	(2,806.2)
(Loss) / income from discontinued operations, net of tax									(402.9)	15,914.5	6,861
Net (loss) / income									(3,920.7)	15,097.2	4,054.8
(Income) attributable to noncontrolling interest									(6.6)	(6.1)	(4.2)
Net (loss) / income attributable to shareholders									(3,927.3)	15,091.1	4,050.6
Other comprehensive (loss) / income, net of tax									2,959.1	(544.3)	(28.7)
Comprehensive (loss) / income attributable to ordinary shareholders									(968.2)	14,546.8	4,021.9
Eliminations [Member]
Non-operating income / (expense):
(Earnings) / losses of equity interest subsidiaries									(9,379.3)	43,271.7	11,799.4
Net income / (loss) from continuing operations, net of tax									9,379.3	(43,271.7)	(11,799.4)
Net (loss) / income									9,379.3	(43,271.7)	(11,799.4)
Net (loss) / income attributable to shareholders									9,379.3	(43,271.7)	(11,799.4)
Other comprehensive (loss) / income, net of tax									(7,935.1)	3,786.4	32.9
Comprehensive (loss) / income attributable to ordinary shareholders									$ 1,444.2	$ (39,485.3)	$ (11,766.5)

Warner Chilcott Limited ("WC158

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statements of Cash Flows (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash Flows From Operating Activities:
Net (loss) / income	$ 3,123.2	$ (3,954)	$ (723.9)	$ (2,564.2)	$ 1.2	$ 15,221.8	$ (499.9)	$ 256.4	$ (4,118.9)	$ 14,979.5	$ 3,919.4
Reconciliation to net cash provided by operating activities:
Depreciation									171.5	155.8	218.3
Amortization									7,197.1	6,475.2	5,777
Provision for inventory reserve									102.2	181.4	140.9
Share-based compensation									293.3	334.5	690.4
Deferred income tax benefit									(7,783.1)	(1,443.9)	(7,380.1)
Pre-tax gain on sale of businesses to Teva										(24,511.1)
Non-cash tax effect of gain on sale of businesses to Teva										5,285.2
In-process research and development impairments									1,452.3	743.9	511.6
Loss / (gain) on asset sales and impairments, net									3,927.7	5	334.4
Charge to settle Teva related matters									387.4
Loss on forward sale of Teva shares									62.9
Amortization of inventory step-up									131.7	42.4	1,192.9
Amortization of deferred financing costs									27.8	51	298.3
Contingent consideration adjustments, including accretion									(133.2)	(66.8)	108.8
Other, net									(37)	(59.9)	66.4
Non-cash extinguishment of debt									(15.7)
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(349.9)	(331.4)	(454.9)
Additions to product rights and other intangibles									(614.3)	(2)	(154.7)
Sale of businesses to Teva										33,804.2
Additions to investments									(9,783.8)	(15,743.5)	(24.3)
Proceeds from sale of investments and other assets									15,153.3	7,771.6	883
Proceeds from sales of property, plant and equipment									7.1	33.3	140.1
Acquisitions of businesses, net of cash acquired									(5,290.4)	(1,198.9)	(37,510.1)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility									3,550	1,050	30,137.7
Debt issuance and other financing costs									(20.6)		(310.8)
Payments on debt, including capital lease obligations and credit facility									(6,413.6)	(10,848.7)	(5,134.2)
Payments of contingent consideration and other financing									(511.6)	(161.1)	(230.1)
Effect of currency exchange rate changes on cash and cash equivalents									21.4	(8.5)	(6.5)
Net (decrease) / increase in cash and cash equivalents									93.2	628	846
Cash and cash equivalents at beginning of period				1,724				1,096	1,724	1,096	250
Cash and cash equivalents at end of period	1,817.2				1,724				1,817.2	1,724	1,096
Warner Chilcott Limited Parent Guarantor [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(3,927.3)	15,091.1	4,050.6
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									3,927.3	(15,091.1)	(4,050.6)
Dividends from subsidiaries									1,668.2	2,034.8	208.1
Changes in assets and liabilities (net of effects of acquisitions)										0.1	(0.1)
Net cash provided by / (used in) operating activities									1,668.2	2,034.9	208
Cash Flows From Investing Activities:
Additions to investments											(9,000.8)
Net cash (used in) / provided by investing activities											(9,000.8)
Cash Flows From Financing Activities:
Dividend to Parent									(1,668.2)	(2,034.8)	(208.1)
Contribution from Parent											9,000.8
Net cash provided by / (used in) financing activities									(1,668.2)	(2,034.8)	8,792.7
Net (decrease) / increase in cash and cash equivalents										0.1	(0.1)
Cash and cash equivalents at beginning of period				0.1					0.1		0.1
Cash and cash equivalents at end of period	0.1				0.1				0.1	0.1
Allergan Capital S.a.r.l. (Guarantor) [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(4,000.9)	11,598.1	5,431.4
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									4,841.4	(9,342.8)	(4,336.5)
Amortization of deferred financing costs										23.5	272.5
Dividends from subsidiaries											208.1
Other, net									(10)
Changes in assets and liabilities (net of effects of acquisitions)									(4,228.1)	16,536.2	(370.6)
Net cash provided by / (used in) operating activities									(3,397.6)	18,815	1,204.9
Cash Flows From Investing Activities:
Additions to investments									(4,389.6)	(6,351.8)	(9,000.8)
Proceeds from sale of investments and other assets									7,866.4
Net cash (used in) / provided by investing activities									3,476.8	(10,548.7)	(9,000.8)
Loans to Parents										(4,196.9)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility										1,050	9,110
Financing structure and other activity with affiliates											(5,500)
Debt issuance and other financing costs											(167.1)
Payments on debt, including capital lease obligations and credit facility										(8,815.9)	(4,431.7)
Dividend to Parent											(208.1)
Contribution from Parent											9,000.8
Net cash provided by / (used in) financing activities										(7,765.9)	7,803.9
Net (decrease) / increase in cash and cash equivalents									79.2	500.4	8
Cash and cash equivalents at beginning of period				513.9				13.5	513.9	13.5	5.5
Cash and cash equivalents at end of period	593.1				513.9				593.1	513.9	13.5
Allergan Funding SCS (Issuer) [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(2.7)	3.3	0.3
Reconciliation to net cash provided by operating activities:
Non-cash extinguishment of debt									17.6
Amortization of deferred financing costs									23.3	23.3	20.9
Changes in assets and liabilities (net of effects of acquisitions)									(241.5)	473.4	122.5
Net cash provided by / (used in) operating activities									(203.3)	500	143.7
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility									3,020.9		20,955.6
Financing structure and other activity with affiliates											(20,955.6)
Debt issuance and other financing costs									(17.5)		(143.7)
Payments on debt, including capital lease obligations and credit facility									(2,800)	(500)
Net cash provided by / (used in) financing activities									203.4	(500)	(143.7)
Net (decrease) / increase in cash and cash equivalents									0.1
Cash and cash equivalents at end of period	0.1								0.1
Allergan Finance LLC (Issuer and Guarantor) [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(632.3)	18,594.6	3,302.1
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									610.6	(18,837.8)	(3,412.3)
Depreciation											0.2
Share-based compensation											51.6
Non-cash extinguishment of debt									12.2
Amortization of deferred financing costs									4.5	4.2	4.1
Changes in assets and liabilities (net of effects of acquisitions)									2,148.3	237	97.7
Net cash provided by / (used in) operating activities									2,143.3	(2)	43.4
Cash Flows From Investing Activities:
Additions to property, plant and equipment											(42.9)
Net cash (used in) / provided by investing activities											(42.9)
Cash Flows From Financing Activities:
Payments on debt, including capital lease obligations and credit facility									(2,143.3)
Net cash provided by / (used in) financing activities									(2,143.3)
Net (decrease) / increase in cash and cash equivalents										(2)	0.5
Cash and cash equivalents at beginning of period								2		2	1.5
Cash and cash equivalents at end of period											2
Non-Guarantors [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(4,736.8)	13,081.8	3,069.8
Reconciliation to net cash provided by operating activities:
Depreciation									171.5	155.8	218.1
Amortization									7,197.1	6,475.2	5,777
Provision for inventory reserve									102.2	181.4	140.9
Share-based compensation									293.3	334.5	638.8
Deferred income tax benefit									(7,783.1)	(1,443.9)	(7,380.1)
Pre-tax gain on sale of businesses to Teva										(24,511.1)
Non-cash tax effect of gain on sale of businesses to Teva										5,285.2
In-process research and development impairments									1,452.3	743.9	511.6
Loss / (gain) on asset sales and impairments, net									3,927.7	5	334.4
Net income impact of other-than-temporary loss on investment in Teva securities									3,273.5
Charge to settle Teva related matters									387.4
Loss on forward sale of Teva shares									62.9
Amortization of inventory step-up									131.7	42.4	1,192.9
Non-cash extinguishment of debt									(45.5)
Amortization of deferred financing costs											0.8
Contingent consideration adjustments, including accretion									(133.2)	(66.8)	108.8
Other, net									(27)	(59.9)	66.4
Changes in assets and liabilities (net of effects of acquisitions)									3,207.3	(17,957.6)	(1,199.2)
Net cash provided by / (used in) operating activities									7,481.3	(17,734.1)	3,480.2
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(349.9)	(331.4)	(412)
Additions to product rights and other intangibles									(614.3)	(2)	(154.7)
Sale of businesses to Teva										33,804.2
Additions to investments									(5,394.2)	(9,391.7)	(24.3)
Proceeds from sale of investments and other assets									7,286.9	7,771.6	883
Proceeds from sales of property, plant and equipment									7.1	33.3	140.1
Acquisitions of businesses, net of cash acquired									(5,290.4)	(1,198.9)	(37,510.1)
Net cash (used in) / provided by investing activities									(4,354.8)	21,649.8	(37,078)
Loans to Parents										(9,035.3)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility									529.1		72.1
Financing structure and other activity with affiliates											26,455.6
Debt issuance and other financing costs									(3.1)
Payments on debt, including capital lease obligations and credit facility									(1,470.3)	(1,532.8)	(702.5)
Payments of contingent consideration and other financing									(511.6)	(161.1)	(230.1)
Dividend to Parent									(1,668.2)	(2,034.8)	(208.1)
Contribution from Parent											9,000.8
Net cash provided by / (used in) financing activities									(3,124.1)	(3,728.7)	34,387.8
Effect of currency exchange rate changes on cash and cash equivalents									21.4	(8.5)	(6.5)
Net (decrease) / increase in cash and cash equivalents									23.8	178.5	783.5
Cash and cash equivalents at beginning of period				1,199.2				1,020.7	1,199.2	1,020.7	237.2
Cash and cash equivalents at end of period	1,223				1,199.2				1,223	1,199.2	1,020.7
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net (loss) / income									(3,920.7)	15,097.2	4,054.8
Reconciliation to net cash provided by operating activities:
Depreciation									171.5	155.8	218.3
Amortization									7,197.1	6,475.2	5,777
Provision for inventory reserve									102.2	181.4	140.9
Share-based compensation									293.3	334.5	690.4
Deferred income tax benefit									(7,783.1)	(1,443.9)	(7,380.1)
Pre-tax gain on sale of businesses to Teva										(24,511.1)
Non-cash tax effect of gain on sale of businesses to Teva										5,285.2
In-process research and development impairments									1,452.3	743.9	511.6
Loss / (gain) on asset sales and impairments, net									3,927.7	5	334.4
Net income impact of other-than-temporary loss on investment in Teva securities									3,273.5
Charge to settle Teva related matters									387.4
Loss on forward sale of Teva shares									62.9
Amortization of inventory step-up									131.7	42.4	1,192.9
Non-cash extinguishment of debt									(15.7)
Amortization of deferred financing costs									27.8	51	298.3
Contingent consideration adjustments, including accretion									(133.2)	(66.8)	108.8
Other, net									(37)	(59.9)	66.4
Changes in assets and liabilities (net of effects of acquisitions)									886	(710.9)	(1,349.7)
Non-cash extinguishment of debt									(15.7)
Net cash provided by / (used in) operating activities									6,023.7	1,579	4,664
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(349.9)	(331.4)	(454.9)
Additions to product rights and other intangibles									(614.3)	(2)	(154.7)
Sale of businesses to Teva										33,804.2
Additions to investments									(9,783.8)	(15,743.5)	(24.3)
Proceeds from sale of investments and other assets									15,153.3	7,771.6	883
Proceeds from sales of property, plant and equipment									7.1	33.3	140.1
Acquisitions of businesses, net of cash acquired									(5,290.4)	(1,198.9)	(37,510.1)
Net cash (used in) / provided by investing activities									(878)	11,101.1	(37,120.9)
Loans to Parents										(13,232.2)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility									3,550	1,050	30,137.7
Debt issuance and other financing costs									(20.6)		(310.8)
Payments on debt, including capital lease obligations and credit facility									(6,413.6)	(10,848.7)	(5,134.2)
Payments of contingent consideration and other financing									(511.6)	(161.1)	(230.1)
Dividend to Parent									(1,668.2)	(2,034.8)	(208.1)
Contribution from Parent											9,000.8
Net cash provided by / (used in) financing activities									(5,064)	(11,994.6)	33,255.3
Effect of currency exchange rate changes on cash and cash equivalents									21.4	(8.5)	(6.5)
Net (decrease) / increase in cash and cash equivalents									103.1	677	791.9
Cash and cash equivalents at beginning of period				$ 1,713.2				$ 1,036.2	1,713.2	1,036.2	244.3
Cash and cash equivalents at end of period	$ 1,816.3				$ 1,713.2				1,816.3	1,713.2	1,036.2
Eliminations [Member]
Cash Flows From Operating Activities:
Net (loss) / income									9,379.3	(43,271.7)	(11,799.4)
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									(9,379.3)	43,271.7	11,799.4
Dividends from subsidiaries									(1,668.2)	(2,034.8)	(416.2)
Net cash provided by / (used in) operating activities									(1,668.2)	(2,034.8)	(416.2)
Cash Flows From Investing Activities:
Additions to investments											18,001.6
Net cash (used in) / provided by investing activities											18,001.6
Cash Flows From Financing Activities:
Dividend to Parent									1,668.2	2,034.8	416.2
Contribution from Parent											(18,001.6)
Net cash provided by / (used in) financing activities									$ 1,668.2	$ 2,034.8	$ (17,585.4)

Compensation - Schedule of Comp

Compensation - Schedule of Compensation Charges (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Compensation Related Costs [Line Items]
Wages and salaries	$ 1,892.8	$ 2,108.7	$ 2,252.3
Stock-based compensation	308	396.1	925.7
Pensions	82.7	156.8	99.9
Social welfare	150.4	165	185.1
Other benefits	265.1	321	271.6
Total compensation charges	2,699	3,147.6	3,734.6
Continuing Operations [Member]
Compensation Related Costs [Line Items]
Total compensation charges	$ 2,699	2,578.4	2,597.7
Discontinued Operations [Member]
Compensation Related Costs [Line Items]
Total compensation charges		$ 569.2	$ 1,136.9

Concentration - Additional Info

Concentration - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017ManufacturerCustomer	Dec. 31, 2016Customer
Concentration Risk [Line Items]
Number of customer outside the U.S and Canada in relation to 10% global sales	0
Percentage of gross accounts receivable due from largest customers	58.00%	59.00%
Number of largest customers	3	3
Concentration risk, supplier	No third party manufacturer accounted for 10% or more of the Company’s products sold based on third-party revenues for the year ended December 31, 2017.
Number of manufacturers accounted more than 10% of company's product sold | Manufacturer	0
U.S. and Canada [Member]
Concentration Risk [Line Items]
Percentage of other individual customers in relation to net revenues	10.00%
Percentage of individual customers in relation to global sales	10.00%
Customer Concentration Risk [Member] | Revenues [Member] | Minimum [Member]
Concentration Risk [Line Items]
Concentration risk percentage	10.00%

Concentration - Schedule of Con

Concentration - Schedule of Concentration on Revenues (Detail) - U.S. and Canada [Member] - Revenues [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
McKesson Corporation [Member]
Concentration Risk [Line Items]
Concentration risk percentage	23.00%	23.00%	27.00%
Cardinal Health, Inc. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	19.00%	18.00%	20.00%
AmerisourceBergen Corporation [Member]
Concentration Risk [Line Items]
Concentration risk percentage	19.00%	18.00%	19.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - USD ($)	Feb. 06, 2018	Jan. 31, 2018
Elastagen Pty Ltd [Member]
Subsequent Event [Line Items]
Business acquisition date	Feb. 6, 2018
Payments to acquire business, cash	$ 95,000,000
Elastagen Pty Ltd [Member] | Maximum [Member]
Subsequent Event [Line Items]
Additional consideration payable	$ 165,000,000
Repros Therapeutics, Inc. [Member]
Subsequent Event [Line Items]
Business acquisition date		Jan. 31, 2018
Payments to acquire business, cash		$ 31,000,000

Schedule II - Valuation and 163

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation And Qualifying Accounts [Abstract]
Allowance for doubtful accounts, Balance at beginning of period	$ 75.7	$ 80.6	$ 4.8
Allowance for doubtful accounts, Charged to costs and expenses	11.6	3.5	8.4
Allowance for doubtful accounts, Deductions/ Write-offs	(1.7)	(8.4)	(7.3)
Allowance for doubtful accounts, Other	7.4		74.7
Allowance for doubtful accounts, Balance at end of period	93	75.7	80.6
Tax valuation allowance, Balance at beginning of period	183.9	196.2	474
Tax valuation allowance, Charged to costs and expenses	230.1	183.8	(335.6)
Tax valuation allowance, Other	(10.2)	(196.1)	57.8
Tax valuation allowance, Balance at end of period	$ 403.8	$ 183.9	$ 196.2

Supplementary Data - Quarterly

Supplementary Data - Quarterly Consolidated Financial Data and Market Price Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Selected Quarterly Financial Information [Abstract]
Net revenues	$ 4,326.1	$ 4,034.3	$ 4,007.4	$ 3,572.9	$ 3,864.3	$ 3,622.2	$ 3,684.8	$ 3,399.3	$ 15,940.7	$ 14,570.6	$ 12,688.1
Net income/(loss)	$ 3,123.2	$ (3,954)	$ (723.9)	$ (2,564.2)	$ 1.2	$ 15,221.8	$ (499.9)	$ 256.4	$ (4,118.9)	$ 14,979.5	$ 3,919.4
Basic earnings per share	$ 9.21	$ (12.07)	$ (2.37)	$ (7.86)	$ (0.20)	$ 38.58	$ (1.44)	$ 0.47	$ (13.19)	$ 38.18	$ 10.01
Diluted earnings per share	8.88	(12.07)	(2.37)	(7.86)	(0.20)	38.58	(1.44)	0.47	$ (13.19)	$ 38.18	$ 10.01
Market price per share:
High	210.98	256.15	248.91	249.32	244.66	261.27	277.96	310.83
Low	$ 163.58	$ 202.66	$ 218.73	$ 210.80	$ 184.50	$ 228.68	$ 195.50	$ 261.60